Appendix A
2015 Financial Report
INTRODUCTION

Our Financial Review is provided to assist readers in understanding the results of operations, financial condition and cash flows of Pfizer Inc. (the Company). It should be read in conjunction with the consolidated financial statements and Notes to Consolidated Financial Statements. The discussion in this Financial Review contains forward-looking statements that involve substantial risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, such as those discussed in Part 1, Item 1A, “Risk Factors” of our 2015 Annual Report on Form 10-K and in the “Forward-Looking Information and Factors That May Affect Future Results”; “Our Operating Environment” and “Our Strategy” sections of this Financial Review.

The Financial Review is organized as follows:

- **Overview of Our Performance, Operating Environment, Strategy and Outlook** .................................................. Beginning on page 2
  This section provides information about the following: Our Business; Our 2015 Performance; Our Operating Environment; The Global Economic Environment, Our Strategy; Our Business Development Initiatives, such as acquisitions, dispositions, licensing and collaborations; and Our Financial Guidance for 2016.

- **Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions** .......... Beginning on page 12
  This section discusses those accounting policies and estimates that we consider important in understanding our consolidated financial statements. For additional discussion of our accounting policies, see Notes to Consolidated Financial Statements—Note 1. Basis of Presentation and Significant Accounting Policies.

- **Analysis of the Consolidated Statements of Income** .......................................................... Beginning on page 19
  This section includes a Revenues Overview section as well as the following sub-sections:
  - **Revenues-Major Products** ........................................... Beginning on page 24
    This sub-section provides an overview of several of our biopharmaceutical products.
  - **Product Developments-Biopharmaceutical** .................................................. Beginning on page 28
    This sub-section provides an overview of important biopharmaceutical product developments.
  - **Costs and Expenses** ................................................. Beginning on page 31
    This sub-section provides a discussion about our costs and expenses.
  - **Provision for Taxes on Income** ............................................. Beginning on page 34
    This sub-section provides a discussion of items impacting our tax provisions.
  - **Discontinued Operations** ............................................ Beginning on page 35
  - **Adjusted Income** .................................................. Beginning on page 35
    This sub-section provides a discussion of an alternative view of performance used by management.

- **Analysis of Operating Segment Information** .................................................. Beginning on page 42
  This section provides a discussion of the performance of each of our operating segments.

- **Analysis of the Consolidated Statements of Comprehensive Income** .................................................. Beginning on page 48
  This section provides a discussion of changes in certain components of other comprehensive income.

- **Analysis of the Consolidated Balance Sheets** .................................................. Beginning on page 49
  This section provides a discussion of changes in certain balance sheet accounts, including Accumulated other comprehensive loss.

- **Analysis of the Consolidated Statements of Cash Flows** .................................................. Beginning on page 50
  This section provides an analysis of our consolidated cash flows for the three years ended December 31, 2015.

- **Analysis of Financial Condition, Liquidity and Capital Resources** .................................................. Beginning on page 51
  This section provides an analysis of selected measures of our liquidity and of our capital resources as of December 31, 2015 and December 31, 2014, as well as a discussion of our outstanding debt and other commitments that existed as of December 31, 2015 and December 31, 2014. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer’s future activities.

- **New Accounting Standards** ............................................. Beginning on page 56
  This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted.

- **Forward-Looking Information and Factors That May Affect Future Results** .................................................. Beginning on page 58
  This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this Financial Review relating to, among other things, our anticipated operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans and plans relating to share repurchases and dividends. Such forward-looking statements are based on management’s plans and assumptions, which are inherently susceptible to uncertainty and changes in circumstances. Also included in this section are discussions of Financial Risk Management and Contingencies, including legal and tax matters.

Certain amounts in our Financial Review may not add due to rounding. All percentages have been calculated using unrounded amounts.
OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK

Our Business

We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines, vaccines and medical devices, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered by other companies (Alliance revenues).

The majority of our revenues come from the manufacture and sale of biopharmaceutical products. The biopharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges which can significantly impact our results. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures and competition. We also face challenges as a result of the global economic environment. For additional information about these factors and challenges, see the “Our Operating Environment” section of this Financial Review and in Part I, Item 1A, “Risk Factors,” of our 2015 Annual Report on Form 10-K.

The financial information included in our consolidated financial statements for our subsidiaries operating outside the United States (U.S.) is as of and for the year ended November 30 for each year presented. Pfizer’s fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented.

References to developed markets in this Financial Review include the U.S., Western Europe, Japan, Canada, Australia, Scandinavia, South Korea, Finland and New Zealand; and references to emerging markets in this Financial Review include, but are not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.

References to operational variances in this Financial Review refer to variances excluding the impacts of foreign exchange.

On November 23, 2015, we announced that we have entered into a definitive merger agreement with Allergan plc (Allergan), a global pharmaceutical company incorporated in Ireland, under which we have agreed to combine with Allergan in a stock transaction valued at $363.63 per Allergan share, for a total enterprise value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on November 20, 2015 (the last trading day prior to the announcement) and certain other assumptions. Subject to the terms and conditions of the merger agreement, the businesses of Pfizer and Allergan will be combined under a single company and Pfizer would become a wholly-owned subsidiary of Allergan, which is organized under the laws of Ireland and which, subject to the approval by Allergan shareholders, will be renamed “Pfizer plc”. We anticipate that the parent company will be treated as a non-U.S. corporation (and, therefore, a non-U.S. tax resident) under the applicable U.S. federal income tax rules, although the U.S. Internal Revenue Service (IRS) may challenge that treatment. The completion of the transaction, which is expected in the second half of 2016, is subject to certain conditions, including receipt of regulatory approval in certain jurisdictions, including the U.S. and European Union (EU), the receipt of necessary approvals from both Pfizer and Allergan shareholders, and the completion of Allergan’s pending divestiture of its generics business to Teva Pharmaceuticals Industries Ltd. Readers are encouraged to review the joint proxy statement/prospectus we will file with the U.S. Securities and Exchange Commission (SEC) seeking stockholder approval of the transaction. That document will include important information regarding the proposed transaction. While we have taken actions and incurred costs associated with the pending combination that are reflected in our financial statements, the pending combination with Allergan will not be reflected in our financial statements until consummation. See the “Our Business Development Initiatives” section of this Financial Review and Notes to Consolidated Financial Statements—Note 19. Pending Combination with Allergan for additional information.

On September 3, 2015 (the acquisition date), we acquired Hospira, Inc. (Hospira) for approximately $16.1 billion in cash ($15.7 billion, net of cash acquired). Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira, and, in accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions and the “Significant Accounting Policies and Application of Critical Accounting Estimates—Acquisition of Hospira” section of this Financial Review for additional information. Hospira is now a subsidiary of Pfizer and its commercial operations are now included within the Global Established Pharmaceutical (GEP) segment. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps. We expect to generate $800 million of annual cost synergies by 2018 in connection with the Hospira acquisition. Based on our past experience, the one-time costs to generate the synergies are expected to be approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired in-process research and development (IPR&D) rights), incurred for up to a three-year period post-acquisition. See the “Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review.

On June 24, 2013, we completed the full disposition of our Animal Health business, Zoetis Inc. (Zoetis), and recognized a gain of approximately $10.3 billion, net of tax, in Gain on disposal of discontinued operations—net of tax in our consolidated statement of income for the year ended December 31, 2013. The operating results of this business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations—net of tax in our consolidated statements of income. See Notes to Consolidated Financial Statements—Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Divestitures for additional information.
Our 2015 Performance

Revenues—2015

Revenues in 2015 were $48.9 billion, a decrease of 2% compared to 2014. This reflects an operational increase of $3.0 billion, or 6%, which was more than offset by the unfavorable impact of foreign exchange of $3.8 billion, or 8%.

The following provides an analysis of our 2015 operational revenue growth for Pfizer standalone revenues:

<table>
<thead>
<tr>
<th>(BILLIONS OF DOLLARS)</th>
<th>Year Ended December 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operational revenues—Pfizer-standalone increase:</td>
<td></td>
</tr>
<tr>
<td>Operational consolidated revenues increase</td>
<td>$3.0</td>
</tr>
<tr>
<td>Less: Revenues from legacy Hospira</td>
<td>$(1.5)</td>
</tr>
<tr>
<td>Revenues from vaccines acquired from Baxter</td>
<td>$(0.2)</td>
</tr>
<tr>
<td>Operational revenues—Pfizer-standalone increase</td>
<td>$1.3</td>
</tr>
<tr>
<td>Components of operational revenues—Pfizer-standalone increase:</td>
<td></td>
</tr>
<tr>
<td>Operational revenue growth from certain key products—net</td>
<td>$4.5</td>
</tr>
<tr>
<td>Operational revenue decrease due to product losses of exclusivity and co-promotion expirations</td>
<td>$(3.2)</td>
</tr>
<tr>
<td>Operational revenues—Pfizer-standalone increase</td>
<td>$1.3</td>
</tr>
</tbody>
</table>

See the “Analysis of the Consolidated Statements of Income—Revenues—Overview” section below for more information, including a discussion of key drivers of our revenue performance.

Income from Continuing Operations Before Provision for Taxes on Income—2015

Income from continuing operations before provision for taxes on income was $9.0 billion in 2015 compared to $12.2 billion in 2014, primarily reflecting, among other items, in addition to the operational and foreign exchange impacts for Revenues described above:

- higher restructuring charges and certain acquisition-related costs (up $902 million) (see also the Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives);
- foreign currency loss ($806 million) and an inventory impairment charge ($72 million) related to Venezuela in 2015 (see also the “Costs and Expenses—Cost of Sales” and the “Analysis of Financial Condition, Liquidity and Capital Resources—Global Economic Conditions—Venezuela Operations” sections of this Financial Review and Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net);
- higher selling, informational and administrative expenses (up $711 million) (see also the “Costs and Expenses—Selling, Informational and Administrative Expenses (SI&A Expenses)” section of this Financial Review);
- higher Other, net (up $668 million) (see also the Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net); and
- higher asset impairments (up $349 million) (see also the Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net);

partially offset by:

- lower research and development expenses (down $703 million) (see also the “Costs and Expenses—Research and Development (R&D) Expenses” section of this Financial Review);
- lower amortization of intangible assets (down $311 million) (see also the “Costs and Expenses—Amortization of Intangible Assets” section of this Financial Review); and
- lower net interest expense (down $207 million) (see also the Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net).

For information on our tax provision and effective tax rate see the “Provision for Taxes on Income” section of the Financial Review and Notes to Consolidated Financial Statements—Note 5. Tax Matters.

Our Operating Environment

Industry-Specific Challenges

Intellectual Property Rights and Collaboration/Licensing Rights

The loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights can have a significant adverse effect on our revenues. Many of our branded products have multiple patents that expire at varying dates, thereby strengthening our overall patent protection. However, once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we
lose exclusivity on these products, and generic pharmaceutical manufacturers generally produce similar products and sell them for a lower price. The date at which generic competition commences may be different from the date that the patent or regulatory exclusivity expires. However, when generic competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time.

Our biotechnology products, including BeneFIX, ReFacto, Xyntha and Enbrel (we market Enbrel outside the U.S. and Canada), may face competition in the future from biosimilars (also referred to as follow-on biologics). If competitors are able to obtain marketing approval for biosimilars that reference our biotechnology products, our biotechnology products may become subject to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. Expiration or successful challenge of applicable patent rights could trigger this competition, assuming any relevant exclusivity period has expired. However, biosimilar manufacturing is complex. At least initially upon approval of a biosimilar competitor, biosimilar competition with respect to biologics may not be as significant as generic competition with respect to small molecule drugs.

We have lost exclusivity for a number of our products in certain markets and we have lost collaboration rights with respect to a number of our alliance products in certain markets, and we expect certain products and alliance products to face significantly increased generic competition over the next few years.

Specifically:

Recent Losses and Expected Losses of Product Exclusivity

The following table provides information about certain of our products recently experiencing, or expected to experience in 2016, patent expirations or loss of regulatory exclusivity in the U.S., Europe or Japan, showing, by product, the key dates or expected key dates, the markets impacted and the revenues associated with those products in those markets:

(MILLIONS OF DOLLARS) | Product Revenues in Markets Impacted
--- | ---
**Products** | Key Dates**(a)** | Markets Impacted | Year Ended December 31,
--- | --- | --- | ---
Detrol IR and Detrol LA**(b)** | September 2012 | Major European markets | 2015 2014 2013
 | January 2014 | U.S. |
 | **$35** | **87** | **428** |
Viagra | June 2013 | Major European markets |
 | May 2014 | Japan |
 | **76** | **120** | **310** |
Rapamune | January 2014 | U.S. |
 | June 2015 | Major European markets |
 | **129** | **254** | **253** |
Inspira**(c)** | March 2014 | Major European markets |
 | **74** | **160** | **150** |
Lyrica**(d)** | July 2014 | Major European markets |
 | **1,048** | **1,634** | **1,458** |
Celebrex**(e)** | November 2014 | Major European markets |
 | December 2014 | U.S. |
 | **189** | **1,872** | **2,084** |
Zyvox**(f)** | First half of 2015 | Major European markets |
 | January 2016 | U.S. |
 | **564** | **1,020** | **1,013** |
Enbrel**(g)** | August 2015 | Major European markets |
 | September 2015 | Japan |
 | **2,402** | **2,832** | **2,776** |
Relpax | December 2016 | U.S. |
 | **233** | **244** | **218** |
Vfend | July 2016 | Major European markets |
 | January 2016 | Japan |
 | **349** | **403** | **413** |
Tygacil | April 2016 | U.S. |
 | **110** | **112** | **150** |

**(a)** Unless stated otherwise, “Key Dates” indicate patent-based expiration dates.
**(b)** In January 2014, generic versions of Detrol LA became available in the U.S. pursuant to a settlement agreement.
**(c)** In March 2014, regulatory exclusivity for Inspra expired in most major European markets, allowing generic companies to submit applications for marketing authorizations for their generic products.
**(d)** In July 2014, regulatory exclusivity for Lyrica expired in the EU, allowing generic companies to submit applications for marketing authorizations for their generic products.
**(e)** In December 2014, generic versions of Celebrex became available pursuant to settlement agreements with several generic manufacturers.
**(f)** Pursuant to terms of a settlement agreement, certain formulations of Zyvox became subject to generic competition in the U.S. in January 2015. Other formulations of Zyvox became subject to generic competition in the U.S. in the first half of 2015.
**(g)** In January 2016, the European Commission approved an etanercept biosimilar referencing Enbrel.
Recent Losses and Expected Losses of Collaboration Rights

The following table provides information about certain of our alliance revenue products that have experienced or that are expected to experience in 2016 losses of collaboration rights, showing, by product, the date of the loss of the collaboration rights, the markets impacted and the alliance revenues associated with those products in those markets:

<table>
<thead>
<tr>
<th>Products</th>
<th>Date of Loss of Collaboration Rights</th>
<th>Markets Impacted</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spiriva(a)</td>
<td>April 2014 (U.S.), between 2012 and 2016 (Japan, certain European countries, Australia, Canada and South Korea)</td>
<td>U.S., Japan, certain European countries, Australia, Canada and South Korea</td>
<td>$27</td>
</tr>
<tr>
<td>Enbrel(b)</td>
<td>October 2013</td>
<td>U.S. and Canada</td>
<td>—</td>
</tr>
<tr>
<td>Rebif(c)</td>
<td>End of 2015</td>
<td>U.S.</td>
<td>371</td>
</tr>
</tbody>
</table>

(a) Our collaboration with Boehringer Ingelheim for Spiriva expires on a country-by-country basis between 2012 and 2016. On April 29, 2014, our alliance in the U.S. came to an end.
(b) The U.S. and Canada co-promotion term of our collaboration agreement with Amgen Inc. for Enbrel expired on October 31, 2013. While we are entitled to royalties until October 31, 2016, those royalties have been and are expected to continue to be significantly less than our share of Enbrel profits from U.S. and Canada sales prior to the expiration. In addition, while our share of the profits from this co-promotion agreement previously was included in Revenues, our royalties after October 31, 2013 are and will be included in Other (income)/deductions—net, in our consolidated statements of income. Outside the U.S. and Canada, we continue to have the exclusive rights to market Enbrel.
(c) Our collaboration agreement with EMD Serono Inc. to co-promote Rebif in the U.S. expired at the end of 2015.

In addition, we expect to lose exclusivity for various other products in various markets over the next few years. For additional information, see the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business”, of our 2015 Annual Report on Form 10-K.

Our financial results in 2015 and our 2016 financial guidance, respectively, reflect the impact and projected impact of the loss of exclusivity of various products and the expiration of certain alliance product contract rights discussed above. For additional information about our 2016 financial guidance, see the “Our Financial Guidance for 2016” section of this Financial Review.

We will continue to aggressively defend our patent rights whenever we deem appropriate. For more detailed information about our significant products, see the discussion in the “Revenues—Major Products” and “Revenues—Selected Product Descriptions” sections of this Financial Review. For a discussion of certain recent developments with respect to patent litigation, see Notes to Consolidated Financial Statements—Note 17A1. Commitments and Contingencies: Legal Proceedings—Patent Litigation.

Regulatory Environment/Pricing and Access—U.S. Healthcare Legislation

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (together, the U.S. Healthcare Legislation, and also known as the Affordable Care Act or ACA), was enacted in the U.S. For additional information, see the “Government Regulation and Price Constraints” section in Part I, Item 1, “Business”, of our 2015 Annual Report on Form 10-K. The U.S. Healthcare Legislation also created a framework for the approval of biosimilars (also known as follow-on biologics) following the expiration of 12 years of exclusivity for the innovator biologic, with a potential six-month pediatric extension. For additional information on the biosimilar approval pathway, the U.S. Food and Drug Administration’s (FDA) guidance documents and competition from biosimilar manufacturers, see the “Patents and Intellectual Property—Biotechnology Products” and “Government Regulation and Price Constraints—Biosimilar Regulation” sections in Part I, Item 1 “Business”, of our 2015 Annual Report on Form 10-K.

Impacts on our 2015 Results

We recorded the following amounts in 2015 as a result of the U.S. Healthcare Legislation:

- $977 million recorded as a reduction to Revenues, related to the higher, extended and expanded rebate provisions and the Medicare “coverage gap” discount provision, as well as an increase in Medicaid rebates; and
- $251 million recorded in Selling, informational and administrative expenses, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes) based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs. The decrease in the impact of the U.S. Healthcare Legislation on Selling, informational and administrative expenses in 2015 compared to 2014 was primarily a result of the non-recurrence of the $215 million charge in 2014 to account for an additional year of the non-tax deductible Branded Prescription Drug Fee, partially offset by a lower favorable true-up in 2015, compared to the favorable true-up in 2014, associated with the final invoice for the respective prior-calendar year received from the federal government, which reflected a lower share than that of the initial invoice.
Impacts on our 2014 Results

We recorded the following amounts in 2014 as a result of the U.S. Healthcare Legislation:

- $631 million recorded as a reduction to Revenues, related to the higher, extended and expanded rebate provisions and the Medicare “coverage gap” discount provision; and
- $362 million recorded in Selling, informational and administrative expenses, related to the fee payable to the federal government. 2014 included a $215 million charge to account for an additional year of the non-tax deductible Branded Prescription Drug Fee in accordance with final regulations issued in the third quarter of 2014 by the IRS. The amount in 2014 also reflected a favorable true-up associated with the final 2013 invoice received from the federal government, which reflected a lower share than that of the initial 2013 invoice.

The final regulations issued by the IRS did not change the payment schedule for the Branded Prescription Drug Fee; accordingly there was no cash flow impact in 2014 from the $215 million charge.

Impacts on our 2013 Results

We recorded the following amounts in 2013 as a result of the U.S. Healthcare Legislation:

- $458 million recorded as a reduction to Revenues, related to the higher, extended and expanded rebate provisions and the Medicare “coverage gap” discount provision; and
- $280 million recorded in Selling, informational and administrative expenses, related to the fee payable to the federal government.

Regulatory Environment/Pricing and Access—Government and Other Payer Group Pressures

Governments, managed care organizations and other payer groups continue to seek increasing discounts on our products through a variety of means, such as leveraging their purchasing power, implementing price controls, and demanding price cuts (directly or by rebate actions). In Europe, Japan, China, Canada, South Korea and some other international markets, governments provide healthcare at low direct cost to patients and regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system. In the U.S., a primary government activity with implications for pharmaceutical pricing is deficit reduction. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, and/or any significant additional taxes or fees that may be imposed on us, as part of any broad deficit-reduction effort could have an adverse impact on our results of operations.

Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. A number of the candidates for the 2016 U.S. presidential elections have introduced such policy proposals, and a November 2015 U.S. Department of Health and Human Services forum dedicated to drug pricing could lead to further proposals. We believe medicines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We continue to work with stakeholders in an effort to ensure access to medicines within an efficient and affordable healthcare system. In addition, certain regulatory changes to be implemented in 2016 may affect Pfizer’s obligations under the Medicaid drug rebate program, but the impact of those changes is not yet known.

The ACA, which expanded the role of the U.S. government as a healthcare payer, is accelerating changes in the U.S. healthcare marketplace, and the potential for additional pricing and access pressures continues to be significant. Many of these developments may impact drug utilization, in particular branded drug utilization. Some employers, seeking to avoid the tax on high-cost health insurance in the ACA originally to be imposed in 2018 (now to be imposed in 2020, per the terms of the fiscal year 2016 omnibus appropriations legislation), are already scaling back healthcare benefits. Some health plans and pharmacy benefit managers are seeking greater pricing predictability from pharmaceutical manufacturers in contractual negotiations. Other health plans and pharmacy benefit managers are increasing their focus on spending on specialty medicines by implementing co-insurance in place of a flat co-payment. Because co-insurance passes on a percentage of a drug’s cost to the patient, this shift has the potential to significantly increase patient out-of-pocket costs.

Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Longer term, we are seeing a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward providers for cost reductions. These new payment models can, at times, lead to lower prices for, and restricted access to, new medicines. At the same time, these models can also expand utilization by encouraging physicians to screen, diagnose and focus on outcomes.

In response to the evolving U.S. and global healthcare spending landscape, we are continuing to work with health authorities, health technology assessment and quality measurement bodies and major U.S. payers throughout the product-development process to better understand how these entities value our compounds and products. Further, we are seeking to develop stronger internal capabilities focused on demonstrating the value of the medicines that we discover or develop, register and manufacture, by recognizing patterns of usage of our medicines and competitor medicines along with patterns of healthcare costs.

Regulatory Environment—Pipeline Productivity

The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our businesses. We have encountered increasing regulatory scrutiny of drug safety and efficacy, even as we continue to gather safety and other data on our products, before and after the products have been launched. Our product lines must be replenished over time in order to offset revenue losses when products lose their market exclusivity, as well as to provide for earnings growth. We devote considerable resources to R&D activities. These activities involve a high degree of risk and cost and may take many years, and
Despite the challenging financial markets, Pfizer maintains a strong financial position. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. Our long-term debt is rated high quality by both Standard & Poor’s (S&P) and Moody’s Investors Service (Moody’s). As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified, available-for-sale debt securities. For further discussion about our financial condition, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this Financial Review.

These and other industry-wide factors that may affect our businesses should be considered along with information presented in the “Forward-Looking Information and Factors That May Affect Future Results” section of this Financial Review and in Part I, Item 1A, “Risk Factors,” of our 2015 Annual Report on Form 10-K.
Our Strategy

We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our products and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize access to patients and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our company’s purpose of innovating to bring therapies to patients that extend and significantly improve their lives. By doing so, we expect to create value for the patients we serve and for our shareholders.

Commercial Operations

We manage our commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments, each of which has been led by a single manager in 2015 and 2014—the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). Effective February 8, 2016, the Innovative Products business is led by a single manager. The Established Products business consists of the Global Established Pharmaceutical segment (GEP), which is also led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof of concept. Each business has a geographic footprint across developed and emerging markets.

Some additional information about each business and operating segment follows:

### Innovative Products Business

**Global Innovative Pharmaceutical segment:**

GIP focuses on developing and commercializing novel, value-creating medicines that significantly improve patients’ lives. Key therapeutic areas include inflammation/immunology, cardiovascular/metabolic, neuroscience/pain and rare diseases and include leading brands such as Xeljanz, Eliquis, Lyrica (U.S. and Japan), Enbrel (outside the U.S. and Canada) and Viagra (U.S. and Canada).

### Established Products Business

**Global Vaccines, Oncology and Consumer Healthcare segment:**

VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets several well-known, over-the-counter (OTC) products. Each of the three businesses in VOC operates as a separate, global business, with distinct specialization in terms of the science and market approach necessary to deliver value to consumers and patients.

**Global Established Pharmaceutical segment:**

GEP includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars and infusion systems.

We expect that the GIP and VOC biopharmaceutical portfolios of innovative, largely patent-protected, in-line and newly launched products will be sustained by ongoing investments to develop promising assets and targeted business development in areas of focus to ensure a pipeline of highly-differentiated product candidates in areas of unmet medical need. The assets managed by these groups are science-driven, highly differentiated and generally require a high-level of engagement with healthcare providers and consumers.

GEP is expected to generate strong consistent cash flow by providing patients around the world with access to effective, lower-cost, high-value treatments. GEP leverages our biologic development, regulatory and manufacturing expertise to seek to advance its biosimilar development portfolio. Additionally, GEP leverages capabilities in formulation development and manufacturing expertise to help advance its generic sterile injectables portfolio. In addition, GEP may also engage in targeted business development to further enable its biosimilar strategies. GEP has the knowledge and resources within R&D to develop small molecules, including injectables, and biosimilars. On September 3, 2015, we acquired Hospira, and its commercial operations are now included within GEP. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income, primarily GEP’s operating results, for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. For additional information about the Hospira acquisition, see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions.

For additional information about our operating structure, see Notes to Consolidated Financial Statements—Note 18. Segment, Geographic and Other Revenue Information: Segment Information.

For additional information about the 2015 performance of each of our operating segments, see the “Analysis of Operating Segment Information” section of this Financial Review.

Following the closing of the pending combination with Allergan, the Vaccines and Oncology businesses are expected to be combined with the Global Innovative Pharmaceutical business and we expect to create a new global business, Global Specialty and Consumer Brands, that includes our Consumer Healthcare business and Allergan’s ophthalmology and aesthetics businesses, as well as Botox Therapeutic and Cosmetic. Allergan’s Anda distribution capabilities and brands in women’s health and anti-infectives are expected to be combined with the Global Established Pharmaceutical business.
Research Operations

We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline that will deliver value in the near term and over time. Our R&D priorities include delivering a pipeline of differentiated therapies with the greatest scientific and commercial promise, innovating new capabilities that can position Pfizer for long-term leadership and creating new models for biomedical collaboration that will expedite the pace of innovation and productivity. To that end, our R&D primarily focuses on six high-priority areas that have a mix of small molecules and large molecules—immunology and inflammation; cardiovascular and metabolic diseases; oncology; vaccines; neuroscience and pain; and rare diseases. Another area of focus is biosimilars. With the acquisition of Hospira, we have expanded our biosimilars pipeline and added R&D capabilities for sterile injectables and infusion systems.

While a significant portion of R&D is done internally through the Worldwide Research and Development (WRD) organization, we continue to seek to enhance our pipeline of potential future products by entering into collaborations, alliance and license agreements with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us to co-develop, license or acquire promising compounds, technologies or capabilities. Collaboration, alliance and license agreements and equity- or debt-based investments allow us to share risk and cost, to access external scientific and technological expertise, and enable us to advance our own products as well as in-licensed or acquired products.

For additional information about R&D by operating segment, see the “Analysis of Operating Segment Information” section of this Financial Review. For additional information about our pending new drug applications and supplemental filings, see the “Analysis of the Consolidated Statements of Income—Product Developments—Biopharmaceuticals” section of this Financial Review. For additional information about recent transactions and strategic investments that we believe have the potential to advance our pipeline and maximize the value of our in-line products, see the “Our Business Development Initiatives” section of this Financial Review.

Business Development

We continue to build on our broad portfolio of businesses and to expand our R&D pipeline through various business development transactions. For additional information about recent transactions and strategic investments that we believe have the potential to advance our pipeline, enhance our product portfolio and maximize the value of our in-line products, see the “Our Business Development Initiatives” section of this Financial Review.

Intellectual Property Rights

We continue to aggressively defend our patent rights against increasingly aggressive infringement whenever appropriate, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access. In addition, we will continue to employ innovative approaches designed to prevent counterfeit pharmaceuticals from entering the supply chain and to achieve greater control over the distribution of our products, and we will continue to participate in the generics market for our products, whenever appropriate, once they lose exclusivity. For additional information about our current efforts to enforce our intellectual property rights, see Notes to Consolidated Financial Statements—Note 17A. Commitments and Contingencies: Legal Proceedings—Patent Litigation. For information on risks related to patent protection and intellectual property claims by third parties, see “Risks Related to Intellectual Property” in Part I. Item 1A “Risk Factors” in our 2015 Annual Report on Form 10-K.

Capital Allocation and Expense Management

We seek to maintain a strong balance sheet and robust liquidity so that we continue to have the financial resources necessary to take advantage of prudent commercial, research and business development opportunities and to directly enhance shareholder value through share repurchases and dividends. For additional information about our financial condition, liquidity, capital resources, share repurchases and dividends, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this Financial Review.

On November 23, 2015, we announced that we have entered into a definitive merger agreement with Allergan, a global pharmaceutical company incorporated in Ireland, under which we have agreed to combine with Allergan in a stock transaction valued at $363.63 per Allergan share, for a total enterprise value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on November 20, 2015 (the last trading day prior to the announcement) and certain other assumptions. See the “Our Business”, “Our Business Development Initiatives” and “Analysis of Financial Condition, Liquidity and Capital Resources” sections of this Financial Review for additional information.


On February 9, 2015, we entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase shares of our common stock. This agreement was entered into under our previously announced share repurchase authorization. In July 2015, we completed the agreement. For additional information, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this Financial Review and Notes to Consolidated Financial Statements—Note 12. Equity. In November 2015, we announced that, consistent with 2015, we expect to execute an approximately $5 billion accelerated share repurchase program in the first half of 2016. We anticipate additional future share repurchases to continue following the consummation of the pending combination with Allergan. The actual size and timing of any such share repurchases will depend on actual and expected financial results.

In December 2015, the Board of Directors authorized a new $11 billion share repurchase program to be utilized over time. Also, on December 14, 2015, our Board of Directors declared a first-quarter 2016 dividend of $0.30 per share, an increase from the $0.28 per-share
We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities. We are especially interested in opportunities in our high-priority therapeutic areas—immunology and inflammation; cardiovascular and metabolic diseases; oncology; vaccines; neuroscience and pain; and rare diseases—and in emerging markets and established products, including biosimilars. We continue to evaluate business development transactions that have the potential to strengthen one or both of our businesses and their capabilities, such as our recent acquisition of Hospira and our pending combination with Allergan, as well as collaborations, and alliance and license agreements with other companies, including our collaborations with Cellectis SA, OPKO Health, Inc. and Merck KGaA. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also consider business development activities that will advance our businesses. We are continuing to consider whether a further separation of our Innovative Products and Established Products businesses would be in the best interests of our shareholders. However, no decision has been made regarding any such potential separation; we anticipate making a decision regarding such potential separation by no later than the end of 2018. For additional information on our business development activities, see Notes to Consolidated Financial Statements—Note 2. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment, Notes to Consolidated Financial Statements—Note 19. Pending Combination with Allergan and the “Significant Accounting Policies and Application of Critical Accounting Estimates—Acquisition of Hospira” section of this Financial Review.

The more significant recent transactions and events are described below:

**Agreement to Combine with Allergan plc (Allergan)—**On November 23, 2015, we announced that we have entered into a definitive merger agreement with Allergan, a global pharmaceutical company incorporated in Ireland.

**Acquisition of Hospira—**On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for approximately $16.1 billion in cash ($15.7 billion, net of cash acquired).

**Acquisition of a Minority Interest in AM-Pharma B.V. (AM-Pharma)—**In April 2015, we acquired a minority equity interest in AM-Pharma, a privately-held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon delivery of the clinical trial report after completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. Results from the current Phase II trial for recAP are expected in 2017. Under the terms of the agreement, we paid $87.5 million for both the exclusive option and the minority equity interest, which was recorded as a cost-method investment in Non-Consolidated Investments and Cost-Method Investment, and we may make additional payments of up to $512.5 million upon exercise of the option and potential launch of any product that may result from this investment.

**Collaboration with OPKO Health, Inc. (OPKO)—**In December 2014, we entered into a collaborative agreement with OPKO to develop and commercialize OPKO’s long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. We have received the exclusive license to commercialize hGH-CTP worldwide. OPKO will have the clinical activities and will be responsible for funding the development programs for the key indications, which include Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications, all postmarketing studies, manufacturing and commercialization activities for all indications, and we will lead the manufacturing activities related to product development. The transaction closed on January 28, 2015, upon termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. In February 2015, we made an upfront payment of $295 million to OPKO, which was recorded in Research and development expenses, and OPKO is eligible to receive up to an additional $275 million upon achievement of certain regulatory milestones. OPKO is also eligible to receive royalty payments associated with the commercialization of hGH-CTP for Adult GHD, which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalty revenue will be tiered and capped at up to a maximum of $275 million in total opex sharing for both hGH-CTP and our product, Genotropin.

**Acquisition of Marketed Vaccines Business of Baxter International Inc. (Baxter)—**On December 1, 2014 (which falls in the first fiscal quarter of 2015 for our international operations), we acquired Baxter’s portfolio of marketed vaccines for a final purchase price of $648 million. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis.

**Collaboration with Merck KGaA—**In November 2014, we entered into a collaborative agreement with Merck KGaA, to jointly develop and commercialize avelumab, the proposed international non-proprietary name for the investigational anti-PD-L1 antibody (MSB0010718C), currently in development as a potential treatment for multiple types of cancer. We and Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA’s broad portfolio of approved and investigational oncology therapies. The collaboration with Merck KGaA has initiated 28 programs, monotherapy and combination trials, including seven pivotal trials in Phase IB/2 or Phase 3 (two in lung cancer, two in gastric cancer, and one in each of bladder cancer, Merkel cell carcinoma and ovarian cancer) and received FDA breakthrough therapy designation for avelumab in metastatic Merkel cell carcinoma. We and Merck KGaA are also combining resources and expertise to advance Pfizer’s anti-PD-1 antibody into...
Phase 1 trials. Under the terms of the agreement, in the fourth quarter of 2014, we made an upfront payment of $850 million to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately $2.0 billion. Both companies will jointly fund all development and commercialization costs, and split equally any profits generated from selling any anti-PD-L1 or anti-PD-1 products from this collaboration. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and several other key markets, and co-promotion activities were initiated in key select markets in 2015. In 2014, we recorded $1.2 billion of Research and development expenses associated with this collaborative arrangement, composed of the $850 million upfront cash payment as well as an additional amount of $309 million, reflecting the estimated fair value of the co-promotion rights given to Merck KGaA.

- **Acquisition of InnoPharma, Inc. (InnoPharma)**—On September 24, 2014, we completed our acquisition of InnoPharma, a privately-held pharmaceutical development company, for an upfront cash payment of $225 million and contingent consideration of up to $135 million.

- **License from Cellectis SA (Cellectis)**—In June 2014, we entered into a global arrangement with Cellectis to develop Chimeric Antigen Receptor T-cell immunotherapies in the field of oncology directed at select cellular surface antigen targets. In August 2014, in connection with this licensing agreement, we made an upfront payment of $80 million to Cellectis, which was recorded in Research and development expenses. We will also fund research and development costs associated with 15 Pfizer-selected targets and, for the benefit of Cellectis, a portion of the R&D costs associated with four Cellectis-selected targets within the arrangement. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per product that results from the Pfizer-selected targets. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer.

- **Investment in ViiV Healthcare Limited (ViiV)**—On January 21, 2014, the European Commission approved Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV, an equity-method investee. This approval, in accordance with the agreement between GlaxoSmithKline plc and Pfizer, triggered a reduction in our equity interest in ViiV from 12.6% to 11.7% and an increase in GlaxoSmithKline plc’s equity interest in ViiV from 77.4% to 78.3%, effective April 1, 2014. As a result, in 2014, we recognized a loss of approximately $30 million in Other (income)/deductions—net. We account for our investment in ViiV under the equity method due to the significant influence that we continue to have through our board representation and minority veto rights.

- **Collaboration with Eli Lilly & Company (Lilly)**—In October 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer’s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. Following the decision by the FDA in March 2015 to lift the partial clinical hold on the tanezumab development program, we received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which is recorded as deferred revenue in our consolidated balance sheet and is being recognized into Other (income)/deductions—net over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015, which will consist of six studies in approximately 7,000 patients across osteoarthritis, chronic low back pain and cancer pain. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones.

- **Divestiture of Zoetis**—On June 24, 2013, we completed the full disposition of Zoetis. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.

- **Collaboration with Merck & Co., Inc. (Merck)**—In April 2013, we announced that we entered into a worldwide (except Japan) collaboration agreement with Merck for the development and commercialization of Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor currently in Phase 3 development for the treatment of type 2 diabetes.

- **Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)**—On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun), a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. In the first quarter of 2013, we and Hisun contributed certain assets to Hisun Pfizer. Hisun Pfizer is 49% owned by Pfizer and 51% owned by Hisun. Our contributions constituted a business, as defined by U.S. GAAP, and in 2013, we recognized a pre-tax gain of approximately $459 million in Other (income)/deductions—net. The decline in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, as a result of lower than expected recent performance, increased competition, a slowdown in the China economy in relation to their products, as well as changes in the regulatory environment.

- **License of Nexium OTC Rights**—In August 2012, we entered into an agreement with AstraZeneca PLC (AstraZeneca) for the exclusive, global, over-the-counter (OTC) rights for Nexium, a leading prescription drug approved to treat the symptoms of gastroesophageal reflux disease. In connection with this Consumer Healthcare licensing agreement, we made an upfront payment of $250 million to AstraZeneca, which was recorded in Research and development expenses when incurred. On May 27, 2014, we launched Nexium 24HR in the U.S., and on July 11, 2014, we paid AstraZeneca a related $200 million product launch milestone payment. On August 1, 2014, we launched Nexium Control in Europe, and on September 15, 2014, we paid AstraZeneca a related $50 million product launch milestone payment. These post-approval milestone payments were recorded in Identifiable intangible assets, less accumulated amortization and are being amortized over the estimated useful life of the Nexium brand. Included in Other current liabilities at December 31, 2015 are accrued milestone payments to AstraZeneca of $93 million. AstraZeneca is eligible to receive additional milestone payments of up to $200 million, based on the level of worldwide sales as well as quarterly royalty payments based on worldwide sales.
The following table provides our financial guidance for full-year 2016(a), (b):

<table>
<thead>
<tr>
<th>Description</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported revenues</td>
<td>$49.0 to $51.0 billion</td>
</tr>
<tr>
<td>Adjusted cost of sales as a percentage of reported revenues</td>
<td>21.0% to 22.0%</td>
</tr>
<tr>
<td>Adjusted selling, informational and administrative expenses</td>
<td>$13.2 to $14.2 billion</td>
</tr>
<tr>
<td>Adjusted research and development expenses</td>
<td>$7.3 to $7.8 billion</td>
</tr>
<tr>
<td>Adjusted other (income)/deductions</td>
<td>Approximately ($300 million) of income</td>
</tr>
<tr>
<td>Effective tax rate on adjusted income</td>
<td>Approximately 24.0%</td>
</tr>
<tr>
<td>Reported diluted Earnings per Share (EPS)</td>
<td>$1.54 to $1.67</td>
</tr>
<tr>
<td>Adjusted diluted EPS</td>
<td>$2.20 to $2.30</td>
</tr>
</tbody>
</table>

The following table provides a reconciliation of 2016 Adjusted income and Adjusted diluted EPS guidance to the 2016 Reported net income attributable to Pfizer Inc. and Reported diluted EPS attributable to Pfizer Inc. common shareholders guidance:

<table>
<thead>
<tr>
<th>Description</th>
<th>Full-Year 2016 Guidance(a), (b)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Net Income</td>
</tr>
<tr>
<td>Adjusted income/diluted EPS guidance(b)</td>
<td>$13.6 - $14.2</td>
</tr>
<tr>
<td>Purchase accounting impacts of transactions completed as of December 31, 2015</td>
<td>(2.8)</td>
</tr>
<tr>
<td>Restructuring, implementation and other acquisition-related costs</td>
<td>(0.7) - (0.9)</td>
</tr>
<tr>
<td>Business and legal entity alignment costs</td>
<td>(0.4)</td>
</tr>
<tr>
<td>Reported net income attributable to Pfizer Inc./diluted EPS guidance</td>
<td>$9.5 - $10.3</td>
</tr>
</tbody>
</table>

(a) The 2016 financial guidance reflects the following:
- Does not assume the completion of any business-development transactions not completed as of December 31, 2015, including any one-time upfront payments associated with such transactions. Our 2016 financial guidance excludes any impact from the pending combination with Allergan. The transaction is expected to close during the second half of 2016.
- Excludes the potential effects of the resolution of litigation-related matters not substantially resolved as of February 12, 2016.
- Exchange rates assumed are as of mid-January 2016.
- Guidance for 2016 reported revenues reflects the anticipated negative impact of $2.3 billion due to recent and expected generic competition for certain products that have recently lost or are anticipated to soon lose patent protection.
- Guidance for 2016 reported revenues also reflects the anticipated negative impact of $2.3 billion as a result of unfavorable changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2015, including $0.8 billion due to the estimated significant negative currency impact related to Venezuela. The anticipated negative impact on reported and adjusted diluted EPS resulting from unfavorable changes in foreign exchange rates compared to foreign exchange rates from 2015 is approximately $0.16, including $0.07 due to the estimated significant negative currency impact related to Venezuela.
- Guidance for reported and adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 6.2 billion shares.

(b) For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the “Adjusted Income” section of this Financial Review.

For additional information about our actual and anticipated costs and cost savings associated with our cost-reduction initiatives announced in 2014, the Hospira acquisition, and our global commercial structure, which was established in 2014, see the “Costs and Expenses—Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this Financial Review and Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Our 2016 financial guidance is subject to a number of factors and uncertainties—as described in the “Our Operating Environment”, “Our Strategy” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this Financial Review and Part I, Item 1A, “Risk Factors,” of our 2015 Annual Report on Form 10-K.

SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS

For a description of our significant accounting policies, see Notes to Consolidated Financial Statements—Note 1. Basis of Presentation and Significant Accounting Policies. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: (i) Acquisitions (Note 1D); (ii) Fair Value (Note 1E); (iii) Revenues (Note 1G); (iv) Asset Impairments (Note 1K); (v) Income Tax Contingencies (Note 1O); (vi) Pension and Postretirement Benefit Plans (Note 1P); and Legal and Environmental Contingencies (Note 1Q).

Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. See also Notes to Consolidated Financial Statements—Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions for a discussion about the risks associated with estimates and assumptions.
Acquisitions and Fair Value

For a discussion about the application of Fair Value to our recent acquisitions, see “Acquisition of Hospira” below and Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions.

For a discussion about the application of Fair Value to our investments, see Notes to Consolidated Financial Statements—Note 7A. Financial Instruments: Selected Financial Assets and Liabilities.

For a discussion about the application of Fair Value to our benefit plan assets, see Notes to Consolidated Financial Statements—Note 11D. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Plan Assets.

For a discussion about the application of Fair Value to our asset impairment reviews, see “Asset Impairment Reviews” below.

Revenues

Our gross product revenues are subject to a variety of deductions that are generally estimated and recorded in the same period that the revenues are recognized, and primarily represent rebates, chargebacks and sales allowances to government agencies, wholesalers/distributors and managed care organizations with respect to our pharmaceutical products. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period, and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period.

Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by program, type of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters.

Asset Impairment Reviews

We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in the Notes to Consolidated Financial Statements—Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.

Examples of events or circumstances that may be indicative of impairment include:

- A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.
- A significant adverse change in the extent or manner in which an asset is used. For example, restrictions imposed by the FDA or other regulatory authorities could affect our ability to manufacture or sell a product.
- A projection or forecast that indicates losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor’s product that results in a significant loss of market share or the inability to achieve the previously projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payers. For in-process research and development (IPR&D) projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.

Identifiable Intangible Assets

As a result of our identifiable intangible asset impairment review work, we recognized a number of impairments of identifiable intangible assets for the years ended December 31, 2015, 2014 and 2013. See Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net.

When we are required to determine the fair value of intangible assets other than goodwill, we use an income approach, specifically the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the asset, which includes the application of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, in general, intangible assets other than goodwill that are most at risk of impairment include IPR&D assets (approximately $1.2 billion as of December 31, 2015) and newly
When we estimate the fair value of our Consumer Healthcare reporting unit, we use a combination of approaches and methods. We have both Internal Revenue Code qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees.

Factors That May Affect Future Results

As a result of our goodwill impairment review work, we concluded that none of our goodwill was impaired as of December 31, 2015, and we do not believe the risk of impairment is significant at this time.

Goodwill

As a result of our goodwill impairment review work, we concluded that none of our goodwill was impaired as of December 31, 2015, and we do not believe the risk of impairment is significant at this time.

When we are required to determine the fair value of a reporting unit, as appropriate for the individual reporting unit, we mainly use the income approach but we may also use the market approach, or a weighted-average combination of both approaches.

• The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, the method that we use is the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

• The market approach is a historical approach to estimating fair value and relies primarily on external information. Within the market approach are two methods that we may use:
  ◦ Guideline public company method—this method employs market multiples derived from market prices of stocks of companies that are engaged in the same or similar lines of business and that are actively traded on a free and open market and the application of the identified multiples to the corresponding measure of our reporting unit’s financial performance.
  ◦ Guideline transaction method—this method relies on pricing multiples derived from transactions of significant interests in companies engaged in the same or similar lines of business and the application of the identified multiples to the corresponding measure of our reporting unit’s financial performance.

The market approach is only appropriate when the available external information is robust and deemed to be a reliable proxy for the specific reporting unit being valued; however, these assessments may prove to be incomplete or inaccurate. Some of the more significant estimates and assumptions inherent in this approach include: the selection of appropriate guideline companies and transactions and the determination of applicable premiums and discounts based on any differences in ownership percentages, ownership rights, business ownership forms or marketability between the reporting unit and the guideline companies and transactions.

Specifically:

• When we estimate the fair value of our four biopharmaceutical reporting units, we rely solely on the income approach. We use the income approach exclusively as the use of the comparable guideline company method is not practical or reliable. For the income approach, we use the discounted cash flow method.

• When we estimate the fair value of our Consumer Healthcare reporting unit, we use a combination of approaches and methods. We use the income approach and the market approach, which we weight equally in our analysis. We weight them equally as we have equal confidence in the appropriateness of the approaches for this reporting unit. For the income approach, we use the discounted cash flow method and for the market approach, we use both the guideline public company method and the guideline transaction method, which we weight equally to arrive at our market approach value.

For all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the “Forward-Looking Information and Factors That May Affect Future Results” section of this Financial Review and Part I. Item 1A “Risk Factors” in our 2015 Annual Report on Form 10-K.

Benefit Plans

The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both Internal Revenue Code qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees.
The accounting for benefit plans is highly dependent on actuarial estimates, assumptions and calculations, which can result from a complex series of judgments about future events and uncertainties. The assumptions and actuarial estimates required to estimate the employee benefit obligations for the defined benefit and postretirement plans include the discount rate; expected salary increases; certain employee-related factors, such as turnover, retirement age and mortality (life expectancy); expected return on assets; and healthcare cost trend rates.

In the fourth quarter of 2014, we approved a change, effective January 1, 2016, to the U.S. postretirement medical plan to transfer certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy (Employer Group Waiver Plan). This change resulted in a decrease to the postretirement benefit obligation of approximately $600 million as of December 31, 2014.

As of December 31, 2015, the noncurrent portion of our pension benefit obligations, net, and our postretirement benefit obligations, net decreased, in the aggregate, by approximately $2.1 billion compared to December 31, 2014. The decrease reflects, among other things, an increase in our discount rate assumptions used in the measurement of the plan obligations, a $1 billion voluntary contribution made in January, 2015, a plan amendment approved in June 2015 that introduced a cap on costs for certain groups within the U.S. postretirement medical plan, and a rise in the comparative strength of the U.S. dollar, as compared to other currencies.

Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.

<table>
<thead>
<tr>
<th>Assumption</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected annual rate of return on plan assets</td>
<td>8.0%</td>
<td>8.3%</td>
<td>8.5%</td>
</tr>
<tr>
<td>Actual annual rate of return on plan assets</td>
<td>(0.8)</td>
<td>6.8</td>
<td>11.3</td>
</tr>
<tr>
<td>Discount rate used to measure the plan obligations</td>
<td>4.5</td>
<td>4.2</td>
<td>5.2</td>
</tr>
</tbody>
</table>

International Pension Plans

<table>
<thead>
<tr>
<th>Assumption</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected annual rate of return on plan assets</td>
<td>5.2</td>
<td>5.5</td>
<td>5.8</td>
</tr>
<tr>
<td>Actual annual rate of return on plan assets</td>
<td>3.6</td>
<td>13.2</td>
<td>13.1</td>
</tr>
<tr>
<td>Discount rate used to measure the plan obligations</td>
<td>3.1</td>
<td>3.0</td>
<td>3.9</td>
</tr>
</tbody>
</table>

(a) For detailed assumptions associated with our benefit plans, see Notes to Consolidated Financial Statements—Note 11B. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Actuarial Assumptions.

Expected Annual Rate of Return on Plan Assets

The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and our long-term assessment of forward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our targeted asset allocation in our respective plans.

The expected annual rate of return on plan assets for our U.S. plans and the majority of our international plans is applied to the fair value of plan assets at each year-end and the resulting amount is reflected in our net periodic benefit costs in the following year. In January 2016, Pfizer made a voluntary contribution of $1.0 billion to plan assets. In 2016, this contribution will be included in the plan asset balance for purposes of determining the expected return on plan assets.

The following table illustrates the sensitivity to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets, holding all other assumptions constant (in millions, pre-tax):

<table>
<thead>
<tr>
<th>Assumption</th>
<th>Change</th>
<th>Increase in 2016 Net Periodic Benefit Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected annual rate of return on plan assets</td>
<td>50 basis point decline</td>
<td>$98</td>
</tr>
</tbody>
</table>

The actual return on plan assets resulted in a net gain on our plan assets of approximately $163 million during 2015.

Discount Rate Used to Measure Plan Obligations

The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated and modified, as required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect the rates at which the pension benefits could be effectively settled. The discount rate used to measure the plan obligations for our international plans is determined at least annually by reference to investment grade corporate bonds, rated AA/Aa or better, including, when there are sufficient data, a yield-curve approach. These discount rate determinations are made in consideration of local requirements.

The measurement of the plan obligations at the end of the year will affect the amount of service cost, interest cost and amortization expense reflected in our net periodic benefit costs in the following year.
Acquisition of Hospira

Description of Transaction

On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for approximately $16.1 billion in cash ($15.7 billion, net of cash acquired).

Recording of Assets Acquired and Liabilities Assumed

Our acquisition of Hospira has been accounted for using the acquisition method of accounting, which generally requires that most assets acquired and liabilities assumed be recorded at fair value as of the acquisition date. A single estimate of fair value results from a complex series of judgments about future events and uncertainties and relies heavily on estimates and assumptions. Our judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. For instance, the determination of asset lives can impact our results of operations as different types of assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.

For the provisional amounts recognized for the Hospira assets acquired and liabilities assumed as of the acquisition date, see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions. The estimated values are not yet finalized and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses. We expect to finalize the amounts of assets acquired and liabilities assumed as soon as possible but no later than one year from the acquisition date. The following amounts are subject to change:

- Amounts for certain balances included in working capital (excluding inventories), certain investments and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.
- Amounts for intangibles, inventory and property, plant and equipment, pending finalization of valuation efforts for acquired intangible assets as well as the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain property, plant and equipment assets.
- Amounts for income tax assets, receivables and liabilities, pending the filing of Hospira pre-acquisition tax returns and the receipt of certain information including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.

Below is a summary of the methodologies and significant assumptions used in estimating the fair value of certain classes of assets and liabilities of Hospira.

For financial instruments acquired from Hospira, our valuation approach was consistent with our valuation methodologies used for our legacy Pfizer financial instruments. For additional information on the valuation of our financial instruments, see Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

Inventories—The fair value of acquired inventory ($1.9 billion) was determined as follows:

- **Finished goods**—Estimated selling price, less an estimate of costs to be incurred to sell the inventory, and an estimate of a reasonable profit allowance for that selling effort.
- **Work in process**—Estimated selling price of an equivalent finished good, less an estimate of costs to be incurred to complete the work-in-process inventory, an estimate of costs to be incurred to sell the inventory and an estimate of a reasonable profit allowance for those manufacturing and selling efforts.
- **Raw materials and supplies**—Estimated cost to replace the raw materials and supplies.

The fair value of inventory will be recognized in our results of operations as the inventory is sold. Based on internal forecasts and estimates of months of inventory on hand, we expect that the acquisition date inventory will be substantially sold and recognized in Cost of sales over a weighted-average estimated period of approximately eight months after the acquisition date.
Some of the more significant estimates and assumptions inherent in the estimate of the fair value of inventory include stage of completion, costs to complete, costs to dispose and selling price. All of these judgments and estimates can materially impact our results of operations.

Property, Plant and Equipment—The fair value of acquired property, plant and equipment is determined using a variety of valuation approaches, depending on the nature of the asset and the quality of available information. The fair value of acquired property, plant and equipment was primarily determined as follows:

- **Land**—Market, a sales comparison approach that measures value of an asset through an analysis of sales and offerings of comparable property.
- **Buildings, Machinery and equipment and Furniture and fixtures**—Replacement cost, an approach that measures the value of an asset by estimating the cost to acquire or construct comparable assets. For buildings that are not highly specialized or that could be income producing if leased to a third party, we also considered market and income factors.
- **Construction in progress**—Replacement cost, generally assumed to equal historical book value.

The amounts recorded for the major components of acquired property, plant and equipment are as follows:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Useful Lives (Years)</th>
<th>Amounts Recognized As of Acquisition Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Land</td>
<td>$111</td>
<td></td>
</tr>
<tr>
<td>Buildings</td>
<td>33—50</td>
<td>556</td>
</tr>
<tr>
<td>Machinery and equipment</td>
<td>8—20</td>
<td>1,060</td>
</tr>
<tr>
<td>Furniture, fixtures and other</td>
<td>3—12</td>
<td>141</td>
</tr>
<tr>
<td>Construction in progress</td>
<td></td>
<td>542</td>
</tr>
<tr>
<td>Total Property, plant and equipment</td>
<td></td>
<td>$2,410</td>
</tr>
</tbody>
</table>

The fair value of property, plant and equipment will be recognized in our results of operations over the expected useful life of the individual depreciable assets.

Some of the more significant inputs, estimates and assumptions inherent in the estimate of the fair value of property, plant and equipment include the nature, age, condition or location of the land, buildings, machinery and equipment, furniture and fixtures, and construction in progress, as applicable, as well as the estimate of market and replacement cost and the determination of the appropriate valuation premise, in-use or in-exchange. The in-use valuation premise assesses the value of an asset when used in combination with other assets (for example, on an installed basis), while the in-exchange valuation assesses the value of an asset on a stand alone basis. All of these judgments and estimates can materially impact our results of operations.

Identifiable Intangible Assets—The fair value of acquired identifiable intangible assets generally is determined using an income approach. This method starts with a forecast of all of the expected future net cash flows associated with the asset and then adjusts the forecast to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

The fair value of acquired identifiable intangible assets is composed of finite-lived developed technology rights with a weighted-average life of approximately 17 years ($7.7 billion); other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ($550 million); and IPR&D assets ($995 million). For information about our identifiable intangible assets, see Notes to Consolidated Financial Statements—Note 10. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

As of the acquisition date, we recognized IPR&D assets of $660 million for biosimilar programs and $335 million for sterile injectable programs.

**Biosimilar IPR&D Acquired Assets:**

- In order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, in September 2015 we opted to return to Celltrion Inc. and Celltrion Healthcare, Co., Ltd. (collectively Celltrion) rights that Hospira had previously acquired to potential biosimilars to Ritu-xan® (rituximab) and Herceptin® (trastuzumab). In connection with the return of these rights, we wrote-off these IPR&D assets, totaling $170 million. See the “Product Developments—Biopharmaceutical” section of this Financial Review and Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information.

- The higher value remaining biosimilar IPR&D assets acquired from Hospira have been submitted to the FDA for approval and include the following potential biosimilars for (i) epoetin alfa (treatment of anemia in dialysis and oncology applications) and (ii) infliximab (rheumatoid arthritis and gastrointestinal disorders). These biosimilars and filgrastim (oncology) are already available in certain markets outside the U.S. Filgrastim in the U.S. market and other biosimilar IPR&D assets acquired from Hospira are in late-stage development. See the “Product Developments—Biopharmaceutical” section of this Financial Review for additional information about these programs.

**Sterile Injectable IPR&D Acquired Assets:**

- The sterile injectable IPR&D assets acquired from Hospira are in various therapeutic areas including anti-infectives, oncology, cardiovascular and neurology, among others. The sterile injectable IPR&D assets are in various stages of development with anticipated launch dates across 2016, 2017 and 2018.

The fair value of finite-lived identifiable intangible assets will be recognized in our results of operations over the expected useful life of the individual assets.
Some of the more significant estimates and assumptions inherent in the estimate of the fair value of identifiable intangible assets include all assumptions associated with forecasting product profitability from the perspective of a market participant.

Specifically:

- **Revenue**—We use historical, forecast, industry or other sources of market data including estimates of sales volume, selling prices, market penetration, market share and year-over-year growth rates over the product’s life cycle.

- **Cost of sales, Sales and marketing expenses, General and administrative expenses**—We use historical, forecast, industry or other sources of market data to estimate the costs associated with the identifiable intangible asset over the product’s life cycle.

- **R&D expenses**—In the case of approved products, we estimate the appropriate level of ongoing R&D support, and for unapproved compounds, we estimate the amount and timing of costs to develop the R&D into viable products.

- **Estimated life of the asset**—We assess the asset's life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory or economic barriers to entry, expected changes in standards of practice for indications addressed by the asset, as well as obsolescence factors and estimated contract renewal rates.

- **Inherent risk**—We use a discount rate that is primarily based on the weighted-average cost of capital with an additional premium to reflect the risks associated with the specific intangible asset, such as country risks (political, inflation, currency and property risks) and commercial risks. In addition, for unapproved assets, an additional risk factor is added for the risk of technical and regulatory success, called the probability of technical and regulatory success (PTRS).

- **The discount rates used in the intangible asset valuations ranged from 11% to 16%, and the estimated cash flows were projected over periods extending up to 20 years or more. For IPR&D assets, the PTRS rates ranged from 44% to 88%. Within this broad range, we recorded approximately $20 million of assets with a PTRS of 44%, $220 million of assets with a PTRS of 45% to 75% and $755 million of assets with a PTRS above 75% ($585 million after the write-off of the acquired biosimilar IPR&D assets discussed above). All of these judgments and estimates can materially impact our results of operations.**

For IPR&D assets, the risk of failure has been factored into the fair value measure and there can be no certainty that these assets ultimately will yield a successful product.

**Contingencies**—For acquisition date contingencies, see Notes to Consolidated Financial Statements—Note 2. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions.
### ANALYSIS OF THE CONSOLIDATED STATEMENTS OF INCOME

**Revenues—Overview**

Total revenues were $48.9 billion in 2015, a decrease of 2% compared to 2014, which reflects an operational increase of $3.0 billion, or 6%, more than offset by the unfavorable impact of foreign exchange of $3.8 billion, or 8%, in 2015 compared to 2014. The operational increase was primarily the result of:

- the performance of several key products in developed markets, including the continued strong uptake of Prevnar 13 among adults (largely in the U.S.), Ibrance (nearly all in the U.S.), Eliquis, Lyrica (GIP) (primarily in the U.S. and Japan), Xeljanz (primarily in the U.S.), Viagra (GIP) (primarily in the U.S.) and Nexium 24HR (primarily in the U.S.) (collectively, up approximately $4.1 billion);
- inclusion of legacy Hospira operations of $1.5 billion;
- a 7% operational increase in revenues in emerging markets, reflecting continued strong operational growth, primarily from Prevenar 13, Lipitor and Enbrel (up approximately $810 million); and
- inclusion of the vaccines acquired from Baxter of $178 million,

partially offset by:

- the loss of exclusivity and immediate multi-source generic competition for Celebrex in the U.S. in December 2014 and certain other developed markets (down approximately $1.8 billion), and the loss of exclusivity for Lyrica (GEP) in certain developed Europe markets (down approximately $420 million), for Zyvox in the U.S. (down approximately $420 million), for Rapamune in the U.S. (down approximately $120 million) and for certain other products (collectively, down approximately $530 million);
- the performance of certain other products in developed markets and BeneFIX in the U.S. (collectively, down approximately $370 million); and
- the termination of the Spiriva co-promotion collaboration in certain countries (down approximately $100 million).

Total revenues were $49.6 billion in 2014, a decrease of 4% compared to 2013, which reflects an operational decrease of $1.1 billion, or 2%, and the unfavorable impact of foreign exchange of approximately $912 million, or 8%, in 2014 compared to 2013. The operational decrease was primarily the result of:

- the expiration of the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada (approximately $1.4 billion);
Pfizer Inc. and Subsidiary Companies

2015 Financial Report

- the loss of exclusivity and subsequent multi-source generic competition for Detrol LA, Celebrex and Geodon in the U.S., Viagra in most major European markets, and Aricept and Lyrica in Canada (aggregate decline of approximately $937 million) and certain other products (approximately $300 million);
- the continued erosion of branded Lipitor in the U.S. and most other developed markets due to generic competition and the operational decline of certain products, including Norvasc, Effexor, atorvastatin, Metaxalone, Zosyn/Tazocin, Ziprasidone, Genotropin, Tygacil, Centrum, Advil and Vfend (approximately $938 million); and
- the ongoing termination of the Spiriva collaboration in certain countries (approximately $490 million), partially offset by:
  - the operational growth of certain products in certain developed markets, including Lyrica, Prevnar, Eliquis, Xeljanz, Xalkori, Inlyta and Nexium 24HR in the U.S. as a result of its May 2014 launch, among others (approximately $1.8 billion); and
  - a 7% operational increase in revenues in emerging markets (approximately $900 million), including strong operational growth from Prevenar as well as from Lipitor, primarily in China, and from Enbrel, primarily in Latin America.

See the “Intellectual Property Rights and Collaboration/Licensing Rights” section of this Financial Report for information about (i) recent losses of product exclusivity impacting product revenues, (ii) recent and expected losses of collaboration rights impacting alliance revenues and (iii) losses and expected losses of product exclusivity in 2016.

In addition, we expect to lose exclusivity for various other products in various markets over the next few years. For additional information, see the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business”, of our 2015 Annual Report on Form 10-K.

We have significant operations outside the U.S., with revenues exceeding $500 million in the following number of countries:

![Number of Non-U.S. Countries with $500MM+ Revenues](chart)

The U.S. and Japan are our two largest national markets:

![Revenues by Market](chart)

Our policy relating to the supply of pharmaceutical inventory at domestic wholesalers, and in major international markets, is to generally maintain stocking levels under one month on average and to keep monthly levels consistent from year to year based on patterns of utilization. We historically have been able to closely monitor these customer stocking levels by purchasing information from our customers directly or by obtaining other third-party information. We believe our data sources to be directionally reliable but cannot verify their accuracy. Further, as we do not control this third-party data, we cannot be assured of continuing access. Unusual buying patterns and utilization are promptly investigated.

Revenue Deductions

Our gross product revenues are subject to a variety of deductions that are generally estimated and recorded in the same period that the revenues are recognized, and primarily represent rebates, chargebacks and sales allowances to government agencies, wholesalers/distributors and managed care organizations with respect to our pharmaceutical products. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period.

Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year
individual product growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by program, type of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters.

The following table provides information about deductions from revenues:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>Medicare rebates&lt;sup&gt;a&lt;/sup&gt;</td>
<td>$1,002</td>
</tr>
<tr>
<td>Medicaid and related state program rebates&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1,263</td>
</tr>
<tr>
<td>Performance-based contract rebates&lt;sup&gt;a&lt;/sup&gt;,&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2,253</td>
</tr>
<tr>
<td>Chargebacks&lt;sup&gt;c&lt;/sup&gt;</td>
<td>4,961</td>
</tr>
<tr>
<td>Sales allowances&lt;sup&gt;d&lt;/sup&gt;</td>
<td>4,200</td>
</tr>
<tr>
<td>Sales returns and cash discounts</td>
<td>1,385</td>
</tr>
<tr>
<td><strong>Total&lt;sup&gt;e&lt;/sup&gt;</strong></td>
<td><strong>$15,014</strong></td>
</tr>
</tbody>
</table>

<sup>a</sup> Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.

<sup>b</sup> Performance-based contract rebates include contract rebates with managed care customers within the U.S., including health maintenance organizations and pharmacy benefit managers, who receive rebates based on the achievement of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted performance for specific products or sales milestones.

<sup>c</sup> Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.

<sup>d</sup> Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.

<sup>e</sup> For 2015, associated with the following segments: GIP ($4.3 billion); VOC ($1.5 billion); and GEP ($9.1 billion). For 2014, associated with the following segments: GIP ($3.3 billion); VOC ($1.2 billion); and GEP ($9.1 billion). For 2013, associated with the following segments: GIP ($2.8 billion); VOC ($1.0 billion); and GEP ($8.9 billion).

The total deductions from revenues for 2015 increased 10% compared to 2014, primarily as a result of:

- an increase in chargebacks from certain Innovative Business products, GEP products including products that have lost exclusivity in the U.S. during 2015, as well as the addition in 2015 of Hospira sterile injectables, which are subject to chargebacks; and
- an increase in Medicaid and related state program rebates, primarily as a result of updated estimates of sales related to these programs, and, a decrease in Managed Medicaid estimated rebates in the second quarter of 2014, partially offset by:
  - a decrease in sales allowances primarily in Asia and Europe. In Asia, the decrease is due to lower Lipitor sales and the end of a partnership arrangement for Caduet. In Europe, price declines primarily on GEP products were driven by government decrees that progressively reduce pricing on products that have lost exclusivity.

For additional rebate accrual information, see Notes to Consolidated Financial Statements—Note 1G. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable.

Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $3.9 billion as of December 31, 2015, of which approximately $2.6 billion is included in Other current liabilities, $272 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Trade accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $3.4 billion as of December 31, 2014, of which approximately $2.0 billion is included in Other current liabilities, $300 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Trade accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet. Total accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts as of December 31, 2015 increased by approximately $500 million compared to December 31, 2014, primarily due to the addition of Hospira accruals.
Revenues by Segment and Geographic Area

The following table provides worldwide revenues by operating segment and geographic area:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating Segments</strong>(a):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIP</td>
<td>$13,954</td>
<td>$13,861</td>
<td>$14,317</td>
<td>$6,946</td>
<td>$6,243</td>
<td>$6,610</td>
<td>$7,008</td>
<td>$7,619</td>
<td>$7,507</td>
<td>1</td>
<td>(3)</td>
<td>(8)</td>
<td>(8)</td>
<td>1</td>
</tr>
<tr>
<td>VOC</td>
<td>12,803</td>
<td>10,144</td>
<td>9,285</td>
<td>7,500</td>
<td>4,715</td>
<td>4,122</td>
<td>5,303</td>
<td>5,428</td>
<td>5,163</td>
<td>26</td>
<td>9</td>
<td>14</td>
<td>(2)</td>
<td>5</td>
</tr>
<tr>
<td>GEP</td>
<td>21,587</td>
<td>25,149</td>
<td>27,619</td>
<td>7,030</td>
<td>7,903</td>
<td>9,217</td>
<td>14,557</td>
<td>17,245</td>
<td>18,400</td>
<td>(14)</td>
<td>(9)</td>
<td>(11)</td>
<td>(14)</td>
<td>(6)</td>
</tr>
<tr>
<td>Other**(b)**</td>
<td>48,345</td>
<td>49,154</td>
<td>51,221</td>
<td>21,476</td>
<td>18,861</td>
<td>20,149</td>
<td>26,868</td>
<td>30,292</td>
<td>31,070</td>
<td>(2)</td>
<td>(4)</td>
<td>(6)</td>
<td>(11)</td>
<td>(3)</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td>$48,051</td>
<td>$49,605</td>
<td>$51,584</td>
<td>$21,704</td>
<td>$19,073</td>
<td>$20,274</td>
<td>$27,147</td>
<td>$30,532</td>
<td>$31,310</td>
<td>(2)</td>
<td>(4)</td>
<td>(6)</td>
<td>(11)</td>
<td>(2)</td>
</tr>
</tbody>
</table>

(a) GIP = the Global Innovative Pharmaceutical segment; VOC = the Global Vaccines, Oncology and Consumer Healthcare segment; and GEP = the Global Established Pharmaceutical segment. On September 3, 2015, we acquired Hospira and its commercial operations are now included within GEP. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income, primarily GEP’s operating results, for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.

(b) Includes revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and also includes the revenues related to our manufacturing and supply agreements with Zoetis Inc. (Zoetis).

Revenues

We recorded direct product sales of more than $1 billion for each of seven products in 2015, and for each of ten products in 2014 and 2013. We recorded more than $1 billion in Alliance revenues in 2015 (primarily Eliquis) and 2013. These direct product sales and alliance revenues relate to our manufacturing and supply agreements with Zoetis.

2015 v. 2014

See the Revenues—Overview section of this Analysis of the Consolidated Statements of Income for a discussion of performance of worldwide revenues.

Geographically,

- in the U.S., revenues increased $2.6 billion, or 14%, in 2015, compared to 2014, reflecting, among other things:
  - the performance of several key products, including Prevnar 13 primarily in adults (up approximately $1.9 billion), Ibrance (which was launched in the U.S. in February 2015, up approximately $720 million), as well as Lyrica (GIP), Eliquis, Xeljanz, Viagra (GIP) and Nexium 24HR (collectively, up approximately $1.0 billion in 2015), and
  - the inclusion of four months of legacy Hospira U.S. operations of $1.2 billion in 2015, partially offset by:
    - losses of exclusivity and associated multi-source generic competition forCelebrex in the U.S. in December 2014 (down approximately $1.6 billion in 2015);
    - the loss of exclusivity for Zyvox and Rapamune, as well as the termination of our Spiriva co-promotion collaboration (collectively, down approximately $620 million in 2015); and
    - the performance of Lipitor and Benefix (collectively, down approximately $160 million in 2015).
- in our international markets, revenues decreased $3.4 billion, or 11%, in 2015, compared to 2014. Foreign exchange unfavorably impacted international revenues by approximately $3.8 billion, or 12% in 2015. Operationally, revenues increased by $402 million or 1%, in 2015 compared to 2014 reflecting, among other things:
  - the operational increase in revenues in emerging markets, reflecting continued strong operational growth primarily from the Innovative Products business, including Prevenar and Enbrel, among other products, and Lipitor (up approximately $600 million in 2015); and
  - higher revenues in developed markets for Eliquis and Lyrica (GIP), as well as from vaccines acquired in December 2014 from Baxter (in Europe) (collectively, up approximately $590 million in 2015); and
  - the inclusion of three months of legacy Hospira international operations of $270 million in 2015, partially offset by:
    - lower revenues in developed markets for Lyrica (GEP), Celebrex, Inspra and Viagra (GEP) as a result of the loss of exclusivity, as well as the performance of Lipitor and Norvasc in developed markets, and Zosyn/Tazocin in emerging markets (collectively, down approximately $1.0 billion in 2015).

In 2015, international revenues represented 56% of total revenues, compared to 62% in 2014. Excluding foreign exchange, international revenues in 2015 represented 59% of total revenues, compared to 62% in 2014.
2014 v. 2013

See the Revenues—Overview section of this Analysis of the Consolidated Statements of Income for a discussion of performance of worldwide revenues.

Geographically,

• in the U.S., revenues decreased $1.2 billion or 6% in 2014, compared to 2013, reflecting, among other things:
  o lower Alliance revenues, primarily due to Enbrel, reflecting the expiration of the co-promotion term of the collaboration agreement in October 2013 (down approximately $1.3 billion in 2014), and Spiriva, reflecting the final-year terms, and termination on April 29, 2014, of the co-promotion collaboration, which, per the terms of the collaboration agreement, resulted in a decline of our share of Spiriva revenue (down approximately $395 million in 2014); and
  o lower revenues from Detrol LA due to loss of exclusivity (down approximately $321 million in 2014), Celebrex due to loss of exclusivity in December 2014 (down approximately $198 million), and lower revenues from Lipitor (down approximately $191 million in 2014),
  partially offset by:
    o the strong performance of Lyrica (up approximately $352 million in 2014) as well as the growth of Prevnar, Xeljanz, Eliquis, Xalkori and Inlyta (collectively, up approximately $760 million in 2014).

• in our international markets, revenues decreased $778 million, or 2%, in 2014, compared to 2013, primarily due to the unfavorable impact of foreign exchange of approximately $912 million in 2014, or 3%. Operationally, revenues increased slightly by $134 million, in 2014 compared to 2013 reflecting, among other things:
  o higher operational revenues for Lipitor in China, Lyrica in developed markets, Enbrel outside Canada, and the performance of recently launched products Eliquis, Xalkori, and Inlyta (collectively, up approximately $941 million in 2014); and
  o the operational growth of Prevenar and Xeljanz (collectively, up approximately $228 million in 2014),
  partially offset by:
    o the operational decline of certain products, including Norvasc, Zithromax, Xalabrands, Detrol, Effexor and Chantix/Champix, in developed international markets, and Sutent in China (collectively, down approximately $320 million in 2014);
    o lower revenues as a result of the loss of exclusivity and subsequent multi-source generic competition for Viagra in most major European markets and Lyrica in Canada (collectively, down approximately $248 million in 2014);
    o lower Alliance revenues (down approximately $218 million in 2014, excluding Eliquis), primarily due to the expiration of the co-promotion term of the collaboration agreement for Enbrel in Canada, the ongoing termination of the Spiriva collaboration agreement in certain countries, the loss of exclusivity for Aricept in Canada and the termination of the co-promotion agreement for Aricept in Japan in December 2012; and
    o the continued erosion of branded Lipitor in most international developed markets (down approximately $197 million in 2014).

In 2014, international revenues represented 62% of total revenues, compared to 61% in 2013. Excluding foreign exchange, international revenues in 2014 represented 62% of total revenues, compared to 62% in 2013.

For additional information about operating segment revenues, see the “Analysis of Operating Segment Information” section of this Financial Review.
### Revenues—Major Products

The following table provides revenue information for several of our major products:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td><strong>INNOVATIVE PRODUCTS BUSINESS</strong>&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIP&lt;sup&gt;c,e&lt;/sup&gt;</td>
<td>$ 26,758</td>
<td>$ 24,005</td>
</tr>
<tr>
<td>Lyrica GIP&lt;sup&gt;e&lt;/sup&gt;</td>
<td>3,655</td>
<td>3,350</td>
</tr>
<tr>
<td>Enbrel (Outside the U.S. and Canada)</td>
<td>3,333</td>
<td>3,850</td>
</tr>
<tr>
<td>Viagra GIP&lt;sup&gt;e&lt;/sup&gt;</td>
<td>1,297</td>
<td>1,181</td>
</tr>
<tr>
<td>BeneFIX</td>
<td>752</td>
<td>856</td>
</tr>
<tr>
<td>Chantix/champix</td>
<td>671</td>
<td>647</td>
</tr>
<tr>
<td>Genotropin</td>
<td>617</td>
<td>723</td>
</tr>
<tr>
<td>Refacto AF/Xyntha</td>
<td>533</td>
<td>631</td>
</tr>
<tr>
<td>Xeljanz</td>
<td>523</td>
<td>308</td>
</tr>
<tr>
<td>Toviaz</td>
<td>267</td>
<td>288</td>
</tr>
<tr>
<td>BMP2</td>
<td>232</td>
<td>228</td>
</tr>
<tr>
<td>Rapamune</td>
<td>218</td>
<td>229</td>
</tr>
<tr>
<td>Alliance revenue GIP&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td>1,254</td>
<td>762</td>
</tr>
<tr>
<td>All other GIP&lt;sup&gt;d,e&lt;/sup&gt;</td>
<td>465</td>
<td>469</td>
</tr>
<tr>
<td><strong>VOC&lt;sup&gt;d&lt;/sup&gt;</strong></td>
<td>$ 12,603</td>
<td>$ 10,144</td>
</tr>
<tr>
<td>Prevnar family&lt;sup&gt;j&lt;/sup&gt;</td>
<td>6,245</td>
<td>4,464</td>
</tr>
<tr>
<td>Sulent</td>
<td>1,120</td>
<td>1,174</td>
</tr>
<tr>
<td>Ibrance</td>
<td>723</td>
<td>—</td>
</tr>
<tr>
<td>Xalkori</td>
<td>488</td>
<td>438</td>
</tr>
<tr>
<td>Inlyta</td>
<td>430</td>
<td>410</td>
</tr>
<tr>
<td>FSME-IMMUN/TeicoVac</td>
<td>104</td>
<td>—</td>
</tr>
<tr>
<td>All other VOC&lt;sup&gt;d&lt;/sup&gt;</td>
<td>298</td>
<td>211</td>
</tr>
<tr>
<td>Consumer Healthcare</td>
<td>3,395</td>
<td>3,446</td>
</tr>
<tr>
<td><strong>ESTABLISHED PRODUCTS BUSINESS</strong>&lt;sup&gt;j&lt;/sup&gt;</td>
<td>$ 21,587</td>
<td>$ 25,149</td>
</tr>
<tr>
<td>Legacy Established Products&lt;sup&gt;j&lt;/sup&gt;</td>
<td>$ 11,745</td>
<td>$ 13,016</td>
</tr>
<tr>
<td>Lipitor</td>
<td>1,860</td>
<td>2,061</td>
</tr>
<tr>
<td>Premarin family</td>
<td>1,018</td>
<td>1,076</td>
</tr>
<tr>
<td>Norvasc</td>
<td>991</td>
<td>1,112</td>
</tr>
<tr>
<td>Xalatan/Xalacom</td>
<td>399</td>
<td>495</td>
</tr>
<tr>
<td>Zolofr</td>
<td>374</td>
<td>423</td>
</tr>
<tr>
<td>Relapax</td>
<td>352</td>
<td>362</td>
</tr>
<tr>
<td>EpiPen</td>
<td>339</td>
<td>294</td>
</tr>
<tr>
<td>Effexor</td>
<td>288</td>
<td>344</td>
</tr>
<tr>
<td>Zithromax/Zmax</td>
<td>275</td>
<td>311</td>
</tr>
<tr>
<td>Xanox/Xanox XR</td>
<td>224</td>
<td>253</td>
</tr>
<tr>
<td>Cardura</td>
<td>210</td>
<td>263</td>
</tr>
<tr>
<td>Neurontin</td>
<td>196</td>
<td>210</td>
</tr>
<tr>
<td>Diflucan</td>
<td>181</td>
<td>208</td>
</tr>
<tr>
<td>Tikosyn</td>
<td>179</td>
<td>141</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>170</td>
<td>201</td>
</tr>
<tr>
<td>Unasyn</td>
<td>118</td>
<td>96</td>
</tr>
<tr>
<td>All other Legacy Established Products&lt;sup&gt;j&lt;/sup&gt;</td>
<td>4,571</td>
<td>5,145</td>
</tr>
<tr>
<td><strong>Peri-LOE Products&lt;sup&gt;j&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lyrica GEP&lt;sup&gt;e&lt;/sup&gt;</td>
<td>1,183</td>
<td>1,818</td>
</tr>
<tr>
<td>Zyvox</td>
<td>883</td>
<td>1,352</td>
</tr>
<tr>
<td>Celebrex</td>
<td>830</td>
<td>2,699</td>
</tr>
<tr>
<td>Pristiq</td>
<td>715</td>
<td>737</td>
</tr>
<tr>
<td>Vfend</td>
<td>682</td>
<td>756</td>
</tr>
<tr>
<td>Viagra GEP&lt;sup&gt;e&lt;/sup&gt;</td>
<td>411</td>
<td>504</td>
</tr>
<tr>
<td>Revalto</td>
<td>260</td>
<td>276</td>
</tr>
<tr>
<td>All other Peri-LOE Products&lt;sup&gt;j&lt;/sup&gt;</td>
<td>362</td>
<td>714</td>
</tr>
<tr>
<td><strong>Sterile Injectable Pharmaceuticals</strong>&lt;sup&gt;f&lt;/sup&gt;</td>
<td>$ 3,944</td>
<td>$ 3,277</td>
</tr>
<tr>
<td>Medrol</td>
<td>402</td>
<td>381</td>
</tr>
<tr>
<td>Sulperazone</td>
<td>339</td>
<td>354</td>
</tr>
<tr>
<td>Fragmin</td>
<td>335</td>
<td>364</td>
</tr>
<tr>
<td>Tygacil</td>
<td>304</td>
<td>323</td>
</tr>
</tbody>
</table>

---

<sup>a</sup> Revenues—Major Products

<sup>b</sup> Revenues—Major Products

<sup>c</sup> Revenues—Major Products

<sup>d</sup> Revenues—Major Products

<sup>e</sup> Revenues—Major Products

<sup>f</sup> Revenues—Major Products

<sup>g</sup> Revenues—Major Products

<sup>h</sup> Revenues—Major Products

<sup>i</sup> Revenues—Major Products

<sup>j</sup> Revenues—Major Products
References to GIP, V, O, and GEP indicate the business to which the revenues relate. GIP = the Global Innovative Pharmaceutical segment; V = the Global Vaccines business; O = the Global Oncology business; and GEP = the Global Established Pharmaceutical segment.

### Revenues—Selected Product Descriptions

References to GIP, V, O, and GEP indicate the business to which the revenues relate. GIP = the Global Innovative Pharmaceutical segment; V = the Global Vaccines business; O = the Global Oncology business; and GEP = the Global Established Pharmaceutical segment.

- **Prevnar/Prevenar 13 (V),** is our pneumococcal conjugate vaccine for the prevention of certain types of pneumococcal disease. Overall, worldwide revenues for Prevnar/Prevenar 13 increased 46% operationally in 2015, compared to 2014. Foreign exchange had an unfavorable impact on worldwide revenues of 6% in 2015, compared to 2014.

  In the U.S., revenues for Prevnar increased 87% in 2015, compared to 2014, mainly due to continued strong uptake among adults following the positive recommendation from the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) for use in adults aged 65 and older in the third quarter of 2014 and the success of the commercial programs which helped to maximize vaccinations across all channels. We believe the “catch-up” opportunity (i.e., the opportunity to reach adults aged 65 and older who have not been previously vaccinated with Prevnar) in adults in the U.S. will continue to be large given current demographics and aging trends. However, the remaining population of adults aged 65 years and older will likely require additional effort to capture. As a result, the opportunity will moderate over time as this “catch-up” opportunity becomes fully realized.

  Internationally, revenues for Prevenar increased 9% operationally in 2015, compared to 2014, primarily reflecting increased volume in emerging markets primarily due to Prevenar’s inclusion in additional national immunization programs in certain emerging markets. Foreign exchange had an unfavorable impact on international revenues of 13% in 2015, compared to 2014.

  In 2014, the ACIP voted to recommend Prevenar 13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which for adults includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. These ACIP recommendations were subsequently approved by the directors at the CDC and U.S. Department of Health and Human Services, and were published in the Morbidity and Mortality Weekly Report in September 2014 by the CDC. As with other vaccines, the CDC regularly monitors the impact of vaccination and reviews the recommendations; in this case, however, the CDC announced formally that it will conduct this review in 2018. Currently, we are working with a number of U.S. investigators to monitor the proportion of community-acquired pneumonia caused by the serotypes included in Prevnar 13 and continue to observe trends.

  In March 2015, the European Commission approved an expanded indication for the use of Prevenar 13 for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from our landmark Community-Acquired Pneumonia Immunization Trial in Adults (CAPITA), which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease (IPD) in adults aged 65 and older.
• **Lyrica** (GEP (revenues from all of Europe, Russia, Turkey, Israel and Central Asia)/GIP (all other revenues)) is indicated in the U.S. for three neuropathic pain conditions, fibromyalgia and adjunctive therapy for adult patients with partial onset seizures. In certain markets outside the U.S., indications include neuropathic pain (peripheral and central), fibromyalgia, and the generalized anxiety disorder. Worldwide revenues for Lyrica were relatively flat operationally in 2015, compared to 2014. Foreign exchange had an unfavorable impact on worldwide revenues of 6% in 2015, compared to 2014.

  In the U.S., revenues increased 15% in 2015, compared to 2014, driven by price and volume increases, and investment in direct-to-consumer advertising combined with strong field force performance, partially offset by higher rebates.

  Internationally, Lyrica revenues decreased 11% operationally in 2015, compared to 2014, due to losses of exclusivity in certain developed Europe markets, partially offset by operational growth primarily in Japan. Foreign exchange had an unfavorable impact on international revenues of 13% in 2015, compared to 2014.

  Worldwide revenues from Lyrica in our GIP segment increased 13% operationally in 2015, compared to 2014, and in our GEP segment, revenues from Lyrica decreased 23% operationally in 2015, compared to 2014.

• **Enbrel** (GIP, outside the U.S. and Canada), indicated for the treatment of moderate-to-severe rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis (a type of arthritis affecting the spine), and nonradiographic axial spondyloarthritis, recorded a 1% operational increase in worldwide revenues, excluding the U.S. and Canada, in 2015, compared to 2014. Results were favorably impacted by demand in certain markets in Europe and the timing of government purchases in Africa Middle East offset primarily by the change in the distribution channel in the U.K. Foreign exchange had an unfavorable impact of 14% in 2015, compared to 2014.

• **Lipitor** (GEP) is indicated for the treatment of elevated LDL-cholesterol levels in the blood. Lipitor faces generic competition in all major developed markets. Branded Lipitor recorded worldwide revenues of $1.9 billion, or a 4% operational decrease in 2015, compared to 2014. Foreign exchange had an unfavorable impact of 6% in 2015, compared to 2014.

  In the U.S., revenues decreased 33% in 2015 compared to 2014, primarily due to lower volumes and higher rebates.

  In our international markets, revenues were relatively flat operationally in 2015, compared to 2014, driven by volume growth in emerging markets, primarily in China, offset by brand erosion due to generic competition and increased payer pressure in developed markets. Foreign exchange had an unfavorable impact on international revenues of 7% in 2015, compared to 2014.

• **Viagra** (GIP (revenues from U.S. and Canada)/GEP (all other revenues excluding U.S. and Canada)) is indicated for the treatment of erectile dysfunction. Viagra worldwide revenues increased 5% operationally in 2015, compared to 2014, primarily due to operational growth in the U.S. and emerging markets. Foreign exchange had an unfavorable impact of 4% in 2015, compared to 2014. International revenues decreased 7% operationally in 2015, compared to 2014, primarily from brand erosion due to generic competition and increased payer pressure in developed markets, partially offset by volume growth in China. Foreign exchange had an unfavorable impact on international revenues of 11% in 2015, compared to 2014. Revenues in the U.S. increased 11% in 2015, compared to 2014, primarily driven by increased pill quantity per prescription, higher purchases from the U.S. Department of Veterans Affairs/Department of Defense, and price increases, partially offset by lower patient demand.

• **Sutent** (O) is indicated for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC); gastrointestinal stromal tumors after disease progression on, or intolerance to, imatinib mesylate; and advanced pancreatic neuroendocrine tumor. Sutent worldwide revenues increased 7% operationally in 2015, compared to 2014, primarily due to greater demand in emerging markets as well as price increases in the U.S. Foreign exchange had an unfavorable impact of 12% in 2015, compared to 2014.

• Our **Premarin** family of products (GEP) helps women address moderate-to-severe menopausal symptoms. Premarin worldwide revenues decreased 4% operationally in 2015, compared to 2014. Revenues in the U.S. in 2015 were unfavorably impacted by prescription volume declines and lower market growth, partially offset by price increases. Foreign exchange had an unfavorable impact of 1% in 2015, compared to 2014.

• **Norvasc** (GEP) is indicated for the treatment of hypertension. Norvasc worldwide revenues decreased 3% operationally in 2015, compared to 2014, due to generic erosion in Japan, partially offset by volume growth in emerging markets, primarily in China. Foreign exchange had an unfavorable impact of 8% in 2015, compared to 2014.

• **Zyvox** (GEP) is among the world’s best-selling branded agents used to treat serious Gram-positive pathogens, including methicillin-resistant *staphylococcus-aureus*. Zyvox worldwide revenues decreased 27% operationally in 2015, compared to 2014. Foreign exchange had an unfavorable impact of 8% in 2015, compared to 2014.

  In the U.S., revenues decreased 61% due to generic competition beginning in the first half of 2015, as well as pricing pressures.

  Internationally, Zyvox revenues increased 7% operationally in 2015 compared to 2014, primarily due to volume growth in China. Foreign exchange had an unfavorable impact on international revenues of 15% in 2015, compared to 2014.

• **Celebrex** (GEP) is indicated for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis worldwide and for the management of acute pain in adults in the U.S., Japan and certain other markets. Celebrex recorded a 66% decrease in worldwide operational revenues in 2015, compared to 2014, primarily driven by the loss of exclusivity and associated generic competition in the U.S. and certain other developed markets. Foreign exchange had an unfavorable impact of 3% in 2015 compared to 2014.

  In the U.S., revenues decreased 92% in 2015 compared to 2014, driven by the loss of exclusivity and launch of multi-source generic competition in December 2014.

  Internationally, Celebrex revenues decreased 20% operationally in 2015, compared to 2014, driven by the loss of exclusivity and launch of multi-source generic competition in most developed markets. Foreign exchange had an unfavorable impact on international revenues of 9% in 2015, compared to 2014.
Beniflex and ReFacto AF/Xyntha (GIP) are hemophilia products using state-of-the-art manufacturing that assist patients with their lifelong bleeding disorders. BeneFIX worldwide revenues decreased 5% operationally in 2015, compared to 2014, primarily as a result of the erosion of market share in the U.S. due to the launch of competing new extended half-life treatment options. Foreign exchange had an unfavorable impact on revenues of 7% in 2015, compared to 2014. ReFacto AF/Xyntha recorded a 5% operational decrease in worldwide revenues in 2015, compared to 2014, largely due to price erosion in the U.K. and Australia, erosion of market share in the U.S. due to the launch of competing new extended half-life treatment options and loss of the annual 2015 contract in Iraq. Foreign exchange had an unfavorable impact on revenues of 11% in 2015, compared to 2014.

Ibrance (O) was approved and launched in the U.S., Macau, Chile and Albania as a first-line treatment for certain forms of advanced breast cancer. Ibrance recorded worldwide revenues of $723 million in 2015, nearly all of which were recorded in the U.S.

Pristiq (GEP) is indicated for the treatment of major depressive disorder in the U.S. and in various other countries. Pristiq has also been indicated for treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause in Thailand, Mexico, the Philippines and Ecuador. Pristiq recorded a 1% operational increase in worldwide revenues in 2015, compared to 2014. Foreign exchange had an unfavorable impact on revenues of 4% the 2015, compared to 2014. In the U.S., Pristiq revenues were relatively flat in 2015 compared to 2014 due to price increases offset by decreased market share. Internationally, Pristiq revenues increased 5% operationally due to volume growth in certain markets. Foreign exchange had an unfavorable impact on international revenues of 16% in 2015, compared to 2014.

Chantix/Champix (GIP) is approved as an aid to smoking-cessation treatment in adults 18 years of age and older in multiple markets worldwide. Worldwide revenues increased 9% operationally in 2015, compared to 2014. Foreign exchange had an unfavorable impact on revenues of 5% in 2015, compared to 2014. In the U.S., Chantix revenues increased 13% in 2015, compared to 2014, primarily due to two price increases and higher year-over-year demand driven by steadily improving coverage by insurers in response to the requirements of the Affordable Care Act and direct-to-consumer advertising on TV, partially offset by intensified competition by over-the-counter nicotine replacement therapies that utilize TV and retail channels and higher-than-expected Medicaid rebates. Internationally, Champix revenues increased 4% operationally in 2015, compared to 2014, primarily due to a significant tobacco tax increase in Korea and strong growth across emerging markets. Foreign exchange had an unfavorable impact on international revenues of 13% in 2015, compared to 2014.

Xeljanz (GIP) is approved for use as a second-line therapy for the treatment of adult patients with moderate to severe active rheumatoid arthritis (after traditional disease-modifying antirheumatic drugs) in more than 40 markets including the U.S., Japan, Australia, Canada, Switzerland and Brazil. Xeljanz recorded a 72% increase in worldwide revenues operationally in 2015, compared to 2014. In the U.S., Xeljanz revenues increased 63% in 2015, compared to 2014 driven by continued adoption by rheumatologists, growing awareness among patients and price increases. Foreign exchange had a 2% unfavorable impact in 2015, compared to 2014.

Xalkori (O) is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Xalkori worldwide revenues increased 20% operationally in 2015, compared to 2014, as a result of a steady increase in diagnostic rates for the ALK gene mutation across key markets, which has led to more patients being treated, and price increases in the U.S. Foreign exchange had a 9% unfavorable impact in 2015, compared to 2014.

Inlyta (O) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of a prior systemic treatment. Worldwide revenues increased 14% operationally in 2015, compared to 2014, primarily due to increased demand across key markets with greater access and reimbursement, particularly in Europe, as well as price increases in the U.S. Foreign exchange had a 9% unfavorable impact on revenues in 2015, compared to 2014.

Alliance revenues (GEP/GIP) increased 45% operationally in 2015, compared to 2014, mainly due to:

- an increase in Eliquis alliance revenues as a result of increased market share, partially offset by:
  - the termination of the Spiriva (GEP) co-promotion collaboration, which resulted in a decrease of approximately $143 million operationally in 2015, compared to 2014.
- Eliquis (apixaban) (GEP) is being jointly developed and commercialized by Pfizer and Bristol-Myers Squibb (BMS). The two companies share commercialization expenses and profit/losses equally on a global basis. In April 2015, we signed an agreement with BMS to transfer full commercialization rights in certain smaller markets to us, beginning in the third quarter of 2015. BMS supplies the product to us at cost plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant (NOAC) market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients. Eliquis (apixaban) is approved for multiple indications in major markets around the world:
  - to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF);
  - for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy; and
  - for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery. The NOAC class penetration continues to expand across key markets. Eliquis has become the most prescribed oral anticoagulant in new to brand prescriptions among cardiologists in the U.S., Japan, and several other markets. Eliquis share uptake with primary care physicians has also been strong, following the launch, in the fourth quarter of 2014, of the treatment indications for DVT and PE and reduction in the risk of recurrent DVT and PE.

See the “Our Operating Environment—Intellectual Property Rights and Collaboration/Licensing Rights” section of this Financial Review, for information regarding the expiration of various contract rights relating to Spiriva, Enbrel and Rebif.

See Notes to Consolidated Financial Statements—Note 17. Commitments and Contingencies for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.
PRODUCT DEVELOPMENTS—BIOPHARMACEUTICAL

We continue to invest in R&D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.

We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline that will deliver value in the near term and over time. Our R&D priorities include delivering a pipeline of differentiated therapies with the greatest scientific and commercial promise, innovating new capabilities that can position Pfizer for long-term leadership and creating new models for biomedical collaboration that will expedite the pace of innovation and productivity. To that end, our R&D primarily focuses on six high-priority areas that have a mix of small molecules and large molecules—immunology and inflammation; cardiovascular and metabolic diseases; oncology; vaccines; neuroscience and pain; and rare diseases. Another area of focus is biosimilars. With the acquisition of Hospira, we have expanded our biosimilars pipeline and added R&D capabilities for sterile injectables and infusion systems.

A comprehensive update of Pfizer’s development pipeline, including assets from the Hospira acquisition, was published on February 2, 2016 and is available at www.pfizer.com/pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for candidates from Phase 2 through registration.

The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>INDICATION</th>
<th>DATE APPROVED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xeljanz (Tofacitinib)</td>
<td>Extended-release 11mg tablets for the once-daily treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response or intolerance to methotrexate</td>
<td>February 2016</td>
</tr>
<tr>
<td>Ibrance (Palbociclib)</td>
<td>An oral and selective reversible inhibitor of the CDK 4 and 6 kinases for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy</td>
<td>February 2016</td>
</tr>
<tr>
<td>Ibrance (Palbociclib)</td>
<td>An oral and selective reversible inhibitor of the CDK 4 and 6 kinases in combination with letrozole for the treatment of postmenopausal women with estrogen receptor-positive (ER+), HER2- advanced breast cancer as an initial endocrine-based therapy for their metastatic disease</td>
<td>February 2015</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>PROPOSED INDICATION</th>
<th>DATE FILED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xalkori (Crizotinib)</td>
<td>Treatment of ROS1-positive non-small cell lung cancer</td>
<td>December 2015</td>
</tr>
<tr>
<td>ALO-02 (oxycodeone HCl/ naltrexone/HCl)</td>
<td>A Mu-type opioid receptor agonist for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate</td>
<td>February 2015</td>
</tr>
<tr>
<td>Retacrit®</td>
<td>A potential biosimilar to Epogen® and Procrit® (epoetin alfa)</td>
<td>February 2015</td>
</tr>
<tr>
<td>Tafamidis meglumine®(c)</td>
<td>Treatment of transthyretin familial amyloid polyneuropathy</td>
<td>February 2012</td>
</tr>
</tbody>
</table>

* The dates set forth in this column are the dates on which the FDA accepted our submissions.

(b) In October 2015, we received a “complete response” letter from the FDA with respect to our biologics license application for Retacrit, our proposed biosimilar to epoetin alpha, which was submitted for all indications of the reference product. We are working diligently to address the content of the letter.

(c) In October 2015, we received a “complete response” letter from the FDA with respect to our supplemental NDA for Xeljanz for the treatment of adult patients with moderate to severe chronic plaque psoriasis. While we have yet to meet with the FDA to discuss their concerns, we recognize that overcoming the issues raised may be difficult, especially in light of the evolving marketplace. We will consider our investment in the psoriasis indication for Xeljanz following this discussion with the FDA.

(d) In May 2012, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a “complete response” letter with respect to the tafamidis NDA. The FDA has requested the completion of a second efficacy study, and also has asked for additional information on the data within the current tafamidis NDA. We continue to work with the FDA to define a path forward.

In February 2008, the FDA advised it expected to convene an advisory committee pending responses to the “approvable letters” for the Viviant (bazedoxifene) NDAs for the treatment and prevention of post-menopausal osteoporosis, which were received in December 2007 and May 2008. In view of the approval of Duavee (conjugated estrogens/bazedoxifene), we submitted a request to withdraw the NDAs for Viviant in December 2015.
REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN

<table>
<thead>
<tr>
<th>PRODUCT (Chemical Name)</th>
<th>DESCRIPTION OF EVENT</th>
<th>DATE APPROVED</th>
<th>DATE FILED*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xalkori (Crizotinib)</td>
<td>Application filed in the EU for the treatment of ROS1-positive non-small cell lung cancer</td>
<td>February 2016</td>
<td>—</td>
</tr>
<tr>
<td>Eliquis (Apixaban)</td>
<td>Approval in Japan for the treatment and prevention of recurrence of venous thromboembolism (deep vein thrombosis and pulmonary embolism)</td>
<td>December 2015</td>
<td>—</td>
</tr>
<tr>
<td>Xalkori (Crizotinib)</td>
<td>Approval in the EU for first line treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer</td>
<td>November 2015</td>
<td>—</td>
</tr>
<tr>
<td>Effexor SR (Venlafaxine HCl)</td>
<td>Approval in Japan for treatment of depression/depressed state</td>
<td>September 2015</td>
<td>—</td>
</tr>
<tr>
<td>Ibrance (Palbociclib)</td>
<td>Application filed in the EU for palbociclib in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), HER2- advanced or metastatic breast cancer, as well as for the treatment of recurrent advanced breast cancer</td>
<td>—</td>
<td>August 2015</td>
</tr>
<tr>
<td>Xeljanz (Tofacitinib)</td>
<td>Application filed in Japan for treatment of psoriasis vulgaris and psoriatic arthritis with inadequate response to existing therapies</td>
<td>—</td>
<td>March 2015</td>
</tr>
</tbody>
</table>

* For applications in the EU, the dates set forth in this column are the dates on which the European Medicines Agency (EMA) validated our submissions.

(a) This indication for Eliquis (apixaban) was developed and is being commercialized in collaboration with Bristol-Myers Squibb (BMS).

LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS

<table>
<thead>
<tr>
<th>PRODUCT (Chemical Name)</th>
<th>PROPOSED INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bosulif (Bosutinib)</td>
<td>First-line treatment for patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia, which is being developed in collaboration with Avillion Group</td>
</tr>
<tr>
<td>Inlyta (Axitinib)</td>
<td>Adjuvant treatment of renal cell carcinoma, which is being developed in collaboration with SFJ Pharmaceuticals Group</td>
</tr>
<tr>
<td>Ibrance (Palbociclib)</td>
<td>Treatment of high-risk early breast cancer, in collaboration with the German Breast Group</td>
</tr>
<tr>
<td>Ibrance (Palbociclib)</td>
<td>Treatment of HR+ early breast cancer, in collaboration with the Alliance Foundation Trials, LLC, and the Austrian Breast Colorectal Cancer Study Group</td>
</tr>
<tr>
<td>Lyrica (Pregabalin)</td>
<td>Peripheral neuropathic pain</td>
</tr>
<tr>
<td>Lyrica (Pregabalin)</td>
<td>CR (once-a-day) dosing</td>
</tr>
<tr>
<td>Sutent (Sunitinib)</td>
<td>Adjuvant treatment of renal cell carcinoma</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Treatment of psoriasis (ex-US)</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Treatment of ulcerative colitis</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Treatment of psoriatic arthritis</td>
</tr>
<tr>
<td>Vyndaqel (Tafamidis meglumine)</td>
<td>Adult symptomatic transthyretin cardiomyopathy</td>
</tr>
</tbody>
</table>
Avelumab (PF-06834635) (MSB0010718C)
A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung cancer, which is being developed in collaboration with Merck KGaA, Germany

Avelumab (PF-06834635) (MSB0010718C)
A monoclonal antibody that inhibits PD-L1 for maintenance treatment, in the first-line setting, for patients with urothelial cancer, which is being developed in collaboration with Merck KGaA, Germany

Avelumab (PF-06834635) (MSB0010718C)
A monoclonal antibody that inhibits PD-L1 for maintenance treatment of advanced or metastatic gastric/gastro-esophageal junction cancers, which is being developed in collaboration with Merck KGaA, Germany

Avelumab (PF-06834635) (MSB0010718C)
Third-line treatment in advanced or metastatic gastric/gastro-esophageal junction cancers, which is being developed in collaboration with Merck KGaA, Germany

Bococizumab
A monoclonal antibody that inhibits PCSK9 for the treatment of hyperlipidemia and prevention of cardiovascular events

Dacomitinib
A pan-HER tyrosine kinase inhibitor for the first-line treatment of patients with advanced non-small cell lung cancer with EGFR activating mutations, which is being developed in collaboration with SFJ Pharmaceuticals Group

Ertugliflozin
An oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, which is being developed in collaboration with Merck & Co., Inc.

Inotuzumab ozogamicin
An antibody drug conjugate, consisting of an anti-CD22 monotherapy antibody linked to a cytotoxic agent, calicheamicyn, for the treatment of acute lymphoblastic leukemia

PF-06836922
A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKO Health, Inc.

PF-06438179
A potential biosimilar to Remicade® (infliximab)

PF-05280014
A potential biosimilar to Herceptin® (trastuzumab)

PF-05280056
A potential biosimilar to Rituxan® (rituximab)

PF-06439535
A potential biosimilar to Avastin® (bevacizumab)

PF-06410293
A potential biosimilar to Humira® (adalimumab)

Rivipansel (GMI-1070)
A pan-selectin inhibitor for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease, which was licensed from GlycoMimetics Inc.

Tanezumab
An anti-nerve growth factor monoclonal antibody for the treatment of pain, which is being developed in collaboration with Eli Lilly & Company

Trumenba
A prophylactic vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age (ex-U.S.)

Inflectra™
In 2009, Hospira entered into an agreement to develop and market certain biosimilar molecules with Celltrion Inc. and Celltrion Healthcare, Co., Ltd. (collectively Celltrion) including Inflectra™ (infliximab) for patients with autoimmune diseases. In Europe, Inflectra has now launched in 36 markets. Celltrion possesses the right to commercialize its infliximab product in the same European markets as Hospira. We have exclusive commercialization rights from Celltrion to their infliximab product in the U.S., Canada and certain other territories. In August 2014, Celltrion submitted a potential infliximab biosimilar for FDA approval in the U.S., and in February 2016, the FDA’s Arthritis Advisory Committee provided a non-binding recommendation to the FDA for approval across all indications. In December 2014, Hospira launched Inflectra in Canada. Inflectra has also been approved in certain markets, where Hospira will market it as Remsima™.

In September 2015, in order to eliminate certain redundancies in Pfizer’s biosimilar drug products pipeline created as a result of the acquisition of Hospira, Pfizer opted to return to Celltrion rights that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). In connection with the return of the acquired rights, we incurred charges of $215 million, which are included in Restructuring charges and certain acquisition-related costs. See Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives for additional information.

Additional product-related programs are in various stages of discovery and development. Also, see the discussion in the “Our Business Development Initiatives” section of this Financial Review.
COSTS AND EXPENSES

Cost of Sales

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>$ 9,648</td>
<td>$ 9,577</td>
</tr>
<tr>
<td>As a percentage of Revenues</td>
<td>19.7%</td>
<td>19.3%</td>
</tr>
</tbody>
</table>

2015 v. 2014

Cost of sales increased 1% in 2015, compared to 2014, primarily due to:

- an increase in sales volumes due to (i) the inclusion of four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations and the vaccine portfolio operations acquired from Baxter in fiscal 2015, both of which are comprised of inventory measured at fair value on the acquisition date (approximately $2.1 billion); and (ii) the net increase in sales volume of Pfizer legacy products; and
- non-recurring charges of $72 million related to manufacturing plant pension obligations and $72 million related to inventory impairment in Venezuela in 2015 related to the foreign currency change described in the “Global Economic Conditions—Venezuela Operations” section in this Financial Review,

partially offset by:
- favorable foreign exchange of 10% in 2015;
- a change in the profit deferred in inventory relating to inventory that had not been sold to third parties resulting in a non-cash benefit of $306 million; and, to a lesser extent
- manufacturing efficiencies; and
- a decrease in royalty expense associated with products that recently lost marketing exclusivity.

The increase in Cost of sales as a percentage of Revenues in 2015, compared to 2014, was primarily due to:

- an unfavorable change in product mix due to (i) the inclusion of four months of legacy Hospira U.S. operations, three months of legacy Hospira international operations, and the vaccine portfolio operations acquired from Baxter in fiscal 2015, both of which are comprised of inventory measured at fair value on the acquisition date; and (ii) the impact of losses of exclusivity;

partially offset by:
- a change in the profit deferred in inventory relating to inventory that had not been sold to third parties (described above);
- manufacturing efficiencies;
- favorable foreign exchange;
- a decrease in royalty expenses associated with products that have recently lost marketing exclusivity; and
- an increase in alliance revenues which have no associated cost of sales.

2014 v. 2013

Cost of sales increased as a percentage of Revenues in 2014, compared to the same period in 2013. These increases are primarily due to the impact of loss of exclusivity and unfavorable changes in product mix, resulting from, among other things, the loss of Enbrel alliance revenue after October 31, 2013, when the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and the loss of Spiriva alliance revenue in the U.S. as of April 29, 2014. Cost of sales in 2014 were relatively flat compared to 2013 as the unfavorable impact due to the changes in product mix discussed above was largely offset by favorable foreign exchange of 3%.

Selling, Informational and Administrative (SI&A) Expenses

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>$ 14,809</td>
<td>$ 14,097</td>
</tr>
<tr>
<td>As a percentage of Revenues</td>
<td>30.3%</td>
<td>28.4%</td>
</tr>
</tbody>
</table>

2015 v. 2014

SI&A expenses increased 5% in 2015, compared to 2014, primarily due to:

- increased investments to support recently launched products and other in-line biopharmaceutical products and certain Consumer Healthcare brands;
- a non-recurring charge of $419 million related to the settlement of pension obligations in accordance with an offer to certain terminated employees who are vested in their pension benefits to elect a lump-sum payment or annuity of their deferred vested pension benefits; and
- the inclusion of four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations,
partially offset by:

- the favorable impact of foreign exchange of 6%;
- lower expenses associated with certain products that have recently lost marketing exclusivity;
- lower field force, advertising and promotional expenses, reflecting the benefits of cost-reduction and productivity initiatives; as well as
- the non-recurrence of a $215 million charge to account for an additional year of the non-tax deductible Branded Prescription Drug Fee in accordance with final regulations issued in the third quarter of 2014 by the U.S. Internal Revenue Service (IRS).

**2014 v. 2013**

Si&A expenses decreased 2% in 2014, compared to 2013, primarily due to:

- lower expenses for field force and marketing expenses, reflecting the benefits of cost-reduction and productivity initiatives, partly in response to product losses of exclusivity;
- a reduction related to a true-up of the 2013 fee payable to the federal government under the U.S. Healthcare Legislation based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs; and
- the favorable impact of foreign exchange of 1%,

partially offset by:

- increased investments in recently launched products and certain in-line products, as well as the launch and pre-launch marketing expenses for Trumenba (meningitis B vaccine) and Ibrance (palbociclib); and
- a $215 million charge to account for an additional year of the non-tax deductible Branded Prescription Drug Fee in accordance with final regulations issued in the third quarter of 2014 by the IRS.

### Research and Development (R&D) Expenses

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td><strong>Research and development expenses</strong></td>
<td>$ 7,690</td>
<td>$ 8,393</td>
</tr>
<tr>
<td>As a percentage of Revenues</td>
<td>15.7%</td>
<td>16.9%</td>
</tr>
</tbody>
</table>

**2015 v. 2014**

R&D expenses decreased 8% in 2015, compared to 2014, primarily due to:

- the non-recurrence of a charge associated with a collaborative arrangement with Merck KGaA, announced in November 2014, to jointly develop and commercialize avelumab, an investigational anti-PD-L1 antibody currently in development as a potential treatment for multiple types of cancer. The charge included an $850 million upfront cash payment as well as an additional amount of $309 million, reflecting the estimated fair value of certain co-promotion rights for Xalkori given to Merck KGaA (for further discussion, see the “Our Business Development Initiatives” section of this Financial Review);
- lower clinical trial expenses for various studies for certain previously approved products, including as a result of the completion of postmarketing commitments;
- lower upfront payments associated with certain licensing agreements compared to 2014; and
- the favorable impact of foreign exchange of 2%,

partially offset by:

- higher clinical trial spend for certain oncology and GIP pipeline programs;
- the $295 million upfront payment to OPKO in the first quarter of 2015 associated with a worldwide development and commercialization agreement;
- increased investment in biosimilar and sterile injectable development programs; and
- the inclusion of four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.

**2014 v. 2013**

R&D expenses increased 26% in 2014, compared to 2013, primarily due to:

- a charge associated with a collaborative arrangement with Merck KGaA, announced in November 2014, to jointly develop and commercialize avelumab, an investigational anti-PD-L1 antibody currently in development as a potential treatment for multiple types of cancer. The charge includes an $850 million upfront cash payment as well as an additional amount of $309 million, reflecting the estimated fair value of certain co-promotion rights for Xalkori given to Merck KGaA (for further discussion, see the “Our Business Development Initiatives” section of this Financial Review); and
- costs associated with ongoing Phase 3 programs for certain new drug candidates, including bococizumab and ertugliflozin (in collaboration with Merck), investments in Ibrance (palbociclib) and our vaccines portfolio, including Trumenba, as well as potential new indications for previously approved products, especially for Xeljanz.

See also the “Analysis of Operating Segment Information” section of this Financial Review.
Description of Research and Development Operations

Innovation is critical to the success of our company and drug discovery and development is time-consuming, expensive and unpredictable.

Our R&D spending is conducted through a number of matrix organizations—Research Units, within our Worldwide Research and Development organization, are generally responsible for research assets (assets that have not yet achieved proof-of-concept); Business Units are generally responsible for development assets (assets that have achieved proof-of-concept); and science-based and other platform-services organizations (for technical support and other services). For additional information by operating segment, see the “Analysis of Operating Segment Information” section of this Financial Review.

We take a holistic approach to our R&D operations and manage the operations on a total-company basis through our matrix organizations described above. Specifically, a single committee, co-chaired by members of our R&D and commercial organizations, is accountable for aligning resources among all of our R&D projects and for seeking to ensure that our company is focusing its R&D resources in the areas where we believe that we can be most successful and maximize our return on investment. We believe that this approach also serves to maximize accountability and flexibility.

Our Research Units are organized in a variety of ways (by therapeutic area or combinations of therapeutic areas, by discipline, by location, etc.) to enhance flexibility, cohesiveness and focus. Because of our structure, we can rapidly redeploy resources within a Research Unit between various projects as necessary because the workforce shares similar skills, expertise and/or focus.

Our science-based and other platform-services organizations, where a significant portion of our R&D spending occurs, provide technical expertise and other services to the various R&D projects, and are organized into science-based functions such as Pharmaceutical Sciences, Medicinal Chemistry, Drug Safety, and Development Operations, and non-science-based functions, such as Facilities, Business Technology and Finance. As a result, within each of these functions, we are able to migrate resources among projects, candidates and/or targets in any therapeutic area and in most phases of development, allowing us to react quickly in response to evolving needs.

Generally, we do not disaggregate total R&D expense by development phase or by therapeutic area since, as described above, we do not manage a significant portion of our R&D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, as conditions change, we believe that any prior-period information about R&D expense by development phase or by therapeutic area would not necessarily be representative of future spending.

Amortization of Intangible Assets

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>$3,728</td>
<td>$4,039</td>
</tr>
<tr>
<td>As a percentage of Revenues</td>
<td>7.6%</td>
<td>8.1%</td>
</tr>
</tbody>
</table>

Amortization of intangible assets decreased 8% in 2015, compared to 2014, and 12% in 2014, compared to 2013, primarily due to assets that became fully amortized at the end of their estimated useful lives. The decrease in Amortization of intangible assets in 2015 was partially offset by purchase accounting charges of approximately $161 million pre-tax related to the identifiable intangible assets acquired from Hospira.

See also Notes to Consolidated Financial Statements—Note 10A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/ Productivity Initiatives

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>$1,152</td>
<td>$250</td>
</tr>
<tr>
<td>Total additional depreciation—asset restructuring</td>
<td>122</td>
<td>261</td>
</tr>
<tr>
<td>Total implementation costs</td>
<td>203</td>
<td>270</td>
</tr>
<tr>
<td>Costs associated with acquisitions and cost-reduction/ productivity initiatives(i)</td>
<td>$1,478</td>
<td>$781</td>
</tr>
</tbody>
</table>

(i) Comprises Restructuring charges and certain acquisition-related costs as well as costs associated with our cost-reduction/productivity initiatives included in Cost of sales, Research and development expenses and/or Selling, informational and administrative expenses, as appropriate.

* Calculation not meaningful.

Included in Restructuring charges and certain acquisition-related costs are (i) restructuring charges of $811 million in 2015 for employee termination costs, asset impairments and other exit costs largely associated with our acquisition of Hospira; (ii) transaction costs, such as banking, legal, accounting and other similar services, directly related to our pending combination with Allergan and our acquisition of Hospira of $123 million in 2015; and (iii) integration costs, representing external, incremental costs directly related to integrating acquired businesses, and primarily including expenditures for consulting and the integration of systems and processes of $219 million in 2015, primarily related to our acquisition of Hospira. For information about costs associated with the acquisition of Hospira and expected total costs, see Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/ Productivity Initiatives.
In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. We expect to generate $800 million of annual cost synergies by 2018 in connection with the Hospira acquisition. Based on our past experience, the one-time costs to generate the synergies are expected to be approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired in-process research and development rights), incurred for up to a three-year period post-acquisition.

In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives. We also have an ongoing manufacturing plant network rationalization and optimization initiative underway. For information about these programs and expected total costs, see Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives. The expected ongoing annual cost savings associated with the above-mentioned programs (but not including expected cost savings associated with the Hospira acquisition), in the aggregate, are estimated to be approximately $2.4 billion by the end of 2016.

The expected costs and cost savings in 2016 associated with these activities, as well as the Hospira acquisition, are reflected in our financial guidance for 2016. See also the “Our Financial Guidance for 2016” section of this Financial Review.

In addition to these major initiatives, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.

### Other (Income)/Deductions—Net

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>$2,860</td>
<td>$1,009</td>
</tr>
</tbody>
</table>

* Calculation not meaningful.

For information about the components of Other (income)/deductions—net, see Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net.

See also the “Analysis of Operating Segment Information” section of this Financial Review.

### PROVISION FOR TAXES ON INCOME

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Provision for taxes on income</td>
<td>$1,990</td>
<td>$3,120</td>
</tr>
<tr>
<td>Effective tax rate on continuing operations</td>
<td>22.2%</td>
<td>25.5%</td>
</tr>
</tbody>
</table>

In all three years presented, our effective tax rate on continuing operations was impacted by favorable audit settlements and from the expiration of certain statutes of limitations in multiple jurisdictions covering various periods, among other factors. For details about these discrete elements that impacted our tax provisions, see Notes to Consolidated Financial Statements—Note 5A. Tax Matters: Taxes on Income from Continuing Operations.

#### 2015 v. 2014

The lower effective tax rate in 2015 compared to 2014 was primarily the result of:
- the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business;
- the non-recurrence of the non-deductibility of the $215 million charge to account for an additional year of the Branded Prescription Drug Fee in accordance with the final regulations issued in the third quarter of 2014 by the Internal Revenue Service (IRS); and
- the tax benefits associated with certain tax initiatives, partially offset by:
  - the non-deductibility of a foreign currency loss related to Venezuela; and
  - the non-deductibility of a charge for the agreement in principle to resolve claims relating to Protonix.

#### 2014 v. 2013

The lower effective tax rate in 2014 compared to 2013 was primarily the result of:
- the non-recurrence of the unfavorable tax rate associated with patent litigation settlement income of $1.3 billion recorded in 2013;
- the non-recurrence of the non-deductibility of the $292 million of goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer recorded in 2013;
- the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; and
Pfizer Inc. and Subsidiary Companies

- the non-recurrence of the non-deductibility of the $223 million loss on an option to acquire the remaining interest in Teuto in 2013, since we expect to retain the investment indefinitely and income in 2014 resulting from a decline in the non-tax deductible estimated loss, from the aforementioned option,

  partially offset by:

- the non-deductibility of the $215 million charge to account for an additional year of the Branded Prescription Drug Fee in accordance with final regulations issued in the third quarter of 2014 by the IRS;
- a decrease in the favorable impact of the U.S. R&D tax credit as compared to 2013;
- the non-recurrence of the U.S. tax benefits of approximately $430 million, representing tax and interest, resulting from a settlement with the IRS with respect to audits of the Wyeth tax returns for the year 2006 through date of acquisition; and
- a decrease in 2014 of the favorable impact of the resolution of certain tax positions, pertaining to prior years with various foreign tax authorities, and from the expiration of certain statutes of limitations as compared to 2013.

Changes in Tax Laws

On February 28, 2013, the Governor of Puerto Rico signed into law Act No. 2-2013, amending Sections 2101 and 2102 of the Puerto Rico Internal Revenue Code of 1994, which provided for an excise tax that was effective beginning in 2011 (Act 154). The excise tax is imposed on the purchase of products by multinational corporations and their affiliates from their Puerto Rico affiliates. As originally adopted, the excise tax was to be in effect from 2011 through 2016 and the tax rate was to decline over time from 4% in 2011 to 1% in 2016. Act No. 2-2013 extended the excise tax through 2017 and, effective July 1, 2013, increased the tax rate to 4% for all years through 2017. The impact of Act No. 2-2013 is being recorded in Cost of sales and Provision for taxes on income, as appropriate. All expected impacts in 2016 have been reflected in our financial guidance for 2016.

On December 18, 2015, the President of the United States signed into law the Protecting Americans from Tax Hikes Act of 2015 (the 2015 Act), which generally provides for the temporary or permanent extension, retroactive to January 1, 2015, of certain tax benefits and credits that had expired, including the U.S. R&D tax credit, which was extended permanently. Given the enactment date of the 2015 Act, the benefit related to our 2015 R&D spending was recorded in 2015. All expected impacts in 2016 have been reflected in our financial guidance for 2016.

DISCONTINUED OPERATIONS

For information about our discontinued operations, see Notes to Consolidated Financial Statements—Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Divestitures.

ADJUSTED INCOME

General Description of Adjusted Income Measure

Adjusted income is an alternative view of performance used by management, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income, and certain components of Adjusted income, in order to portray the results of our major operations—the discovery, development, manufacture, marketing and sale of prescription medicines, consumer healthcare (OTC) products, and vaccines—prior to considering certain income statement elements. We have defined Adjusted income as Net income attributable to Pfizer Inc. before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Similarly, we have defined the Adjusted income components as Revenues, Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets and Other (income)/deductions—net each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. The Adjusted income measure and the Adjusted income component measures are not, and should not be viewed as, a substitute for U.S. GAAP net income or U.S. GAAP net income components.

The Adjusted income measure is an important internal measurement for Pfizer. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. The following are examples of how the Adjusted income measure is utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income basis;
- our annual budgets are prepared on an Adjusted income basis; and
- senior management’s annual compensation is derived, in part, using this Adjusted income measure. Adjusted income is the performance metric utilized in the determination of bonuses under the Pfizer Inc. Executive Annual Incentive Plan that is designed to limit the bonuses payable to the Executive Leadership Team (ELT) for purposes of Internal Revenue Code Section 162(m). Subject to the Section 162(m) limitation, the bonuses are funded from a pool based on the performance measured by three financial metrics, including adjusted diluted earnings per share, which is derived from Adjusted income. This metric accounts for 40% of the bonus pool funding. The pool applies to the bonus plans for virtually all bonus-eligible, non-sales-force employees worldwide, including the ELT members and other members of senior management. In addition, commencing with the 2015 Performance Share Awards, adjusted operating income will be one of the measures utilized to determine payout. Adjusted operating income is derived from Adjusted income.

Despite the importance of this measure to management in goal setting and performance measurement, Adjusted income is a non-GAAP financial measure that has no standardized meaning prescribed by U.S. GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted income (unlike U.S. GAAP net income) may not be comparable to the calculation of similar measures of other companies. Adjusted income is presented solely to permit investors to more fully understand how management assesses performance.
We also recognize that, as an internal measure of performance, the Adjusted income measure has limitations, and we do not restrict our performance-management process solely to this metric. A limitation of the Adjusted income measure is that it provides a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and does not provide a comparable view of our performance to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a group of pharmaceutical industry peers (pre-2015) or a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer’s long-term incentive compensation plans.

See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for 2015, 2014 and 2013 below.

**Purchase Accounting Adjustments**

Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts, primarily associated with Pharmacia Corporation (acquired in 2003), Wyeth (acquired in 2009), King Pharmaceuticals, Inc. (acquired in 2011) and Hospira, Inc. (Hospira) (acquired in 2015), can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, depreciation related to the increase/decrease in fair value of the acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.

Certain of the purchase accounting adjustments can occur through 20 or more years, but this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by trying to provide a degree of parity to internally developed intangible assets for which research and development costs previously have been expended.

However, a completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through Adjusted income. This component of Adjusted income is derived solely from the impacts of the items listed in the first paragraph of this section. We have not factored in the impacts of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our research and development costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting sales, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our Adjusted income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.

**Acquisition-Related Costs**

Adjusted income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.

We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in connection with a business combination result primarily from the need to eliminate duplicate assets, activities or employees—a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in other, more normal, business contexts.

The integration and restructuring costs associated with a business combination may occur over several years, with the more significant impacts typically ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the highly regulated nature of the pharmaceutical business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the FDA and/or other global regulatory authorities.

**Discontinued Operations**

Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such operations such as the gains on the full disposition of our former Animal Health business (Zoetis) in June 2013. We believe that this presentation is meaningful to investors because, while we review our businesses and product lines for strategic fit with our operations, we do not build or run our businesses with the intent to sell them. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.
Certain Significant Items

Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be a major non-acquisition-related restructuring charge and associated implementation costs for a program that is specific in nature with a defined term, such as those related to our global commercial structure reorganization and our other non-acquisition-related cost-reduction and productivity initiatives; amounts related to certain disposals of businesses, products or facilities that do not qualify as discontinued operations under U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation; or charges related to certain legal matters, such as certain of those discussed in Notes to Consolidated Financial Statements—Note 17A. Commitments and Contingencies: Legal Proceedings and in Part II, Item 1, “Legal Proceedings” in our Quarterly Reports on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain significant items.
## Reconciliation of GAAP Reported to Non-GAAP Adjusted Information—Certain Line Items

**2015**

<table>
<thead>
<tr>
<th>IN MILLIONS, EXCEPT PER COMMON SHARE DATA</th>
<th>GAAP Reported</th>
<th>Purchase Accounting Adjustments(^{(a)})</th>
<th>Acquisition-Related Costs(^{(a)})</th>
<th>Discontinued Operations(^{(a)})</th>
<th>Certain Significant Items(^{(a)})</th>
<th>Non-GAAP Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$ 48,851</td>
<td>$ —</td>
<td>$ —</td>
<td>$ —</td>
<td>$ —</td>
<td>$ 48,851</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>9,648</td>
<td>(413)</td>
<td>(75)</td>
<td>—</td>
<td>(140)</td>
<td>9,021</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>14,809</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(484)</td>
<td>14,324</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>7,690</td>
<td>7</td>
<td>—</td>
<td>—</td>
<td>(44)</td>
<td>7,653</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>3,728</td>
<td>(3,598)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>130</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>1,152</td>
<td>—</td>
<td>(820)</td>
<td>—</td>
<td>(333)</td>
<td>—</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>2,860</td>
<td>52</td>
<td>—</td>
<td>—</td>
<td>(3,321)</td>
<td>(409)</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>8,965</td>
<td>3,953</td>
<td>894</td>
<td>—</td>
<td>4,321</td>
<td>18,133</td>
</tr>
<tr>
<td>Provision for taxes on income(^{(b)})</td>
<td>1,990</td>
<td>1,110</td>
<td>303</td>
<td>—</td>
<td>949</td>
<td>4,352</td>
</tr>
<tr>
<td>Income from continuing operations</td>
<td>6,975</td>
<td>2,843</td>
<td>591</td>
<td>—</td>
<td>3,372</td>
<td>13,781</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>11</td>
<td>—</td>
<td>—</td>
<td>(11)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Net income attributable to noncontrolling interests</td>
<td>26</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>26</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc.</td>
<td>6,960</td>
<td>2,843</td>
<td>591</td>
<td>(11)</td>
<td>3,372</td>
<td>13,755</td>
</tr>
<tr>
<td>Earnings per common share attributable to Pfizer Inc.—diluted</td>
<td>1.11</td>
<td>0.45</td>
<td>0.09</td>
<td>—</td>
<td>0.54</td>
<td>2.20</td>
</tr>
</tbody>
</table>

**2014**

<table>
<thead>
<tr>
<th>IN MILLIONS, EXCEPT PER COMMON SHARE DATA</th>
<th>GAAP Reported</th>
<th>Purchase Accounting Adjustments(^{(a)})</th>
<th>Acquisition-Related Costs(^{(a)})</th>
<th>Discontinued Operations(^{(a)})</th>
<th>Certain Significant Items(^{(a)})</th>
<th>Non-GAAP Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$ 49,605</td>
<td>$ —</td>
<td>$ —</td>
<td>$ —</td>
<td>$ (198)</td>
<td>$ 49,406</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>9,577</td>
<td>101</td>
<td>(53)</td>
<td>—</td>
<td>(491)</td>
<td>9,134</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>14,097</td>
<td>1</td>
<td>—</td>
<td>—</td>
<td>(377)</td>
<td>13,721</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>8,393</td>
<td>2</td>
<td>—</td>
<td>—</td>
<td>(1,243)</td>
<td>7,153</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>4,039</td>
<td>(3,884)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>155</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>250</td>
<td>—</td>
<td>(130)</td>
<td>—</td>
<td>(121)</td>
<td>—</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>1,009</td>
<td>139</td>
<td>—</td>
<td>—</td>
<td>(1,716)</td>
<td>(567)</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>12,240</td>
<td>3,641</td>
<td>183</td>
<td>—</td>
<td>3,749</td>
<td>19,812</td>
</tr>
<tr>
<td>Provision for taxes on income(^{(b)})</td>
<td>3,120</td>
<td>1,085</td>
<td>76</td>
<td>—</td>
<td>969</td>
<td>5,250</td>
</tr>
<tr>
<td>Income from continuing operations</td>
<td>9,119</td>
<td>2,556</td>
<td>107</td>
<td>—</td>
<td>2,780</td>
<td>14,562</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>48</td>
<td>—</td>
<td>—</td>
<td>(48)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Net income attributable to noncontrolling interests</td>
<td>32</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>32</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc.</td>
<td>9,135</td>
<td>2,556</td>
<td>107</td>
<td>(48)</td>
<td>2,780</td>
<td>14,530</td>
</tr>
<tr>
<td>Earnings per common share attributable to Pfizer Inc.—diluted</td>
<td>1.42</td>
<td>0.40</td>
<td>0.02</td>
<td>(0.01)</td>
<td>0.43</td>
<td>2.26</td>
</tr>
</tbody>
</table>

See end of tables for notes \(^{(a)}\) and \(^{(b)}\).
## Pfizer Inc. and Subsidiary Companies

### 2015 Financial Report

<table>
<thead>
<tr>
<th>IN MILLIONS, EXCEPT PER COMMON SHARE DATA</th>
<th>GAAP Reported</th>
<th>Purchase Accounting Adjustments(a)</th>
<th>Acquisition-Related Costs(a)</th>
<th>Discontinued Operations(a)</th>
<th>Certain Significant Items(a)</th>
<th>Non-GAAP Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$51,584</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$(132)</td>
<td>$51,452</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>9,586</td>
<td>23</td>
<td>(116)</td>
<td>—</td>
<td>(220)</td>
<td>9,273</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>14,355</td>
<td>8</td>
<td>(8)</td>
<td>—</td>
<td>(183)</td>
<td>14,172</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>6,678</td>
<td>3</td>
<td>—</td>
<td>—</td>
<td>(127)</td>
<td>6,554</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>4,599</td>
<td>(4,438)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>161</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>1,182</td>
<td>—</td>
<td>(252)</td>
<td>—</td>
<td>(930)</td>
<td>—</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>(532)</td>
<td>60</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>636</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>15,716</td>
<td>4,344</td>
<td>376</td>
<td>—</td>
<td>692</td>
<td>21,128</td>
</tr>
<tr>
<td>Provision for taxes on income(b)</td>
<td>4,306</td>
<td>1,198</td>
<td>(7)</td>
<td>—</td>
<td>313</td>
<td>5,810</td>
</tr>
<tr>
<td>Income from continuing operations</td>
<td>11,410</td>
<td>3,146</td>
<td>383</td>
<td>—</td>
<td>379</td>
<td>15,318</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>10,662</td>
<td>—</td>
<td>—</td>
<td>(10,662)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Net income attributable to noncontrolling interests</td>
<td>69</td>
<td>—</td>
<td>—</td>
<td>(39)</td>
<td>—</td>
<td>30</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc.</td>
<td>22,003</td>
<td>3,146</td>
<td>383</td>
<td>(10,623)</td>
<td>379</td>
<td>15,288</td>
</tr>
<tr>
<td>Earnings per common share attributable to Pfizer Inc.—diluted</td>
<td>3.19</td>
<td>0.46</td>
<td>0.06</td>
<td>(1.54)</td>
<td>0.05</td>
<td>2.22</td>
</tr>
</tbody>
</table>

(a) For details of adjustments, see “Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income” below.

(b) The effective tax rate on Non-GAAP Adjusted income was 24.0% in 2015, 26.5% in 2014 and 27.5% in 2013. The effective tax rate for 2015 compared with 2014 was favorably impacted by the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business. The effective tax rate in 2014 compared to 2013 was favorably impacted by the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, partially offset by a decrease in the favorable impact of the resolution of certain tax positions, pertaining to prior years, with various foreign tax authorities and from the expiration of certain statutes of limitations, as well as a decrease in the favorable impact of the U.S. R&D tax credit compared to 2013.
# Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income

Adjusted income, as shown above, excludes the following items:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purchase accounting adjustments</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amortization, depreciation and other(a)</td>
<td>$ 3,540</td>
<td>$ 3,742</td>
<td>$ 4,367</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>413</td>
<td>(101)</td>
<td>(23)</td>
</tr>
<tr>
<td>Total purchase accounting adjustments—pre-tax</td>
<td>$ 3,953</td>
<td>3,641</td>
<td>4,344</td>
</tr>
<tr>
<td>Income taxes(b)</td>
<td>(1,110)</td>
<td>(1,085)</td>
<td>(1,198)</td>
</tr>
<tr>
<td>Total purchase accounting adjustments—net of tax</td>
<td>2,843</td>
<td>2,556</td>
<td>3,146</td>
</tr>
<tr>
<td><strong>Acquisition-related costs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring charges(c)</td>
<td>479</td>
<td>50</td>
<td>108</td>
</tr>
<tr>
<td>Transaction costs(c)</td>
<td>123</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Integration costs(c)</td>
<td>218</td>
<td>80</td>
<td>144</td>
</tr>
<tr>
<td>Additional depreciation—asset restructuring(d)</td>
<td>75</td>
<td>53</td>
<td>124</td>
</tr>
<tr>
<td>Total acquisition-related costs—pre-tax</td>
<td>894</td>
<td>183</td>
<td>376</td>
</tr>
<tr>
<td>Income taxes(e)</td>
<td>(303)</td>
<td>(76)</td>
<td>7</td>
</tr>
<tr>
<td>Total acquisition-related costs—net of tax</td>
<td>591</td>
<td>107</td>
<td>383</td>
</tr>
<tr>
<td><strong>Discontinued operations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued operations—net of tax(f)</td>
<td>(11)</td>
<td>(48)</td>
<td>(10,662)</td>
</tr>
<tr>
<td>Discontinued operations—net of tax, attributable to noncontrolling interests</td>
<td>—</td>
<td>—</td>
<td>39</td>
</tr>
<tr>
<td>Total discontinued operations—net of tax, attributable to Pfizer Inc.</td>
<td>(11)</td>
<td>(48)</td>
<td>(10,623)</td>
</tr>
<tr>
<td><strong>Certain significant items</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring charges(g)</td>
<td>333</td>
<td>121</td>
<td>930</td>
</tr>
<tr>
<td>Implementation costs and additional depreciation—asset restructuring(h)</td>
<td>251</td>
<td>478</td>
<td>398</td>
</tr>
<tr>
<td>Foreign currency loss and inventory impairment related to Venezuela(i)</td>
<td>878</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Charge related to pension settlement(i)</td>
<td>491</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Upfront fee associated with collaborative arrangement(h)</td>
<td>—</td>
<td>1,163</td>
<td>—</td>
</tr>
<tr>
<td>Additional year of Branded Prescription Drug Fee(i)</td>
<td>—</td>
<td>215</td>
<td>—</td>
</tr>
<tr>
<td>Patent litigation settlement income(m)</td>
<td>—</td>
<td>—</td>
<td>(1,342)</td>
</tr>
<tr>
<td>Certain other legal matters, net(n)</td>
<td>968</td>
<td>999</td>
<td>21</td>
</tr>
<tr>
<td>Gain associated with the transfer of certain product rights(h)</td>
<td>—</td>
<td>—</td>
<td>(459)</td>
</tr>
<tr>
<td>Certain asset impairments(h)</td>
<td>787</td>
<td>440</td>
<td>836</td>
</tr>
<tr>
<td>Business and legal entity alignment costs(i)</td>
<td>282</td>
<td>168</td>
<td>—</td>
</tr>
<tr>
<td>Costs associated with the Zoetis IPO(g)</td>
<td>—</td>
<td>—</td>
<td>18</td>
</tr>
<tr>
<td>Other(n)</td>
<td>332</td>
<td>165</td>
<td>290</td>
</tr>
<tr>
<td>Total certain significant items—pre-tax</td>
<td>4,321</td>
<td>3,749</td>
<td>692</td>
</tr>
<tr>
<td>Income taxes(r)</td>
<td>(949)</td>
<td>(969)</td>
<td>(313)</td>
</tr>
<tr>
<td>Total certain significant items—net of tax</td>
<td>3,372</td>
<td>2,780</td>
<td>379</td>
</tr>
<tr>
<td><strong>Total purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items—net of tax, attributable to Pfizer Inc.</strong></td>
<td>$ 6,795</td>
<td>$ 5,394</td>
<td>$(6,715)</td>
</tr>
</tbody>
</table>

(a) Included primarily in Amortization of intangible assets.
(b) Included in Provision for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate.
(c) Included in Restructuring charges and certain acquisition-related costs (see Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives). Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations. Transaction costs represent external costs directly related to our pending combination with Allergan plc and the acquisition of Hospira, and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In 2015, restructuring charges and integration costs primarily relate to our acquisition of Hospira on September 3, 2015. All of these costs and charges are included in Restructuring charges and certain acquisition-related costs.
(d) Represents the impact of changes in estimated useful lives of assets involved in restructuring actions related to acquisitions. For 2015 and 2014, included in Cost of sales. For 2013, included in Cost of sales ($116 million) and Selling informational and administrative expenses ($8 million).
(1) Included in Provision for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. As applicable, each period may also include the impact of the re-measurement of certain deferred tax liabilities resulting from our plant network restructing activities: in 2014, there was a favorable impact; and in 2013, there was an unfavorable impact.

(2) Included in Discontinued operations—net of tax. For 2015 and 2014, represents post-close adjustments. For 2013, virtually all relates to our former Animal Health business, through June 24, 2013, the date of disposal (see Notes to Consolidated Financial Statements—Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Divestitures).

(3) Amounts relate to our cost-reduction and productivity initiatives not related to acquisitions. Included in Restructuring charges and certain acquisition-related costs (see Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives).

(5) Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives). For 2015, virtually all included in Cost of sales ($145 million), Selling, informational and administrative expenses ($383 million) and Research and development expenses ($19 million). For 2014, virtually all included in Cost of sales ($253 million), Selling, informational and administrative expenses ($141 million) and Research and development expenses ($383 million). For 2013, virtually all included in Selling, informational and administrative expenses ($156 million), Research and development expenses ($127 million) and Cost of sales ($115 million).

(6) In 2015, represents (i) an $806 million foreign currency loss included in Other (income)/deductions—net related to recent conditions in Venezuela, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation are no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.30, but rather at the SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant amounts of Venezuelan bolivars related to intercompany U.S. dollar-denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy; and (ii) a $72 million charge included in Cost of sales related to inventory impairment in Venezuela related to the foreign currency change described above.

(7) Included in Cost of sales ($72 million) and Selling, informational and administrative expenses ($419 million). In 2015, primarily represents a non-recurring charge related to settlement of pension obligations in accordance with an offer to certain terminated employees who are vested in their pension benefits to elect a lump-sum payment or annuity of their deferred vested pension benefits.

(8) Virtually all included in Research and development expenses. Represents a charge associated with a collaborative arrangement with Merck KGaA, announced in November 2014, to jointly develop and commercialize avelumab, an investigational anti-PD-L1 antibody currently in development as a potential treatment for multiple types of cancer. The charge includes an $850 million upfront cash payment as well as an additional amount of $309 million, reflecting the estimated fair value of the co-promotion rights for Xalkori given to Merck KGaA.

(9) Included in Selling, informational and administrative expenses. In 2014, represents a charge to account for an additional year of the non-tax deductible Branded Prescription Drug Fee in accordance with final regulations issued in the third quarter of 2013 for the IRS.

(10) In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages resulting from their ‘at-risk’ launches of generic Protonix in the U.S. Included in Other (income)/deductions—net (see the ‘Other (Income)/Deductions—Net’ section of this Financial Review and Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net).

(11) Included in Other (income)/deductions—net (see the ‘Other (Income)/Deductions—Net’ section of this Financial Review and Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net).

(12) Included in Other (income)/deductions—net. In 2015 and 2014, represents expenses for changes to our infrastructure to align our operations, as well as reporting for our business segments established in 2014.

(13) Represents costs incurred in connection with the initial public offering of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For 2013, included in Other (income)/deductions—net (see the “Other (Income)/Deductions—Net” section of this Financial Review and Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net).

(14) For 2015, virtually all included in Cost of sales ($149 million income), and Other (income)/deductions—net ($473 million). For 2014, virtually all included in Revenues ($198 million), Cost of sales ($238 million), Selling, informational and administrative expenses ($21 million) and Other (income)/deductions—net ($103 million). For 2013, included in Revenues ($132 million), Cost of sales ($105 million), Selling, informational and administrative expenses ($26 million) and Other (income)/deductions—net ($291 million). For 2015, includes, among other things, a change in the profit deferred in inventory relating to inventory that had not been sold to third parties that is included in Cost of sales (non-cash benefit of $221 million), losses of $239 million, which are included in Other (income)/deductions—net, and are related to our share of an equity method investee’s charges incurred for its re-measurement of a contingent consideration liability, and charges of $173 million related to the write-down of assets to net realizable value that are primarily included in Other (income)/deductions—net. In 2013, includes an estimated loss on an option to acquire the remaining interest in Laboratório Teuto Brasileiro S.A. (Teuto), a 40%-owned generics company in Brazil (approximately $223 million). In 2014, includes income resulting from a decline in the estimated loss from the aforementioned option (approximately $55 million). In 2014, includes, among other things, income associated with the manufacturing and supply agreements with Zoetis Inc. that are virtually all included in Revenues ($272 million) and Cost of sales ($237 million). For 2013, includes, among other things, income associated with the manufacturing and supply agreements with Zoetis Inc. that are included in Revenues ($132 million) and Cost of sales ($116 million).

(16) Included in Provision for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The amount in 2015 was favorably impacted by tax benefits associated with certain tax initiatives. In addition, the amount in 2015 was unfavorably impacted by a non-deductible foreign currency loss related to Venezuela and the non-deductible charge for the agreement in principle to resolve claims relating to Protonix. The amount in 2014 was favorably impacted by the decline in the non-tax deductible estimated loss recorded in the third quarter of 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and unfavorably impacted by a non-tax deductible charge to account for an additional year of the Branded Prescription Drug Fee in accordance with final regulations issued in the third quarter of 2014 by the IRS. The amount in 2013 was favorably impacted by U.S. tax benefits of approximately $430 million, representing tax and interest, resulting from a settlement with the IRS with respect to audits of the Wyeth tax returns for the years 2006 through date of acquisition and unfavorably impacted by (i) the tax rate associated with the patent litigation settlement income, (ii) the non-deductibility of goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer, and (iii) the aforementioned non-tax deductible estimated loss related to the Teuto option, since we expect to retain the investment indefinitely, and the non-deductibility of an impairment charge related to our equity-method investment in Teuto. See Notes to Consolidated Financial Statements—Note 5A. Tax Matters: Taxes on Income from Continuing Operations.
ANALYSIS OF OPERATING SEGMENT INFORMATION

The following tables and associated notes provide additional information about the performance of our three operating segments—the Global Innovative Pharmaceutical segment (GIP); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC); and the Global Established Pharmaceutical segment (GEP). For additional information about each operating segment, see the “Our Strategy—Commercial Operations” section of this Financial Review and Notes to Consolidated Financial Statements—Note 18. Segment, Geographic and Other Revenue Information.

### 2015

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>GIP(a)</th>
<th>VOC(a)</th>
<th>Total Innovative Products(b)</th>
<th>Established Products GEP(c)</th>
<th>Other(c)</th>
<th>Non-GAAP Adjusted(d)</th>
<th>Reconciling Items(e)</th>
<th>GAAP Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$13,954</td>
<td>$12,803</td>
<td>$ 26,758</td>
<td>$ 21,587</td>
<td>$ 506</td>
<td>$ 48,851</td>
<td>—</td>
<td>$ 48,851</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>1,561</td>
<td>2,089</td>
<td>3,650</td>
<td>4,486</td>
<td>884</td>
<td>9,021</td>
<td>627</td>
<td>9,648</td>
</tr>
<tr>
<td>% of revenue</td>
<td>11.2%</td>
<td>16.3%</td>
<td>13.6%</td>
<td>20.8%</td>
<td>*</td>
<td>18.5%</td>
<td>*</td>
<td>19.7%</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>3,611</td>
<td>3,195</td>
<td>6,807</td>
<td>3,572</td>
<td>3,945</td>
<td>14,324</td>
<td>485</td>
<td>14,809</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>1,987</td>
<td>1,043</td>
<td>3,030</td>
<td>758</td>
<td>3,865</td>
<td>7,653</td>
<td>37</td>
<td>7,690</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>46</td>
<td>48</td>
<td>94</td>
<td>36</td>
<td>—</td>
<td>130</td>
<td>3,598</td>
<td>3,728</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1,152</td>
<td>1,152</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>(1,008)</td>
<td>(79)</td>
<td>(1,087)</td>
<td>(150)</td>
<td>827</td>
<td>(409)</td>
<td>3,269</td>
<td>2,860</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>$ 7,757</td>
<td>$ 6,507</td>
<td>$ 14,264</td>
<td>$ 12,885</td>
<td>$(9,016)</td>
<td>$ 18,133</td>
<td>$(9,168)</td>
<td>$ 8,965</td>
</tr>
</tbody>
</table>

### 2014

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>GIP(a)</th>
<th>VOC(a)</th>
<th>Total Innovative Products(b)</th>
<th>Established Products GEP(c)</th>
<th>Other(c)</th>
<th>Non-GAAP Adjusted(d)</th>
<th>Reconciling Items(e)</th>
<th>GAAP Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$13,861</td>
<td>$10,144</td>
<td>$ 24,005</td>
<td>$ 25,149</td>
<td>$ 253</td>
<td>$ 49,406</td>
<td>$ 198</td>
<td>$ 49,605</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>1,858</td>
<td>1,991</td>
<td>3,848</td>
<td>4,570</td>
<td>716</td>
<td>9,134</td>
<td>443</td>
<td>9,577</td>
</tr>
<tr>
<td>% of revenue</td>
<td>13.4%</td>
<td>19.6%</td>
<td>16.0%</td>
<td>18.2%</td>
<td>*</td>
<td>18.5%</td>
<td>*</td>
<td>19.3%</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>3,606</td>
<td>2,556</td>
<td>6,162</td>
<td>3,903</td>
<td>3,655</td>
<td>13,721</td>
<td>377</td>
<td>14,097</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>1,625</td>
<td>925</td>
<td>2,549</td>
<td>657</td>
<td>3,946</td>
<td>7,153</td>
<td>1,241</td>
<td>8,393</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>45</td>
<td>24</td>
<td>69</td>
<td>85</td>
<td>—</td>
<td>155</td>
<td>3,884</td>
<td>4,039</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>(1,052)</td>
<td>(44)</td>
<td>(1,096)</td>
<td>(265)</td>
<td>794</td>
<td>(567)</td>
<td>1,577</td>
<td>1,009</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>$ 7,780</td>
<td>$ 4,692</td>
<td>$ 12,472</td>
<td>$ 16,199</td>
<td>$(8,859)</td>
<td>$ 19,812</td>
<td>$(7,573)</td>
<td>$ 12,240</td>
</tr>
</tbody>
</table>

### 2013(f)

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>GIP(a)</th>
<th>VOC(a)</th>
<th>Total Innovative Products(b)</th>
<th>Established Products GEP(c)</th>
<th>Other(c)</th>
<th>Non-GAAP Adjusted(d)</th>
<th>Reconciling Items(e)</th>
<th>GAAP Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$14,317</td>
<td>$ 9,285</td>
<td>$ 23,602</td>
<td>$ 27,619</td>
<td>$ 232</td>
<td>$ 51,452</td>
<td>$ 132</td>
<td>$ 51,584</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>1,833</td>
<td>1,843</td>
<td>3,675</td>
<td>4,732</td>
<td>866</td>
<td>9,273</td>
<td>313</td>
<td>9,586</td>
</tr>
<tr>
<td>% of revenue</td>
<td>12.8%</td>
<td>19.8%</td>
<td>15.6%</td>
<td>17.1%</td>
<td>*</td>
<td>18.0%</td>
<td>*</td>
<td>18.6%</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>3,194</td>
<td>2,326</td>
<td>5,520</td>
<td>4,714</td>
<td>3,938</td>
<td>14,172</td>
<td>183</td>
<td>14,355</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>1,242</td>
<td>912</td>
<td>2,154</td>
<td>737</td>
<td>3,663</td>
<td>6,554</td>
<td>124</td>
<td>6,678</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>45</td>
<td>13</td>
<td>58</td>
<td>100</td>
<td>3</td>
<td>161</td>
<td>4,438</td>
<td>4,599</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>—</td>
<td>6</td>
<td>6</td>
<td>(5)</td>
<td>—</td>
<td>—</td>
<td>1,182</td>
<td>1,182</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>(545)</td>
<td>(31)</td>
<td>(576)</td>
<td>(216)</td>
<td>957</td>
<td>164</td>
<td>(696)</td>
<td>(532)</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>$ 8,549</td>
<td>$ 4,216</td>
<td>$ 12,765</td>
<td>$ 17,552</td>
<td>$(9,189)</td>
<td>$ 21,128</td>
<td>$(5,412)</td>
<td>$ 15,716</td>
</tr>
</tbody>
</table>

(a) Amounts represent the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment.

(b) Total Innovative Products represents the sum of the GIP and VOC segments.
Other comprises the revenues and costs included in our Adjusted income components (see footnote (d) below) that are managed outside of our three operating segments and includes the following:

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PCS(i)</td>
<td>WRD(ii)</td>
<td>Medical(iii)</td>
</tr>
<tr>
<td><strong>Revenues</strong></td>
<td>$ 506</td>
<td>$ 253</td>
<td>$ 232</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>396</td>
<td>165</td>
<td>142</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>13 2 149 3,711</td>
<td>19 — 1144 3,454</td>
<td>3 2,799 23 823</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>3 2,945 29 878</td>
<td>3 3,056 27 850</td>
<td>3 3,056 27 850</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>— — — — —</td>
<td>— — — — —</td>
<td>— — — — —</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>— — — 3 (3) —</td>
<td>— — — 795 67 —</td>
<td>— — — 795 67 —</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>(1) (77) —</td>
<td>(3) (66) —</td>
<td>(2) (66) —</td>
</tr>
<tr>
<td><strong>Income from continuing operations before provision for taxes on income</strong></td>
<td>$ 96 $ (2,870) $ (177) $ (5,430) $ (636)</td>
<td>$ 69 $ (2,989) $ (171) $ (5,200) $ (567)</td>
<td>$ 75 $ (2,735) $ (169) $ (5,689) $ (671)</td>
</tr>
</tbody>
</table>

(i) PCS—the revenues and costs of Pfizer CentreSource (PCS), our contract manufacturing and bulk pharmaceutical chemical sales operation. In 2015, PCS also includes revenues and expenses related to our manufacturing and supply agreements with Zoetis Inc.

(ii) WRD—the research and development (R&D) expenses managed by our Worldwide Research and Development organization (WRD), which is generally responsible for research projects until proof-of-concept is achieved and then for transitioning those projects to the appropriate operating segment for possible clinical and commercial development. This organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.

(iii) Medical—the costs associated with our Pfizer Medical organization (Medical), which, during the years 2013 through 2015, was responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, partnerships with global public health and medical associations, regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes.
Financial Review
Pfizer Inc. and Subsidiary Companies

(i) Corporate—the costs associated with Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments.

(ii) Other Unallocated—other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.

For information purposes only, for 2015, we estimate that Other costs, in the aggregate and as described above, but excluding (i) the revenues and costs associated with PCS; (ii) net interest-related expense not attributable to an operating segment and included in Corporate (approximately $831 million in Other (income)/deductions—net); and (iii) net gains on investments not attributable to an operating segment and included in Corporate (approximately $104 million in Other (income)/deductions—net), are generally associated with our operating segments, as follows:

<table>
<thead>
<tr>
<th>(PERCENTAGES)</th>
<th>GIP</th>
<th>VOC</th>
<th>GEP</th>
</tr>
</thead>
<tbody>
<tr>
<td>WRD/Medical Costs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>55% - 57%</td>
<td>17% - 19%</td>
<td>24% - 26%</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>49% - 53%</td>
<td>35% - 38%</td>
<td>12% - 14%</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Total WRD/Medical Costs</td>
<td>48% - 52%</td>
<td>35% - 38%</td>
<td>13% - 15%</td>
</tr>
</tbody>
</table>

| Corporate/Other Unallocated Costs |      |     |     |
| Cost of sales | (12%) - (14%) | (9%) - (11%) | 118% - 120% |
| Selling, informational and administrative expenses | 27% - 29% | 24% - 26% | 44% - 48% |
| Research and development expenses | 46% - 50% | 37% - 40% | 13% - 15% |
| Other (income)/deductions—net | * | * | * |
| Total Corporate/Other Unallocated Costs | 26% - 29% | 22% - 25% | 46% - 49% |

| Total WRD/Medical and Corporate/Other Unallocated Costs |      |     |     |
| Cost of sales | (12%) - (14%) | (9%) - (11%) | 118% - 120% |
| Selling, informational and administrative expenses | 28% - 30% | 24% - 26% | 43% - 47% |
| Research and development expenses | 48% - 52% | 35% - 38% | 13% - 15% |
| Other (income)/deductions—net | * | * | * |
| Total WRD/Medical and Corporate/Other Unallocated Costs | 34% - 37% | 27% - 30% | 34% - 37% |

* Amounts not material. After excluding net interest expense included in Corporate and net gains on investments not attributable to an operating segment and included in Corporate, Other (income)/deductions—net approximates $97 million of expense.

The percentages provided in the table above do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment operated as a standalone company during the period presented.

- **WRD/Medical**—The information provided in the table above for WRD and Medical was substantially all derived from our estimates of the costs incurred in connection with the R&D projects associated with each operating segment.
- **Corporate/Other Unallocated**—Virtually all of the information provided in the table above for Corporate and Other Unallocated was derived using proportional allocation methods based on global, regional or country revenues or global, regional or country headcount, as well as certain cost metrics, as appropriate, such as those derived from R&D and manufacturing costs. Management believes that the allocations of Corporate and Other Unallocated costs are reasonable.

(1) See the “Adjusted Income” section of this Financial Review for a definition of these “Adjusted Income” components.

(2) Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive, unusual items that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP Adjusted measure of performance, see the “Adjusted Income” section of this Financial Review.

(3) As our operations were not managed under the new structure until the beginning of the first quarter of 2014, certain costs and expenses could not be directly attributed to one of the new operating segments. As a result, our operating segment results for 2013 include allocations. The amounts subject to allocation methods in 2013 were approximately $2.1 billion, of selling, informational and administrative expenses and approximately $800 million, of R&D expenses.

- The selling, informational and administrative expenses were allocated using proportional allocation methods based on associated selling costs, revenues or product-specific costs, as applicable.
- The R&D expenses were allocated based on product-specific R&D costs or revenue metrics, as applicable.
- Management believes that the allocations are reasonable.
- Calculation not meaningful.

Global Innovative Pharmaceutical Operating Segment

2015 vs. 2014

- **Revenues** increased 1% in 2015, compared to 2014. Foreign exchange had an unfavorable impact of 8% on GIP revenues in 2015, compared to 2014. Revenues increased by 9% operationally in 2015, compared to 2014, primarily due to the following operational factors:
  - strong operational performance of Eliquis globally, Lynica, primarily in the U.S. and Japan, as well as Xeljanz, Viagra and Chantix, all primarily in the U.S. (collectively, up approximately $1.5 billion in 2015), partially offset by:
    - a decline in Rapamune revenues in the U.S. due to generic competition which began in October 2014 (down approximately $120 million in 2015), and
    - declines in the hemophilia portfolio in the U.S. due to increased competition (collectively down approximately $100 million).
Total GIP revenues from emerging markets were $1.6 billion in 2015, consistent with $1.6 billion in 2014, reflecting 9% operational growth, which was offset by the unfavorable impact of foreign exchange.

- Cost of sales as a percentage of Revenues decreased 2.2 percentage points in 2015, compared to 2014, primarily driven by a decrease in royalty expense, favorable foreign exchange and an increase in alliance revenues, which have no associated cost of sales. The decrease in Cost of sales of 16% in 2015, compared to 2014, was primarily driven by favorable foreign exchange and, to a lesser extent, a decrease in royalty expense.

- The slight increase in Selling, informational and administrative expenses in 2015, compared to 2014, reflects additional investment in Eliquis, Lyrica and certain other products, largely offset by favorable foreign exchange and reduced investment in certain other products.

- The increase in Research and development expenses of 22% in 2015, compared to 2014, primarily reflects the $295 million upfront payment to OPKO Health, Inc. made in the first quarter of 2015 and increased investment in certain late-stage pipeline programs, primarily bococizumab, partially offset by lower clinical trial expenses for certain previously approved products.

- The unfavorable change in Other (income)/deductions—net of 4% in 2015, compared to 2014, primarily reflects a decrease in royalty-related income, partially offset by an increase in our equity income from certain equity-method investments.

2014 vs. 2013:

- Revenues decreased 3% in 2014, compared to 2013. Foreign exchange had an unfavorable impact of 1% on GIP revenues in 2014, compared to 2013. Revenues decreased by 2% operationally in 2014, compared to 2013, primarily due to the following operational factors:
  - the expiration of the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada on October 31, 2013 (down approximately $1.4 billion in 2014); and
  - loss of exclusivity for Lyrica in Canada in February 2013 (a decline of approximately $67 million in 2014), partially offset by:
    - strong operational growth from Lyrica, primarily in the U.S. and Japan, and Enbrel outside the U.S. and Canada, as well as the performance of recently launched products, including Eliquis, primarily in the U.S. and most other developed markets, and Xeljanz primarily in the U.S. (a combined increase of approximately $1.1 billion in 2014).

Total GIP revenues from emerging markets were $1.6 billion in 2014.

- Cost of sales as a percentage of Revenues increased 0.6 percentage points in 2014, compared to 2013, due to the loss of Enbrel alliance revenue after October 31, 2013 when the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired as well as an unfavorable change in product mix. The increase in Cost of sales primarily reflects an unfavorable change in product mix.

- Selling, informational and administrative expenses increased 13% in 2014 compared to 2013, reflecting increased investment in recently launched products and certain in-line products.

- Research and development expenses increased 31% in 2014 compared to 2013, reflecting incremental investment in late-stage pipeline products.

- The favorable change in Other (income)/deductions—net of 93% in 2014, compared to 2013, primarily reflects an increase in royalty-related income, primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. As noted above, on that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and Pfizer became entitled to royalties for a 36-month period thereafter.

**Global Vaccines, Oncology and Consumer Healthcare Operating Segment**

**Global Vaccines, Oncology and Consumer Healthcare Revenues**

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Global Vaccines</td>
<td>$6,454</td>
<td>$4,480</td>
</tr>
<tr>
<td>Consumer Healthcare</td>
<td>3,395</td>
<td>3,446</td>
</tr>
<tr>
<td>Global Oncology</td>
<td>2,954</td>
<td>2,218</td>
</tr>
<tr>
<td>Total VOC</td>
<td>$12,803</td>
<td>$10,144</td>
</tr>
</tbody>
</table>

2015 vs. 2014:

- Revenues increased 26% in 2015, compared to 2014, which includes an increase of 34% operationally in 2015.
  - Global Vaccines Revenues increased 44% in 2015, compared to 2014, reflecting an operational increase in revenues of 51% in 2015. The increase was primarily due to an increase of 87% in 2015 in Prevnar family revenue in the U.S., primarily driven by continued strong uptake of Prevnar 13 among adults following the positive recommendation from ACIP for use in adults aged 65 and older in the third quarter of 2014. International revenues increased 18% operationally in 2015, driven by the Prevenar family, which grew 9% operationally in 2015, compared to 2014, primarily reflecting Prevenar’s inclusion in additional national immunization programs in certain emerging markets. International revenues were also favorably impacted by the inclusion in 2015 of revenues associated with the acquisition of Baxter’s portfolio of marketed vaccines in Europe.
Foreign exchange had an unfavorable impact of 7% on Vaccines revenues in 2015 compared to 2014.

Total Vaccines revenues from emerging markets were $1.2 billion in 2015 compared to $1.0 billion in 2014, reflecting 22% operational growth which was partially offset by the unfavorable impact of foreign exchange.

- **Global Oncology Revenues** increased 33% in 2015, compared to 2014, reflecting an operational increase in revenues of 43% in 2015, primarily driven by continued strong momentum following the February 2015 U.S. launch of Ibrance for advanced breast cancer and, to a lesser extent, stronger demand for Xalkori, Sutent and Inlyta in most markets.

Foreign exchange had an unfavorable impact of 10% on Oncology revenues in 2015 compared to 2014.

Total Oncology revenues from emerging markets were $397 million in 2015 compared to $375 million in 2014, reflecting 22% operational growth which was partially offset by the unfavorable impact of foreign exchange.

- **Consumer Healthcare Revenues** decreased 1% in 2015, compared 2014, reflecting an operational increase in revenues of 5% in 2015, primarily due to the launch of Nexium 24HR in the U.S. in late-May 2014, as well as increased demand for key brands such as Centrum, and operational growth in certain emerging markets.

Foreign exchange had an unfavorable impact of 6% on Consumer Healthcare revenues in 2015, compared to 2014.

Total Consumer Healthcare revenues from emerging markets were $909 million in 2015 compared to $943 million in 2014, reflecting 7% operational growth, which was more than offset by the unfavorable impact of foreign exchange of 11%.

- **Cost of sales** as a percentage of Revenues decreased 3.3 percentage points in 2015, compared to 2014, primarily driven by manufacturing efficiencies, a favorable change in product mix and favorable foreign exchange. The increase in Cost of sales of 5% in 2015, compared to 2014, was primarily due to an increase in sales volumes, driven primarily by continued strong uptake of Prevnar 13 among adults, as well as the acquisition of Baxter’s portfolio of marketed vaccines in Europe, largely offset by favorable foreign exchange and manufacturing efficiencies.

- **Selling, informational and administrative expenses** increased 25% in 2015, compared to 2014, primarily driven by higher promotional expenses in the U.S., primarily for newly launched Consumer Healthcare product line extensions, Prevnar 13 in adults and Ibrance, partially offset by favorable foreign exchange.

- **Research and development expenses** increased 13% in 2015, compared to 2014, primarily reflecting increased costs associated with our vaccine and oncology programs, primarily our anti-PD-L1 alliance with Merck KGaA and Ibrance, partially offset by lower clinical trial spend for Trumenba, Prevnar 13 adult and certain oncology products.

**2014 vs. 2013:**

- **Revenues** increased 9% in 2014, compared to 2013, which includes an increase of 11% operationally in 2014.

  - **Global Vaccines Revenues** increased 13% in 2014, compared to 2013, reflecting an operational increase in revenues of 15% in 2014. The increase was primarily due to the performance of Prevnar 13 in the U.S., primarily reflecting the timing of government purchasing patterns, increased prices and increased demand among adults following the positive recommendation from ACIP for use in adults aged 65 and over. International revenues for the Prevnar family increased 10% operationally in 2014, which primarily reflects increased shipments associated with the Global Alliance for Vaccines and Immunization (GAVI) as well as the timing of government purchases in various emerging markets compared with 2013.

  Foreign exchange had an unfavorable impact of 2% on Vaccines revenues in 2014 compared to 2013.

  Total Vaccines revenues from emerging markets were $1.0 billion in 2014.

  - **Global Oncology Revenues** increased 12% in 2014, compared 2013, reflecting an increase in revenues of 14% operationally in 2014, due to continued strong underlying demand for recent product launches, Xalkori and Inlyta globally, as well as growth from Bosulif, primarily in the U.S.

  Foreign exchange had an unfavorable impact of 2% on Oncology revenues in 2014, compared to 2013.

  Total Oncology revenues from emerging markets were $375 million in 2014.

  - **Consumer Healthcare Revenues** increased 3% in 2014, compared to 2013, reflecting an operational increase in revenues of 5% in 2014, primarily due to the launch of Nexium 24HR in the U.S. in late-May 2014 and growth of vitamin supplement products in emerging markets, partially offset by a decrease in revenues for respiratory products in the U.S. and Canada due to a less severe cold and flu incidence, and due to Ibrance due to the 2013 launch of Advil Film-Coated, which triggered increased retail purchases in the prior year.

  Foreign exchange had an unfavorable impact of 2% on Consumer Healthcare revenues in 2014, compared to 2013.

  Total Consumer Healthcare revenues from emerging markets were $943 million in 2014.

- **Cost of sales** increased 8% in 2014, compared to 2013, primarily due to an increase in sales volumes, partially offset by favorable foreign exchange.

- **Selling informational and administrative expenses** increased 10% in 2014, compared to 2013, primarily driven by Consumer Healthcare expenses incurred to support the launch of Nexium 24HR in the U.S., Prevnar 13 adult investment, as well as the launch and pre-launch marketing expenses for Trumenba (meningitis B vaccine) and Ibrance (palbociclib).

- **Research and development expenses** increased 1% in 2014, compared to 2013, reflecting increased investment in Ibrance (palbociclib) and our vaccines portfolio (including Trumenba), as well as costs associated with our anti-PD-L1 alliance with Merck KGaA, partially offset by lower costs for certain oncology programs.
Global Established Pharmaceutical Operating Segment

2015 vs. 2014:
- **Revenues** decreased 14% in 2015, compared to 2014. Foreign exchange had an unfavorable impact of 7% on GEP revenues in 2015, compared to 2014. Revenues decreased by 7% operationally in 2015, primarily due to the following operational factors:
  - the loss of exclusivity and associated launch of multi-source generic competition for Celebrex in the U.S. in December 2014, for Zyvox in the U.S. beginning in the first half of 2015, for Lyrica in certain developed Europe markets beginning in the first quarter of 2015, and Inspra in developed Europe markets beginning in August 2014 (collectively, down by approximately $2.5 billion in 2015);
  - a decline in Lipitor revenues in developed markets as a result of continued generic competition (down approximately $160 million in 2015);
  - the decline in Zosyn/Tazocin revenues due to a disruption in supply due to manufacturing issues (down approximately $160 million in 2015); and
  - the termination of the co-promotion collaboration for Spiriva (down approximately $110 million in 2015), partially offset by:
    - the inclusion of legacy Hospira operations, which contributed $1.5 billion; and
    - growth in emerging markets (excluding legacy Hospira), where revenues increased 2% operationally in 2015 (up by approximately $160 million in 2015).

Total GEP revenues from emerging markets were $7.1 billion in 2015, compared to $7.5 billion in 2014, reflecting 3% operational growth, which was more than offset by the unfavorable impact of foreign exchange of 9%.

- **Cost of sales** as a percentage of **Revenues** increased 2.6 percentage points in 2015, compared to 2014, primarily due to the impact of losses of exclusivity resulting in an unfavorable change in product mix and the inclusion of legacy Hospira operations, partially offset by favorable foreign exchange. The decrease in **Cost of sales** of 2% in 2015, compared to 2014, was primarily driven by favorable foreign exchange and lower volumes as a result of products losing exclusivity, offset by the inclusion of legacy Hospira operations.

- **Selling, informational and administrative expenses** decreased 8% in 2015, compared to 2014, primarily due to lower field force, advertising and promotional expenses reflecting the benefits of cost-reduction and productivity initiatives, as well as favorable foreign exchange, partially offset by the inclusion of legacy Hospira operations, an increase in certain general and administrative expenses and higher cost for the U.S. Branded Prescription Drug Fee compared to the prior year.

- **Research and development expenses** increased 15% in 2015, compared to 2014, reflecting the inclusion of legacy Hospira operations and increased investment in biosimilar development programs and sterile injectable development programs acquired as part of our acquisition of InnoPharma, Inc. partially offset by lower clinical trial expenses related to postmarketing commitments, primarily for Celebrex and Pristiq.

- The unfavorable change in **Other (income)/deductions—net** of 43% in 2015, compared to 2014, primarily reflects the non-recurrence of prior year gains on the sale of product rights, unfavorable foreign exchange and a decrease in our equity income from our equity-method investment in China (Hisun Pfizer), partially offset by other income gains.

2014 vs. 2013:
- **Revenues** decreased 9% in 2014, compared to 2013. Foreign exchange had an unfavorable impact of 2% on GEP revenues in 2014 compared to 2013. Revenues decrease 7% operationally in 2014, compared to 2013, primarily due to the following operational factors:
  - the loss of exclusivity and subsequent launch of multi-source generic competition for Detrol LA in the U.S. in January 2014, Celebrex in the U.S. in December 2014 and developed Europe in November 2014, Viagra in most major European markets in June 2013 as well as Aricept in Canada in December 2013 (aggregate decline of approximately $826 million in 2014);
  - the expiration or near-term expiration of the co-promotion collaboration for Spiriva in most countries, which has resulted in a decline in Pfizer’s share of Spiriva revenues (down approximately $490 million in 2014);
  - a decline in branded Lipitor revenues in the U.S. and most other developed markets as a result of continued generic competition (down approximately $388 million in 2014);
  - the decline of certain products, including Effexor, Norvasc, atorvastatin, Zosyn/Tazocin, Metaxalone, Ziprasidone and Tygacil (down approximately $428 million in 2014);
  - a decline due to loss of exclusivity for certain other products in developed markets (down approximately $170 million in 2014); and
  - a decline in Aricept, not including Canada, revenues primarily due to the termination of the co-promotion agreement in Japan in December 2012 (down approximately $75 million in 2014), partially offset by:
    - the growth of Lipitor in China (up approximately $164 million in 2014);
    - the strong performance of Lyrica in Europe (growth of approximately $144 million in 2014); and
    - the contribution from the collaboration with Mylan Inc. to market generic drugs in Japan (approximately $37 million in 2014).

Total GEP revenues from emerging markets were $7.5 billion in 2014.
• Cost of sales as a percentage of Revenues increased by 1.1 percentage points in 2014 compared to 2013, primarily due to the impact of losses of exclusivity and an unfavorable change in product mix. The 3% decrease in Cost of sales was primarily driven by favorable foreign exchange.

• Selling, informational and administrative expenses decreased 17% in 2014, compared to 2013, due to lower expenses for field force and marketing expenses, reflecting the benefits of cost-reduction and productivity initiatives.

• Research and development expenses decreased 11% in 2014 compared to 2013, due to lower clinical trial expenses and the benefits from cost-reduction and productivity initiatives, partially offset by increased spending on our biosimilars development programs.

ANALYSIS OF THE CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Changes in the components of Accumulated other comprehensive loss reflect the following:

2015
• For Foreign currency translation adjustments, net, reflects primarily the strengthening of the U.S. dollar against the euro, Brazilian real, Canadian dollar, Australian dollar, British pound, Mexican peso and Japanese yen.

• For Unrealized holding gains on derivative financial instruments, net and Unrealized holding gains/(losses) on available-for-sale securities, net, reflects the impact of fair value remeasurements and the reclassification of realized amounts into income. For additional information, see Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

• For Benefit plans: actuarial gains/(losses), net, primarily reflects the reclassification into income of amounts related to (i) the amortization of changes in the pension benefit obligation previously recognized in Other comprehensive income, (ii) lower actual return on plan assets as compared to the expected return on assets, and (iii) settlement activity, as well as the impact of foreign exchange. For additional information, see Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans and the “Significant Accounting Policies and Application of Critical Accounting Estimates––Benefit Plans” section of this Financial Review.

• For Benefit plans: prior service credits and other, net, reflects a $507 million reduction in our U.S. Postretirement Plan obligation due to a plan amendment approved in June 2015 that introduced a cap on costs for certain groups within the plan, partially offset by the reclassification into income of amounts related to (i) amortization of changes in prior service costs and credits previously recognized in Other comprehensive income and (ii) curtailment activity. For additional information, see Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.

2014
• For Foreign currency translation adjustments, reflects primarily the weakening of the euro against the U.S. dollar, and, to a lesser extent, the weakening of the Japanese yen, Canadian dollar, Brazilian real and U.K. pound against the U.S dollar. Also, includes the reclassification of amounts associated with legal entity dispositions into income.

• For Unrealized holding gains on derivative financial instruments, net reflects the impact of fair value remeasurements and the reclassification of realized amounts into income. For additional information, see Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

• For Unrealized holding gains/(losses) on available-for-sale securities, net reflects the impact of fair value remeasurements and the reclassification of realized amounts into income. For additional information, see Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

• For Benefit plans: actuarial gains/(losses), net, reflects the actuarial losses related primarily to a decrease in the discount rate. For additional information, see Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans and the “Significant Accounting Policies and Application of Critical Accounting Estimates––Benefit Plans” section of this Financial Review.

• For Benefit plans: prior service credits and other, net, reflects an amendment to our post-retirement plans that decreased the benefit obligation by transferring certain plan participants to a retiree drug coverage program eligible for a Medicare Part D plan subsidy. For additional information, see Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.

2013
• For Foreign currency translation adjustments, reflects the weakening of several currencies against the U.S. dollar, primarily the Japanese yen, the Australian dollar, the Canadian dollar and the Brazilian real, partially offset by the strengthening of several currencies against the U.S. dollar, primarily the euro and to a lesser extent the U.K. pound, as well as the reclassification of amounts associated with dispositions into income.

• For Unrealized holding gains on derivative financial instruments, net reflects the impact of fair value remeasurements and the reclassification of realized gains into income. For additional information, see Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

• For Unrealized holding gains/(losses) on available-for-sale securities, net reflects the impact of fair value remeasurements and the reclassification of realized gains into income. For additional information, see Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

• For Benefit plans: actuarial gains/(losses), net, reflects the impact of actuarial gains (due to an increase in the discount rate and higher than expected returns on plan assets) and the reclassification of certain amounts related to amortization and curtailments/settlements into income. For additional information, see Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans and the “Significant Accounting Policies and Application of Critical Accounting Estimates––Benefit Plans” section of this Financial Review.
ANALYSIS OF THE CONSOLIDATED BALANCE SHEETS

For information about certain of our financial assets and liabilities, including Cash and cash equivalents, Short-term investments, Long-term investments, Short-term borrowings, including current portion of long-term debt, and Long-term debt, see “Analysis of the Consolidated Statements of Cash Flows” section of this Financial Review, the “Analysis of Financial Condition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources” section of this Financial Review and Notes to Consolidated Financial Statements—Note 7. Financial Instruments.

For information about certain balances in Trade accounts receivable, less allowance for doubtful accounts, see also the “Analysis of Financial Condition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources: Accounts Receivable” section of this Financial Review.

For information about events and circumstances impacting our tax-related accounts, see Notes to Consolidated Financial Statements—Note 5. Tax Matters.

For a description of changes in Total Equity, see the consolidated statements of equity.

The changes in our asset and liability accounts as of December 31, 2015, compared to December 31, 2014, generally reflect, among other things, the impact of assets acquired and liabilities assumed as part of the acquisition of Hospira (see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions), and decreases due to changes in foreign currency exchange rates, some of which impacts were significant.

The following explanations exclude the impact of the acquisition of Hospira and foreign exchange:

- For Trade accounts receivable, less allowance for doubtful accounts, the change also reflects the timing of sales and collections in the normal course of business.
- For Inventories, the change also reflects an increase to inventory, resulting from a change in the profit deferred in inventory relating to inventory that had not been sold to third parties, inventory acquired as part of the acquisition of Baxter’s portfolio of marketed vaccines, recorded at acquisition-date fair value as well as inventory builds in the normal course of business, partially offset by planned inventory reductions.
- For Other current assets, the change also reflects the decrease in the receivables associated with our derivative financial instruments as well as the timing of receipts and payments in the normal course of business.
- For Property, plant and equipment, less accumulated depreciation, the change also reflects depreciation, mainly offset by capital additions.
- For Identifiable intangible assets, less accumulated amortization, the change also reflects amortization and to a lesser extent impairments, partially offset by identifiable intangible assets acquired as part of the acquisition of Baxter’s portfolio of marketed vaccines. For additional information about our intangible assets, see Notes to Consolidated Financial Statements—Note 10A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets. For additional information about the asset impairment charges, see Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net. For additional information about the assets acquired as part of the acquisition of Baxter’s portfolio of marketed vaccines, see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions.
- For Trade accounts payable, the change also reflects the timing of purchases and payments in the normal course of business.
- For Accrued compensation and related items, the change also reflects a higher bonus accrual attributable to performance and a change in the structure of our compensation whereby fixed compensation for certain previously non-bonus eligible colleagues was reduced and replaced with an equal amount of variable compensation tied to the performance of the Company and is paid annually.
- For Other current liabilities, the change also reflects an increase in the payables associated with our derivative financial instruments, a net increase in legal-related liabilities, mainly the accrual for the agreement in principle to resolve claims relating to Protonix, partially offset by payments of certain legal claims, as well as the timing of other payments and accruals in the normal course of business. For additional information, see Notes to Consolidated Financial Statements—Note 17A4. Commitments and Contingencies: Legal Proceedings—Government Investigations.
- For Pension benefit obligations, net, and Postretirement benefit obligations, net, the change reflects, among other things, a $1.0 billion voluntary pension contribution in January 2015, an increase in our discount rate assumptions used in the measurement of the plan obligations, a $507 million reduction in our U.S. Postretirement Plan obligation due to a plan amendment approved in June 2015 that introduced a cap on costs for certain groups within the plan, and a rise in the comparative strength of the U.S. dollar, as compared to other currencies. For additional information, see Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.
- For Other noncurrent liabilities, the change reflects an increase in the payables associated with our derivative financial instruments and, to a lesser extent, the deferral of an upfront payment received as part of our tanezumab collaborative arrangement, partially offset by other payments and changes in accruals in the normal course of business.
- For Accumulated other comprehensive loss, the change primarily reflects foreign currency translation adjustments for 2015. For additional information see the “Analysis of the Consolidated Statements of Comprehensive Income” section of this Financial Review.
ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
</tr>
<tr>
<td>Cash provided by/(used in):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating activities</td>
<td>$14,512</td>
<td>$16,883</td>
</tr>
<tr>
<td>Investing activities</td>
<td>(2,980)</td>
<td>(5,654)</td>
</tr>
<tr>
<td>Financing activities</td>
<td>(10,233)</td>
<td>(9,986)</td>
</tr>
<tr>
<td>Effect of exchange-rate changes on cash and cash equivalents</td>
<td>(1,000)</td>
<td>(83)</td>
</tr>
<tr>
<td>Net increase/(decrease) in Cash and cash equivalents</td>
<td>$298</td>
<td>$1,160</td>
</tr>
</tbody>
</table>

* Calculation not meaningful.

In the Consolidated Statements of Cash Flows, the line item, Other changes in assets and liabilities, net of acquisitions and divestitures, is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements. Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our consolidated balance sheets.

Operating Activities

2015 v. 2014

Our net cash provided by operating activities was $14.5 billion in 2015, compared to $16.9 billion in 2014. The decrease in net cash provided by operating activities reflects the change in operating earnings as well as a $1.0 billion voluntary pension contribution in January 2015, and the timing of other receipts and payments in the ordinary course of business, including higher payments related to certain liabilities associated with legal matters, partially offset by the upfront cash payment of $850 million in 2014 in connection with our collaborative arrangement with Merck KGaA.

In 2015, the change in the line item called Other adjustments, net, primarily reflects the non-cash changes in the equity losses related to the Hisun and ViV equity-method investments.

In 2015 and 2014, the line item Other changes in assets and liabilities, net of acquisitions and divestitures, primarily reflects changes, in the normal course of business, in accounts receivable, inventories, other current assets, other noncurrent assets, accounts payable, accrued compensation and other current and non-current liabilities. For 2015, this line item also includes the adjustments necessary to reflect the payments of certain liabilities associated with legal matters accrued in prior periods, including Neurontin-related matters, partially offset by the deferral of an upfront payment received as part of our tanezumab collaborative arrangement. For additional information about accounts receivable, see also the “Selected Measures of Liquidity and Capital Resources: Accounts Receivable” section of this Financial Review. For additional information about our legal accruals, see Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net.

2014 v. 2013

Our net cash provided by operating activities was $16.9 billion in 2014, compared to $17.7 billion in 2013. The decrease in net cash provided by operating activities reflects the change in operating earnings impacted by the timing of receipts and payments in the ordinary course of business, as well as the upfront cash payment of $850 million in connection with our collaborative arrangement with Merck KGaA. For additional information, see Notes to Consolidated Financial Statements—Note 2C. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Collaborative Arrangements.

In 2014, the change in the line item called Other adjustments, net, primarily reflects the non-cash changes in the estimated loss on the Teuto call/put option. For additional information, see Notes to Consolidated Financial Statements—Note 2E. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Equity-Method Investments.

Investing Activities

2015 v. 2014

Our net cash used in investing activities was $3.0 billion in 2015, compared to $5.7 billion in 2014. The decrease in net cash used in investing activities was primarily attributable to:

- net redemptions of investments of $14.6 billion in 2015, compared to net purchases of investments of $4.2 billion in 2014, partially offset by:
  - cash paid of $15.7 billion, net of cash acquired, in 2015 for the acquisition of Hospira (see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions); and
2014 v. 2013

Our net cash used in investing activities was $5.7 billion in 2014, compared to $10.5 billion in 2013. The decrease in net cash used in investing activities was primarily attributable to:

- net purchases of investments of $4.2 billion in 2014, compared to $9.4 billion in 2013,

partially offset by:

- cash paid of $195 million, net of cash acquired, for the acquisition of InnoPharma in 2014.

Financing Activities

2015 v. 2014

Our net cash used in financing activities was $10.2 billion in 2015, compared to $10.0 billion in 2014. The increase in net cash used in financing activities was primarily attributable to:

- net principal payments on long-term debt of $3.0 billion in 2015, compared to net proceeds from issuance of long-term debt of $2.4 billion in 2014; and

- purchases of common stock of $6.2 billion in 2015, compared to $5.0 billion in 2014,

partially offset by:

- net proceeds from short-term borrowings of $4.3 billion in 2015, compared to net payments on short-term borrowings of $1.8 billion in 2014.

2014 v. 2013

Our net cash used in financing activities was $10.0 billion in 2014, compared to $15.0 billion in 2013. The decrease in net cash used in financing activities was primarily attributable to:

- purchases of common stock of $5.0 billion in 2014, compared to $16.3 billion in 2013,

partially offset by:

- net proceeds from borrowings of $548 million in 2014, compared to net proceeds from borrowings of $6.0 billion in 2013; and

- proceeds from the exercise of stock options of $1.0 billion in 2014, compared to $1.8 billion in 2013.

Supplemental Schedule of Non-Cash Investing and Financing Information

In 2015, we exchanged $1.7 billion debt of our recently acquired subsidiary Hospira for virtually the same amount of Pfizer Inc. debt.

In 2013, we had the following non-cash transactions:

- we sold Zoetis common stock for Pfizer common stock valued at $11.4 billion;
- we exchanged Zoetis common stock for the retirement of Pfizer commercial paper issued in 2013 for $2.5 billion;
- we exchanged Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012 for $1.0 billion;
- we transferred certain product rights, valued at $1.2 billion, to an equity-method investment (Hisun Pfizer); and
- we contributed an investment, valued at $447 million, in connection with the resolution of a legal matter (Quigley).


ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future, which include:

- the working capital requirements of our operations, including our research and development activities;
- investments in our business;
- dividend payments and potential increases in the dividend rate;
- share repurchases;
- the cash requirements associated with our cost-reduction/productivity initiatives;
- paying down outstanding debt;
• contributions to our pension and postretirement plans; and
• business-development activities.

For additional information about our share-purchase plans, see the “Share-Purchase Plans and Accelerated Share Repurchase Agreement” section of this Financial Review.

Our long-term debt is rated high-quality by both Standard & Poor’s (S&P) and Moody’s Investors Service (Moody’s). See the “Credit Ratings” section below. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified and available-for-sale debt securities.

**Selected Measures of Liquidity and Capital Resources**

The following table provides certain relevant measures of our liquidity and capital resources:

<table>
<thead>
<tr>
<th>As of December 31,</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selected financial assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents&lt;sup&gt;a&lt;/sup&gt;</td>
<td>$3,641</td>
<td>$3,343</td>
</tr>
<tr>
<td>Short-term investments&lt;sup&gt;a&lt;/sup&gt;</td>
<td>19,649</td>
<td>32,779</td>
</tr>
<tr>
<td>Long-term investments&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15,999</td>
<td>17,518</td>
</tr>
<tr>
<td><strong>Debt:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short-term borrowings, including current portion of long-term debt</td>
<td>10,160</td>
<td>5,141</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>28,818</td>
<td>31,541</td>
</tr>
<tr>
<td><strong>Selected net financial assets&lt;sup&gt;b&lt;/sup&gt;</strong></td>
<td>$312</td>
<td>$16,958</td>
</tr>
<tr>
<td>Working capital&lt;sup&gt;c&lt;/sup&gt;</td>
<td>14,405</td>
<td>34,007</td>
</tr>
<tr>
<td>Ratio of current assets to current liabilities&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.49:1</td>
<td>2.58:1</td>
</tr>
<tr>
<td>Total Pfizer Inc. shareholders’ equity per common share&lt;sup&gt;d&lt;/sup&gt;</td>
<td>10.48</td>
<td>11.33</td>
</tr>
</tbody>
</table>

<sup>a</sup> See Notes to Consolidated Financial Statements—Note 7. Financial Instruments for a description of certain assets held and for a description of credit risk related to our financial instruments held.

<sup>b</sup> Selected net financial assets decreased during 2015 as net cash provided by operating activities decreased, and cash paid for the Hospira acquisition, dividend payments and share purchases, among other things, more than offset the redemptions/sales, net of purchases, of investments and proceeds from the exercise of stock options. For additional information, see the “Analysis of the Consolidated Statements of Cash Flows” section of this Financial Review.

<sup>c</sup> The presentation of all deferred taxes as noncurrent in accordance with a new accounting standard that we adopted at December 31, 2015 impacted working capital and the ratio of current assets to current liabilities. Net current deferred tax assets of $2.1 billion at December 31, 2014 were reclassified to noncurrent assets and noncurrent liabilities, as appropriate (see Notes to Consolidated Financial Statements—Note 1B. Adoption of New Accounting Standards). The decrease in working capital is due to the acquisition of Hospira, as well as the timing of accruals, cash receipts and payments in the ordinary course of business. For additional information on the acquisition of Hospira, see Notes to Consolidated Financial Statements—Note 2A. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Acquisitions.

<sup>d</sup> Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury stock).

For additional information about the sources and uses of our funds, see the “Analysis of the Consolidated Balance Sheets” and “Analysis of the Consolidated Statements of Cash Flows” sections of this Financial Review.

On May 15, 2014, we completed a public offering of $4.5 billion aggregate principal amount of senior unsecured notes (see Notes to Consolidated Financial Statements—Note 7D. Financial Instruments: Long-Term Debt).

On June 3, 2013, we completed a public offering of $4.0 billion aggregate principal amount of senior unsecured notes. In addition, we repaid at maturity our 3.625% senior unsecured notes, which had a balance of $2.4 billion at December 31, 2012, and, in December 2013, we redeemed the aggregate principal amount of $1.8 billion of our 5.50% senior unsecured notes that were due in February 2014.

**Domestic and International Short-Term Funds**

Many of our operations are conducted outside the U.S., and significant portions of our cash, cash equivalents and short-term investments are held internationally. We generally hold up to $10 billion of our short-term funds in U.S. tax jurisdictions. The amount of funds held in U.S. tax jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). Repatriation of overseas funds can result in additional U.S. federal, state and local income tax payments. We record U.S. deferred tax liabilities for certain unremitted earnings, but when amounts earned overseas are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. taxes is provided.
Accounts Receivable

We continue to monitor developments regarding government and government agency receivables in several European markets where economic conditions remain challenging and uncertain. Historically, payments from a number of these European governments and government agencies extend beyond the contractual terms of sale. Specifically, we have received limited payments in 2015 from the Greek government on outstanding receivables; the majority of such receivables pertain to 2015 revenues. Also, the Greek government has restructured its debt to other third parties in the third quarter of 2015. Accordingly, we have adjusted our allowance for doubtful accounts to reflect these events, and have $50 million in net receivables as of December 31, 2015. Reported revenues from Greece for the year ended December 31, 2015 were $233 million.

We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on an analysis of the following: (i) payments received to date; (ii) the consistency of payments from customers; (iii) direct and observed interactions with the governments (including court petitions) and with market participants (for example, the factoring industry); and (iv) various third-party assessments of repayment risk (for example, rating agency publications and the movement of rates for credit default swap instruments).

As of December 31, 2015, we had about $772 million in aggregate gross accounts receivable from governments and/or government agencies in Italy, Spain, Greece and Portugal where economic conditions remain challenging and uncertain. Such receivables in excess of one year from the invoice date, totaling $66 million, were as follows: $39 million in Italy; $12 million in Portugal; $8 million in Greece; and $7 million in Spain.

Although certain European governments and government agencies sometimes delay payments beyond the contractual terms of sale, we seek to appropriately balance repayment risk with the desire to maintain good relationships with our customers and to ensure a humanitarian approach to local patient needs.

We will continue to closely monitor repayment risk and, when necessary, we will continue to adjust our allowance for doubtful accounts.

Our assessments about the recoverability of accounts receivables can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Notes to Consolidated Financial Statements—Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions.

Credit Ratings

Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating. The pending combination with Allergan could result in a downgrade of our ratings.

The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:

<table>
<thead>
<tr>
<th>NAME OF RATING AGENCY</th>
<th>Pfizer Commercial Paper Rating</th>
<th>Pfizer Long-Term Debt Rating</th>
<th>Outlook</th>
<th>Date of Last Rating Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moody’s</td>
<td>P-1</td>
<td>A1</td>
<td>Stable</td>
<td>October 2009</td>
</tr>
<tr>
<td>S&amp;P</td>
<td>A-1+</td>
<td>AA</td>
<td>Negative Watch</td>
<td>November 2015</td>
</tr>
</tbody>
</table>

Debt Capacity

We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We maintain cash and cash equivalent balances and short-term investments in excess of our commercial paper and other short-term borrowings. As of December 31, 2015, we had access to $8.1 billion of lines of credit, of which $687 million expire within one year. Of these lines of credit, $7.9 billion are unused, of which our lenders have committed to loan us $7.1 billion at our request. Also, $7.0 billion of our unused lines of credit, all of which expire in 2020, may be used to support our commercial paper borrowings. Under the terms of a substantial majority of our line of credit agreements, upon the merger with Allergan, the lenders under the agreements may elect to require immediate repayment of any amounts then outstanding and cancel the outstanding lines of credit. We expect to either amend the existing credit agreements or secure new credit agreements to replace these agreements.

Global Economic Conditions—General

The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. As markets conditions change, we continue to monitor our liquidity position.

Global Economic Conditions—Venezuela Operations

Our Venezuela operations continue to operate with the U.S. dollar as the functional currency due to the hyperinflationary status of the Venezuelan economy.

On February 13, 2013, the Venezuelan government devalued its currency from a rate of 4.3 to 6.3 of Venezuelan currency to the U.S. dollar. We incurred a foreign currency loss of $80 million immediately on the devaluation as a result of remeasuring the local balance sheets.
In the second quarter of 2015, the Venezuelan government identified three official rates of exchange. These are the CENCOEX rate of 6.3; the SICAD rate of 13.5 (as of February 2016); and the SIMADI rate of 200 (as of February 2016). News reports state the Venezuelan government announced that, effective February 18, 2016, the CENCOEX rate of 6.3 would be replaced by the rate of 10.0; that the SICAD rate would cease to be offered; and, the operation of the SIMADI rate would change.

Recent conditions in Venezuela had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation are no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.3, but at the SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant conversion of Venezuelan bolivars related to intercompany U.S. dollar denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a restructuring charge of $39 million related to a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy. The effect of that change in expectation was a foreign currency loss of $806 million included in Other (income)/deductions—net. See Notes to Consolidated Financial Statements—Note 4. Other (Income)/Deductions—Net. In addition, we had an inventory impairment loss of $72 million included in Cost of sales.

We expect to use the SIMADI rate in 2016 for remeasurement purposes of the remaining net assets. We cannot predict whether there will be further devaluations of the Venezuelan currency or whether our use of the SIMADI official rate will continue to be supported by evolving facts and circumstances. Further, other potential actions by the Venezuelan government in response to economic uncertainties could impact the recoverability of our investment in Venezuela, which could result in an impairment charge and, under extreme circumstances, could impact our ability to continue to operate in the country in the same manner as we have historically.

As of December 31, 2015, our net monetary assets in Venezuela that are subject to revaluation totaled approximately $27 million (remeasured at the SIMADI 200 rate). Our Venezuela Revenues for 2015 are equivalent to approximately $34 million (converted using the SIMADI 200 rate).

### Contractual Obligations

**Payments due under contractual obligations as of December 31, 2015, mature as follows:**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term debt, including current portion (a)</td>
<td>32,538</td>
<td>3,720</td>
<td>6,812</td>
<td>5,171</td>
<td>16,835</td>
</tr>
<tr>
<td>Interest payments on long-term debt obligations (b)</td>
<td>16,944</td>
<td>1,170</td>
<td>2,371</td>
<td>1,978</td>
<td>11,425</td>
</tr>
<tr>
<td>Other long-term liabilities (c)</td>
<td>3,390</td>
<td>388</td>
<td>794</td>
<td>688</td>
<td>1,521</td>
</tr>
<tr>
<td>Lease commitments (d)</td>
<td>1,849</td>
<td>206</td>
<td>370</td>
<td>265</td>
<td>1,009</td>
</tr>
<tr>
<td>Purchase obligations and other (e)</td>
<td>3,727</td>
<td>1,072</td>
<td>711</td>
<td>659</td>
<td>1,284</td>
</tr>
<tr>
<td>Uncertain tax positions (f)</td>
<td>73</td>
<td>73</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>

(a) Long-term debt consists of senior unsecured notes, including fixed and floating rate, foreign currency denominated, and other notes.

(b) Our calculations of expected interest payments incorporate only current period assumptions for interest rates, foreign currency translation rates and hedging strategies (see Notes to Consolidated Financial Statements—Note 7. Financial Instruments), and assume that interest is accrued through the maturity date or expiration of the related instrument.

(c) Includes expected payments relating to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans. Excludes amounts relating to our U.S. qualified pension plans and international pension plans, all of which have a substantial amount of plan assets, because the required funding obligations are not expected to be material and/or because such liabilities do not necessarily reflect future cash payments, as the impact of changes in economic conditions on the fair value of the pension plan assets and/or liabilities can be significant. In January 2016, we made a $1.0 billion voluntary contribution to the U.S. qualified plans. We do not anticipate making any additional contributions to the U.S. qualified plans in 2016. Also, excludes $4.5 billion of liabilities related to legal matters, employee terminations and the fair value of derivative financial instruments and other, most of which do not represent contractual obligations. See also our liquidity discussion above in this “Analysis of Financial Condition, Liquidity and Capital Resources” section, as well as the Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives, Note 7A. Financial Instruments: Selected Financial Assets and Liabilities, Note 11E. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Cash Flows, and Note 17. Commitments and Contingencies.

(d) Includes operating and capital lease obligations.

(e) Includes agreements to purchase goods and services that are enforceable and legally binding and includes amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur.

(f) Includes only income tax amounts currently payable. We are unable to predict the timing of tax settlements related to our noncurrent obligations for uncertain tax positions as tax audits can involve complex issues and the resolution of those issues may span multiple years, particularly if subject to negotiation or litigation.

The above table includes amounts for potential milestone payments under collaboration, licensing or other arrangements, if the payments are deemed reasonably likely to occur. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization milestones, which may span several years and which may never occur.

In 2016, we expect to spend approximately $1.9 billion on property, plant and equipment. This represents an increase of approximately $500 million over 2015 capital spending in order to fund a full year of Hospira capital needs, as well as capital required to support the integration of the Hospira business, early-stage implementation of changes to our infrastructure to align our operations to our business segments established in 2014, incremental manufacturing investment to address increasing regulatory requirements as well as for business-driven capacity expansion. We rely largely on operating cash flows to fund our capital investment needs. Due to our significant operating cash flows, we believe we have the ability to meet our capital investment needs and anticipate no delays to planned capital expenditures.

### Off-Balance Sheet Arrangements

In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to...
make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2015, recorded amounts for the estimated fair value of these indemnifications were not significant.

Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.

Share-Purchase Plans and Accelerated Share Repurchase Agreement

Our December 2011 $10 billion share-purchase plan was exhausted in the first quarter of 2013. Our November 2012 $10 billion share-purchase plan was exhausted in the fourth quarter of 2013. On June 27, 2013, we announced that the Board of Directors had authorized a $10 billion share-purchase plan, which was exhausted in the first quarter of 2015. On October 23, 2014, we announced that the Board of Directors had authorized an additional $11 billion share-purchase plan, and share repurchases commenced thereunder in January 2015. In December 2015, the Board of Directors authorized a new $11 billion share repurchase program to be utilized over time.

On February 9, 2015, we entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase shares of our common stock. This agreement was entered into under our previously announced share repurchase authorization. Pursuant to the terms of the agreement, on February 11, 2015, we paid $5 billion to GS&Co. and received approximately 151 million shares of our common stock from GS&Co. This agreement was completed in July 2015, and pursuant to the agreement’s settlement terms, we elected to settle the agreement in cash and paid an additional $160 million to GS&Co. on July 13, 2015, resulting in a total of approximately $5.2 billion paid to GS&Co. The final average price paid for the shares delivered under the accelerated share repurchase agreement was $34.13 per share. For additional information, see Notes to Consolidated Financial Statements—Note 12. Equity.

After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through year-end 2015, our remaining share-purchase authorization was approximately $16.4 billion at December 31, 2015.

In November 2015, we announced that, consistent with 2015, we expect to execute an approximately $5 billion accelerated share repurchase program in the first half of 2016. We anticipate additional future share repurchases to continue following the consummation of the pending combination with Allergan. The actual size and timing of any such share repurchases will depend on actual and expected financial results.

Dividends on Common Stock

We paid dividends on our common stock of $6.9 billion in 2015, $6.6 billion in 2014 and $6.6 billion in 2013. In December 2015, our Board of Directors declared a first-quarter 2016 dividend of $0.30 per share, payable on March 2, 2016, to shareholders of record at the close of business on February 5, 2016. The first-quarter 2016 cash dividend will be our 309th consecutive quarterly dividend.

Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our businesses and to seek to increase shareholder value. Our dividends are not restricted by debt covenants. The definitive merger agreement we entered into with Allergan in November 2015 includes a provision that Pfizer may continue to pay regular quarterly cash dividends on Pfizer’s common stock of not more than $0.28 per share per quarter (subject to annual adjustment, if any, in a manner consistent with past practice by Pfizer’s Board of Directors), consistent with past practice as to timing of declaration, record date and payment date. On December 14, 2015, we declared a $0.30 dividend per share for the first quarter of 2016, which is in compliance with the definitive merger agreement. While the dividend level remains a decision of Pfizer’s Board of Directors and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events.

Pending Combination with Allergan plc

On November 23, 2015, we announced that we have entered into a definitive merger agreement with Allergan, a global pharmaceutical company incorporated in Ireland, under which we have agreed to combine with Allergan in a stock transaction valued at $363.63 per Allergan share, for a total enterprise value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on November 20, 2015 (the last trading day prior to the announcement) and certain other assumptions. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares by virtue of a share split, and Pfizer shareholders will have the option of receiving one share of the combined company for each of their Pfizer shares or receiving cash instead of shares of the combined company for some or all of their Pfizer shares, provided that the aggregate amount of cash to be paid in the merger will not be less than $6 billion or greater than $12 billion. In the event that elections to receive cash and shares in the merger would otherwise result in an aggregate of less than $6 billion or greater than $12 billion of cash being paid out in the merger, then the share elections and cash elections will be subject to proration. The completion of the transaction, which is expected in the second half of 2016, is subject to certain conditions, including receipt of regulatory approval in certain jurisdictions, including the U.S. and EU, the receipt of necessary approvals from both Pfizer and Allergan shareholders, and the completion of Allergan’s pending divestiture of its generics business to Teva Pharmaceuticals Industries Ltd. The merger agreement also provides that the businesses of Pfizer and Allergan will be combined under the existing Allergan entity, which, subject to approval by Allergan shareholders, will be renamed “Pfizer plc.”
NEW ACCOUNTING STANDARDS
Recently Issued Accounting Standards, Not Adopted as of December 31, 2015
See Notes to Consolidated Financial Statements—Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

The following table provides a brief description of recently issued accounting standards, not yet adopted:

<table>
<thead>
<tr>
<th>Standard</th>
<th>Description</th>
<th>Effective Date</th>
<th>Effect on the Financial Statements or Other Significant Matters</th>
</tr>
</thead>
<tbody>
<tr>
<td>In November 2014, the Financial Accounting Standards Board (FASB) issued amended guidance related to accounting for <strong>hybrid financial instruments</strong> issued or held as investments.</td>
<td>The new guidance clarifies that for hybrid financial instruments in the form of stock, the assessment of whether the embedded derivative is clearly and closely related to the host instrument must consider the economic characteristics and risks of the entire hybrid financial instrument, including the embedded derivative feature that is being evaluated for separate accounting from the host contract.</td>
<td>January 1, 2016.</td>
<td>We do not expect that the provisions of this new standard will have any material impact on our consolidated financial statements.</td>
</tr>
<tr>
<td>In August 2014, the FASB issued amended guidance related to disclosure of uncertainties about the ability of an entity to continue as a <strong>going concern</strong>.</td>
<td>The new guidance requires management of all entities to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern and, as necessary, to provide related footnote disclosures.</td>
<td>December 31, 2016. Earlier application is permitted.</td>
<td>We do not expect that the provisions of this new standard will have any impact on our consolidated financial statements.</td>
</tr>
<tr>
<td>In July 2015, the FASB issued an update related to <strong>inventory</strong>.</td>
<td>The new guidance requires that inventory be measured at the lower of cost or net realizable value.</td>
<td>January 1, 2017. Earlier application is permitted as of the beginning of an interim or annual reporting period.</td>
<td>We do not expect the provisions of this new standard will have a material impact on our consolidated financial statements.</td>
</tr>
<tr>
<td>In May 2014, the FASB issued amended guidance related to <strong>revenue from contracts with customers</strong>. In August 2014, the FASB issued updated guidance deferring the effective date of the revenue recognition standard.</td>
<td>The new guidance introduces a new principles-based framework for revenue recognition and disclosure.</td>
<td>January 1, 2018. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.</td>
<td>We have not yet completed our final review of the impact of this guidance, although we currently do not anticipate a material impact on our revenue recognition practices. We continue to review variable consideration, potential disclosures, and our method of adoption to complete our evaluation of the impact on our consolidated financial statements. In addition, we continue to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact our current conclusions.</td>
</tr>
<tr>
<td>In September 2015, the FASB issued an update to its guidance on <strong>business combinations</strong>.</td>
<td>The new guidance requires that an acquirer recognize adjustments to provisional amounts identified during the measurement period be recorded in the reporting period determined. The new guidance also requires that the acquirer records, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts. These are calculated as if the accounting had been completed as of the acquisition date. The new guidance also requires separate presentation on the face of the income statement, or disclosure within the notes for the portion of the amount that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date.</td>
<td>January 1, 2016. Effective for all adjustments made to provisional amounts reported for acquisitions still in the measurement stage as of the effective date.</td>
<td>We will use this guidance for any adjustments made after January 1, 2016 to any provisional amounts reported for acquisitions, but do not expect it to have a material impact on our consolidated financial statements.</td>
</tr>
</tbody>
</table>
### Standard

In January 2016, the FASB issued an update to its guidance on recognition and measurement of financial **assets and liabilities**.

<table>
<thead>
<tr>
<th>Description</th>
<th>Effective Date</th>
<th>Effect on the Financial Statements or Other Significant Matters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Among other things, the new guidance makes the following targeted changes to existing guidance:</td>
<td>January 1, 2018. Earlier application is not allowed for the amendments in the update, described here, that have potential to impact our consolidated financial statements.</td>
<td>We are assessing the impact of the provisions of this new guidance on our consolidated financial statements.</td>
</tr>
<tr>
<td>1. Requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. When a qualitative assessment indicates that impairment exists, the investment is required to be measured at fair value.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In February 2016, the FASB issued an update to its guidance on leases.

The new ASU provides guidance for both lessee and lessor accounting models. Among other things, the new guidance requires that a right of use asset and a lease liability be recognized for leases with a duration of greater than one year.

<table>
<thead>
<tr>
<th>Description</th>
<th>Effective Date</th>
<th>Effect on the Financial Statements or Other Significant Matters</th>
</tr>
</thead>
<tbody>
<tr>
<td>The new ASU provides guidance for both lessee and lessor accounting models. Among other things, the new guidance requires that a right of use asset and a lease liability be recognized for leases with a duration of greater than one year.</td>
<td>January 1, 2019. Earlier application is permitted</td>
<td>We have not yet completed our review of the impact of this guidance. However, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet.</td>
</tr>
</tbody>
</table>
This report and other written or oral statements that we make from time to time contain forward-looking statements that set forth anticipated results based on management’s plans and assumptions. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, business plans and prospects, our acquisition of Hospira, our pending combination with Allergan plc, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, plans relating to share repurchases and dividends, government regulation and financial results, including, in particular, the financial guidance set forth in the “Our Financial Guidance for 2016” section of this Financial Review, the anticipated costs and cost savings set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook” and “Costs and Expenses—Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” sections of this Financial Review and in Notes to Consolidated Financial Statements—Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives, the benefits, including synergies, expected from our recent acquisition of Hospira, the expected timing of completion, tax treatment and benefits of our pending combination with Allergan and the expected timing of a decision regarding a potential separation of our Innovative Products and Established Products businesses, set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook” section of this Financial Review, the planned capital spending set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources—Selected Measures of Liquidity and Capital Resources—Contractual Obligations” section of this Financial Review and the contributions that we expect to make from our general assets to the Company’s pension and postretirement plans during 2016 set forth in the “Analysis of Financial Condition, Liquidity and Capital Resources—Selected Measures of Liquidity and Capital Resources—Contractual Obligations” section of this Financial Review and in Notes to Consolidated Financial Statements—Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

• the outcome of research and development activities, including, without limitation, the ability to meet anticipated pre-clinical and clinical trial commencement and completion dates, regulatory submission and approval dates, and launch dates for product candidates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data;

• decisions by regulatory authorities regarding whether and when to approve our drug applications, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling, ingredients and other matters that could affect the availability or commercial potential of our products; and uncertainties regarding our ability to address the comments in complete response letters received by us with respect to certain of our drug applications to the satisfaction of the FDA;

• the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;

• the outcome of post-approval clinical trials, which could result in the loss of marketing approval for a product or changes in the labeling for, and/or increased or new concerns about the safety or efficacy of, a product that could affect its availability or commercial potential;

• risks associated with interim data, including the risk that final results of studies for which interim data have been provided and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further clinical development of the applicable product candidate or indication;

• the success of external business-development activities, including the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all;

• competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;

• the implementation by the FDA and regulatory authorities in certain other countries of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;

• the ability to meet generic and branded competition after the loss of patent protection for our products or competitor products;

• the ability to successfully market both new and existing products domestically and internationally;

• difficulties or delays in manufacturing;

• trade buying patterns;

• the impact of existing and future legislation and regulatory provisions on product exclusivity;

• trends toward managed care and healthcare cost containment;

• the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented, and/or any significant additional taxes or fees that may be imposed on the pharmaceutical industry as part of any broad deficit-reduction effort;

• the impact of U.S. healthcare legislation enacted in 2010—the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act—and of any modification, repeal or invalidation of any of the provisions thereof;
• U.S. federal or state legislation or regulatory action affecting, among other things, pharmaceutical product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; restrictions on direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;

• legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;

• the exposure of our operations outside the U.S. to possible capital and exchange controls, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;

• contingencies related to actual or alleged environmental contamination;

• claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;

• any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;

• legal defense costs, insurance expenses, settlement costs, the risk of an adverse decision or settlement and the adequacy of reserves related to product liability, patent protection, government investigations, consumer, commercial, securities, antitrust, environmental and tax issues, ongoing efforts to explore various means for resolving asbestos litigation, and other legal proceedings;

• our ability to protect our patents and other intellectual property, both domestically and internationally;

• interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;

• governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals;

• any significant issues involving our largest wholesaler customers, which account for a substantial portion of our revenues;

• the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;

• any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal requirements and industry standards;

• any significant issues that may arise related to our joint ventures and other third-party business arrangements;

• changes in U.S. generally accepted accounting principles;

• uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; and the related risk that our allowance for doubtful accounts may not be adequate;

• any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas;

• growth in costs and expenses;

• changes in our product, segment and geographic mix;

• the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;

• the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls, withdrawals and other unusual items, including our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including those related to our research and development organization, and of the internal separation of our commercial operations into our current operating structure;

• the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;

• risks related to internal control over financial reporting;

• risks and uncertainties related to our recent acquisition of Hospira, including, among other things, the ability to realize the anticipated benefits of the acquisition of Hospira, including the possibility that expected synergies and accretion will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; and unknown liabilities; and

• risks and uncertainties related to our pending combination with Allergan, including, without limitation, the failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the transaction) and shareholder approvals or to satisfy any of the other conditions to the transaction on a timely basis or at all, the occurrence of events that may give rise to a right of one or both of the parties to terminate the merger agreement, adverse effects on the market price of Pfizer’s common stock and on Pfizer’s operating results because of a failure to complete the transaction in the anticipated time frame or at all, failure to realize the expected benefits and synergies of the transaction, restructuring in connection with the transaction and subsequent integration of Pfizer and Allergan, negative effects of the announcement or the consummation of the transaction on the market price of Pfizer’s common stock and on Pfizer’s operating results, risks relating to the value of the Allergan shares to be issued in the transaction, significant transaction costs and/or unknown liabilities, the risk of litigation and/or regulatory actions, the loss of key senior management or scientific staff, general economic and business conditions that affect the
We are subject to interest rate risk on our investments and on our borrowings. We manage interest rate risk in the aggregate, while focusing on Pfizer’s immediate and intermediate liquidity needs.

With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. Our floating-rate assets are subject to the risk that short-term interest rates may fall and, as a result, the investments would generate less interest income. Fixed-rate investments provide a known amount of interest income regardless of a change in interest rates. We sometimes use interest rate swaps in our financial investment portfolio.

For details about these and other financial instruments, including fair valuation methodologies, see Notes to Consolidated Financial Statements—Note 7A. Financial Instruments: Selected Financial Assets and Liabilities.

The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this sensitivity analysis, holding all other assumptions constant and assuming that a change in one currency’s rate relative to the U.S. dollar would not have any effect on another currency’s rates relative to the U.S. dollar, if the dollar were to depreciate against all other currencies by 10%, as of December 31, 2015, the expected adverse impact on our net income would not be significant.

Interest Rate Risk

We are subject to interest rate risk on our investments and on our borrowings. We manage interest rate risk in the aggregate, while focusing on Pfizer’s immediate and intermediate liquidity needs.

With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. Our floating-rate assets are subject to the risk that short-term interest rates may fall and, as a result, the investments would generate less interest income. Fixed-rate investments provide a known amount of interest income regardless of a change in interest rates. We sometimes use interest rate swaps in our financial investment portfolio.
With respect to our long-term borrowings, we strive to maintain a predominantly floating-rate basis position, but here too, we may change our strategy depending upon prevailing market conditions. We generally issue debt with a fixed rate, and then use interest rate swaps to convert it into floating-rate debt as we deem appropriate in the circumstances. This effective floating rate debt serves to offset some of the interest rate risks associated with our short-term and floating-rate investments.

For details about these and other financial instruments, including fair valuation methodologies, see Notes to Consolidated Financial Statements—Note 7A. Financial Instruments: Selected Financial Assets and Liabilities.

The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this sensitivity analysis, holding all other assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point decrease in interest rates as of December 31, 2015, the expected adverse impact on our net income would not be significant.

**Contingencies**

**Legal Matters**

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications (see Notes to Consolidated Financial Statements—Note 17. Commitments and Contingencies).

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.
Management’s Report

We prepared and are responsible for the financial statements that appear in our 2015 Financial Report. These financial statements are in conformity with accounting principles generally accepted in the United States of America and, therefore, include amounts based on informed judgments and estimates. We also accept responsibility for the preparation of other financial information that is included in this document.

Report on Internal Control Over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. The Company’s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2015. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). Based on our assessment and those criteria, management believes that the Company maintained effective internal control over financial reporting as of December 31, 2015.

Pfizer Inc. acquired Hospira, Inc. on September 3, 2015, and management excluded from its assessment of the effectiveness of Pfizer Inc.’s internal control over financial reporting as of December 31, 2015, Hospira, Inc.’s and its subsidiaries’ internal control over financial reporting associated with total assets of $24.2 billion and total revenues of $1.5 billion included in the consolidated financial statements of Pfizer Inc. and Subsidiary Companies as of and for the year ended December 31, 2015.


Ian Read
Chairman and Chief Executive Officer

Frank D’Amelio
Principal Financial Officer

Loretta Cangialosi
Principal Accounting Officer

February 29, 2016
The Audit Committee reviews Pfizer’s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process, including the system of internal controls.

The Committee met and held discussions with management and the independent registered public accounting firm regarding the fair and complete presentation of Pfizer’s results and the assessment of Pfizer’s internal control over financial reporting. We discussed significant accounting policies applied in Pfizer’s financial statements, as well as, when applicable, alternative accounting treatments. Management represented to the Committee that the consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America, and the Committee reviewed and discussed the consolidated financial statements with management and the independent registered public accounting firm. The Committee discussed with the independent registered public accounting firm matters required to be discussed under applicable Public Company Accounting Oversight Board (PCAOB) standards.

In addition, the Committee reviewed and discussed with the independent registered public accounting firm the auditor’s independence from Pfizer and its management. As part of that review, we received the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent accountant’s communications with the Audit Committee concerning independence, and the Committee discussed the independent registered public accounting firm’s independence from Pfizer.

We also considered whether the independent registered public accounting firm’s provision of non-audit services to Pfizer is compatible with the auditor’s independence. The Committee concluded that the independent registered public accounting firm is independent from Pfizer and its management.

As part of our responsibilities for oversight of Pfizer’s Enterprise Risk Management process, we reviewed and discussed company policies with respect to risk assessment and risk management, including discussions of individual risk areas, as well as an annual summary of the overall process.

The Committee discussed with Pfizer’s Internal Audit Department and independent registered public accounting firm the overall scope of and plans for their respective audits. The Committee meets with the Chief Internal Auditor, Chief Compliance and Risk Officer and representatives of the independent registered public accounting firm, in regular and executive sessions to discuss the results of their examinations, the evaluations of Pfizer’s internal controls, and the overall quality of Pfizer’s financial reporting and compliance programs.

In reliance on the reviews and discussions referred to above, the Committee has recommended to the Board of Directors, and the Board has approved, that the audited financial statements be included in Pfizer’s Annual Report on Form 10-K for the year ended December 31, 2015, for filing with the U.S. Securities and Exchange Commission. The Committee has selected, and the Board of Directors has ratified, the selection of Pfizer’s independent registered public accounting firm for 2016.

W. Don Cornwell
Chair, Audit Committee
February 29, 2016

Suzanne Nora Johnson
February 29, 2016

Shantanu Narayen
February 29, 2016

Stephen W. Sanger
February 29, 2016

Joseph J. Echevarria
February 29, 2016

The Audit Committee Report does not constitute soliciting material, and shall not be deemed to be filed or incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates the Audit Committee Report by reference therein.
The Board of Directors and Shareholders of Pfizer Inc.:

We have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies as of December 31, 2015 and 2014, and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2015. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Pfizer Inc. and Subsidiary Companies as of December 31, 2015 and 2014, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2015, in conformity with U.S. generally accepted accounting principles.

As discussed in Note 1B to the consolidated financial statements, the Company has adopted on a retrospective basis FASB Accounting Standards Update No. 2015-17, Balance Sheet Classification of Deferred Taxes classifying all deferred tax assets, liabilities and associated valuation allowances as non-current.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Pfizer Inc. and Subsidiary Companies’ internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 29, 2016 expressed an unqualified opinion on the effective operation of the Company’s internal control over financial reporting.

February 29, 2016
The Board of Directors and Shareholders of Pfizer Inc.:

We have audited the internal control over financial reporting of Pfizer Inc. and Subsidiary Companies as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Pfizer Inc. and Subsidiary Companies’ management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Pfizer Inc. and Subsidiary Companies maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework (2013) issued by COSO.

Pfizer Inc. acquired Hospira, Inc. on September 3, 2015, and management excluded from its assessment of the effectiveness of Pfizer Inc.’s internal control over financial reporting as of December 31, 2015, Hospira, Inc.’s internal control over financial reporting associated with total assets of $24.2 billion and total revenues of $1.5 billion included in the consolidated financial statements of Pfizer Inc. and Subsidiary Companies as of and for the year ended December 31, 2015. Our audit of internal control over financial reporting of Pfizer Inc. also excluded an evaluation of the internal control over financial reporting of Hospira, Inc.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Pfizer Inc. and Subsidiary Companies as of December 31, 2015 and 2014, and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2015, and our report dated February 29, 2016 expressed an unqualified opinion on those consolidated financial statements.

KPMG LLP
New York, New York

February 29, 2016
## Consolidated Statements of Income

Pfizer Inc. and Subsidiary Companies

MILLIONS, EXCEPT PER COMMON SHARE DATA

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$48,851</td>
<td>$49,605</td>
<td>$51,584</td>
</tr>
<tr>
<td>Costs and expenses:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of sales(a)</td>
<td>9,648</td>
<td>9,577</td>
<td>9,586</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses(a)</td>
<td>14,809</td>
<td>14,097</td>
<td>14,355</td>
</tr>
<tr>
<td>Research and development expenses(a)</td>
<td>7,690</td>
<td>8,393</td>
<td>6,678</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>3,728</td>
<td>4,039</td>
<td>4,599</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>1,152</td>
<td>250</td>
<td>1,182</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>2,860</td>
<td>1,009</td>
<td>(532)</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income</td>
<td>8,965</td>
<td>12,240</td>
<td>15,716</td>
</tr>
<tr>
<td>Provision for taxes on income</td>
<td>1,990</td>
<td>3,120</td>
<td>4,306</td>
</tr>
<tr>
<td>Income from continuing operations</td>
<td>6,975</td>
<td>9,119</td>
<td>11,410</td>
</tr>
<tr>
<td>Discontinued operations:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from discontinued operations—net of tax</td>
<td>17</td>
<td>(6)</td>
<td>308</td>
</tr>
<tr>
<td>Gain/(loss) on disposal of discontinued operations—net of tax</td>
<td>(6)</td>
<td>55</td>
<td>10,354</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>11</td>
<td>48</td>
<td>10,662</td>
</tr>
<tr>
<td>Net income before allocation to noncontrolling interests</td>
<td>6,986</td>
<td>9,168</td>
<td>22,072</td>
</tr>
<tr>
<td>Less: Net income attributable to noncontrolling interests</td>
<td>26</td>
<td>32</td>
<td>69</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc.</td>
<td>$6,960</td>
<td>$9,135</td>
<td>$22,003</td>
</tr>
<tr>
<td>Earnings per common share—basic:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc. common shareholders</td>
<td>$1.13</td>
<td>$1.43</td>
<td>$1.67</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>—</td>
<td>0.01</td>
<td>1.56</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders</td>
<td>$1.13</td>
<td>$1.44</td>
<td>$3.23</td>
</tr>
<tr>
<td>Earnings per common share—diluted:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc. common shareholders</td>
<td>$1.11</td>
<td>$1.41</td>
<td>$1.85</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>—</td>
<td>0.01</td>
<td>1.54</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders</td>
<td>$1.11</td>
<td>$1.42</td>
<td>$3.19</td>
</tr>
<tr>
<td>Weighted-average shares—basic</td>
<td>6,176</td>
<td>6,346</td>
<td>6,813</td>
</tr>
<tr>
<td>Weighted-average shares—diluted</td>
<td>6,257</td>
<td>6,424</td>
<td>6,895</td>
</tr>
<tr>
<td>Cash dividends paid per common share</td>
<td>$1.12</td>
<td>$1.04</td>
<td>$0.96</td>
</tr>
</tbody>
</table>


Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.
## Consolidated Statements of Comprehensive Income

**Pfizer Inc. and Subsidiary Companies**

**2015 Financial Report**

<table>
<thead>
<tr>
<th>(MILLIONS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income before allocation to noncontrolling interests</td>
<td>$ 6,986</td>
<td>$ 9,168</td>
<td>$ 22,072</td>
</tr>
<tr>
<td>Foreign currency translation adjustments, net</td>
<td>$(3,110)</td>
<td>$(1,992)</td>
<td>$(535)</td>
</tr>
<tr>
<td>Reclassification adjustments</td>
<td>—</td>
<td>62</td>
<td>144</td>
</tr>
<tr>
<td>Unrealized holding gains on derivative financial instruments, net</td>
<td>204</td>
<td>24</td>
<td>488</td>
</tr>
<tr>
<td>Reclassification adjustments for realized (gains)/losses</td>
<td>368</td>
<td>477</td>
<td>(94)</td>
</tr>
<tr>
<td>Unrealized holding gains/(losses) on available-for-sale securities, net</td>
<td>165</td>
<td>501</td>
<td>394</td>
</tr>
<tr>
<td>Reclassification adjustments for realized (gains)/losses</td>
<td>846</td>
<td>640</td>
<td>151</td>
</tr>
<tr>
<td>Unrealized holding gains/(losses) on available-for-sale securities, net</td>
<td>796</td>
<td>222</td>
<td>(237)</td>
</tr>
<tr>
<td>Benefit plans: actuarial gains/(losses), net</td>
<td>37</td>
<td>4,173</td>
<td>3,714</td>
</tr>
<tr>
<td>Reclassification adjustments related to amortization</td>
<td>550</td>
<td>195</td>
<td>581</td>
</tr>
<tr>
<td>Reclassification adjustments related to settlements, net</td>
<td>671</td>
<td>101</td>
<td>175</td>
</tr>
<tr>
<td>Other</td>
<td>199</td>
<td>188</td>
<td>48</td>
</tr>
<tr>
<td>Benefit plans: prior service credits and other, net</td>
<td>1,383</td>
<td>(3,690)</td>
<td>4,518</td>
</tr>
<tr>
<td>Reclassification adjustments related to amortization</td>
<td>432</td>
<td>746</td>
<td>151</td>
</tr>
<tr>
<td>Reclassification adjustments related to curtailments, net</td>
<td>(160)</td>
<td>(73)</td>
<td>(58)</td>
</tr>
<tr>
<td>Other</td>
<td>32</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Other comprehensive income/(loss), before tax</td>
<td>237</td>
<td>672</td>
<td>86</td>
</tr>
<tr>
<td>Tax provision/(benefit) on other comprehensive income/(loss)</td>
<td>(1,705)</td>
<td>(4,988)</td>
<td>4,521</td>
</tr>
<tr>
<td>Other comprehensive income/(loss) before allocation to noncontrolling interests</td>
<td>528</td>
<td>(946)</td>
<td>1,928</td>
</tr>
<tr>
<td>Comprehensive income before allocation to noncontrolling interests</td>
<td>$ (2,232)</td>
<td>$ (4,042)</td>
<td>$ 2,593</td>
</tr>
<tr>
<td>Less: Comprehensive income/(loss) attributable to noncontrolling interests</td>
<td>4,754</td>
<td>5,126</td>
<td>24,665</td>
</tr>
<tr>
<td>Comprehensive income attributable to Pfizer Inc.</td>
<td>$ 4,755</td>
<td>$ 5,090</td>
<td>$ 24,658</td>
</tr>
</tbody>
</table>

(a) Reclassified into Gain on disposal of discontinued operations—net of tax in the consolidated statements of income.
(b) Reclassified into Other (income)/deductions—net in the consolidated statements of income.
(c) Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the consolidated statements of income. For additional information, see Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans.
(d) See Note 5E. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income/(Loss). Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.
### Consolidated Balance Sheets

**Pfizer Inc. and Subsidiary Companies**

**68**

**2015 Financial Report**

As of December 31,  
(MILLIONS, EXCEPT PREFERRED STOCK ISSUED AND PER COMMON SHARE DATA)

<table>
<thead>
<tr>
<th>Assets</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$3,641</td>
<td>$3,343</td>
</tr>
<tr>
<td>Short-term investments</td>
<td>19,649</td>
<td>32,779</td>
</tr>
<tr>
<td>Trade accounts receivable, less allowance for doubtful accounts: 2015—$384; 2014—$412</td>
<td>8,176</td>
<td>8,401</td>
</tr>
<tr>
<td>Inventories</td>
<td>7,513</td>
<td>5,663</td>
</tr>
<tr>
<td>Current tax assets</td>
<td>2,662</td>
<td>2,566</td>
</tr>
<tr>
<td>Other current assets</td>
<td>2,163</td>
<td>2,843</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>43,804</td>
<td>55,595</td>
</tr>
<tr>
<td>Long-term investments</td>
<td>15,999</td>
<td>17,518</td>
</tr>
<tr>
<td>Property, plant and equipment, less accumulated depreciation</td>
<td>13,766</td>
<td>11,762</td>
</tr>
<tr>
<td>Identifiable intangible assets, less accumulated amortization</td>
<td>40,356</td>
<td>35,166</td>
</tr>
<tr>
<td>Goodwill</td>
<td>48,242</td>
<td>42,069</td>
</tr>
<tr>
<td>Noncurrent deferred tax assets and other noncurrent tax assets</td>
<td>1,794</td>
<td>1,944</td>
</tr>
<tr>
<td>Other noncurrent assets</td>
<td>3,499</td>
<td>3,513</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$167,460</td>
<td>$167,566</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Equity</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade accounts payable</td>
<td>3,620</td>
<td>3,210</td>
</tr>
<tr>
<td>Dividends payable</td>
<td>1,852</td>
<td>1,711</td>
</tr>
<tr>
<td>Income taxes payable</td>
<td>418</td>
<td>531</td>
</tr>
<tr>
<td>Accrued compensation and related items</td>
<td>2,359</td>
<td>1,841</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>10,990</td>
<td>9,153</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>29,399</td>
<td>21,587</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>28,818</td>
<td>31,541</td>
</tr>
<tr>
<td>Pension benefit obligations, net</td>
<td>6,310</td>
<td>7,885</td>
</tr>
<tr>
<td>Postretirement benefit obligations, net</td>
<td>1,809</td>
<td>2,379</td>
</tr>
<tr>
<td>Noncurrent deferred tax liabilities</td>
<td>26,877</td>
<td>23,317</td>
</tr>
<tr>
<td>Other taxes payable</td>
<td>3,992</td>
<td>4,353</td>
</tr>
<tr>
<td>Other noncurrent liabilities</td>
<td>5,257</td>
<td>4,883</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>102,463</td>
<td>95,944</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Commitments and Contingencies</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2015—649; 2014—717</td>
<td>26</td>
<td>29</td>
</tr>
<tr>
<td>Common stock, $0.05 par value; 12,000 shares authorized; issued: 2015—9,178; 2014—9,110</td>
<td>459</td>
<td>455</td>
</tr>
<tr>
<td>Additional paid-in capital</td>
<td>81,016</td>
<td>78,977</td>
</tr>
<tr>
<td>Treasury stock, shares at cost: 2015—3,003; 2014—2,819</td>
<td>(79,252)</td>
<td>(73,021)</td>
</tr>
<tr>
<td>Retained earnings</td>
<td>71,993</td>
<td>72,176</td>
</tr>
<tr>
<td>Accumulated other comprehensive loss</td>
<td>(9,522)</td>
<td>(7,316)</td>
</tr>
<tr>
<td>Total Pfizer Inc. shareholders’ equity</td>
<td>64,720</td>
<td>71,301</td>
</tr>
<tr>
<td>Equity attributable to noncontrolling interests</td>
<td>278</td>
<td>321</td>
</tr>
<tr>
<td><strong>Total equity</strong></td>
<td>64,998</td>
<td>71,622</td>
</tr>
<tr>
<td><strong>Total liabilities and equity</strong></td>
<td>$167,460</td>
<td>$167,566</td>
</tr>
</tbody>
</table>

Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.
### Consolidated Statements of Equity

**Pfizer Inc. and Subsidiary Companies**

**2015 Financial Report**

<table>
<thead>
<tr>
<th>PFIZER INC. SHAREHOLDERS</th>
<th>Preferred Stock</th>
<th>Common Stock</th>
<th>Treasury Stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>(MILLIONS, EXCEPT PREFERRED SHARES)</td>
<td>Shares</td>
<td>Stated Value</td>
<td>Shares</td>
</tr>
<tr>
<td><strong>Balance, January 1, 2013</strong></td>
<td>967</td>
<td>$39</td>
<td>8,956</td>
</tr>
<tr>
<td>Net income</td>
<td>22,003</td>
<td>22,003</td>
<td>69</td>
</tr>
<tr>
<td>Other comprehensive income/(loss), net of tax</td>
<td>2,655</td>
<td>2,655</td>
<td>(62)</td>
</tr>
<tr>
<td>Cash dividends declared:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common stock</td>
<td>(6,509)</td>
<td>(6,509)</td>
<td>(6,509)</td>
</tr>
<tr>
<td>Preferred stock</td>
<td>(2)</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>Noncontrolling interests</td>
<td>(121)</td>
<td>(121)</td>
<td></td>
</tr>
<tr>
<td>Share-based payment transactions</td>
<td>95</td>
<td>5</td>
<td>2,390</td>
</tr>
<tr>
<td>Purchases of common stock</td>
<td>(563)</td>
<td>(16,290)</td>
<td>(16,290)</td>
</tr>
<tr>
<td>Preferred stock conversions and redemptions</td>
<td>(138)</td>
<td>(5)</td>
<td>—</td>
</tr>
<tr>
<td>Sale of 19.9% of subsidiary through an IPO(a)</td>
<td>2,297</td>
<td>—</td>
<td>27</td>
</tr>
<tr>
<td>Acquisition of common stock in exchange offer(a)</td>
<td>(405)</td>
<td>(11,408)</td>
<td>(11,408)</td>
</tr>
<tr>
<td>Deconsolidation of subsidiary sold(a)</td>
<td>(145)</td>
<td>(145)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>—</td>
<td>—</td>
<td>(7)</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2013</strong></td>
<td>829</td>
<td>33</td>
<td>9,051</td>
</tr>
<tr>
<td>Net income</td>
<td>9,135</td>
<td>—</td>
<td>9135</td>
</tr>
<tr>
<td>Other comprehensive income/(loss), net of tax</td>
<td>(4,045)</td>
<td>—</td>
<td>(4,045)</td>
</tr>
<tr>
<td>Cash dividends declared:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common stock</td>
<td>(6,690)</td>
<td>—</td>
<td>(6,690)</td>
</tr>
<tr>
<td>Preferred stock</td>
<td>(2)</td>
<td>—</td>
<td>(2)</td>
</tr>
<tr>
<td>Noncontrolling interests</td>
<td>(6)</td>
<td>—</td>
<td>(6)</td>
</tr>
<tr>
<td>Share-based payment transactions</td>
<td>59</td>
<td>3</td>
<td>1,693</td>
</tr>
<tr>
<td>Purchases of common stock</td>
<td>(165)</td>
<td>(5,000)</td>
<td>(5,000)</td>
</tr>
<tr>
<td>Preferred stock conversions and redemptions</td>
<td>(112)</td>
<td>(4)</td>
<td>(4)</td>
</tr>
<tr>
<td>Other</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2014</strong></td>
<td>717</td>
<td>29</td>
<td>9,110</td>
</tr>
<tr>
<td>Net income</td>
<td>6,960</td>
<td>—</td>
<td>6,960</td>
</tr>
<tr>
<td>Other comprehensive income/(loss), net of tax</td>
<td>(2,206)</td>
<td>—</td>
<td>(2,206)</td>
</tr>
<tr>
<td>Cash dividends declared:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common stock</td>
<td>(7,141)</td>
<td>—</td>
<td>(7,141)</td>
</tr>
<tr>
<td>Preferred stock</td>
<td>(2)</td>
<td>—</td>
<td>(2)</td>
</tr>
<tr>
<td>Noncontrolling interests</td>
<td>(16)</td>
<td>—</td>
<td>(16)</td>
</tr>
<tr>
<td>Share-based payment transactions</td>
<td>67</td>
<td>3</td>
<td>2,015</td>
</tr>
<tr>
<td>Purchases of common stock</td>
<td>(182)</td>
<td>(6,160)</td>
<td>(6,160)</td>
</tr>
<tr>
<td>Preferred stock conversions and redemptions</td>
<td>(68)</td>
<td>(3)</td>
<td>(3)</td>
</tr>
<tr>
<td>Other</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2015</strong></td>
<td>649</td>
<td>26</td>
<td>9,178</td>
</tr>
</tbody>
</table>


Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.
## Consolidated Statements of Cash Flows

### Pfizer Inc. and Subsidiary Companies

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year Ended December 31,</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Operating Activities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income before allocation to noncontrolling interests</td>
<td>$6,986</td>
<td>$9,168</td>
<td>$22,072</td>
</tr>
<tr>
<td>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>5,157</td>
<td>5,537</td>
<td>6,410</td>
</tr>
<tr>
<td>Asset write-offs and impairments</td>
<td>1,119</td>
<td>531</td>
<td>1,145</td>
</tr>
<tr>
<td>Foreign currency loss related to Venezuela</td>
<td>806</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Gain/(loss) on disposal of discontinued operations</td>
<td>6</td>
<td>(51)</td>
<td>(10,446)</td>
</tr>
<tr>
<td>Gain associated with the transfer of certain product rights to an equity-method investment</td>
<td>—</td>
<td>—</td>
<td>(459)</td>
</tr>
<tr>
<td>Deferred taxes from continuing operations</td>
<td>(20)</td>
<td>320</td>
<td>1,726</td>
</tr>
<tr>
<td>Deferred taxes from discontinued operations</td>
<td>2</td>
<td>(3)</td>
<td>(23)</td>
</tr>
<tr>
<td>Share-based compensation expense</td>
<td>669</td>
<td>586</td>
<td>523</td>
</tr>
<tr>
<td>Gain/(loss) on disposal of discontinued operations</td>
<td>6</td>
<td>(51)</td>
<td>(10,446)</td>
</tr>
<tr>
<td>Deferred taxes from continuing operations</td>
<td>(20)</td>
<td>320</td>
<td>1,726</td>
</tr>
<tr>
<td>Share-based compensation expense</td>
<td>669</td>
<td>586</td>
<td>523</td>
</tr>
<tr>
<td>Benefit plan contributions (in excess of)/less than expense</td>
<td>(617)</td>
<td>(199)</td>
<td>296</td>
</tr>
<tr>
<td>Other adjustments, net</td>
<td>(160)</td>
<td>(430)</td>
<td>(182)</td>
</tr>
<tr>
<td>Other changes in assets and liabilities, net of acquisitions and divestitures:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade accounts receivable</td>
<td>21</td>
<td>148</td>
<td>940</td>
</tr>
<tr>
<td>Inventories</td>
<td>(199)</td>
<td>175</td>
<td>(538)</td>
</tr>
<tr>
<td>Other assets</td>
<td>249</td>
<td>1,156</td>
<td>(822)</td>
</tr>
<tr>
<td>Trade accounts payable</td>
<td>254</td>
<td>297</td>
<td>382</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>474</td>
<td>(845)</td>
<td>(3,117)</td>
</tr>
<tr>
<td>Other tax accounts, net</td>
<td>(235)</td>
<td>492</td>
<td>(223)</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>$14,512</td>
<td>16,883</td>
<td>17,684</td>
</tr>
<tr>
<td><strong>Investing Activities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of property, plant and equipment</td>
<td>(1,397)</td>
<td>(1,199)</td>
<td>(1,206)</td>
</tr>
<tr>
<td>Purchases of short-term investments</td>
<td>(28,581)</td>
<td>(50,954)</td>
<td>(42,761)</td>
</tr>
<tr>
<td>Proceeds from redemptions/sales of short-term investments</td>
<td>40,064</td>
<td>47,374</td>
<td>41,127</td>
</tr>
<tr>
<td><strong>Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</strong></td>
<td>5,768</td>
<td>3,930</td>
<td>(4,277)</td>
</tr>
<tr>
<td>Purchases of long-term investments</td>
<td>(9,542)</td>
<td>(10,718)</td>
<td>(11,020)</td>
</tr>
<tr>
<td>Proceeds from redemptions/sales of long-term investments</td>
<td>6,929</td>
<td>6,145</td>
<td>7,555</td>
</tr>
<tr>
<td>Acquisitions of businesses, net of cash acquired</td>
<td>(16,466)</td>
<td>(195)</td>
<td>(15)</td>
</tr>
<tr>
<td>Acquisitions of intangible assets</td>
<td>(99)</td>
<td>(384)</td>
<td>(259)</td>
</tr>
<tr>
<td><strong>Other investing activities, net</strong></td>
<td>344</td>
<td>347</td>
<td>312</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(2,980)</td>
<td>(5,654)</td>
<td>(10,544)</td>
</tr>
<tr>
<td><strong>Financing Activities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proceeds from short-term borrowings</td>
<td>5,557</td>
<td>13</td>
<td>4,323</td>
</tr>
<tr>
<td>Principal payments on short-term borrowings</td>
<td>(3,965)</td>
<td>(10)</td>
<td>(4,234)</td>
</tr>
<tr>
<td><strong>Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less</strong></td>
<td>2,717</td>
<td>(1,841)</td>
<td>3,475</td>
</tr>
<tr>
<td>Proceeds from issuance of long-term debt ref)</td>
<td>—</td>
<td>4,491</td>
<td>6,618</td>
</tr>
<tr>
<td>Principal payments on long-term debt</td>
<td>(3,003)</td>
<td>(2,104)</td>
<td>(4,146)</td>
</tr>
<tr>
<td>Purchases of common stock</td>
<td>(6,160)</td>
<td>(5,000)</td>
<td>(16,290)</td>
</tr>
<tr>
<td>Cash dividends paid</td>
<td>(6,940)</td>
<td>(6,609)</td>
<td>(6,580)</td>
</tr>
<tr>
<td>Proceeds from exercise of stock options</td>
<td>1,263</td>
<td>1,002</td>
<td>1,750</td>
</tr>
<tr>
<td>Other financing activities, net</td>
<td>298</td>
<td>72</td>
<td>109</td>
</tr>
<tr>
<td><strong>Net cash used in financing activities</strong></td>
<td>(10,233)</td>
<td>(9,986)</td>
<td>(14,975)</td>
</tr>
<tr>
<td><strong>Effect of exchange-rate changes on cash and cash equivalents</strong></td>
<td>(1,000)</td>
<td>(83)</td>
<td>(63)</td>
</tr>
<tr>
<td><strong>Net increase/(decrease) in cash and cash equivalents</strong></td>
<td>298</td>
<td>1,160</td>
<td>(7,898)</td>
</tr>
<tr>
<td>Cash and cash equivalents, beginning</td>
<td>3,343</td>
<td>2,183</td>
<td>10,081</td>
</tr>
<tr>
<td>Cash and cash equivalents, end</td>
<td>$3,641</td>
<td>$3,343</td>
<td>$2,183</td>
</tr>
</tbody>
</table>

- Continued -
### Supplemental Cash Flow Information

<table>
<thead>
<tr>
<th>Non-cash transactions:</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange of Hospira subsidiary debt for Pfizer debt&lt;sup&gt;(b)&lt;/sup&gt;</td>
<td>$ 1,669</td>
<td>$ —</td>
<td>$ —</td>
</tr>
<tr>
<td>Sale of subsidiary common stock (Zoetis) for Pfizer common stock&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>$ —</td>
<td>$ —</td>
<td>11,408</td>
</tr>
<tr>
<td>Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>$ —</td>
<td>$ —</td>
<td>2,479</td>
</tr>
<tr>
<td>Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>$ —</td>
<td>$ —</td>
<td>992</td>
</tr>
<tr>
<td>Contribution of an investment in connection with the resolution of a legal matter (Quigley)</td>
<td>$ —</td>
<td>$ —</td>
<td>447</td>
</tr>
</tbody>
</table>

Cash paid during the period for:

<table>
<thead>
<tr>
<th>Income taxes</th>
<th>$ 2,383</th>
<th>$ 2,100</th>
<th>$ 2,874</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest</td>
<td>1,302</td>
<td>1,550</td>
<td>1,729</td>
</tr>
</tbody>
</table>

<sup>(a)</sup> In 2013, includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), which is net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Divestitures.

<sup>(b)</sup> In October 2015, Pfizer exchanged $1.7 billion debt of its recently acquired subsidiary Hospira for virtually the same amount of Pfizer Inc. debt. See Note 7D. Financial Instruments: Long-Term Debt.

<sup>(c)</sup> See Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Divestitures.

<sup>(d)</sup> See Note 2E. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment: Equity-Method Investments.

Amounts may not add due to rounding.

See Notes to Consolidated Financial Statements, which are an integral part of these statements.
Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the United States (U.S.), the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Taxes paid on intercompany sales transactions are deferred until recognized upon sale of the asset to a third party.

In the consolidated balance sheet as of December 31, 2014, we performed certain reclassifications to conform to the current period presentation of all deferred taxes as noncurrent in accordance with the adoption of a new accounting standard (for additional information, see Note 1B). We also performed certain other reclassifications in the consolidated balance sheet as of December 31, 2014 to conform to the current period presentation, none of which were material to our financial statements.

On November 23, 2015, we announced that we have entered into a definitive merger agreement with Allergan plc (Allergan), a global pharmaceutical company incorporated in Ireland, under which we have agreed to combine with Allergan in a stock transaction valued at $32.18 on November 20, 2015 (the last trading day prior to the announcement) and certain other assumptions. While we have taken actions and incurred costs associated with the pending combination that are reflected in our financial statements, the pending combination with Allergan will not be reflected in our financial statements until consummation. See Note 19 for additional information.

On September 3, 2015 (the acquisition date), we acquired Hospira, Inc. (Hospira), a provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars. The total consideration for the acquisition was approximately $16.1 billion in cash. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Hospira, and, in accordance with our domestic and international reporting periods, our consolidated financial statements for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. Hospira is now a subsidiary of Pfizer and its commercial operations are now included within the Global Established Pharmaceutical (GEP) segment. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps. See Note 2A for additional information.

On December 31, 2015, we adopted a new accounting standard that requires all deferred tax assets and liabilities to be classified as noncurrent in the consolidated statement of income for the year ended December 31, 2013. The operating results of this business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations—net of tax in the consolidated statement of income for the year ended December 31, 2013. For additional information, see Note 2D. Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

B. Adoption of New Accounting Standards

We adopted a new accounting and disclosure standard as of January 1, 2015 that limits the presentation of discontinued operations to when the disposal of the business operation represents a strategic shift that has had or will have a major effect on our operations and financial results. This new standard is applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. In 2015, we did not have any disposals within the scope of this new standard and, therefore, there were no impacts to our consolidated financial statements from the adoption of this new standard.

On December 31, 2015, we adopted a new accounting standard that requires all deferred tax assets and liabilities to be classified as noncurrent in the balance sheet. We elected to apply this new standard retrospectively. The impact of the change in presentation is that all deferred tax assets and liabilities that were previously reported in current assets and current liabilities, totaling net current deferred tax assets of $2.1 billion as of December 31, 2014 have been reclassified to noncurrent assets and noncurrent liabilities, as appropriate. For additional information, see Note 5C.

C. Estimates and Assumptions

In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired in-process research & development (IPR&D) assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals
Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.

As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our financial statements on a prospective basis, unless they are required to be treated retrospectively under relevant accounting standards. It is possible that others, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

D. Acquisitions

Our consolidated financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&D is expensed.

Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in Other (income)/deductions—net.

Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

E. Fair Value

We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.

When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:

- Income approach, which is based on the present value of a future stream of net cash flows.
- Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
- Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.

Our fair value methodologies depend on the following types of inputs:

- Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).
- Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).
- Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

F. Foreign Currency Translation

For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in Other comprehensive income/(loss). The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in Other (income)/deductions—net. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in Other (income)/deductions—net, and we translate non-monetary items at historical rates.
G. Revenues and Trade Accounts Receivable

Revenue Recognition—We record revenues from product sales when the goods are shipped and title passes to the customer. At the time of sale, we also record estimates for a variety of revenue deductions, such as rebates, chargebacks, sales allowances and sales returns. When we cannot reasonably estimate the amount of future sales returns and/or other revenue deductions, we record revenues when the risk of product return and/or additional revenue deductions has been substantially eliminated.

Deductions from Revenues—Our gross product revenues are subject to a variety of deductions, that generally are estimated and recorded in the same period that the revenues are recognized, and primarily represent rebates, chargebacks and sales allowances to government agencies, wholesalers/distributors and managed care organizations with respect to our pharmaceutical products. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period.

Specifically:

• In the U.S., we record provisions for pharmaceutical Medicare, Medicaid, and performance-based contract rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period’s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap,” also known as the “doughnut hole,” based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.

• Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government’s total unbudgeted pharmaceutical spending or on specific product sales thresholds, and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.

• Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual as we settle these deductions generally within two to five weeks of incurring the liability.

• Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.

• We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.

Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $3.9 billion as of December 31, 2015, of which approximately $2.6 billion is included in Other current liabilities, $272 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Trade accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet. Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled $3.4 billion as of December 31, 2014, of which approximately $2.0 billion is included in Other current liabilities, $300 million is included in Other noncurrent liabilities and approximately $1.1 billion is included against Trade accounts receivable, less allowance for doubtful accounts, in our consolidated balance sheet. Total accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts as of December 31, 2015 increased by approximately $500 million compared to December 31, 2014, primarily due to the addition, in 2015, of Hospira accruals.

Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from Revenues.

Collaborative Arrangements—Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of Revenues, when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded when our collaboration partners ship the product and title passes to their customer. The related expenses for selling and marketing these products are included in Selling, informational and administrative expenses. In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when our collaboration partners sell the product and title passes to their customers. All royalty payments to collaboration partners are included in Cost of sales.

Trade Accounts Receivable—Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.
H. Cost of Sales and Inventories

We carry inventories at the lower of cost or market. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.

I. Selling, Informational and Administrative Expenses

Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.

Advertising expenses totaled approximately $3.1 billion in 2015, $3.1 billion in 2014 and $3.0 billion in 2013. Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs.

J. Research and Development Expenses

Research and development (R&D) costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

R&D expenses related to upfront and milestone payments for intellectual property rights totaled $429 million in 2015, $1.4 billion in 2014 and $203 million in 2013. For additional information, see Note 2B and Note 2C.

K. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets

Long-lived assets include:

- Property, plant and equipment, less accumulated depreciation—These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.

- Identifiable intangible assets, less accumulated amortization—These acquired assets are recorded at cost. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined. Intangible assets associated with IPR&D projects are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.

- Goodwill—Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate.

We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.

Specifically:

- For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate.

- For indefinite-lived intangible assets, such as Brands and IPR&D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.

- For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.

Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.
L. Restructuring Charges and Certain Acquisition-Related Costs

We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in Restructuring charges and certain acquisition-related costs are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. (If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate). Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other costs incurred in connection with a business acquisition are expensed as incurred.

Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

M. Cash Equivalents and Statement of Cash Flows

Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as Short-term investments.

Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.

N. Investments and Derivative Financial Instruments

Our investments are comprised of the following: trading securities, available-for-sale securities, held-to-maturity securities (when we have both the positive intent and ability to hold the investment to maturity) and private equity investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.

• Trading securities are carried at fair value, with changes in fair value reported in Other (income)/deductions—net.
• Available-for-sale debt and equity securities are carried at fair value, with changes in fair value reported in Other comprehensive income/(loss) until realized.
• Held-to-maturity debt securities are carried at amortized cost.
• Private equity securities are carried at equity-method or cost. For equity investments where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity method, we record our share of the investee’s income and expenses in Other (income)/deductions—net. The excess of the cost of the investment over our share of the equity of the investee as of the acquisition date is allocated to the identifiable assets of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which typically does not include amounts of contingent consideration.

Realized gains or losses on sales of investments are determined by using the specific identification cost method.

We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.

Derivative financial instruments are carried at fair value in various balance sheet categories (see Note 7A), with changes in fair value reported in Net income or, for derivative financial instruments in certain qualifying hedging relationships, in Other comprehensive income/(loss) (see Note 7E).

A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

O. Tax Assets and Liabilities and Income Tax Contingencies

Current tax assets primarily includes (i) tax effects associated with intercompany transfers of assets within our consolidated group, which are recognized in the consolidated statement of income when the asset transferred is sold to a third-party or recovered through amortization of the asset’s remaining economic life; and (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations.

Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.

We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the
amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.

Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to more-likely-than-not; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision for taxes on income and are classified on our consolidated balance sheet with the related tax liability.

Amounts recorded for valuation allowances and income tax contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

P. Pension and Postretirement Benefit Plans

The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both qualified and supplemental (non-qualified) defined benefit and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement benefit obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic benefit costs are recognized, as required, into Cost of sales, Selling, Informational and administrative expenses and/or Research and development expenses, as appropriate.

Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

Q. Legal and Environmental Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.

Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.

R. Share-Based Payments

Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into Cost of sales, Selling, Informational and administrative expenses and/or Research and development expenses, as appropriate.

Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see Note 1C.


A. Acquisitions

Hospira, Inc. (Hospira)

On September 3, 2015 (the acquisition date), we acquired Hospira, a leading provider of sterile injectable drugs and infusion technologies as well as a provider of biosimilars, for $90 per share in cash. The total fair value of consideration transferred for Hospira was approximately $16.1 billion in cash ($15.7 billion, net of cash acquired). Hospira is now a subsidiary of Pfizer. The combination of local Pfizer and Hospira entities may be pending in various jurisdictions and integration is subject to completion of various local legal and regulatory steps.
Hospira’s principal business was the development, manufacture, marketing and distribution of generic acute-care and oncology injectables, biosimilars and integrated infusion therapy and medication management systems. Hospira’s broad portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. We believe our acquisition of Hospira has strengthened our GEP business, as GEP now has a broadened portfolio of generic and branded sterile injectables, marketed biosimilars, medication management systems and biosimilars in development.

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date. The estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date.

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Amounts Recognized as of Acquisition Date (Provisional)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Working capital, excluding inventories (a)</td>
<td>$274</td>
</tr>
<tr>
<td>Inventories</td>
<td>1,924</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>2,410</td>
</tr>
<tr>
<td>Identifiable intangible assets, excluding in-process research and development (b)</td>
<td>8,270</td>
</tr>
<tr>
<td>In-process research and development</td>
<td>995</td>
</tr>
<tr>
<td>Other noncurrent assets</td>
<td>408</td>
</tr>
<tr>
<td>Long-term debt (1,928)</td>
<td></td>
</tr>
<tr>
<td>Benefit obligations (117)</td>
<td></td>
</tr>
<tr>
<td>Net income tax accounts (c) (3,394)</td>
<td></td>
</tr>
<tr>
<td>Other noncurrent liabilities (39)</td>
<td></td>
</tr>
<tr>
<td>Total identifiable net assets</td>
<td>8,803</td>
</tr>
<tr>
<td>Goodwill</td>
<td>7,284</td>
</tr>
<tr>
<td>Net assets acquired/total consideration transferred</td>
<td>$16,087</td>
</tr>
</tbody>
</table>

(a) Includes cash and cash equivalents, short-term investments, accounts receivable, other current assets, assets held for sale, accounts payable and other current liabilities.
(b) Comprised of finite-lived developed technology rights with a weighted-average life of approximately 17 years ($7.7 billion) and other finite-lived identifiable intangible assets with a weighted-average life of approximately 12 years ($550 million).
(c) As of the acquisition date, included in Current tax assets ($79 million), Noncurrent deferred tax assets and other noncurrent tax assets ($25 million), Income taxes payable ($5 million), Noncurrent deferred tax liabilities ($3.4 billion) and Other taxes payable ($114 million, including accrued interest of $5 million).

The following items are subject to change:

- Amounts for certain balances included in working capital (excluding inventories), certain investments and certain legal contingencies, pending receipt of certain information that could affect provisional amounts recorded. We do not believe any adjustments for legal contingencies will have a material impact on our consolidated financial statements.
- Amounts for intangibles, inventory and property, plant and equipment, pending finalization of valuation efforts for acquired intangible assets as well as the completion of certain physical inventory counts and the confirmation of the physical existence and condition of certain property, plant and equipment assets.
- Amounts for income tax assets, receivables and liabilities, pending the filing of Hospira pre-acquisition tax returns and the receipt of information including but not limited to that from taxing authorities, which may change certain estimates and assumptions used.

As of the acquisition date, the fair value of accounts receivable approximated the book value acquired. The gross contractual amount receivable was $570 million, of which $7 million was not expected to be collected.

In the ordinary course of business, Hospira incurs liabilities for environmental, legal and tax matters, as well as guarantees and indemnifications. These matters may include contingencies. Except as specifically excluded by the relevant accounting standard, contingencies are required to be measured at fair value as of the acquisition date if the acquisition-date fair value of the asset or liability arising from a contingency can be determined. If the acquisition-date fair value of the asset or liability cannot be determined, the asset or liability would be recognized at the acquisition date if both of the following criteria are met: (i) it is probable that an asset existed or that a liability had been incurred at the acquisition date, and (ii) the amount of the asset or liability can be reasonably estimated.

- **Environmental Matters**—In the ordinary course of business, Hospira incurs liabilities for environmental matters such as remediation work, asset retirement obligations and environmental guarantees and indemnifications.
- **Legal Matters**—Hospira is involved in various legal proceedings, including product liability, patent, commercial, antitrust and environmental matters and government investigations, of a nature considered normal to its business. The contingencies arising from legal matters are not significant to Pfizer’s financial statements.
- **Tax Matters**—In the ordinary course of business, Hospira incurs liabilities for income taxes. Income taxes are exceptions to both the recognition and fair value measurement principles associated with the accounting for business combinations. Reserves for income tax contingencies continue to be measured under the benefit recognition model as previously used by Hospira (see Note 1O). Net liabilities for income taxes approximated $3.4 billion as of the acquisition date, which includes $112 million for uncertain tax positions. The net tax liability includes the recording of additional adjustments of approximately $3.3 billion for the tax impact of fair value adjustments and approximately $744 million for income tax matters that we intend to resolve in a manner different from what Hospira had planned or intended. For
example, because we plan to repatriate certain overseas funds, we provided deferred taxes on Hospira’s unremitted earnings for which no
taxes have been previously provided by Hospira as it was Hospira’s intention to indefinitely reinvest those earnings.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic
benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill
recorded as part of the acquisition of Hospira includes the following:

• the expected specific synergies and other benefits that we believe will result from combining the operations of Hospira with the operations of
Pfizer;
• any intangible assets that do not qualify for separate recognition, as well as future, as yet unidentified projects and products; and
• the value of the going-concern element of Hospira’s existing businesses (the higher rate of return on the assembled collection of net assets
versus if Pfizer had acquired all of the net assets separately).

Goodwill is not amortized and is not deductible for tax purposes. All of the goodwill related to the acquisition of Hospira is related to our GEP
segment (see Note 10 for additional information).

Actual and Pro Forma Impact of Acquisition—The following table presents information for Hospira’s operations that are included in Pfizer’s
consolidated statements of income beginning from the acquisition date, September 3, 2015 through Pfizer’s domestic and international year-
ends in 2015 (see Note 1A):

(MILLIONS OF DOLLARS)

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$ 1,513</td>
</tr>
<tr>
<td>Net loss attributable to Pfizer Inc. common shareholders(a)</td>
<td>(575)</td>
</tr>
</tbody>
</table>

(a) Includes purchase accounting charges related to (i) the preliminary fair value adjustment for acquisition-date inventory estimated to have been sold ($378 million pre-tax); (ii) amortization expense related to the preliminary fair value of identifiable intangible assets acquired from Hospira ($161 million pre-tax); (iii) depreciation expense related to the preliminary fair value adjustment of fixed assets acquired from Hospira ($34 million pre-tax); and (iv) amortization expense related to the fair value adjustment of long-term debt acquired from Hospira ($13 million income pre-tax), as well as restructuring and integration costs ($556 million pre-tax).

The following table provides supplemental pro forma information as if the acquisition of Hospira had occurred on January 1, 2014:

(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA)

<table>
<thead>
<tr>
<th></th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>Revenues</td>
<td>$ 52,082</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders</td>
<td>7,647</td>
</tr>
<tr>
<td>Diluted earnings per share attributable to Pfizer Inc. common shareholders</td>
<td>1.22</td>
</tr>
</tbody>
</table>

The unaudited supplemental pro forma consolidated results do not purport to reflect what the combined company’s results of operations would
have been had the acquisition occurred on January 1, 2014, nor do they project the future results of operations of the combined company or
reflect the expected realization of any cost savings associated with the acquisition. The actual results of operations of the combined company
can differ significantly from the pro forma adjustments reflected here due to many factors. The unaudited supplemental pro forma financial
information includes various assumptions, including those related to the preliminary purchase price allocation of the assets acquired and the
liabilities assumed from Hospira.

The unaudited supplemental pro forma consolidated results reflect the historical financial information of Pfizer and Hospira, adjusted to give
effect to the acquisition of Hospira as if it had occurred on January 1, 2014, primarily for the following pre-tax adjustments:

• Elimination of Hospira’s historical intangible asset amortization expense (approximately $33 million in 2015 and $77 million in 2014).
• Additional amortization expense (approximately $343 million in 2015 and $496 million in 2014) related to the preliminary estimate of the fair
value of identifiable intangible assets acquired.
• Additional depreciation expense (approximately $54 million in 2015 and $104 million in 2014) related to the preliminary estimate of the fair
value adjustment to property, plant and equipment (PP&E) acquired.
• Adjustment related to the preliminary estimate of the non-recurring fair value adjustment to acquisition-date inventory estimated to have
been sold (the elimination of $340 million of charges in 2015 and the addition of $576 million of charges in 2014).
• Adjustment to decrease interest expense (approximately $18 million in 2015 and $42 million in 2014) related to the fair value adjustment of
Hospira debt.
• Adjustment for non-recurring acquisition-related costs directly attributable to the acquisition (the elimination of $877 million of charges in
2015, and the addition of $877 million of charges in 2014, reflecting non-recurring charges incurred by both Hospira and Pfizer).
The above adjustments were then adjusted for the applicable tax impact. The taxes associated with the adjustments related to the preliminary estimate of the fair value adjustment for acquired intangible assets, property, plant and equipment and inventory reflect the statutory tax rates in the various jurisdictions where the adjustments are expected to be incurred. The taxes associated with the adjustments for the elimination of Hospira’s historical intangible asset amortization expense, the fair value adjustment for the acquired debt and the non-recurring acquisition-related costs directly attributable to the acquisition were based on the tax rate in the jurisdiction in which the related deductible costs were incurred.

Marketed Vaccines Business of Baxter International Inc. (Baxter)

On December 1, 2014 (which falls in the first fiscal quarter of 2015 for our international operations), we acquired Baxter’s portfolio of marketed vaccines for a final purchase price of $648 million. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis and FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis. In connection with this acquisition, we recorded $376 million in Identified intangible assets, less accumulated amortization primarily consisting of $371 million in Developed technology rights. We also recorded $194 million of Inventories and $12 million in Goodwill. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.

InnoPharma, Inc. (InnoPharma)

On September 24, 2014, we completed our acquisition of InnoPharma, a privately-held pharmaceutical development company, for an upfront cash payment of $225 million and contingent consideration with an estimated acquisition-date fair value of approximately $67 million. The contingent consideration consists of up to $135 million in additional milestone payments based on application filing with, and acceptance by, the U.S. Food and Drug Administration (FDA), or approval of marketing applications related to certain pipeline products by the FDA. We believe this acquisition represents a potential innovative growth opportunity for our sterile injectables portfolio in areas such as oncology and central nervous disorders. In connection with this acquisition, we recorded $247 million in Identified intangible assets, less accumulated amortization consisting of $212 million in IPR&D and $35 million in Developed technology rights; $81 million in net deferred tax liabilities; and $125 million in Goodwill. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.

B. Licensing Agreements

Cellectis SA (Cellectis)

In June 2014, we entered into a global arrangement with Cellectis to develop Chimeric Antigen Receptor T-cell immunotherapies in the field of oncology directed at select cellular antigen targets. In August 2014, in connection with this licensing agreement, we made an upfront payment of $80 million to Cellectis, which was recorded in Research and development expenses. We will also fund research and development costs associated with 15 Pfizer-selected targets and, for the benefit of Cellectis, a portion of the research and development costs associated with four Cellectis-selected targets within the arrangement. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per product that results from the Pfizer-selected targets. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer. In addition, in August 2014, we acquired approximately 10% of the capital of Cellectis through the purchase of newly issued shares, for a total investment of approximately $35 million. As of November 30, 2015, Pfizer’s ownership in Cellectis had been reduced to approximately 7.94% of Cellectis’ outstanding shares due to subsequent share issuances by Cellectis, including the initial public offering of Cellectis American Depositary Shares.

Nexium Over-the-Counter Rights

In August 2012, we entered into an agreement with AstraZeneca PLC (AstraZeneca) for the exclusive, global, over-the-counter (OTC) rights for Nexium, a leading prescription drug approved to treat the symptoms of gastroesophageal reflux disease. In connection with this Consumer Healthcare licensing agreement, we made an upfront payment of $250 million to AstraZeneca, which was recorded in Research and development expenses when incurred. On May 27, 2014, we launched Nexium 24HR in the U.S., and on July 11, 2014, we paid AstraZeneca a related $200 million product launch milestone payment. On August 1, 2014, we launched Nexium Control in Europe, and on September 15, 2014, we paid AstraZeneca a related $50 million product launch milestone payment. These post-approval milestone payments were recorded in Identified intangible assets, less accumulated amortization and are being amortized over the estimated useful life of the Nexium brand. Included in Other current liabilities at December 31, 2015 are accrued milestone payments to AstraZeneca of $93 million. AstraZeneca is eligible to receive additional milestone payments of approximately $200 million, based on the level of worldwide sales as well as quarterly royalty payments based on worldwide sales.

C. Collaborative Arrangements

In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.
The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td><strong>Revenues</strong>—Revenues**(a)**</td>
<td>$644</td>
</tr>
<tr>
<td><strong>Revenues</strong>—Alliance revenues**(b)**</td>
<td>1,312</td>
</tr>
<tr>
<td><strong>Total revenues from collaborative arrangements</strong></td>
<td>1,956</td>
</tr>
<tr>
<td><strong>Cost of sales</strong>(c)</td>
<td>(282)</td>
</tr>
<tr>
<td><strong>Selling, informational and administrative expenses</strong>(d)</td>
<td>(287)</td>
</tr>
<tr>
<td><strong>Research and development expenses</strong>(e)</td>
<td>(330)</td>
</tr>
<tr>
<td><strong>Other income/(deductions)—net</strong>(f)</td>
<td>482</td>
</tr>
</tbody>
</table>

(a) Represents sales to our partners of products manufactured by us.

(b) Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2015 reflects an increase in alliance revenues from Eliquis, partially offset by Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014). The decline in 2014 reflects decline in alliance revenues from Enbrel (as a result of the expiration of the co-promotion term of the collaboration agreement on October 31, 2013 in the U.S. and Canada) and Spiriva (as a result of the expiration of the co-promotion collaboration in the U.S. and certain European countries during 2014, combined with the expiration of the collaboration in Australia, Canada and certain other European countries during 2013).

(c) Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $310 million in 2015 (primarily related to our collaboration with OPKO Health, Inc. (OPKO), see below), $1.2 billion in 2014 (related to our collaboration with Merck KGaA, see below), and $67 million in 2013.

(d) Primarily relates to royalties earned by our partners and cost of sales associated with inventory purchased from our partners.

(e) Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.

(f) In 2015, 2014 and 2013, includes royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and we became entitled to royalties for a 36-month period thereafter.

The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under the collaborative arrangements.

In addition, in connection with our collaborative arrangements, we paid post-approval milestones to collaboration partners of $20 million in 2015, $80 million in 2014 and $175 million in 2013. These payments were recorded in **Identifiable intangible assets—Developed technology rights**. We also received upfront and milestone payments from our collaboration partners of $200 million in 2015 primarily related to our collaboration with Eli Lilly & Company (Lilly) (see below) and $128 million in 2013. These amounts were recorded in our consolidated balance sheets as deferred revenue and are being recognized into **Other (income)/deductions—net over a multi-year period**.

**Collaboration with Eli Lilly & Company (Lilly)**

In October 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer’s tanezumab, which provides that Pfizer and Lilly will share development expenses as well as potential revenues and certain product-related costs. Following the decision by the FDA in March 2015 to lift the partial clinical hold on the tanezumab development program, we received a $200 million upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which is recorded as deferred revenue in our consolidated balance sheet and is being recognized into **Other (income)/deductions—net over a multi-year period** beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015, which will consist of six studies in approximately 7,000 patients across osteoarthritis, chronic low back pain and cancer pain. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones.

**Collaboration with OPKO Health, Inc. (OPKO)**

In December 2014, we entered into a collaborative agreement with OPKO to develop and commercialize OPKO’s long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age. hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. We have received the exclusive license to commercialize hGH-CTP worldwide. OPKO will lead the clinical activities and will be responsible for funding the development programs for the key indications, which include Adult and Pediatric GHD and Pediatric SGA. We will be responsible for all development costs for additional indications, all postmarketing studies, manufacturing and commercialization activities for all indications, and we will lead the manufacturing activities related to product development. The transaction closed on January 28, 2015, upon termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. In February 2015, we made an upfront payment of $295 million to OPKO, which was recorded in **Research and development expenses**, and OPKO is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. OPKO is also eligible to receive royalty payments associated with the commercialization of hGH-CTP for Adult GHD, which is subject to regulatory approval. Upon the launch of hGH-CTP for Pediatric GHD, which is subject to regulatory approval, the royalties will transition to tiered gross profit sharing for both hGH-CTP and our product, Genotropin.
Collaboration with Merck KGaA

In November 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, the proposed international non-proprietary name for the investigational anti-PD-L1 antibody (MSB0010718C), currently in development as a potential treatment for multiple types of cancer. We and Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA’s broad portfolio of approved and investigational oncology therapies. The collaboration with Merck KGaA has initiated 28 programs, monotherapy and combination trials, including seven pivotal trials in Phase IB/2 or Phase 3 (two in lung cancer, two in gastric cancer, and one in each of bladder cancer, Merkel cell carcinoma and ovarian cancer) and received FDA breakthrough therapy designation for avelumab in metastatic Merkel cell carcinoma. We and Merck KGaA are also combining resources and expertise to advance our anti-PD-1 antibody into Phase 1 trials. Under the terms of the agreement, in the fourth quarter of 2014, we made an upfront payment of $850 million to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately $2.0 billion. Both companies will jointly fund all development and commercialization costs, and split equally any profits generated from selling any anti-PD-L1 or anti-PD-1 products from this collaboration. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and several other key markets, and co-promotion activities were initiated in key select markets in 2015. In 2014, we recorded $1.2 billion of Research and development expenses associated with this collaborative arrangement, composed of the $850 million upfront cash payment as well as an additional amount of $309 million, reflecting the estimated fair value of the co-promotion rights given to Merck KGaA.

D. Divestitures

Animal Health Business—Zoetis Inc.

On June 24, 2013, we completed the full disposition of our Animal Health business. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.

With respect to the formation and disposition of Zoetis, in 2013:

• Formation of Zoetis—On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.

• Initial Public Offering (19.8% Interest)—On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital.

• Exchange Offer (80.2% Interest)—On June 24, 2013, we exchanged all of our remaining interest in Zoetis, 400.985 million shares of Zoetis Class A common stock (after converting all of our Class B common stock into Class A common stock, representing approximately 80.2% of the total outstanding Zoetis shares), for approximately 408.117 million outstanding shares of Pfizer common stock on a tax-free basis pursuant to an exchange offer made to Pfizer shareholders. The $11.4 billion of Pfizer common stock received in the exchange transaction was recorded in Treasury stock and was valued using the opening price of Pfizer common stock on June 24, 2013, the date we accepted the Zoetis shares for exchange. The gain on the sale of the remaining interest in Zoetis was approximately $10.3 billion, net of income taxes resulting from certain legal entity reorganizations, and was recorded in Gain on disposal of discontinued operations—net of tax in the consolidated statement of income for the year ended December 31, 2013.

In summary, as a result of the above transactions, we received cash and were relieved of debt obligations in the aggregate amount of approximately $6.1 billion and received shares of Pfizer common stock (held in Treasury stock) valued at approximately $11.4 billion.

The operating results of the animal health business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations—net of tax in the consolidated statement of income for the year ended December 31, 2013.

In connection with the above transactions, we entered into a transitional services agreement (TSA) and manufacturing and supply agreements (MSAs) with Zoetis that are designed to facilitate the orderly transfer of business operations to the standalone Zoetis entity. The TSA relates primarily to administrative services, which are generally to be provided within 24 months. Services under the TSA are largely completed as of December 31, 2015. Under the MSAs, we will manufacture and supply certain animal health products to Zoetis for a period of up to five years, with an ability to extend, if necessary, upon mutual agreement of both parties. These agreements are not material and none confers upon us the ability to influence the operating and/or financial policies of Zoetis subsequent to June 24, 2013, the date of disposal.
The following table provides the components of Discontinued operations—net of tax:

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$—</td>
<td>$—</td>
<td>$2,201</td>
</tr>
<tr>
<td>Pre-tax income from discontinued operations (a), (b)</td>
<td>$20</td>
<td>$(9)</td>
<td>408</td>
</tr>
<tr>
<td>Provision for taxes on income (b), (c)</td>
<td>2</td>
<td>$(3)</td>
<td>100</td>
</tr>
<tr>
<td>Income from discontinued operations—net of tax</td>
<td>17</td>
<td>$(6)</td>
<td>308</td>
</tr>
<tr>
<td>Pre-tax gain/(loss) on disposal of discontinued operations (b)</td>
<td>$(6)</td>
<td>51</td>
<td>10,446</td>
</tr>
<tr>
<td>Provision for taxes on income (b), (d)</td>
<td>$(4)</td>
<td>—</td>
<td>92</td>
</tr>
<tr>
<td>Gain/(loss) on disposal of discontinued operations—net of tax</td>
<td>$(6)</td>
<td>55</td>
<td>10,354</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>$11</td>
<td>$48</td>
<td>$10,662</td>
</tr>
</tbody>
</table>

(a) Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal.
(b) Includes post-close adjustments for the periods subsequent to disposal.
(c) Includes a deferred tax expense of $2 million for 2015, a deferred tax benefit of $3 million for 2014 and a deferred tax benefit of $23 million for 2013.
(d) For 2013, primarily reflects income tax expense of $122 million resulting from certain legal entity reorganizations.

The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for any period presented, except that financing activities in 2013 include the cash proceeds from the issuance of senior notes by Zoetis.

E. Equity-Method Investments

Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)

On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd., a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of $250 million, of which our portion was $122.5 million. On January 1, 2013, both parties transferred selected employees to Hisun Pfizer and contributed, among other things, certain rights to commercialized products and products in development, intellectual property rights, and facilities, equipment and distribution/customer contracts. Our contributions in 2013 constituted a business, as defined by U.S. GAAP, and included, among other things, the China rights to certain commercialized products and other products not yet commercialized and all associated intellectual property rights. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas. We hold a 49% equity interest in Hisun Pfizer.

We also entered into certain transition agreements designed to ensure and facilitate the orderly transfer of the business operations to Hisun Pfizer, primarily the Pfizer Products Transition Period Agreement and a related supply and promotional services agreement. These agreements provide for a profit margin on the manufacturing services provided by Pfizer to Hisun Pfizer and govern the supply, promotion and distribution of Pfizer products until Hisun Pfizer is able to provide for its own manufacturing and distribution. While intended to be transitional, these agreements may be extended by mutual agreement of the parties for several years and, possibly, indefinitely. These agreements are not yet commercialized and all associated intellectual property rights. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas. We hold a 49% equity interest in Hisun Pfizer.

In connection with our contributions in the first quarter of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income)/deductions—net (see Note 4), reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our former Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we had an indirect retained interest in the contributed assets. As such, 49% of the gain, or $225 million, represents the portion of the gain associated with that indirect retained interest.

In the third quarter of 2015, we determined that we had an other-than-temporary decline in the value of Hisun Pfizer, and, therefore, in 2015, we recognized a loss of $463 million in Other (income)/deductions—net (see Note 4).

The decline in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, as a result of lower than expected recent performance, increased competition, a slowdown in the China economy in relation to their products, as well as certain changes in the regulatory environment.

In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, utilizing a 12% discount rate in 2015 and a 11.5% discount rate in 2013, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.

We are accounting for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we have over the operations of Hisun Pfizer through our board representation, minority veto rights and 49% voting interest. Our investment in Hisun Pfizer is reported in Long-term investments, and our share of Hisun Pfizer’s net income is recorded in Other (income)/deductions—net. As of
December 31, 2015, the carrying value of our investment in Hisun Pfizer was approximately $775 million and the amount of our underlying equity in the net assets of Hisun Pfizer was approximately $668 million. As of December 31, 2014, the carrying value of our investment in Hisun Pfizer was approximately $1.4 billion, and the amount of our underlying equity in the net assets of Hisun Pfizer was approximately $780 million. The excess of the carrying value of our investment over our underlying equity in the net assets of Hisun Pfizer has been allocated, within the investment account, to goodwill and other intangible assets. The amount allocated to other intangible assets is being amortized into Other (income)/deductions—net over an average estimated useful life of 25 years.

Investment in ViiV Healthcare Limited (ViiV)

Our minority ownership interest in ViiV, a company formed in 2009 by Pfizer and GlaxoSmithKline plc to focus solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines, was impacted by the following events:

- The January 21, 2014 European Commission approval of Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV. This approval triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%, effective April 1, 2014. As a result, in 2014, we recognized a loss of approximately $30 million in Other (income)/deductions—net.
- The August 12, 2013 FDA approval of Tivicay (dolutegravir). This approval triggered a reduction in our interest in ViiV from 13.5% to 12.6% effective October 1, 2013. As a result, in 2013, we recognized a loss of approximately $32 million in Other (income)/deductions—net; and
- The October 31, 2012 acquisition by ViiV of the remaining 50% of Shionogi-ViiV Healthcare LLC, its equity-method investee, from Shionogi & Co., Ltd. in consideration for a 10% interest in ViiV (newly issued shares) and contingent consideration in the form of future royalties. As a result of this transaction, ViiV recorded a gain associated with the step-up on the 50% interest previously held by ViiV. Also, our equity interest in ViiV was reduced from 15.0% to 13.5%.

We account for our investment in ViiV under the equity method due to the significant influence that we continue to have through our board representation and minority veto rights.

Investment in Laboratório Teuto Brasileiro S.A. (Teuto)

We have an option to acquire the remaining 60% of Teuto, a 40%-owned generics company in Brazil, and Teuto’s shareholders have an option to sell their 60% stake in the company to us. Under the terms of our agreement with Teuto’s other shareholders, 2016 is the final year in which the call and put options may be exercised. Our investment in Teuto is accounted for under the equity method due to the significant influence we have over the operations of Teuto through our board representation, minority veto rights and 40% voting interest.

- In 2014, we recorded income of approximately $55 million in Other (income)/deductions—net, resulting from a decline in the estimated loss from the net call/put option recorded in 2013 and an impairment loss of $56 million in Other (income)/deductions—net related to our equity method investment.
- In 2013, we recorded a loss of $223 million in Other (income)/deductions—net related to the net call/put option and an impairment loss of $32 million in Other (income)/deductions—net related to our equity-method investment.

F. Cost-Method Investment

AM-Pharma B.V. (AM-Pharma)

In April 2015, we acquired a minority equity interest in AM-Pharma, a privately-held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon delivery of the clinical trial report after completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. Results from the current Phase II trial for recAP are expected in 2017. Under the terms of the agreement, we paid $87.5 million for both the exclusive option and the minority equity interest, which was recorded as a cost-method investment in Long-term investments, and we may make additional payments of up to $512.5 million upon exercise of the option and potential launch of any product that may result from this investment.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:

- In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired company (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and
- In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as groups such as information technology, shared services and corporate operations.

In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three-year period post-acquisition, we expect to incur costs of approximately $1 billion (not including costs of $215 million in 2015 associated with the return of acquired in-process research and development rights as described in the Current-Period Key Activities section below) associated with the integration of Hospira.
In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives. We have the following initiatives underway associated with these programs:

- Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of four sites over the next several years. In connection with these activities, during 2014-2016, we expect to incur costs of approximately $500 million associated with prior acquisition activity and costs of approximately $1 billion associated with new non-acquisition-related cost-reduction initiatives. Through December 31, 2015, we incurred approximately $354 million and $472 million, respectively, associated with these initiatives.

- New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $250 million. Through December 31, 2015, we incurred approximately $219 million associated with this reorganization.

- Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $850 million. Through December 31, 2015, we incurred approximately $493 million associated with these initiatives.

The costs expected to be incurred during 2014-2016, of approximately $2.6 billion in total for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, integration costs, implementation costs and additional depreciation—asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.

At the end of 2013, we had substantially completed many of the initiatives launched in prior periods.

Current-Period Key Activities

In 2015, we incurred approximately $1.4 billion in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the acquisition of Hospira and the aforementioned programs, primarily associated with our manufacturing and sales operations.

The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restructuring charges(a):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employee terminations</td>
<td>$489</td>
<td>$68</td>
<td>$805</td>
</tr>
<tr>
<td>Asset impairments</td>
<td>254</td>
<td>45</td>
<td>165</td>
</tr>
<tr>
<td>Exit costs</td>
<td>68</td>
<td>58</td>
<td>68</td>
</tr>
<tr>
<td>Total restructuring charges</td>
<td>811</td>
<td>170</td>
<td>1,038</td>
</tr>
<tr>
<td>Transaction costs(b)</td>
<td>123</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Integration costs(c)</td>
<td>219</td>
<td>80</td>
<td>144</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>1,152</td>
<td>250</td>
<td>1,182</td>
</tr>
<tr>
<td>Additional depreciation—asset restructuring recorded in our consolidated statements of income as follows(d):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>117</td>
<td>228</td>
<td>178</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>—</td>
<td>1</td>
<td>19</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>5</td>
<td>31</td>
<td>94</td>
</tr>
<tr>
<td>Total additional depreciation—asset restructuring</td>
<td>122</td>
<td>261</td>
<td>291</td>
</tr>
<tr>
<td>Implementation costs recorded in our consolidated statements of income as follows(e):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>102</td>
<td>78</td>
<td>53</td>
</tr>
<tr>
<td>Selling, informational and administrative expenses</td>
<td>82</td>
<td>140</td>
<td>145</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>14</td>
<td>52</td>
<td>33</td>
</tr>
<tr>
<td>Other (income)/deductions—net</td>
<td>5</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Total implementation costs</td>
<td>203</td>
<td>270</td>
<td>231</td>
</tr>
<tr>
<td>Total costs associated with acquisitions and cost-reduction/productivity initiatives</td>
<td>$1,478</td>
<td>$781</td>
<td>$1,704</td>
</tr>
</tbody>
</table>

(a) In 2015, **Employee terminations** represent the expected reduction of the workforce by approximately 3,900 employees, mainly in sales, corporate and research. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.

The restructuring charges in 2015, which include a $39 million charge related to a 36% reduction in our labor force in Venezuela, are associated with the following:

- Global Innovative Pharmaceutical segment (GIP) ($39 million); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC) ($45 million); the Global Established Pharmaceutical segment (GEP) ($402 million); Worldwide Research and Development and Medical (WRD/M) ($80 million); manufacturing operations ($80 million); and Corporate ($164 million).
The restructuring charges in 2014 are associated with the following:

• GIP ($35 million); VOC ($28 million); GEP ($57 million); WRD/M ($37 million); manufacturing operations ($97 million); and Corporate ($65 million), as well as $149 million of income related to the partial reversal of prior-period restructuring charges not directly associated with the new individual segments, and primarily reflecting a change in estimate with respect to our sales force restructuring plans.

The restructuring charges in 2013 are associated with the following:

• Total operating segments ($496 million); WRD/M ($13 million); manufacturing operations ($356 million); and Corporate ($173 million).

At the beginning of fiscal 2014, we revised our operating segments and are unable to directly associate these prior-period restructuring charges with the new individual segments.

In September 2015, in order to eliminate certain redundancies in our biosimilar drug products pipeline created as a result of the acquisition of Hospira, we opted to return rights to Celltrion Inc. and Celltrion Healthcare, Co., Ltd. (collectively, Celltrion) that Hospira had previously acquired to potential biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab). As such, upon return of the acquired rights, in 2015 we incurred charges of $215 million, which are comprised of (i) a write-off of the applicable IPR&D assets, totaling $170 million, which is included in Asset impairments; (ii) a write-off of amounts prepaid to Celltrion in the amount of $25 million, which is included in Asset impairments; and (iii) a payment to Celltrion of $20 million, which is included in Exit costs. The recorded amounts for the assets acquired from Hospira are provisional and are subject to change. See Note 2A.

(b) Transaction costs represent external costs directly related to the acquisition of Hospira and our pending combination with Allergan and primarily include expenditures for banking, legal, accounting and other similar services.

(c) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.

(d) Additional depreciation—asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following table provides the components of and changes in our restructuring accruals:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Employee Termination</th>
<th>Asset Impairment Charges</th>
<th>Exit Costs</th>
<th>Accrual</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance, January 1, 2014</strong></td>
<td>$1,685</td>
<td>—</td>
<td>$94</td>
<td>$1,779</td>
</tr>
<tr>
<td><strong>Provision</strong></td>
<td>68</td>
<td>45</td>
<td>58</td>
<td>170</td>
</tr>
<tr>
<td><strong>Utilization and other</strong>&lt;sup&gt;(a)&lt;/sup&gt;</td>
<td>(639)</td>
<td>(45)</td>
<td>(100)</td>
<td>(783)</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2014</strong>&lt;sup&gt;(b)&lt;/sup&gt;</td>
<td>1,114</td>
<td>—</td>
<td>52</td>
<td>1,166</td>
</tr>
<tr>
<td><strong>Provision</strong></td>
<td>489</td>
<td>254</td>
<td>68</td>
<td>811</td>
</tr>
<tr>
<td><strong>Utilization and other</strong>&lt;sup&gt;(a)&lt;/sup&gt;</td>
<td>(495)</td>
<td>(254)</td>
<td>(71)</td>
<td>(820)</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2015</strong>&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>$1,109</td>
<td>—</td>
<td>48</td>
<td>$1,157</td>
</tr>
</tbody>
</table>

<sup>(a)</sup> Includes adjustments for foreign currency translation.

<sup>(b)</sup> Included in Other current liabilities ($735 million) and Other noncurrent liabilities ($431 million).

<sup>(c)</sup> Included in Other current liabilities ($776 million) and Other noncurrent liabilities ($381 million).
Note 4. Other (Income)/Deductions—Net

The following table provides components of Other (income)/deductions—net:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest income(a)</td>
<td>$(471)</td>
<td>$(425)</td>
<td>$(403)</td>
</tr>
<tr>
<td>Interest expense(b)</td>
<td>1,199</td>
<td>1,360</td>
<td>1,414</td>
</tr>
<tr>
<td>Net interest expense</td>
<td>728</td>
<td>935</td>
<td>1,011</td>
</tr>
<tr>
<td>Foreign currency loss related to Venezuela(b)</td>
<td>806</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Royalty-related income(c)</td>
<td>(922)</td>
<td>(1,002)</td>
<td>(523)</td>
</tr>
<tr>
<td>Patent litigation settlement income(d)</td>
<td>(282)</td>
<td>168</td>
<td>—</td>
</tr>
<tr>
<td>Other legal matters, net(e)</td>
<td>975</td>
<td>993</td>
<td>35</td>
</tr>
<tr>
<td>Gain associated with the transfer of certain product rights(f)</td>
<td>—</td>
<td>—</td>
<td>(459)</td>
</tr>
<tr>
<td>Net gains on asset disposals(g)</td>
<td>(232)</td>
<td>(288)</td>
<td>(320)</td>
</tr>
<tr>
<td>Certain asset impairments(h)</td>
<td>818</td>
<td>469</td>
<td>878</td>
</tr>
<tr>
<td>Business and legal entity alignment costs(i)</td>
<td>282</td>
<td>168</td>
<td>—</td>
</tr>
<tr>
<td>Costs associated with the Zoetis IPO(j)</td>
<td>—</td>
<td>—</td>
<td>18</td>
</tr>
<tr>
<td>Other, net(k)</td>
<td>403</td>
<td>(265)</td>
<td>170</td>
</tr>
<tr>
<td><strong>Other (income)/deductions—net</strong></td>
<td><strong>$2,860</strong></td>
<td><strong>$1,009</strong></td>
<td><strong>($532)</strong></td>
</tr>
</tbody>
</table>

**(a)** 2015 v. 2014—Interest income increased primarily due to higher investment returns. Interest expense decreased, primarily due to the repayment of a portion of long-term debt in the first quarter of 2015 and the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. 2014 v. 2013—Interest income increased due to higher cash equivalents and investment balances. Interest expense decreased, primarily due to the benefit of the effective conversion of some fixed-rate liabilities to floating-rate liabilities. Capitalized interest expense totaled $32 million in 2015, $41 million in 2014 and $32 million in 2013.

**(b)** In 2015, represents a foreign currency loss related to recent conditions in Venezuela, that had us resolve that our Venezuelan bolivar-denominated net monetary assets that are subject to revaluation are no longer expected to be settled at the Venezuelan government CENCOEX official rate of 6.30, but rather at the SIMADI rate of 200, the lowest official rate. Those conditions included the inability to obtain significant conversions of Venezuelan bolivars related to intercompany U.S. dollar-denominated accounts, an evaluation of the effects of the implementation of a fourth-quarter 2015 operational restructuring, resulting in a 36% reduction in our labor force in Venezuela, and our expectation of the changes in Venezuela’s responses to changes in its economy.

**(c)** Royalty related income increased in 2014 primarily due to royalties earned on sales of Enbrel in the U.S. and Canada after October 31, 2013. On that date, the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada expired, and Pfizer became entitled to royalties until October 31, 2016.

**(d)** In 2013, reflects income from a litigation settlement with Teva Pharmaceutical Industries Ltd. (Teva) and Sun Pharmaceutical Industries Ltd. (Sun) for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S. As of December 31, 2014, all amounts due had been collected.

**(e)** In 2015, primarily includes $784.6 million related to an agreement in principle reached in February 2016 to resolve claims alleging that Wyeth’s practices relating to the calculation of Medicaid rebates for its drug Protonix (pantoprazole sodium) between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws (for additional information, see Note 17A4). In 2014, primarily includes approximately $610 million for Neurontin-related matters (including off-label promotion actions and antitrust actions), $400 million to resolve a securities class action against Pfizer in New York federal court (for additional information, see Note 17A5), and approximately $56 million for an Effexor-related matter, partially offset by $130 million of income from the reversal of two legal accruals where a loss is no longer deemed probable.

**(f)** In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.

**(g)** In 2015, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $164 million; (ii) gross realized losses on sales of available-for-sale debt securities of $960 million; (iii) net gain of $937 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (iv) gains on sales/offset-licensing of product and compound rights of approximately $90 million; and (v) gains on sales of investments in private equity securities of approximately $3 million. Proceeds from the sale of available-for-sale securities were $4.3 billion in 2015.

**(h)** In 2014, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $76 million; (ii) gross realized gains on sales of available-for-sale debt securities of $138 million; (iii) gross realized losses on sales of available-for-sale debt securities of $436 million; (iv) net gain of $323 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; (v) gains on sales/out-licensing of product and compound rights of approximately $135 million; and (vi) gains on sales of investments in private equity securities of approximately $39 million. Proceeds from the sale of available-for-sale securities were $10.2 billion in 2014.

**(i)** In 2013, primarily includes (i) gross realized gains on sales of available-for-sale equity securities of $87 million; (ii) gross realized gains on sales of available-for-sale debt securities of $442 million; (iii) gross realized losses on sales of available-for-sale debt securities of $310 million; (iv) net loss of $137 million from derivative financial instruments used to hedge the foreign exchange component of the divested available-for-sale debt securities; and (v) a gain of $170 million on the sale of various product rights, including a portion of our in-licensed generic sterile injectables portfolio. Proceeds from the sale of available-for-sale securities were $15.2 billion in 2013.

**(j)** In 2015, primarily includes an impairment loss of $463 million related to Pfizer’s 49%-owned equity-method investment with Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun) in China, Hisun Pfizer (for additional information concerning Hisun Pfizer, see Note 2E) and intangible asset impairment charges of $323 million, reflecting (i) $132 million related to indefinite-lived brands; (ii) $120 million related to developed technology rights for the treatment of attention deficit hyperactivity disorder; and (iii) $71 million related to IPR&D compounds. The intangible asset impairment charges for 2015 are associated with the following: GEP ($294 million), WRD ($13 million); and Consumer Healthcare ($17 million).

The intangible asset impairment charges for 2015 reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment.

In 2014, includes intangible asset impairment charges of $396 million, reflecting (i) $190 million for an IPR&D compound for the treatment of skin fibrosis (full write-off); (ii) $159 million for developed technology rights, primarily related to Quillivant XR; and (iii) $47 million for indefinite-lived brands. The intangible asset impairment charges for 2014 are associated with the following: GIP ($12 million); GEP ($168 million); WRD ($190 million); and Consumer Healthcare ($28 million). In addition, 2014 includes an impairment charge of approximately $56 million related to our investment in Teuto.

The intangible asset impairment charges for 2014 reflect, among other things, updated commercial forecasts; and with regard to IPR&D, the impact of changes to the development program and new scientific findings.
In 2015, includes intangible asset impairment charges of $803 million, reflecting (i) $394 million of developed technology rights (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth; (ii) $227 million related to IPR&D compounds; (iii) $109 million of indefinite-lived brands, primarily related to our biopharmaceutical indefinite-lived brand Xanax/Xanax XR; and (iv) $73 million of other finite-lived intangible assets, related to platform technology, that no longer have an alternative future use. The intangible asset impairment charges for 2013 are associated with the following: GIP ($448 million); GEP ($201 million); WRD ($140 million); and Consumer Healthcare ($14 million). In addition, 2013 includes an impairment charge of approximately $43 million for certain private company investments and an impairment charge of $32 million related to our investment in Teuto.

The intangible asset impairment charges for 2015 reflect, among other things, updated commercial forecasts and, with regard to IPR&D, also reflect the impact of new scientific findings and delayed launch dates.

(a) Represents expenses for changes to our infrastructure to align our operations, as well as reporting for our business segments established in 2014.

(b) Represents costs incurred in connection with the IPO of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. For additional information, see Note 2D.

(b) In 2015, includes, among other things, (i) charges of $194 million related to the write-down of assets to net realizable value; (ii) charges of $159 million, reflecting the change in the fair value of contingent consideration liabilities; and (iii) income of $45 million associated with equity-method investees. In 2014, includes, among other things, (i) gains of approximately $40 million, reflecting the change in the fair value of contingent consideration liabilities associated with prior acquisitions; (ii) income associated with equity-method investees of $86 million; and (iii) income of $55 million resulting from a decline in the estimated loss on an option to acquire the remaining interest in Teuto; and (iv) a loss of $30 million due to a change in our ownership interest in ViViT. For additional information concerning Teuto and ViViT, see Note 2E.

The asset impairment charges included in Other (income)/deductions—net in 2015 are based on estimates of fair value.

The following table provides additional information about the intangible assets that were impaired during 2015 in Other (income)/deductions—net:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Fair Value(a)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amount</td>
<td>Level 1</td>
</tr>
<tr>
<td>Intangible assets—IPR&amp;D(b)</td>
<td>$46</td>
<td>—</td>
</tr>
<tr>
<td>Intangible assets—Developed technology rights(b)</td>
<td>$85</td>
<td>—</td>
</tr>
<tr>
<td>Intangible assets—Indefinite-lived Brands(b)</td>
<td>$145</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>$276</td>
<td>—</td>
</tr>
</tbody>
</table>

(a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also Note 1E.

(b) Reflects intangible assets written down to fair value in 2015. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product and the impact of technological risk associated with IPR&D assets; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

The following table provides the components of Income from continuing operations before provision for taxes on income:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>United States</td>
<td>$(6,609)</td>
</tr>
<tr>
<td>International</td>
<td>15,773</td>
</tr>
<tr>
<td>Income from continuing operations before provision for taxes on income(b), (b)</td>
<td>$8,965</td>
</tr>
</tbody>
</table>

(a) 2015 v. 2014—The increase in the domestic loss was primarily due to the loss of exclusivity for Celebrex and Zyprexa, higher restructuring charges and higher selling, informational and administrative expenses, partially offset by the performance of certain products including Prevnar 13 and Ibrance, and the impact of Hospira operations. The decrease in international income is primarily due to a foreign currency loss related to Venezuela, higher asset impairments, and the loss of exclusivity for Lyrica in certain developed markets, partially offset by lower research and development costs.

(b) 2014 v. 2013—The increase in the domestic loss was primarily due to lower revenues, the non-recurrence of income from a litigation settlement in 2013 with Teva and Sun for patent-infringement damages resulting from their “at-risk” launches of generic Protonix in the U.S., higher charges related to other legal matters, a non-tax deductible charge in the third quarter of 2014 to account for an additional year of the Branded Prescription Drug Fee in accordance with final regulations issued by the U.S. Internal Revenue Service (IRS), higher research and development expenses, and higher charges for business and legal entity alignment costs, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, and lower asset impairments. The decrease in international income is primarily related to lower revenues, the non-recurrence of the gain associated with the transfer of certain product rights to Pfizer’s equity-method investment in China (Hisun Pfizer) in 2013, and higher research and development expenses, partially offset by lower amortization of intangible assets, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives and the non-recurrence of certain charges.
The following table provides the components of Provision for taxes on income based on the location of the taxing authorities:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td><strong>United States</strong></td>
<td></td>
</tr>
<tr>
<td>Current income taxes:</td>
<td></td>
</tr>
<tr>
<td>Federal</td>
<td>$67</td>
</tr>
<tr>
<td>State and local</td>
<td>(8)</td>
</tr>
<tr>
<td>Deferred income taxes:</td>
<td></td>
</tr>
<tr>
<td>Federal</td>
<td>300</td>
</tr>
<tr>
<td>State and local</td>
<td>(36)</td>
</tr>
<tr>
<td>Total U.S. tax provision</td>
<td>323</td>
</tr>
<tr>
<td><strong>International</strong></td>
<td></td>
</tr>
<tr>
<td>Current income taxes</td>
<td>1,951</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>(284)</td>
</tr>
<tr>
<td>Total international tax provision</td>
<td>1,667</td>
</tr>
<tr>
<td><strong>Provision for taxes on income</strong></td>
<td>$1,990</td>
</tr>
</tbody>
</table>

In 2015, the Provision for taxes on income was impacted by the following:
- U.S. tax expense of approximately $2.1 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year (see Note 5C);
- Tax benefits of approximately $360 million, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations;
- The permanent extension of the U.S. R&D tax credit, which was signed into law in December 2015, as well as tax benefits associated with certain tax initiatives;
- The non-deductibility of a foreign currency loss related to Venezuela;
- The non-deductibility of a charge for the agreement in principle to resolve claims relating to Protonix; and
- The non-deductibility of a $251 million fee payable to the federal government as a result of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (U.S. Healthcare Legislation).

In 2014, the Provision for taxes on income was impacted by the following:
- U.S. tax expense of approximately $2.2 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in 2014 (see Note 5C);
- Tax benefits of approximately $350 million, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years, primarily with various foreign tax authorities, and from the expiration of certain statutes of limitations;
- The favorable impact of the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely;
- The extension of the U.S. R&D tax credit, which was signed into law in December 2014; and
- The non-deductibility of a $362 million fee payable to the federal government as a result of the U.S. Healthcare Legislation.

In 2013, the Provision for taxes on income was impacted by the following:
- U.S. tax expense of approximately $2.3 billion as a result of providing U.S. deferred income taxes on certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in 2013 (see Note 5C);
- U.S. tax benefits of approximately $430 million, representing tax and interest, resulting from a multi-year settlement with the IRS with respect to audits of the Wyeth tax returns for the years 2006 through date of acquisition, and international tax benefits of approximately $470 million, representing tax and interest, resulting from the resolution of certain tax positions pertaining to prior years with various foreign tax authorities, and from the expiration of certain statutes of limitations;
- The unfavorable tax rate associated with the $1.3 billion of patent litigation settlement income;
- The non-deductibility of the $292 million of goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer;
- The non-deductibility of the $223 million loss on an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and the non-deductibility of a $32 million impairment charge related to our equity-method investment in Teuto;
- The extension of the U.S. R&D tax credit (resulting in the full-year benefit of the 2012 and 2013 U.S. R&D tax credit being recorded in 2013); and
- The non-deductibility of a $280 million fee payable to the federal government as a result of the U.S. Healthcare Legislation.

In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in Provision for taxes on income (see Note 2A).
### B. Tax Rate Reconciliation

The reconciliation of the U.S. statutory income tax rate to our effective tax rate for income from continuing operations follows:

<table>
<thead>
<tr>
<th></th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>U.S. statutory income tax rate</td>
<td>35.0%</td>
</tr>
<tr>
<td>Taxation of non-U.S. operations(a), (b), (c)</td>
<td>(9.6)</td>
</tr>
<tr>
<td>Tax settlements and resolution of certain tax positions(d)</td>
<td>(4.0)</td>
</tr>
<tr>
<td>U.S. Healthcare Legislation(d)</td>
<td>0.9</td>
</tr>
<tr>
<td>U.S. R&amp;D tax credit and manufacturing deduction(d)</td>
<td>(1.0)</td>
</tr>
<tr>
<td>Certain legal settlements and charges(d)</td>
<td>3.1</td>
</tr>
<tr>
<td>All other, net(e)</td>
<td>(2.1)</td>
</tr>
<tr>
<td>Effective tax rate for income from continuing operations</td>
<td>22.2%</td>
</tr>
</tbody>
</table>

(a) For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, as well as changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions”. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year as tax rates outside the U.S. are generally lower than the U.S. statutory income tax rate, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; and (iii) the impact of changes in uncertain tax positions not included in the reconciling item called “Tax settlements and resolution of certain tax positions” is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also Note 5A for the components of pre-tax income and provision for taxes on income, which is based on the location of the taxing authorities, and for information about settlements and other items impacting provision for taxes on income.

(b) In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to generally lower tax rates, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico, Singapore, Costa Rica, and the Dominican Republic. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2031 on income from manufacturing and other operations. Hospira’s infusion technologies business benefits from income tax exemptions in Costa Rica and the Dominican Republic through 2028 and 2019, respectively.

(c) The rate impact in 2015 also includes the non-deductibility of a foreign currency loss related to Venezuela. The favorable rate impact in 2014 also includes the decline in the non-tax deductible loss recorded in 2013 related to an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely. The rate impact in 2013 also includes the non-deductibility of the goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Hisun Pfizer, and the non-deductibility of the loss on an option to acquire the remaining interest in Teuto, since we expect to retain the investment indefinitely, and the non-deductibility of an impairment charge related to our equity-method investment in Teuto. For additional information, see Note 2E.

(d) For a discussion about tax settlements and resolution of certain tax positions, the impact of U.S. Healthcare Legislation, the U.S. R&D tax credit and the impact of certain legal settlements and charges, see Note 5A. The extension of the U.S. R&D tax credit in January 2013 resulted in the full-year benefit of the 2012 and 2013 U.S. R&D tax credit being recorded in 2013.

(e) All other, net in 2015 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business.
C. Deferred Taxes

On December 31, 2015, we adopted a new accounting standard that requires all deferred tax assets and liabilities to be classified as noncurrent in the balance sheet. We elected to apply this new standard retrospectively. The impact of the change in presentation is that all deferred tax assets and liabilities that were previously reported in current assets and current liabilities, totaling net current deferred tax assets of $2.1 billion as of December 31, 2014 have been reclassified to noncurrent assets and noncurrent liabilities, as appropriate.

Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.

The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:

<table>
<thead>
<tr>
<th>2015 Deferred Tax</th>
<th>2014 Deferred Tax</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(MILLIONS OF DOLLARS)</strong></td>
<td></td>
</tr>
<tr>
<td>Assets (Liabilities)</td>
<td>Assets (Liabilities)</td>
</tr>
<tr>
<td>Prepaid/deferred items</td>
<td>$ 2,247</td>
</tr>
<tr>
<td>Inventories</td>
<td>381</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>1,063</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td>65</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>3,302</td>
</tr>
<tr>
<td>Restructurings and other charges</td>
<td>318</td>
</tr>
<tr>
<td>Legal and product liability reserves</td>
<td>730</td>
</tr>
<tr>
<td>Net operating loss/tax credit carryforwards(a)</td>
<td>3,808</td>
</tr>
<tr>
<td>Unremitted earnings(b)</td>
<td>—</td>
</tr>
<tr>
<td>State and local tax adjustments</td>
<td>328</td>
</tr>
<tr>
<td>All other</td>
<td>310</td>
</tr>
<tr>
<td><strong>Total deferred taxes</strong></td>
<td>$ 12,552</td>
</tr>
<tr>
<td><strong>Valuation allowances</strong></td>
<td>(2,029)</td>
</tr>
<tr>
<td><strong>Total deferred taxes liability (c)</strong></td>
<td>$ 10,523</td>
</tr>
</tbody>
</table>

(a) The amounts in 2015 and 2014 are reduced for unrecognized tax benefits of $2.9 billion and $2.6 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.

(b) The increase in 2015 reflects additional accruals for certain funds earned outside the U.S. that will not be indefinitely reinvested overseas, virtually all of which were earned in the current year. For additional information, see Note 5A.

(c) In 2015, Noncurrent deferred tax assets (and other noncurrent tax assets ($732 million), and Noncurrent deferred tax liabilities ($26.8 billion). In 2014, Noncurrent deferred tax assets and other noncurrent tax assets ($915 million), and Noncurrent deferred tax liabilities ($23.3 billion).

We have carryforwards, primarily related to foreign tax credits, net operating and capital losses and charitable contributions, which are available to reduce future U.S. federal and state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2016 to 2035. Certain of our U.S. net operating losses are subject to limitations under Internal Revenue Code Section 382.

Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets.

As of December 31, 2015, we have not made a U.S. tax provision on approximately $80.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2015, is not practicable.

D. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.

For a description of our accounting policies associated with accounting for income tax contingencies, see Note 1O. For a description of the risks associated with estimates and assumptions, see Note 1C.
Uncertain Tax Positions

As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2015 and 2014, we had approximately $4.8 billion and $4.7 billion, respectively, in net unrecognized tax benefits, excluding associated interest.

- Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process and from foreign tax credits that would be generated upon settlement of an uncertain tax position. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2015 and 2014, we had approximately $1.1 billion and $1.5 billion, respectively, in assets associated with uncertain tax positions. In 2015, these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ($963 million) and Noncurrent deferred tax liabilities ($179 million). In 2014, these amounts were included in Noncurrent deferred tax assets and other noncurrent tax assets ($966 million) and Noncurrent deferred tax liabilities ($527 million).

- Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate.

The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance, beginning</td>
<td>($6,182)</td>
<td>($6,087)</td>
<td>($6,315)</td>
</tr>
<tr>
<td>Acquisitions(a)</td>
<td>(110)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Divestitures(b)</td>
<td>—</td>
<td>—</td>
<td>29</td>
</tr>
<tr>
<td>Increases based on tax positions taken during a prior period(c)</td>
<td>(31)</td>
<td>(110)</td>
<td>(205)</td>
</tr>
<tr>
<td>Decreases based on tax positions taken during a prior period(c), (d)</td>
<td>496</td>
<td>473</td>
<td>876</td>
</tr>
<tr>
<td>Decreases based on settlements for a prior period(e)</td>
<td>64</td>
<td>70</td>
<td>571</td>
</tr>
<tr>
<td>Increases based on tax positions taken during the current period(g)</td>
<td>(675)</td>
<td>(795)</td>
<td>(1,178)</td>
</tr>
<tr>
<td>Impact of foreign exchange</td>
<td>319</td>
<td>161</td>
<td>38</td>
</tr>
<tr>
<td>Other, net(e), (f)</td>
<td>199</td>
<td>106</td>
<td>97</td>
</tr>
<tr>
<td>Balance, ending(g)</td>
<td>($5,919)</td>
<td>($6,182)</td>
<td>($6,087)</td>
</tr>
</tbody>
</table>

(a) Primarily related to the acquisition of Hospira. See also note 2A.
(b) Primarily related to the disposition of our Animal Health (Zoetis) business. See also Note 2D.
(c) Primarily included in Provision for taxes on income.
(d) Primarily related to effectively settling certain tax positions with the U.S. and foreign tax authorities. See also Note 5A.
(e) Primarily related to cash payments.
(f) Primarily related to decreases as a result of a lapse of applicable statutes of limitations.
(g) In 2015, included in Income taxes payable ($38 million), Current tax assets ($22 million), Noncurrent deferred tax assets and other noncurrent tax assets ($135 million), Noncurrent deferred tax liabilities ($2.7 billion) and Other taxes payable ($3.0 billion). In 2014, included in Income taxes payable ($13 million), Current tax assets ($27 million), Noncurrent deferred tax assets and other noncurrent tax assets ($186 million), Noncurrent deferred tax liabilities ($2.4 billion) and Other taxes payable ($3.5 billion).

• Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded in Provision for taxes on income in our consolidated statements of income. In 2015, we recorded net interest expense of $71 million. In 2014, we recorded net interest expense of $40 million; and in 2013, we recorded net interest income of $16 million primarily as a result of settling certain tax positions with the U.S. and various foreign tax authorities. Gross accrued interest totaled $714 million as of December 31, 2015 (reflecting a decrease of approximately $5 million as a result of cash payments) and gross accrued interest totaled $643 million as of December 31, 2014 (reflecting a decrease of approximately $18 million as a result of cash payments). In 2015, these amounts were included in Current tax assets ($12 million) and Other taxes payable ($702 million). In 2014, these amounts were included in Current tax assets ($15 million) and Other taxes payable ($628 million). Accrued penalties are not significant. See also Note 5A.

Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:

• With respect to Pfizer Inc., the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014 and 2015 are open, but not under audit. All other tax years are closed.

• With respect to Hospira, Inc., the IRS is auditing 2010-2011 and 2012-2013. Tax years 2014-2015 (through date of acquisition) are open but not under audit. All other tax years are closed. The open tax years and audits for Hospira, Inc. and its subsidiaries are not considered material to Pfizer.
In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2015), Japan (2015), Europe (2007-2015, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2015, primarily reflecting Brazil) and Puerto Rico (2010-2015).

Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next twelve months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $200 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

The following table provides the components of the tax provision/(benefit) on Other comprehensive income/(loss):

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign currency translation adjustments, net$\textsuperscript{(a)}</td>
<td>$90</td>
<td>$42</td>
<td>$111</td>
</tr>
<tr>
<td>Unrealized holding gains on derivative financial instruments, net</td>
<td>(173)</td>
<td>(199)</td>
<td>217</td>
</tr>
<tr>
<td>Reclassification adjustments for realized (gains)/losses</td>
<td>104</td>
<td>262</td>
<td>63</td>
</tr>
<tr>
<td>Unrealized holding gains/(losses) on available-for-sale securities, net</td>
<td>(104)</td>
<td>(56)</td>
<td>57</td>
</tr>
<tr>
<td>Reclassification adjustments for realized (gains)/losses</td>
<td>59</td>
<td>10</td>
<td>57</td>
</tr>
<tr>
<td>Benefit plans: actuarial gains/(losses), net</td>
<td>(23)</td>
<td>(1,146)</td>
<td>1,422</td>
</tr>
<tr>
<td>Reclassification adjustments related to amortization</td>
<td>183</td>
<td>61</td>
<td>205</td>
</tr>
<tr>
<td>Reclassification adjustments related to settlements, net</td>
<td>237</td>
<td>35</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>66</td>
<td>61</td>
<td>2</td>
</tr>
<tr>
<td>Benefit plans: prior service credits and other, net</td>
<td>160</td>
<td>281</td>
<td>56</td>
</tr>
<tr>
<td>Reclassification adjustments related to amortization</td>
<td>(59)</td>
<td>(28)</td>
<td>(23)</td>
</tr>
<tr>
<td>Reclassification adjustments related to curtailments, net</td>
<td>(12)</td>
<td>—</td>
<td>(1)</td>
</tr>
<tr>
<td>Other</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Gross unrecognized tax benefits, exclusive of interest</td>
<td>462</td>
<td>(1,258)</td>
<td>1,631</td>
</tr>
<tr>
<td>Benefit plans: actuarial gains/(losses), net</td>
<td>89</td>
<td>253</td>
<td>32</td>
</tr>
</tbody>
</table>

Tax provision/(benefit) on other comprehensive income/(loss) $528 $ (946) $1,928

$\textsuperscript{(a)} Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following table provides the changes, net of tax, in Accumulated other comprehensive income/(loss):

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Foreign Currency Translation Adjustments</th>
<th>Derivative Financial Instruments</th>
<th>Available-For-Sale Securities</th>
<th>Actuarial Gains/(Losses)</th>
<th>Prior Service Costs/Credits and Other</th>
<th>Accumulated Other Comprehensive Income/(Loss)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance, January 1, 2013</td>
<td>$ (177)</td>
<td>$ (161)</td>
<td>$ 236</td>
<td>$ (6,110)</td>
<td>$ 259</td>
<td>$ (5,953)</td>
</tr>
<tr>
<td>Other comprehensive income/(loss)$\textsuperscript{(a)}</td>
<td>(440)</td>
<td>240</td>
<td>(86)</td>
<td>2,887</td>
<td>54</td>
<td>2,655</td>
</tr>
<tr>
<td>Sale of 19.8% of subsidiary through an IPO$\textsuperscript{(b)}</td>
<td>27</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>27</td>
</tr>
<tr>
<td>Balance, December 31, 2013</td>
<td>(590)</td>
<td>79</td>
<td>150</td>
<td>(3,223)</td>
<td>313</td>
<td>(3,271)</td>
</tr>
<tr>
<td>Other comprehensive income/(loss)$\textsuperscript{(a)}</td>
<td>(2,099)</td>
<td>438</td>
<td>(372)</td>
<td>(2,432)</td>
<td>419</td>
<td>(4,045)</td>
</tr>
<tr>
<td>Balance, December 31, 2014</td>
<td>(2,689)</td>
<td>517</td>
<td>(222)</td>
<td>(5,654)</td>
<td>733</td>
<td>(7,316)</td>
</tr>
<tr>
<td>Other comprehensive income/(loss)$\textsuperscript{(a)}</td>
<td>$ (3,174)</td>
<td>$ (96)</td>
<td>$ (5)</td>
<td>$ 921</td>
<td>$ 148</td>
<td>$ (2,206)</td>
</tr>
<tr>
<td>Balance, December 31, 2015</td>
<td>$ (5,863)</td>
<td>$ 421</td>
<td>$ (227)</td>
<td>$ (4,733)</td>
<td>$ 880</td>
<td>$ (9,522)</td>
</tr>
</tbody>
</table>

$\textsuperscript{(a)} Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $26 million loss in 2015, $3 million gain in 2014 and $62 million loss in 2013.

$\textsuperscript{(b)} Relates to Zoetis (our former Animal Health subsidiary). See Note 2D.

As of December 31, 2015, we estimate that we will reclassify into 2016 income the following pre-tax amounts currently held in Accumulated other comprehensive loss: $437 million of unrealized pre-tax losses on derivative financial instruments (expected to be offset primarily by gains resulting from reclassification adjustments related to available-for-sale securities); $55 million of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and $163 million of prior service credits, primarily related to benefit plan amendments.
Note 7. Financial Instruments

A. Selected Financial Assets and Liabilities

The following table provides additional information about certain of our financial assets and liabilities:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>As of December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td><strong>Selected financial assets measured at fair value on a recurring basis</strong>&lt;sup&gt;(a)&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Trading funds and securities&lt;sup&gt;(b)&lt;/sup&gt;</td>
<td>$287</td>
</tr>
<tr>
<td>Available-for-sale debt securities&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>32,078</td>
</tr>
<tr>
<td>Money market funds</td>
<td>934</td>
</tr>
<tr>
<td>Available-for-sale equity securities&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>603</td>
</tr>
<tr>
<td>Derivative financial instruments in a receivable position&lt;sup&gt;(d), (e)&lt;/sup&gt;:</td>
<td></td>
</tr>
<tr>
<td>Interest rate swaps</td>
<td>837</td>
</tr>
<tr>
<td>Foreign currency swaps</td>
<td>135</td>
</tr>
<tr>
<td>Foreign currency forward-exchange contracts</td>
<td>559</td>
</tr>
<tr>
<td><strong>Total selected financial assets</strong></td>
<td>35,433</td>
</tr>
<tr>
<td><strong>Other selected financial assets</strong></td>
<td></td>
</tr>
<tr>
<td>Held-to-maturity debt securities, carried at amortized cost&lt;sup&gt;(c), (e)&lt;/sup&gt;</td>
<td>1,388</td>
</tr>
<tr>
<td>Private equity securities, carried at equity-method or at cost&lt;sup&gt;(f), (g)&lt;/sup&gt;</td>
<td>1,336</td>
</tr>
<tr>
<td><strong>Total selected financial assets</strong></td>
<td>2,724</td>
</tr>
<tr>
<td><strong>Total selected financial assets</strong></td>
<td>$38,157</td>
</tr>
<tr>
<td><strong>Selected financial liabilities measured at fair value on a recurring basis</strong>&lt;sup&gt;(a)&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Derivative financial instruments in a liability position&lt;sup&gt;(b), (e)&lt;/sup&gt;:</td>
<td></td>
</tr>
<tr>
<td>Interest rate swaps</td>
<td>$139</td>
</tr>
<tr>
<td>Foreign currency swaps</td>
<td>1,489</td>
</tr>
<tr>
<td>Foreign currency forward-exchange contracts</td>
<td>81</td>
</tr>
<tr>
<td><strong>Total selected financial liabilities</strong></td>
<td>1,709</td>
</tr>
<tr>
<td><strong>Total selected financial liabilities</strong></td>
<td>$40,867</td>
</tr>
</tbody>
</table>

<sup>(a)</sup> We use a market approach in valuing financial instruments on a recurring basis. For additional information, see Note 1E. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except less than 1% that use Level 1 inputs.

<sup>(b)</sup> As of December 31, 2015, trading funds and securities are composed of $100 million of trading equity funds, $102 million of trading debt funds, and $85 million of trading equity securities. As of December 31, 2014, trading securities of $105 million is composed of debt and equity securities. The trading equity securities as of December 31, 2015 and the trading debt and equity securities as of December 31, 2014 are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan.

<sup>(c)</sup> Generally, gross unrealized gains and losses are not significant. Unrealized losses related to 2015 available-for-sale debt securities are $593 million and unrealized gains are $44 million. The vast majority of investments in an unrealized loss position relate to foreign currency denominated securities, which are hedged with cross-currency swaps. We have the intent and ability to hold such investments to maturity.

<sup>(d)</sup> Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015; and foreign currency forward-exchange contracts with fair values of $159 million as of December 31, 2014.

<sup>(e)</sup> Short-term borrowings include foreign currency short-term borrowings with fair values of $547 million as of December 31, 2015, which are used as hedging instruments. The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2015 or December 31, 2014. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs.

<sup>(f)</sup> Our private equity securities represent investments in the life sciences sector.

<sup>(g)</sup> Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency swaps with fair values of $234 million and foreign currency forward-exchange contracts with fair values of $54 million as of December 31, 2014.

<sup>(h)</sup> Some carrying amounts may include adjustments for discount or premium amortization or for the effect of hedging the interest rate fair value risk associated with certain financial liabilities by interest rate swaps.

<sup>(i)</sup> Includes foreign currency debt with fair values of $560 million as of December 31, 2014, which are used as hedging instruments.

<sup>(j)</sup> Foreign currency forward-exchange contracts with fair values of $136 million as of December 31, 2015; and foreign currency swaps with fair values of $121 million and foreign currency forward-exchange contracts with fair values of $54 million as of December 31, 2014.

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C.
The following methods and assumptions were used to estimate the fair value of our financial assets and liabilities:

- Trading equity securities—quoted market prices.
- Trading debt securities—observable market interest rates.
- Available-for-sale debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. Loan-backed, receivable-backed, and mortgage-backed securities are valued by third-party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates.
- Money market funds—observable Net Asset Value prices.
- Available-for-sale equity securities—third-party pricing services that principally use a composite of observable prices.
- Derivative financial instruments (assets and liabilities)—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.
- Held-to-maturity debt securities—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves.
- Private equity securities, excluding equity-method investments—application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio.
- Short-term borrowings and long-term debt—third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and our own credit rating.

We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.

The following table provides the classification of these selected financial assets and liabilities in our consolidated balance sheets:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>As of December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>Assets</td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$978</td>
</tr>
<tr>
<td>Short-term investments</td>
<td>19,649</td>
</tr>
<tr>
<td>Long-term investments</td>
<td>15,999</td>
</tr>
<tr>
<td>Other current assets(a)</td>
<td>587</td>
</tr>
<tr>
<td>Other noncurrent assets(b)</td>
<td>944</td>
</tr>
<tr>
<td></td>
<td>$38,157</td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
</tr>
<tr>
<td>Short-term borrowings, including current portion of long-term debt</td>
<td>$10,160</td>
</tr>
<tr>
<td>Other current liabilities(c)</td>
<td>645</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>28,818</td>
</tr>
<tr>
<td>Other noncurrent liabilities(d)</td>
<td>1,064</td>
</tr>
<tr>
<td></td>
<td>$40,687</td>
</tr>
</tbody>
</table>

(a) As of December 31, 2015, derivative instruments at fair value include interest rate swaps ($2 million), foreign currency swaps ($46 million) and foreign currency forward-exchange contracts ($531 million).
(b) As of December 31, 2015, derivative instruments at fair value include interest rate swaps ($835 million), foreign currency swaps ($89 million) and foreign currency forward-exchange contracts ($20 million) and, as of December 31, 2014, include interest rate swaps ($34 million), foreign currency swaps ($494 million) and foreign currency forward-exchange contracts ($531 million).
(c) At December 31, 2015, derivative instruments at fair value include interest rate swaps ($5 million), foreign currency swaps ($560 million) and foreign currency forward-exchange contracts ($80 million) and, as of December 31, 2014, include interest rate swaps ($1 million), foreign currency swaps ($13 million) and foreign currency forward-exchange contracts ($78 million).
(d) As of December 31, 2015, derivative instruments at fair value include interest rate swaps ($134 million), foreign currency swaps ($928 million) and foreign currency forward-exchange contracts ($1 million) and, as of December 31, 2014, include interest rate swaps ($16 million) and foreign currency swaps ($891 million).

In addition, as of December 31, 2015 and 2014, we had long-term receivables where the determination of fair value employs discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. As of December 31, 2015 and 2014, the differences between the estimated fair values and carrying values of these receivables were not significant.

There were no significant impairments of financial assets recognized in any period presented.
B. Investments in Debt Securities

The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>December 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Within 1</td>
</tr>
<tr>
<td>Available-for-sale debt securities</td>
<td></td>
</tr>
<tr>
<td>Western European, Asian and other government debt(a)</td>
<td>$9,795</td>
</tr>
<tr>
<td>Corporate debt(b)</td>
<td>3,153</td>
</tr>
<tr>
<td>U.S. government debt</td>
<td>920</td>
</tr>
<tr>
<td>Western European, Scandinavian and other government agency debt(a)</td>
<td>1,861</td>
</tr>
<tr>
<td>Supranational debt(a)</td>
<td>947</td>
</tr>
<tr>
<td>Federal Home Loan Mortgage Corporation and Federal National Mortgage Association asset-backed securities</td>
<td>2</td>
</tr>
<tr>
<td>Reverse repurchase agreements(c)</td>
<td>875</td>
</tr>
<tr>
<td>Government National Mortgage Association and other U.S. government guaranteed asset-backed securities</td>
<td>266</td>
</tr>
<tr>
<td>Other asset-backed debt(d)</td>
<td>490</td>
</tr>
<tr>
<td>Held-to-maturity debt securities</td>
<td></td>
</tr>
<tr>
<td>Western European government debt(a)</td>
<td>113</td>
</tr>
<tr>
<td>Time deposits, corporate debt and other(b)</td>
<td>1,270</td>
</tr>
<tr>
<td>Total debt securities</td>
<td>$19,693</td>
</tr>
</tbody>
</table>

(a) Issued by governments, government agencies or supranational entities, as applicable, all of which are investment-grade.
(b) Issued by a diverse group of corporations, largely consisting of financial institutions, virtually all of which are investment-grade.
(c) Involving U.S. securities.
(d) Includes loan-backed, receivable-backed, and mortgage-backed securities, all of which are investment-grade and in senior positions in the capital structure of the security. Loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and receivable-backed securities are collateralized by credit cards receivables. Mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. These securities are valued by third party models that use significant inputs derived from observable market data like prepayment rates, default rates, and recovery rates.

C. Short-Term Borrowings

Short-term borrowings include amounts for commercial paper of $4.9 billion as of December 31, 2015 and $570 million as of December 31, 2014. The weighted-average effective interest rate on short-term borrowings outstanding was 1.9% as of December 31, 2015 and 2.5% as of December 31, 2014.

As of December 31, 2015, we had access to $8.1 billion of lines of credit, of which $687 million expire within one year. Of these lines of credit, $7.9 billion are unused, of which our lenders have committed to loan us $7.1 billion at our request. Also, $7.0 billion of our unused lines of credit, all of which expire in 2020, may be used to support our commercial paper borrowings. Under the terms of a substantial majority of our lines of credit agreements, upon the merger with Allergan, the lenders under the agreements may elect to require immediate repayment of any amounts then outstanding and cancel the outstanding lines of credit. We expect to either amend the existing credit agreements or secure new credit agreements to replace these agreements.

D. Long-Term Debt

On September 3, 2015, the Hospira acquisition date, our long-term debt increased due to the addition of an aggregate principal amount of $1,750 million of legacy Hospira debt, recorded at acquisition-date fair value of $1,928 million.

On May 15, 2014, we completed a public offering of $4.5 billion aggregate principal amount of senior unsecured notes.
The following table provides the components of our senior unsecured long-term debt:

<table>
<thead>
<tr>
<th>MILLIONS OF DOLLARS</th>
<th>Maturity Date</th>
<th>As of December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>6.20%^{(a)}</td>
<td>March 2019</td>
<td>$3,276</td>
</tr>
<tr>
<td>7.20%^{(a)}</td>
<td>March 2039</td>
<td>2,856</td>
</tr>
<tr>
<td>4.75% euro^{(b)}</td>
<td>June 2016</td>
<td>—</td>
</tr>
<tr>
<td>5.75% euro^{(b)}</td>
<td>June 2021</td>
<td>2,172</td>
</tr>
<tr>
<td>6.50% U.K. pound^{(b)}</td>
<td>June 2038</td>
<td>2,202</td>
</tr>
<tr>
<td>5.95%^{(c)}</td>
<td>April 2037</td>
<td>2,057</td>
</tr>
<tr>
<td>2.10%^{(c)}</td>
<td>May 2019</td>
<td>1,515</td>
</tr>
<tr>
<td>4.55% euro^{(d)}</td>
<td>May 2017</td>
<td>1,041</td>
</tr>
<tr>
<td>5.50%^{(d)}</td>
<td>February 2016</td>
<td>—</td>
</tr>
<tr>
<td>Notes and other debt with a weighted-average interest rate of 2.83%^{(e)}</td>
<td>2017–2020</td>
<td>6,152</td>
</tr>
<tr>
<td>Notes and other debt with a weighted-average interest rate of 5.18%^{(f)}</td>
<td>2021–2044</td>
<td>5,747</td>
</tr>
<tr>
<td>Foreign currency notes and other foreign currency debt with a weighted-average interest rate of 2.84%^{(g)}</td>
<td>2016</td>
<td>—</td>
</tr>
<tr>
<td><strong>Long-term debt</strong></td>
<td></td>
<td>$28,818</td>
</tr>
<tr>
<td><strong>Current portion of long-term debt (not included above)</strong></td>
<td></td>
<td>$3,720</td>
</tr>
</tbody>
</table>

>^{(a)} Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.50%, plus, in each case, accrued and unpaid interest.

>^{(b)} Instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.50%, plus, in each case, accrued and unpaid interest.

>^{(c)} The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at a comparable government bond rate plus 0.20%, plus, in each case, accrued and unpaid interest.

>^{(d)} The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the price at which the gross redemption yield on the notes would be equal to the gross redemption yield of a comparable European government bond (selected at the discretion of the Trustee) on the basis of the middle market price of such European government bond.

>^{(e)} The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus 0.25% for the 5.95% notes and 0.07% for the 2.10% notes, plus, in each case, accrued and unpaid interest.

>^{(f)} The instrument is redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average of 0.20%, plus, in each case, accrued and unpaid interest.

>^{(g)} Contains debt issuances with a weighted-average maturity of approximately 15 years, and the majority of which are redeemable by us at any time at the greater of 100% of the principal amount of the notes or the sum of the present values of the remaining scheduled payments of principal and interest discounted at the U.S. Treasury rate plus a weighted average of 0.20%, plus, in each case, accrued and unpaid interest.

In October 2015, Pfizer exchanged $1.7 billion debt of its recently acquired subsidiary Hospira for virtually the same amount of Pfizer Inc. debt with the same interest rate and maturity terms as the Hospira debt, leaving a minor amount of outstanding debt in Hospira’s name. In connection with the exchange offers, the indenture governing the Hospira notes and the Hospira notes were amended to, among other things, eliminate substantially all of the restrictive covenants. The net income effect of this exchange was immaterial.

The following table provides the maturity schedule of our Long-term debt as of December 31, 2015:

<table>
<thead>
<tr>
<th>MILLIONS OF DOLLARS</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>After 2020</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maturities</td>
<td>$4,412</td>
<td>$2,400</td>
<td>$4,807</td>
<td>$364</td>
<td>$16,835</td>
<td>$28,818</td>
</tr>
</tbody>
</table>

E. Derivative Financial Instruments and Hedging Activities

Foreign Exchange Risk

A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions.

As of December 31, 2015, the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was $35.7 billion. The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen, and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $2.2 billion U.K. pound debt maturing in 2038.
All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings or in Other comprehensive income/(loss), depending on the nature and purpose of the financial instrument (offset or hedge relationship) and the effectiveness of the hedge relationships, as follows:

- We record in Other comprehensive income/(loss) the effective portion of the gains or losses on foreign currency forward-exchange contracts and foreign currency swaps that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings.

- We recognize the gains and losses on foreign currency forward-exchange contracts and foreign currency swaps that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.

- We recognize the gain and loss impact on foreign currency swaps and foreign currency forward-exchange contracts designated as hedges of our net investments in earnings in three ways: over time—for the periodic net swap payments; immediately—to the extent of any change in the difference between the foreign exchange spot rate and forward rate; and upon sale or substantial liquidation of our net investments—to the extent of change in the foreign exchange spot rates.

- We record in Other comprehensive income/(loss) the foreign exchange gains and losses related to foreign exchange-denominated debt designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments.

Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented.

Interest Rate Risk

Our interest-bearing investments and borrowings are subject to interest rate risk. We strive to invest and borrow primarily on a floating-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. As of December 31, 2015, the aggregate notional amount of interest rate derivative financial instruments was $20.2 billion. The derivative financial instruments primarily hedge U.S. dollar and euro fixed-rate debt.

All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows:

- We recognize the gains and losses on interest rate swaps that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk also in earnings.

Any ineffectiveness is recognized immediately into earnings. There was no significant ineffectiveness for any period presented.
The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Derivative Financial Instruments in Cash Flow Hedge Relationships:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign currency swaps</td>
<td>—</td>
<td>—</td>
<td>$ (826)</td>
<td>$ (799)</td>
<td>$ (613)</td>
<td>$ (808)</td>
</tr>
<tr>
<td>Foreign currency forward-exchange contracts</td>
<td>—</td>
<td>—</td>
<td>1,028</td>
<td>823</td>
<td>980</td>
<td>332</td>
</tr>
<tr>
<td><strong>Derivative Financial Instruments in Net Investment Hedge Relationships:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign currency swaps</td>
<td>—</td>
<td>—</td>
<td>78</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency forward-exchange contracts</td>
<td>(1)</td>
<td>—</td>
<td>256</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Derivative Financial Instruments Not Designated as Hedges:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign currency forward-exchange contracts</td>
<td>(42)</td>
<td>164</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency swaps</td>
<td>(4)</td>
<td>(2)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foreign currency short-term borrowings</td>
<td>—</td>
<td>—</td>
<td>3</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency long-term debt</td>
<td>—</td>
<td>—</td>
<td>33</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>All other net</strong></td>
<td>(16)</td>
<td>(3)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Amount of Gains/(Losses) Recognized in OCI (Effective Portion)</strong></td>
<td>$ (64)</td>
<td>$ 160</td>
<td>$ 461</td>
<td>$ 135</td>
<td>$ 367</td>
<td>$ (477)</td>
</tr>
</tbody>
</table>

(a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income.

(b) Also includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges, as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.

(c) There was no significant ineffectiveness for any period presented.

(d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(loss)—Unrealized holding gains on derivative financial instruments, net. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(loss)—Foreign currency translation adjustments.

For information about the fair value of our derivative financial instruments, and the impact on our consolidated balance sheets, see Note 7A above. Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. As of December 31, 2015, the aggregate fair value of these derivative instruments that are in a net liability position was $1.1 billion, for which we have posted collateral of $1.1 billion in the normal course of business. These features include the requirement to pay additional collateral in the event of a downgrade in our debt ratings. If there had been a downgrade to below an A rating by Standard and Poor’s (S&P) or the equivalent rating by Moody’s Investors Service, on December 31, 2015, we would have been required to post an additional $20 million of collateral to our counterparties. The collateral advanced receivables are reported in Short-term investments.

**F. Credit Risk**

On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of December 31, 2015, we had $2.4 billion due from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, which is included in Cash and cash equivalents, the obligations are reported in Short-term borrowings, including current portion of long-term debt.
### Note 8. Inventories

The following table provides the components of Inventories:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>As of December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>Finished goods</td>
<td>$2,714</td>
</tr>
<tr>
<td>Work in process</td>
<td>3,932</td>
</tr>
<tr>
<td>Raw materials and supplies</td>
<td>867</td>
</tr>
<tr>
<td><strong>Inventories</strong></td>
<td><strong>$7,513</strong></td>
</tr>
<tr>
<td>Noncurrent inventories not included above</td>
<td>$594</td>
</tr>
</tbody>
</table>

(a) Increase primarily due to the acquisition of Hospira inventories, which were recorded at fair value. For additional information, see Note 2A.

(b) Included in Other noncurrent assets. There are no recoverability issues associated with these amounts.

### Note 9. Property, Plant and Equipment

The following table provides the components of Property, plant and equipment:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Useful Lives</th>
<th>As of December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Years)</td>
<td>2015</td>
</tr>
<tr>
<td>Land</td>
<td>—</td>
<td>$588</td>
</tr>
<tr>
<td>Buildings</td>
<td>33-50</td>
<td>9,604</td>
</tr>
<tr>
<td>Machinery and equipment</td>
<td>8-20</td>
<td>10,933</td>
</tr>
<tr>
<td>Furniture, fixtures and other</td>
<td>3-12 1/2</td>
<td>4,351</td>
</tr>
<tr>
<td>Construction in progress</td>
<td>—</td>
<td>1,791</td>
</tr>
<tr>
<td><strong>Less: Accumulated depreciation</strong></td>
<td></td>
<td>27,268</td>
</tr>
<tr>
<td>Property, plant and equipment</td>
<td></td>
<td>$13,502</td>
</tr>
</tbody>
</table>

(a) The increase in total property, plant and equipment is primarily due to the acquisition of Hospira and capital additions, partially offset by depreciation and, to a much lesser extent, impairments, disposals and the impact of foreign exchange.

### Note 10. Identifiable Intangible Assets and Goodwill

**A. Identifiable Intangible Assets**

#### Balance Sheet Information

The following table provides the components of Identifiable intangible assets:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>December 31, 2015</th>
<th>December 31, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gross Carrying Amount</td>
<td>Accumulated Amortization</td>
</tr>
<tr>
<td>Finite-lived intangible assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Developed technology rights</td>
<td>$77,613</td>
<td>$ (47,193)</td>
</tr>
<tr>
<td>Brands</td>
<td>1,973</td>
<td>(928)</td>
</tr>
<tr>
<td>Licensing agreements and other</td>
<td>1,619</td>
<td>(918)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>81,205</strong></td>
<td><strong>(49,040)</strong></td>
</tr>
<tr>
<td>Indefinite-lived intangible assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brands and other</td>
<td>7,021</td>
<td>7,021</td>
</tr>
<tr>
<td>In-process research and development</td>
<td>1,171</td>
<td>1,171</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>8,192</strong></td>
<td><strong>8,192</strong></td>
</tr>
<tr>
<td><strong>Identifiable intangible assets</strong></td>
<td><strong>$89,396</strong></td>
<td><strong>(49,040)</strong></td>
</tr>
</tbody>
</table>

(a) The increase in Identifiable intangible assets, less accumulated amortization, is primarily due to assets acquired as part of the acquisition of Hospira and Baxter’s portfolio of marketed vaccines, partially offset by amortization, impairments and the impact of foreign exchange. For information about the assets acquired as part of the acquisition of Hospira and Baxter’s portfolio of marketed vaccines, see Note 2A. For information about impairments of intangible assets, see Note 4.
Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:

<table>
<thead>
<tr>
<th>Developed technology rights</th>
<th>December 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>GIP</td>
<td>VOC</td>
</tr>
<tr>
<td>22%</td>
<td>29%</td>
</tr>
<tr>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>2%</td>
<td>10%</td>
</tr>
</tbody>
</table>

Developed Technology Rights

Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Prevnar 13/Prevenar 13 Infant and Enbrel and, to a lesser extent, Premarin, Prevnar 13/Prevenar 13 Adult, Pristiq, Tygacil, Refacto AF, Effexor and Benefix. Also included in this category are infusion technologies and the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.

Brands

Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. Most of these assets are associated with our Consumer Healthcare business unit. The more significant components of indefinite-lived brands are the following (in order of significance): Advil, Xanax/Xanax XR, Centrum, Caltrate, Medrol and Preparation H. The more significant components of finite-lived brands are the following (in order of significance): Nexium, Depo-Provera and, to a lesser extent, Advil Cold and Sinus and Idoform Bifiform.

In-Process Research and Development

IPR&D assets represent research and development assets that have not yet received regulatory approval in a major market. The more significant components of IPR&D are the programs for the treatment of staph aureus infections, as well as the sterile injectables and biosimilars IPR&D portfolios acquired as part of the Hospira acquisition and the sterile injectables IPR&D portfolio acquired as part of the InnoPharma acquisition.

IPR&D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated research and development effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of in-process research and development and begin amortization. If the associated research and development effort is abandoned, the related IPR&D assets will likely be written-off, and we will record an impairment charge.

For IPR&D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&D assets will become impaired and be written off at some time in the future.

Amortization

The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately 11 years. Total amortization expense for finite-lived intangible assets was $3.8 billion in 2015, $4.1 billion in 2014 and $4.8 billion in 2013.

The following table provides the annual amortization expense expected for the years 2016 through 2020:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amortization expense</td>
<td>$ 3,885</td>
<td>$ 3,780</td>
<td>$ 3,666</td>
<td>$ 3,386</td>
<td>$ 2,419</td>
</tr>
</tbody>
</table>
B. Goodwill

The following table provides the components of and changes in the carrying amount of **Goodwill**:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>GIP</th>
<th>VOC</th>
<th>GEP</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance, January 1, 2014</strong></td>
<td>$13,210</td>
<td>$11,559</td>
<td>$17,750</td>
<td>$42,519</td>
</tr>
<tr>
<td><strong>Additions</strong>&lt;sup&gt;(a)&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Other</strong>&lt;sup&gt;(b)&lt;/sup&gt;</td>
<td>(178)</td>
<td>(161)</td>
<td>(236)</td>
<td>(575)</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2014</strong></td>
<td>13,032</td>
<td>11,398</td>
<td>17,639</td>
<td>42,069</td>
</tr>
<tr>
<td><strong>Additions</strong>&lt;sup&gt;(c)&lt;/sup&gt;</td>
<td>—</td>
<td>39</td>
<td>7,264</td>
<td>7,333</td>
</tr>
<tr>
<td><strong>Other</strong>&lt;sup&gt;(b)&lt;/sup&gt;</td>
<td>(343)</td>
<td>(317)</td>
<td>(489)</td>
<td>(1,149)</td>
</tr>
<tr>
<td><strong>Balance, December 31, 2015</strong></td>
<td>$12,689</td>
<td>$11,120</td>
<td>$24,433</td>
<td>$48,242</td>
</tr>
</tbody>
</table>

<sup>(a)</sup> Reflects the acquisition of InnoPharma. For additional information, see Note 2A.

<sup>(b)</sup> Primarily reflects the impact of foreign exchange.

<sup>(c)</sup> GEP additions relate to our acquisition of Hospira and are subject to change until we complete the recording of the assets acquired and liabilities assumed from Hospira. For additional information, see Note 2A.

### Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans

The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both Internal Revenue Code-qualified and supplemental (non-qualified) defined benefit plans and contribution plans. A qualified plan meets the requirements of certain sections of the Internal Revenue Code, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. During 2015, we recorded net pension and postretirement benefit obligations of approximately $115 million as a result of the acquisition of Hospira and an additional $122 million for the decision to terminate Hospira’s U.S. qualified pension plan.

#### A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)

The following table provides the annual cost (including, for 2013, costs reported as part of discontinued operations) and changes in **Other comprehensive income/(loss)** for our benefit plans:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>U.S. Qualified&lt;sup&gt;(a)&lt;/sup&gt;</th>
<th>U.S. Supplemental (Non-Qualified)&lt;sup&gt;(b)&lt;/sup&gt;</th>
<th>International&lt;sup&gt;(c)&lt;/sup&gt;</th>
<th>Postretirement Plans&lt;sup&gt;(d)&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Service cost</td>
<td>$287</td>
<td>$253</td>
<td>$301</td>
<td>$22</td>
</tr>
<tr>
<td>Interest cost</td>
<td>676</td>
<td>697</td>
<td>666</td>
<td>54</td>
</tr>
<tr>
<td>Expected return on plan assets</td>
<td>(1,089)</td>
<td>(1,043)</td>
<td>(999)</td>
<td>—</td>
</tr>
<tr>
<td>Amortization of:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actuarial losses</td>
<td>346</td>
<td>63</td>
<td>355</td>
<td>44</td>
</tr>
<tr>
<td>Prior service credits</td>
<td>(5)</td>
<td>(7)</td>
<td>(7)</td>
<td>(2)</td>
</tr>
<tr>
<td>Curtailments</td>
<td>3</td>
<td>2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Settlements</td>
<td>556</td>
<td>52</td>
<td>113</td>
<td>34</td>
</tr>
<tr>
<td>Special termination benefits</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Net periodic benefit costs reported in Income</td>
<td>773</td>
<td>16</td>
<td>429</td>
<td>153</td>
</tr>
<tr>
<td>(Income)/cost reported in Other comprehensive income/(loss)&lt;sup&gt;(e)&lt;/sup&gt;</td>
<td>(396)</td>
<td>2,768</td>
<td>(3,044)</td>
<td>(143)</td>
</tr>
<tr>
<td>(Income)/cost recognized in Comprehensive income</td>
<td>$378</td>
<td>$2,784</td>
<td>$(2,615)</td>
<td>$10</td>
</tr>
</tbody>
</table>

<sup>(a)</sup> 2015 v. 2014—The increase in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) higher settlement activity related to participants accepting the lump-sum option made in an offer to certain plan participants to elect a lump-sum payment to settle Pfizer’s pension obligation with those participants, or to elect an early annuity, and (ii) the increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation (which increased the amount of deferred actuarial losses), and, to a lesser extent, a 2014 change in mortality assumptions (reflecting a longer life expectancy for plan participants). The aforementioned increases were partially offset by (i) a greater expected return on plan assets resulting from an increased plan asset base due to a voluntary contribution of $1.0 billion made at the beginning of January 2015, which in turn was partially offset by a decrease in the expected rate of return on plan assets from 8.5% to 8.3% and (ii) lower interest costs resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.
2014 v. 2013—The decrease in net periodic benefit costs for our U.S. qualified pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses), (ii) lower service cost resulting from cost-reduction initiatives, (iii) lower settlement activity and (iv) greater expected return on plan assets resulting from an increased plan asset base, partially offset by higher interest costs resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation.

(b) 2015 v. 2014—The increase in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (ii) higher settlement activity.

2014 v. 2013—The decrease in net periodic benefit costs for our U.S. supplemental (non-qualified) pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation, (ii) lower settlement activity and (iii) lower interest costs.

(c) 2015 v. 2014—The increase in net periodic benefit costs for our international pension plans was primarily driven by (i) a decrease in the expected return on plan assets due to a lower expected rate of return on plan assets, (ii) an increase in the amounts amortized for actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation, and (iii) higher settlement charges due to the settlement of a pension plan in Sweden. The aforementioned increase in net periodic benefit costs was partially offset by the decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.

2014 v. 2013—The decrease in net periodic benefit costs for our international pension plans was primarily driven by (i) the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation, (ii) lower settlement activity and (iii) lower interest costs.

(d) 2015 v. 2014—The decrease in net periodic benefit costs for our postretirement plans was primarily driven by (i) the increase in the amounts amortized for prior service credits and (ii) an increase in curtailment gain resulting from the implementation of changes to certain retiree medical benefits to adopt programs eligible for the Medicare Part D plan subsidy, as allowed under the employer group waiver plan, and another plan change to establish benefit caps for certain plan participants, as well as (iii) a decrease in interest cost resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation. The aforementioned decreases were partially offset by an increase in actuarial losses resulting from the decrease, in 2014, in the discount rate used to determine the benefit obligation.

2014 v. 2013—The decrease in net periodic benefit costs for our postretirement plans was primarily driven by the decrease in the amounts amortized for actuarial losses resulting from the increase, in 2013, in the discount rate used to determine the benefit obligation (which reduced the amount of deferred actuarial losses).

(e) For details of the changes in Other comprehensive income/(loss), see the benefit plan activity in the consolidated statements of comprehensive income.

The following table provides the amounts in Accumulated other comprehensive loss expected to be amortized into 2016 net periodic benefit costs:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>U.S. Qualified</th>
<th>U.S. Supplemental (Non-Qualified)</th>
<th>International</th>
<th>Postretirement Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial losses</td>
<td>$ (398)</td>
<td>$ (37)</td>
<td>$ (91)</td>
<td>$ (29)</td>
</tr>
<tr>
<td>Prior service credits and other</td>
<td>(5)</td>
<td>1</td>
<td>2</td>
<td>164</td>
</tr>
<tr>
<td>Total</td>
<td>$ (403)</td>
<td>$ (36)</td>
<td>$ (89)</td>
<td>$ 135</td>
</tr>
</tbody>
</table>
B. Actuarial Assumptions

The following table provides the weighted-average actuarial assumptions of our benefit plans:

<table>
<thead>
<tr>
<th>(PERCENTAGES)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weighted-average assumptions used to determine benefit obligations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discount rate:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. qualified pension plans</td>
<td>4.5%</td>
<td>4.2%</td>
<td>5.2%</td>
</tr>
<tr>
<td>U.S. non-qualified pension plans</td>
<td>4.5%</td>
<td>4.0%</td>
<td>4.8%</td>
</tr>
<tr>
<td>International pension plans</td>
<td>3.1%</td>
<td>3.0%</td>
<td>3.9%</td>
</tr>
<tr>
<td>Postretirement plans</td>
<td>4.5%</td>
<td>4.2%</td>
<td>5.1%</td>
</tr>
<tr>
<td>Rate of compensation increase:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. qualified pension plans</td>
<td>2.8%</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>U.S. non-qualified pension plans</td>
<td>2.8%</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>International pension plans</td>
<td>2.6%</td>
<td>2.7%</td>
<td>2.9%</td>
</tr>
<tr>
<td><strong>Weighted-average assumptions used to determine net periodic benefit cost</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discount rate:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. qualified pension plans</td>
<td>4.2%</td>
<td>5.2%</td>
<td>4.3%</td>
</tr>
<tr>
<td>U.S. non-qualified pension plans</td>
<td>4.0%</td>
<td>4.8%</td>
<td>3.9%</td>
</tr>
<tr>
<td>International pension plans</td>
<td>3.0%</td>
<td>3.9%</td>
<td>3.8%</td>
</tr>
<tr>
<td>Postretirement plans</td>
<td>4.2%</td>
<td>5.1%</td>
<td>4.1%</td>
</tr>
<tr>
<td>Expected return on plan assets:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. qualified pension plans</td>
<td>8.3%</td>
<td>8.5%</td>
<td>8.5%</td>
</tr>
<tr>
<td>International pension plans</td>
<td>5.5%</td>
<td>5.8%</td>
<td>5.6%</td>
</tr>
<tr>
<td>Postretirement plans</td>
<td>8.3%</td>
<td>8.5%</td>
<td>8.5%</td>
</tr>
<tr>
<td>Rate of compensation increase:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. qualified pension plans</td>
<td>2.8%</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>U.S. non-qualified pension plans</td>
<td>2.8%</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>International pension plans</td>
<td>2.7%</td>
<td>2.9%</td>
<td>3.1%</td>
</tr>
</tbody>
</table>

The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end.

The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits.

The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to determine the discount rates at year-end 2015 exhibited higher interest rates as compared to the prior year.

The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare cost trend rate assumed for next year(a)</td>
<td>7.4%</td>
<td>7.0%</td>
</tr>
<tr>
<td>Rate to which the cost trend rate is assumed to decline</td>
<td>4.5%</td>
<td>4.5%</td>
</tr>
<tr>
<td>Year that the rate reaches the ultimate trend rate</td>
<td>2037</td>
<td>2027</td>
</tr>
</tbody>
</table>

(a) In 2015 Pfizer started using separate healthcare cost trend rates for U.S. postretirement plan participants based on their age (6.5% for plan participants up to the age of 65, and 7.9% for plan participants age 65 and over). The rate shown in the table is a blended rate, for ease of comparison.

The following table provides the effects as of December 31, 2015 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Increase</th>
<th>Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect on total service and interest cost components</td>
<td>$11</td>
<td>$(11)</td>
</tr>
<tr>
<td>Effect on postretirement benefit obligation</td>
<td>77</td>
<td>(80)</td>
</tr>
</tbody>
</table>

Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see Note 1C.
C. Obligations and Funded Status

The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>U.S. Qualified(a)</th>
<th>U.S. Supplemental (Non-Qualified)(b)</th>
<th>International(c)</th>
<th>Postretirement Plans(d)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Change in benefit obligation</strong>&lt;sup&gt;(e)&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benefit obligation, beginning</td>
<td>$16,575</td>
<td>$13,976</td>
<td>$1,481</td>
<td>$1,341</td>
</tr>
<tr>
<td>Service cost</td>
<td>287</td>
<td>253</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>Interest cost</td>
<td>676</td>
<td>697</td>
<td>54</td>
<td>57</td>
</tr>
<tr>
<td>Employee contributions</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Plan amendments</td>
<td>62</td>
<td>—</td>
<td>4</td>
<td>—</td>
</tr>
<tr>
<td>Changes in actuarial assumptions and other</td>
<td>(774)</td>
<td>2,653</td>
<td>(70)</td>
<td>218</td>
</tr>
<tr>
<td>Foreign exchange impact</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Acquisitions/destitutions/other, net</td>
<td>542</td>
<td>—</td>
<td>9</td>
<td>—</td>
</tr>
<tr>
<td>Curtailments</td>
<td>3</td>
<td>2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Settlements</td>
<td>(2,034)</td>
<td>(308)</td>
<td>(93)</td>
<td>(96)</td>
</tr>
<tr>
<td>Special termination benefits</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(412)</td>
<td>(697)</td>
<td>(65)</td>
<td>(58)</td>
</tr>
<tr>
<td><strong>Benefit obligation, ending</strong>&lt;sup&gt;(f)&lt;/sup&gt;</td>
<td>$14,926</td>
<td>16,575</td>
<td>1,343</td>
<td>1,481</td>
</tr>
<tr>
<td><strong>Change in plan assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fair value of plan assets, beginning</td>
<td>$12,706</td>
<td>12,869</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Actual gain/(loss) on plan assets</td>
<td>(124)</td>
<td>819</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Company contributions</td>
<td>1,000</td>
<td>23</td>
<td>158</td>
<td>154</td>
</tr>
<tr>
<td>Employee contributions</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Foreign exchange impact</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Acquisitions/destitutions, net</td>
<td>496</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Settlements</td>
<td>(2,034)</td>
<td>(308)</td>
<td>(93)</td>
<td>(96)</td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(412)</td>
<td>(697)</td>
<td>(65)</td>
<td>(58)</td>
</tr>
<tr>
<td><strong>Fair value of plan assets, ending</strong></td>
<td>$11,633</td>
<td>12,706</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Funded status—Plan assets less than benefit obligation</strong></td>
<td>$ (3,292)</td>
<td>$ (3,869)</td>
<td>$ (1,343)</td>
<td>$ (1,481)</td>
</tr>
</tbody>
</table>

(a) The favorable change in the funded status of our U.S. qualified plans was primarily due to (i) the plan gains resulting from the increase in the discount rate, and (ii) a $1 billion voluntary contribution to the plans, partially offset by (i) the net impact of the acquisition of Hospira and (ii) a decrease in the actual return on assets.

(b) Our U.S. supplemental (non-qualified) plans are generally not funded and these obligations, which are substantially greater than the annual cash outlay for these liabilities, will be paid from cash generated from operations. The decrease in the benefit obligation is primarily due to an increase in the discount rate.

(c) The favorable change in the international plans’ funded status was primarily due to (i) plan gains related to favorable changes in actuarial assumptions and experience, (ii) an increase in company contributions to plan assets and (iii) foreign exchange impacts.

(d) The favorable change in the funded status of our postretirement plans was primarily due to (i) plan gains resulting from favorable changes in plan assumptions and an increase in the discount rate, and (ii) the impact of a plan amendment approved in June 2015 that introduced a cap on costs for certain groups within the plan, partially offset by (i) the reduced company contributions as the result of reimbursements received for eligible prescription drug expenses for certain retirees and (ii) the acquisition of Hospira.

(e) For the U.S. and international pension plans, the benefit obligation is the projected benefit obligation (PBO). For the postretirement plans, the benefit obligation is the accumulated postretirement benefit obligation (ABO). The ABO for all of our U.S. qualified pension plans was $14.8 billion in 2015 and $16.3 billion in 2014. The ABO for our U.S. supplemental (non-qualified) pension plans was $1.3 billion in 2015 and $1.4 billion in 2014. The ABO for our international pension plans was $8.8 billion in 2015 and $10.3 billion in 2014.
The following table provides information as to how the funded status is recognized in our consolidated balance sheets:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Noncurrent assets(a)</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$—</td>
<td>$572</td>
<td>$509</td>
<td>$—</td>
<td>$—</td>
</tr>
<tr>
<td>Current liabilities(b)</td>
<td>—</td>
<td>—</td>
<td>(126)</td>
<td>(136)</td>
<td>(25)</td>
<td>(45)</td>
<td>(31)</td>
<td>(27)</td>
</tr>
<tr>
<td>Noncurrent liabilities(c)</td>
<td>(3,292)</td>
<td>(3,869)</td>
<td>(1,216)</td>
<td>(1,345)</td>
<td>(1,801)</td>
<td>(2,671)</td>
<td>(1,809)</td>
<td>(2,379)</td>
</tr>
<tr>
<td>Funded status</td>
<td>$ (3,292)</td>
<td>$ (3,869)</td>
<td>$ (1,343)</td>
<td>$ (1,481)</td>
<td>$ (1,255)</td>
<td>$ (2,208)</td>
<td>$ (1,841)</td>
<td>$ (2,406)</td>
</tr>
</tbody>
</table>

(a) Included primarily in Other noncurrent assets.
(b) Included in Accrued compensation and related items.
(c) Included in Pension benefit obligations, net and Postretirement benefit obligations, net, as appropriate.

The following table provides the pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial losses(a)</td>
<td>$ (4,272)</td>
<td>$ (4,735)</td>
<td>$ (419)</td>
<td>$(567)</td>
<td>$(1,979)</td>
<td>$(2,527)</td>
<td>$(523)</td>
<td>$(745)</td>
</tr>
<tr>
<td>Prior service (costs)/credits</td>
<td>(33)</td>
<td>35</td>
<td>4</td>
<td>10</td>
<td>29</td>
<td>36</td>
<td>1,415</td>
<td>1,098</td>
</tr>
<tr>
<td>Total</td>
<td>$ (4,305)</td>
<td>$ (4,700)</td>
<td>$ (415)</td>
<td>$(557)</td>
<td>$(1,949)</td>
<td>$(2,492)</td>
<td>$892</td>
<td>$352</td>
</tr>
</tbody>
</table>

(a) The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our projected benefit obligations, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in Accumulated other comprehensive loss and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants, using the corridor approach. The average amortization periods utilized are 8.2 years for our U.S. qualified plans, 8.1 years for our U.S. supplemental (non-qualified) plans, 17 years for our international plans, and 9.5 years for our postretirement plans.

The following table provides information related to the funded status of selected benefit plans:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pension plans with an accumulated benefit obligation in excess of plan assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fair value of plan assets</td>
<td>$11,633</td>
<td>$12,706</td>
<td>$—</td>
<td>$—</td>
<td>$976</td>
<td>$1,718</td>
</tr>
<tr>
<td>Accumulated benefit obligation</td>
<td>14,755</td>
<td>16,323</td>
<td>1,324</td>
<td>1,481</td>
<td>2,495</td>
<td>4,021</td>
</tr>
<tr>
<td>Pension plans with a projected benefit obligation in excess of plan assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fair value of plan assets</td>
<td>11,633</td>
<td>12,706</td>
<td>$—</td>
<td>$—</td>
<td>1,546</td>
<td>1,999</td>
</tr>
<tr>
<td>Projected benefit obligation</td>
<td>14,926</td>
<td>16,575</td>
<td>1,343</td>
<td>1,481</td>
<td>3,373</td>
<td>4,715</td>
</tr>
</tbody>
</table>

All of our U.S. plans and many of our international plans were underfunded as of December 31, 2015.
### D. Plan Assets

The following table provides the components of plan assets:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>As of December 31, 2015</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>As of December 31, 2014</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S. qualified pension plans</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 417</td>
<td>$ 81</td>
<td>$ 336</td>
<td>—</td>
<td>$ 756</td>
<td>$ 84</td>
<td>$ 672</td>
<td>—</td>
</tr>
<tr>
<td>Equity securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global equity securities</td>
<td>3,720</td>
<td>3,717</td>
<td>2</td>
<td>1</td>
<td>3,394</td>
<td>3,391</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Equity commingled funds</td>
<td>951</td>
<td>—</td>
<td>825</td>
<td>126</td>
<td>1,647</td>
<td>—</td>
<td>1,500</td>
<td>147</td>
</tr>
<tr>
<td>Fixed income securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate debt securities</td>
<td>2,866</td>
<td>3</td>
<td>2,861</td>
<td>2</td>
<td>3,013</td>
<td>—</td>
<td>3,008</td>
<td>5</td>
</tr>
<tr>
<td>Government and agency obligations</td>
<td>989</td>
<td>—</td>
<td>989</td>
<td>—</td>
<td>1,124</td>
<td>—</td>
<td>1,124</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income commingled funds</td>
<td>222</td>
<td>—</td>
<td>222</td>
<td>—</td>
<td>242</td>
<td>—</td>
<td>242</td>
<td>—</td>
</tr>
<tr>
<td>Other investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partnership investments(b)</td>
<td>1,120</td>
<td>—</td>
<td>129</td>
<td>991</td>
<td>1,156</td>
<td>—</td>
<td>198</td>
<td>958</td>
</tr>
<tr>
<td>Insurance contracts</td>
<td>259</td>
<td>—</td>
<td>259</td>
<td>—</td>
<td>278</td>
<td>—</td>
<td>278</td>
<td>—</td>
</tr>
<tr>
<td>Other commingled funds(c)</td>
<td>1,089</td>
<td>—</td>
<td>—</td>
<td>1,089</td>
<td>1,096</td>
<td>—</td>
<td>—</td>
<td>1,096</td>
</tr>
<tr>
<td>Total</td>
<td>11,633</td>
<td>3,801</td>
<td>5,623</td>
<td>2,209</td>
<td>12,706</td>
<td>3,475</td>
<td>7,024</td>
<td>2,207</td>
</tr>
<tr>
<td><strong>International pension plans</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>207</td>
<td>14</td>
<td>193</td>
<td>—</td>
<td>331</td>
<td>25</td>
<td>306</td>
<td>—</td>
</tr>
<tr>
<td>Equity securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global equity securities</td>
<td>901</td>
<td>815</td>
<td>85</td>
<td>—</td>
<td>1,781</td>
<td>1,674</td>
<td>107</td>
<td>—</td>
</tr>
<tr>
<td>Equity commingled funds</td>
<td>2,218</td>
<td>16</td>
<td>2,119</td>
<td>83</td>
<td>1,851</td>
<td>19</td>
<td>1,832</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate debt securities</td>
<td>653</td>
<td>171</td>
<td>481</td>
<td>—</td>
<td>773</td>
<td>183</td>
<td>590</td>
<td>—</td>
</tr>
<tr>
<td>Government and agency obligations</td>
<td>1,224</td>
<td>109</td>
<td>1,114</td>
<td>—</td>
<td>1,213</td>
<td>140</td>
<td>1,073</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income commingled funds</td>
<td>1,216</td>
<td>37</td>
<td>1,142</td>
<td>37</td>
<td>1,037</td>
<td>44</td>
<td>969</td>
<td>24</td>
</tr>
<tr>
<td>Other investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partnership investments(b)</td>
<td>58</td>
<td>—</td>
<td>6</td>
<td>52</td>
<td>61</td>
<td>—</td>
<td>6</td>
<td>55</td>
</tr>
<tr>
<td>Insurance contracts</td>
<td>257</td>
<td>—</td>
<td>21</td>
<td>236</td>
<td>425</td>
<td>1</td>
<td>150</td>
<td>274</td>
</tr>
<tr>
<td>Other(c)</td>
<td>1,227</td>
<td>59</td>
<td>370</td>
<td>798</td>
<td>1,116</td>
<td>46</td>
<td>326</td>
<td>744</td>
</tr>
<tr>
<td>Total</td>
<td>7,999</td>
<td>1,222</td>
<td>5,531</td>
<td>1,206</td>
<td>8,588</td>
<td>2,132</td>
<td>5,359</td>
<td>1,097</td>
</tr>
<tr>
<td><strong>U.S. postretirement plans(d)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>6</td>
<td>—</td>
<td>6</td>
<td>—</td>
<td>18</td>
<td>1</td>
<td>17</td>
<td>—</td>
</tr>
<tr>
<td>Equity securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global equity securities</td>
<td>64</td>
<td>64</td>
<td>—</td>
<td>—</td>
<td>89</td>
<td>89</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Equity commingled funds</td>
<td>16</td>
<td>—</td>
<td>14</td>
<td>2</td>
<td>44</td>
<td>—</td>
<td>40</td>
<td>4</td>
</tr>
<tr>
<td>Fixed income securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate debt securities</td>
<td>49</td>
<td>—</td>
<td>49</td>
<td>—</td>
<td>79</td>
<td>—</td>
<td>79</td>
<td>—</td>
</tr>
<tr>
<td>Government and agency obligations</td>
<td>17</td>
<td>—</td>
<td>17</td>
<td>—</td>
<td>30</td>
<td>—</td>
<td>30</td>
<td>—</td>
</tr>
<tr>
<td>Fixed income commingled funds</td>
<td>4</td>
<td>—</td>
<td>4</td>
<td>—</td>
<td>6</td>
<td>—</td>
<td>6</td>
<td>—</td>
</tr>
<tr>
<td>Other investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partnership investments(b)</td>
<td>19</td>
<td>—</td>
<td>2</td>
<td>17</td>
<td>30</td>
<td>—</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>Insurance contracts</td>
<td>429</td>
<td>—</td>
<td>429</td>
<td>—</td>
<td>437</td>
<td>—</td>
<td>437</td>
<td>—</td>
</tr>
<tr>
<td>Other commingled funds(c)</td>
<td>19</td>
<td>—</td>
<td>—</td>
<td>19</td>
<td>29</td>
<td>—</td>
<td>—</td>
<td>29</td>
</tr>
<tr>
<td>Total</td>
<td>$ 622</td>
<td>$ 64</td>
<td>$ 521</td>
<td>$ 38</td>
<td>$ 762</td>
<td>$ 90</td>
<td>$ 614</td>
<td>$ 58</td>
</tr>
</tbody>
</table>

(a) Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see Note 1E).
(b) Primarily includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.
(c) Primarily includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.
(d) Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.
The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:

**U.S. Qualified Pension Plans**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value, beginning</td>
<td>$ 958</td>
<td>$ 932</td>
<td>$ 1,096</td>
<td>$ 715</td>
<td>$ 274</td>
<td>$ 300</td>
<td>$ 744</td>
<td>$ 500</td>
</tr>
<tr>
<td>Actual return on plan assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assets held, ending</td>
<td>84</td>
<td>104</td>
<td>(8)</td>
<td>47</td>
<td>16</td>
<td>23</td>
<td>25</td>
<td>47</td>
</tr>
<tr>
<td>Assets sold during the period</td>
<td>—</td>
<td>—</td>
<td>(34)</td>
<td>(7)</td>
<td>—</td>
<td>—</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Purchases, sales and settlements, net</td>
<td>(51)</td>
<td>(78)</td>
<td>35</td>
<td>341</td>
<td>(17)</td>
<td>(20)</td>
<td>73</td>
<td>254</td>
</tr>
<tr>
<td>Transfer into/(out of) Level 3</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(19)</td>
</tr>
<tr>
<td>Exchange rate changes</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(37)</td>
<td>(29)</td>
<td>(47)</td>
<td>(46)</td>
</tr>
<tr>
<td>Fair value, ending</td>
<td>$ 991</td>
<td>$ 958</td>
<td>$ 1,089</td>
<td>$ 1,096</td>
<td>$ 236</td>
<td>$ 274</td>
<td>$ 798</td>
<td>$ 744</td>
</tr>
</tbody>
</table>

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C.

Specifically, the following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:

- Cash and cash equivalents, Equity commingled funds, Fixed-income commingled funds—observable prices.
- Global equity securities—quoted market prices.
- Government and agency obligations, Corporate debt securities—observable market prices.
- Other investments—principally unobservable inputs that are significant to the estimation of fair value. These unobservable inputs could include, for example, the investment managers’ assumptions about earnings multiples and future cash flows.

We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness.

**International Pension Plans**

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value, beginning</td>
<td>$ 274</td>
<td>$ 300</td>
<td>$ 744</td>
<td>$ 500</td>
</tr>
<tr>
<td>Actual return on plan assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assets held, ending</td>
<td>16</td>
<td>23</td>
<td>25</td>
<td>47</td>
</tr>
<tr>
<td>Assets sold during the period</td>
<td>—</td>
<td>—</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Purchases, sales and settlements, net</td>
<td>(17)</td>
<td>(20)</td>
<td>73</td>
<td>254</td>
</tr>
<tr>
<td>Transfer into/(out of) Level 3</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(19)</td>
</tr>
<tr>
<td>Exchange rate changes</td>
<td>(37)</td>
<td>(29)</td>
<td>(47)</td>
<td>(46)</td>
</tr>
<tr>
<td>Fair value, ending</td>
<td>$ 236</td>
<td>$ 274</td>
<td>$ 798</td>
<td>$ 744</td>
</tr>
</tbody>
</table>

**U.S. postretirement plans**

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value, beginning</td>
<td>$ 744</td>
<td>$ 500</td>
<td>$ 744</td>
<td>$ 500</td>
</tr>
<tr>
<td>Actual return on plan assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assets held, ending</td>
<td>16</td>
<td>23</td>
<td>25</td>
<td>47</td>
</tr>
<tr>
<td>Assets sold during the period</td>
<td>—</td>
<td>—</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Purchases, sales and settlements, net</td>
<td>(17)</td>
<td>(20)</td>
<td>73</td>
<td>254</td>
</tr>
<tr>
<td>Transfer into/(out of) Level 3</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>(19)</td>
</tr>
<tr>
<td>Exchange rate changes</td>
<td>(37)</td>
<td>(29)</td>
<td>(47)</td>
<td>(46)</td>
</tr>
<tr>
<td>Fair value, ending</td>
<td>$ 744</td>
<td>$ 500</td>
<td>$ 744</td>
<td>$ 500</td>
</tr>
</tbody>
</table>

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see Note 1E. For a description of the risks associated with estimates and assumptions, see Note 1C.

Specifically, the following methods and assumptions were used to estimate the fair value of our pension and postretirement plans’ assets:

- Cash and cash equivalents, Equity commingled funds, Fixed-income commingled funds—observable prices.
- Global equity securities—quoted market prices.
- Government and agency obligations, Corporate debt securities—observable market prices.
- Other investments—principally unobservable inputs that are significant to the estimation of fair value. These unobservable inputs could include, for example, the investment managers’ assumptions about earnings multiples and future cash flows.

We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness.

The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:

**Target Allocation Percentage of Plan Assets**

<table>
<thead>
<tr>
<th>(PERCENTAGES)</th>
<th>2015</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S. qualified pension plans</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>0-10%</td>
<td>3.6%</td>
<td>5.9%</td>
</tr>
<tr>
<td>Equity securities</td>
<td>35-55%</td>
<td>40.2%</td>
<td>39.7%</td>
</tr>
<tr>
<td>Fixed income securities</td>
<td>30-55%</td>
<td>35.0%</td>
<td>34.5%</td>
</tr>
<tr>
<td>Other investments(a)</td>
<td>5-17.5%</td>
<td>21.2%</td>
<td>19.9%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>International pension plans</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>0-10%</td>
<td>2.6%</td>
<td>3.9%</td>
</tr>
<tr>
<td>Equity securities</td>
<td>35-55%</td>
<td>39.2%</td>
<td>42.3%</td>
</tr>
<tr>
<td>Fixed income securities</td>
<td>30-55%</td>
<td>38.8%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Other investments(a)</td>
<td>5-17.5%</td>
<td>19.4%</td>
<td>18.6%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>U.S. postretirement plans</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>0-5%</td>
<td>1.0%</td>
<td>2.4%</td>
</tr>
<tr>
<td>Equity securities</td>
<td>—</td>
<td>12.8%</td>
<td>17.4%</td>
</tr>
<tr>
<td>Fixed income securities</td>
<td>—</td>
<td>11.2%</td>
<td>15.1%</td>
</tr>
<tr>
<td>Other investments</td>
<td>95-100%</td>
<td>75.0%</td>
<td>65.1%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

(a) Actual percentage of plan assets in Other Investments for 2015 includes $259 million related to a group fixed annuity insurance contract that was executed by legacy Wyeth for certain members of its defined benefit plans prior to Pfizer acquiring the company in 2009, and $129 million related to an investment in a partnership whose primary holdings are public equity securities.
Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to minimize net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans’ invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.

Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans’ long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile.

The investment managers of certain commingled funds and private equity funds may be permitted to use derivative securities as described in each respective investment management, subscription, partnership or other governing agreement.

E. Cash Flows

It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.

The following table provides the expected future cash flow information related to our benefit plans:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Pension Plans</th>
<th>Postretirement Plans</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>U.S. Qualified</td>
<td>U.S. Supplemental (Non-Qualified)</td>
</tr>
<tr>
<td>Expected employer contributions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016(a)</td>
<td>$1,000</td>
<td>$126</td>
</tr>
<tr>
<td>Expected benefit payments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>$1,000</td>
<td>$126</td>
</tr>
<tr>
<td>2017</td>
<td>1,655</td>
<td>121</td>
</tr>
<tr>
<td>2018</td>
<td>985</td>
<td>125</td>
</tr>
<tr>
<td>2019</td>
<td>947</td>
<td>110</td>
</tr>
<tr>
<td>2020</td>
<td>959</td>
<td>114</td>
</tr>
<tr>
<td>2021–2025</td>
<td>4,517</td>
<td>512</td>
</tr>
</tbody>
</table>

(a) For the U.S. qualified plans, the $1.0 billion voluntary contribution was paid in January 2016. For the U.S. postretirement plans, the Internal Revenue Code 401(h) reimbursement in January 2016 totaling $198 million is expected to exceed the payments.

The table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments.

F. Defined Contribution Plans

We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehires and transfers to the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer a retirement savings contribution (RSC) in the defined contribution plan. Beginning on January 1, 2018, all non-union employees in those U.S. and Puerto Rico defined benefit plans will receive the RSC in the defined contribution plans. The RSC enhanced benefit consists of a non-contributory employer contribution (that is, not dependent upon the participant making a contribution) determined based on each employee’s eligible compensation, age and years of service. We recorded charges related to the employer contributions to global defined contribution plans of $287 million in 2015, $278 million in 2014 and $266 million in 2013.
Note 12. Equity

A. Common Stock

We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. Our December 2011 $10 billion share-purchase plan was exhausted in the first quarter of 2013. Our November 2012 $10 billion share-purchase plan was exhausted in the fourth quarter of 2013. On June 27, 2013, we announced that the Board of Directors had authorized a $10 billion share-purchase plan, which was exhausted in the first quarter of 2015. On October 23, 2014, we announced that the Board of Directors had authorized an additional $11 billion share-purchase plan (the October 2014 Stock Purchase Plan), and share repurchases commenced thereunder in January 2015. In December 2015, the Board of Directors authorized a new $11 billion share repurchase program to be utilized over time.

On February 9, 2015, we entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase shares of our common stock. This agreement was entered into under our previously announced share repurchase authorization. Pursuant to the terms of the agreement, on February 11, 2015, we paid $5 billion to GS&Co. and received approximately 151 million shares of our common stock from GS&Co. On July 2, 2015, the accelerated share repurchase agreement with GS&Co. was completed, which, per the terms of the agreement, resulted in us owing GS&Co. a certain number of shares of Pfizer common stock or its equivalent dollar value. Pursuant to the agreement’s settlement terms, we elected to settle this amount in cash and paid an additional $160 million to GS&Co. on July 13, 2015, resulting in a total of approximately $5.2 billion paid to GS&Co. The final average price paid for the shares delivered under the accelerated share repurchase agreement was $34.13 per share.

The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreement:

<table>
<thead>
<tr>
<th>(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</th>
<th>2015(a)</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shares of common stock purchased</td>
<td>182</td>
<td>165</td>
<td>563</td>
</tr>
<tr>
<td>Cost of purchase</td>
<td>$6.2</td>
<td>$6.0</td>
<td>$5.0</td>
</tr>
</tbody>
</table>

(a) Includes approximately 151 million shares purchased for $5.2 billion pursuant to the accelerated share repurchase agreement as well as other share repurchases through year-end 2015.

After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through year-end 2015, our remaining share-purchase authorization was approximately $16.4 billion at December 31, 2015.

In addition, on June 24, 2013, we exchanged all of our remaining interest in Zoetis for approximately 405.117 million shares of our common stock, valued at $11.4 billion. The common stock received in the exchange transaction was recorded in Treasury stock. For additional information, see Note 2D.

The definitive merger agreement we entered into with Allergan in November 2015 includes a provision that Pfizer may continue to pay regular quarterly cash dividends on Pfizer’s common stock of not more than $0.28 per share per quarter (subject to annual adjustment, if any, in a manner consistent with past practice by Pfizer’s Board of Directors), consistent with past practice as to timing of declaration, record date and payment date. On December 14, 2015, we declared a $0.30 dividend per share for the first quarter of 2016, which is in compliance with the definitive merger agreement.

B. Preferred Stock

The Series A convertible perpetual preferred stock is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of 6.25%, which are accumulated and paid quarterly. The per-share stated value is $40,300 and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder’s option, into 2,574.87 shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share.

C. Employee Stock Ownership Plans

We have two employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).

Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for the earnings per share (EPS) calculation, and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of December 31, 2015, the Preferred ESOP held preferred shares convertible into approximately 2 million shares of our common stock, and the Common ESOP held approximately 58 million shares of our common stock. As of December 31, 2015, all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. and certain Puerto Rico defined contribution plan participants. The compensation cost related to the common ESOPs was $8 million in 2015, $136 million in 2014 and $133 million in 2013. Prior to 2015, Pfizer matching contributions were primarily invested in the Common ESOP. Beginning in January 2015, Pfizer matching contributions are being invested based on the investment direction of the employees’ own contributions. As a result, the compensation cost related to the Common ESOP was lower in 2015, compared to 2014, while contributions made to other investment funds increased. Therefore, although Pfizer matching contributions have not declined in aggregate, less contributions are being invested in the Common ESOP.
Note 13. Share-Based Payments

Our compensation programs can include share-based payments, in the form of Restricted Stock Units (RSUs), stock options, Portfolio Performance Shares (PPSs), Total Shareholder Return Units (TSRUs), Performance Share Awards (PSAs) and restricted stock grants.

The 2014 Stock Plan (2014 Plan) replaced and superseded the 2004 Stock Plan (2004 Plan), as amended and restated. The 2014 Plan provides for 520 million shares to be authorized for grants, plus any shares remaining available for grant under the 2004 Plan as of April 24, 2014 (the carryforward shares). In addition, the 2014 Plan provides that the number of stock options, Stock Appreciation Rights (SARs) (known as TSRUs), RSUs, restricted stock awards or other performance-based awards that may be granted to any one individual during any 36-month period is limited to 20 million shares, and that RSUs, PPSs, PSAs and restricted stock grants count as three shares, while stock options and TSRUs count as one share, toward the maximum shares available under the 2014 plan. The 2004 Plan provided that the number of stock options, TSRUs or other performance-based awards granted to any one individual during any 36-month period was limited to 8 million shares, and that RSUs, PPSs, PSAs and restricted stock grants counted against the maximum available shares as two shares, while stock options and TSRUs counted as one share. As of December 31, 2015, 494 million shares were available for award.

Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.

A. Impact on Net Income

The following table provides the components of share-based compensation expense and the associated tax benefit (including those reported as part of discontinued operations in 2013):

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>$306</td>
<td>$270</td>
<td>$249</td>
</tr>
<tr>
<td>Stock Options</td>
<td>165</td>
<td>150</td>
<td>140</td>
</tr>
<tr>
<td>Portfolio Performance Shares</td>
<td>147</td>
<td>96</td>
<td>56</td>
</tr>
<tr>
<td>Total Shareholder Return Units</td>
<td>36</td>
<td>37</td>
<td>37</td>
</tr>
<tr>
<td>Performance Share Awards</td>
<td>11</td>
<td>30</td>
<td>34</td>
</tr>
<tr>
<td>Directors’ compensation</td>
<td>4</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Share-based payment expense</td>
<td>669</td>
<td>586</td>
<td>523</td>
</tr>
<tr>
<td>Tax benefit for share-based compensation expense</td>
<td>(198)</td>
<td>(179)</td>
<td>(173)</td>
</tr>
<tr>
<td>Share-based payment expense, net of tax</td>
<td>$471</td>
<td>$407</td>
<td>$350</td>
</tr>
</tbody>
</table>

Amounts capitalized as part of inventory cost were not significant for any period presented.

B. Restricted Stock Units (RSUs)

RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after three years of continuous service from the grant date.

We measure the value of RSU grants as of the grant date using the closing price of Pfizer common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.

The following table summarizes all RSU activity during 2015:

<table>
<thead>
<tr>
<th>Shares (Thousands)</th>
<th>Weighted-Average Grant-Date Fair Value Per Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granted</td>
<td>10,602</td>
</tr>
<tr>
<td>Vested</td>
<td>(10,802)</td>
</tr>
<tr>
<td>Reinvested dividend equivalents</td>
<td>961</td>
</tr>
<tr>
<td>Forfeited</td>
<td>(1,562)</td>
</tr>
<tr>
<td>Nonvested, December 31, 2015</td>
<td>29,135</td>
</tr>
</tbody>
</table>
The following table provides data related to all RSU activity:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td>Total fair value of shares vested</td>
<td>$371</td>
</tr>
<tr>
<td>Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax</td>
<td>$279</td>
</tr>
<tr>
<td>Weighted-average period over which RSU cost is expected to be recognized (years)</td>
<td>1.8</td>
</tr>
</tbody>
</table>

C. Stock Options

Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of Pfizer common stock at a price per share equal to the closing market price of Pfizer common stock on the date of grant.

All eligible employees may receive stock option grants. No stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted since 2005 vest after three years of continuous service from the grant date and have a contractual term of ten years. In most cases, stock options must be held for at least one year from the grant date before any vesting may occur. In the event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period from three months to their remaining term, depending on various conditions.

We measure the value of stock option grants as of the grant date using, for virtually all grants, the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.

The following table provides the weighted-average assumptions used in the valuation of stock options:

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
</tr>
<tr>
<td>Expected dividend yield(a)</td>
</tr>
<tr>
<td>Risk-free interest rate(b)</td>
</tr>
<tr>
<td>Expected stock price volatility(c)</td>
</tr>
<tr>
<td>Expected term (years)(d)</td>
</tr>
</tbody>
</table>

(a) Determined using a constant dividend yield during the expected term of the option.
(b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
(c) Determined using implied volatility, after consideration of historical volatility.
(d) Determined using historical exercise and post-vesting termination patterns.

The following table summarizes all stock option activity during 2015:

<table>
<thead>
<tr>
<th>Shares (Thousands)</th>
<th>Weighted-Average Exercise Price Per Share</th>
<th>Weighted-Average Remaining Contractual Term (Years)</th>
<th>Aggregate Intrinsic Value(a) (Millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding, December 31, 2014</td>
<td>249,112</td>
<td>$24.05</td>
<td></td>
</tr>
<tr>
<td>Granted</td>
<td>46,130</td>
<td>34.59</td>
<td></td>
</tr>
<tr>
<td>Exercised</td>
<td>(56,890)</td>
<td>22.31</td>
<td></td>
</tr>
<tr>
<td>Forfeited</td>
<td>(4,825)</td>
<td>31.24</td>
<td></td>
</tr>
<tr>
<td>Expired</td>
<td>(973)</td>
<td>26.24</td>
<td></td>
</tr>
<tr>
<td>Outstanding, December 31, 2015</td>
<td>232,554</td>
<td>26.41</td>
<td>6.2</td>
</tr>
<tr>
<td>Vested and expected to vest, December 31, 2015(b)</td>
<td>226,804</td>
<td>26.23</td>
<td>6.1</td>
</tr>
<tr>
<td>Exercisable, December 31, 2015</td>
<td>109,561</td>
<td>20.67</td>
<td>4.0</td>
</tr>
</tbody>
</table>

(a) Market price of underlying Pfizer common stock less exercise price.
(b) The number of options expected to vest takes into account an estimate of expected forfeitures.

The following table summarizes data related to all stock option activity:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS, EXCEPTION PER STOCK OPTION AMOUNTS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weighted-average grant-date fair value per stock option</td>
<td>$4.30</td>
</tr>
<tr>
<td>Aggregate intrinsic value on exercise</td>
<td>$666</td>
</tr>
<tr>
<td>Cash received upon exercise</td>
<td>$1,263</td>
</tr>
<tr>
<td>Tax benefits realized related to exercise</td>
<td>$187</td>
</tr>
<tr>
<td>Total compensation cost related to nonvested stock options not yet recognized, pre-tax</td>
<td>$159</td>
</tr>
<tr>
<td>Weighted-average period over which stock option compensation cost is expected to be recognized (years)</td>
<td>1.8</td>
</tr>
</tbody>
</table>
D. Portfolio Performance Shares (PPSs)

PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of Pfizer common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after three years of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer’s long-term product portfolio during a five-year performance period from the year of the grant date. The target number of shares is determined by reference to competitive survey data. The number of shares that may be earned over the performance period ranges from 0% to 200% of the initial award.

We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of Pfizer common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved and/or changes in management’s assessment of the probable vesting term.

The following table summarizes all PPS activity during 2015, with the shares representing the maximum award that could be achieved:

<table>
<thead>
<tr>
<th>Shares (Thousands)</th>
<th>Weighted-Average Intrinsic Value Per Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonvested, December 31, 2014</td>
<td>18,877 $31.15</td>
</tr>
<tr>
<td>Granted</td>
<td>8,537 $34.59</td>
</tr>
<tr>
<td>Vested(a)</td>
<td>(3,403) $34.38</td>
</tr>
<tr>
<td>Forfeited</td>
<td>(1,508) $33.75</td>
</tr>
<tr>
<td>Nonvested, December 31, 2015(a)</td>
<td>22,503 $32.28</td>
</tr>
</tbody>
</table>

(a) Vested and non-vested shares outstanding, but not paid as of December 31, 2015 were 25,895.

The following table provides data related to all PPS activity:

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(MILLIONS OF DOLLARS)</td>
</tr>
<tr>
<td>Total fair value of shares vested</td>
</tr>
<tr>
<td>$60 $60 $— $—</td>
</tr>
<tr>
<td>Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax</td>
</tr>
<tr>
<td>$102 $193 $107 $107</td>
</tr>
<tr>
<td>Weighted-average period over which PPS cost is expected to be recognized (years)</td>
</tr>
<tr>
<td>1.7 1.8 2.0 2.0</td>
</tr>
</tbody>
</table>

E. Total Shareholder Return Units (TSRUs)

TSRUs are awarded to senior and other key management. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the five-year or seven-year term, if and to the extent the total value is positive. The settlement price is the average closing price of Pfizer common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of Pfizer common stock on the date of the grant.

The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture. The target number of shares is determined by reference to the fair value of share-based awards to similar employees in the industry peer group.

We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate.

The following table provides the weighted-average assumptions used in the valuation of TSRUs:

<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Determined using a constant dividend yield during the expected term of the TSRU.</td>
</tr>
<tr>
<td>Expected dividend yield(a)</td>
</tr>
<tr>
<td>3.19% 3.18% 3.45%</td>
</tr>
<tr>
<td>Risk-free interest rate(b)</td>
</tr>
<tr>
<td>1.76% 1.78% 1.03%</td>
</tr>
<tr>
<td>Expected stock price volatility(c)</td>
</tr>
<tr>
<td>18.41% 19.76% 19.68%</td>
</tr>
<tr>
<td>Contractual term (years)</td>
</tr>
<tr>
<td>5.91 5.97 5.98</td>
</tr>
</tbody>
</table>

(a) Determined using the interpolated yield on U.S. Treasury zero-coupon issues.
(b) Determined using implied volatility, after consideration of historical volatility.
The following table summarizes all TSRU activity during 2015:

<table>
<thead>
<tr>
<th>Share Units (Thousands)</th>
<th>Weighted-Average Grant-Date Fair Value Per Share Unit</th>
<th>Weighted-Average Grant Price Per Share Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonvested, December 31, 2014</td>
<td>20,935</td>
<td>$5.29</td>
</tr>
<tr>
<td>Granted</td>
<td>6,394</td>
<td>6.66</td>
</tr>
<tr>
<td>Vested</td>
<td>(8,050)</td>
<td>4.51</td>
</tr>
<tr>
<td>Forfeited</td>
<td>(1,212)</td>
<td>6.22</td>
</tr>
<tr>
<td>Nonvested, December 31, 2015</td>
<td>18,067</td>
<td>$6.07</td>
</tr>
</tbody>
</table>

The following table summarizes all outstanding TSRU activity as of December 31, 2015:

<table>
<thead>
<tr>
<th>Share Units (Thousands)</th>
<th>Weighted-Average Grant Price Per Share Unit</th>
<th>Weighted-Average Remaining Contractual Term (Years)</th>
<th>Aggregate Intrinsic Value (Millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding</td>
<td>35,757</td>
<td>$25.82</td>
<td>2.9</td>
</tr>
<tr>
<td>Vested</td>
<td>17,690</td>
<td>20.26</td>
<td>1.7</td>
</tr>
<tr>
<td>Expected to vest</td>
<td>18,067</td>
<td>31.27</td>
<td>4.2</td>
</tr>
</tbody>
</table>

(a) In 2015, we settled 4,247,428 share units with a weighted-average grant price of $17.69 per share unit.

The following table provides data related to all TSRU activity:

| Year Ended December 31, (MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS) |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| 2015  | 2014  | 2013  |
| Weighted-average grant-date fair value per TSRU | $6.66 | $6.51 | $5.14 |
| Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax | $29 | $30 | $31 |
| Weighted-average period over which TSRU cost is expected to be recognized (years) | 1.8 | 1.8 | 1.6 |

F. Performance Share Awards (PSAs)

PSAs are awarded to senior and other key management. PSAs vest after three years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, for awards granted in 2015, depends upon the achievement of predetermined goals related to two measures: (i) operating income over three one-year periods; and (ii) Total Shareholder Return (TSR) as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the three-year performance period. The number of shares paid from awards granted in 2014 and prior depends upon the achievement of predetermined goals related to Pfizer’s TSR as compared to an industry peer group, for the three-year performance period from the year of the grant date. The target number of shares is determined by reference to the value of share-based awards to similar employees in the industry peer group. The number of shares that are earned over the performance period ranges from 0% to 200% of the initial award.

We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of Pfizer common stock. The values are amortized on a straight-line basis over the probable vesting term into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer’s common stock, changes in the number of shares that are probable of being earned and changes in management’s assessment of the probability that the specified performance criteria will be achieved.

The following table summarizes all PSA activity during 2015, with the shares granted representing the maximum award that could be achieved:

<table>
<thead>
<tr>
<th>Share Units (Thousands)</th>
<th>Weighted-Average Intrinsic Value Per Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonvested, December 31, 2014</td>
<td>4,090</td>
</tr>
<tr>
<td>Granted</td>
<td>1,648</td>
</tr>
<tr>
<td>Vested</td>
<td>(417)</td>
</tr>
<tr>
<td>Forfeited</td>
<td>(1,450)</td>
</tr>
<tr>
<td>Nonvested, December 31, 2015</td>
<td>3,871</td>
</tr>
</tbody>
</table>
The following table provides data related to all PSA activity:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total fair value of shares vested</td>
<td>$14</td>
<td>$39</td>
<td>$40</td>
</tr>
<tr>
<td>Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax</td>
<td>$24</td>
<td>$21</td>
<td>$25</td>
</tr>
<tr>
<td>Weighted-average period over which PSA cost is expected to be recognized (years)</td>
<td>1.9</td>
<td>1.7</td>
<td>1.7</td>
</tr>
</tbody>
</table>

**Note 14. Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders**

The following table provides the detailed calculation of *Earnings per common share (EPS)*:

<table>
<thead>
<tr>
<th>(IN MILLIONS)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Numerator—Basic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from continuing operations</td>
<td>$6,975</td>
<td>$9,119</td>
<td>$11,410</td>
</tr>
<tr>
<td>Less: Net income attributable to noncontrolling interests</td>
<td>26</td>
<td>32</td>
<td>30</td>
</tr>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc.</td>
<td>6,949</td>
<td>9,087</td>
<td>11,380</td>
</tr>
<tr>
<td>Less: Preferred stock dividends—net of tax</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc. common shareholders</td>
<td>6,948</td>
<td>9,086</td>
<td>11,378</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>11</td>
<td>48</td>
<td>10,662</td>
</tr>
<tr>
<td>Less: Discontinued operations—net of tax, attributable to noncontrolling interests</td>
<td>—</td>
<td>—</td>
<td>39</td>
</tr>
<tr>
<td>Discontinued operations—net of tax, attributable to Pfizer Inc. common shareholders</td>
<td>11</td>
<td>48</td>
<td>10,623</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders</td>
<td>$6,959</td>
<td>$9,134</td>
<td>$22,001</td>
</tr>
<tr>
<td><strong>EPS Numerator—Diluted</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</td>
<td>$6,948</td>
<td>9,087</td>
<td>11,380</td>
</tr>
<tr>
<td>Discontinued operations—net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</td>
<td>11</td>
<td>48</td>
<td>10,623</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders and assumed conversions</td>
<td>$6,960</td>
<td>$9,135</td>
<td>$22,003</td>
</tr>
<tr>
<td><strong>EPS Denominator</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted-average number of common shares outstanding—Basic</td>
<td>6,176</td>
<td>6,346</td>
<td>6,813</td>
</tr>
<tr>
<td>Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreement</td>
<td>81</td>
<td>78</td>
<td>82</td>
</tr>
<tr>
<td>Weighted-average number of common shares outstanding—Diluted</td>
<td>6,257</td>
<td>6,424</td>
<td>6,895</td>
</tr>
<tr>
<td>Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans(a)</td>
<td>50</td>
<td>44</td>
<td>43</td>
</tr>
</tbody>
</table>

(a) These common stock equivalents were outstanding for the years ended December 31, 2015, 2014 and 2013, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

**Note 15. Lease Commitments**

We lease properties and equipment for use in our operations. In addition to rent, the leases may require us to pay directly for taxes, insurance, maintenance and other operating expenses or to pay higher rent when operating expenses increase. Rental expense, net of sublease income, was $243 million in 2015, $216 million in 2014 and $233 million in 2013.

The future minimum rental commitments under non-cancelable operating leases follow:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>After 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lease commitments</td>
<td>$202</td>
<td>$196</td>
<td>$170</td>
<td>$143</td>
<td>$119</td>
<td>$1,002</td>
</tr>
</tbody>
</table>

**Note 16. Insurance**

Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability. If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see Note 17).
Note 17. Commitments and Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 5D.

A. Legal Proceedings

Our non-tax contingencies include, but are not limited to, the following:

- Patent litigation, which typically involves challenges to the coverage and/or validity of our patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in a loss of patent protection for the drug at issue, a significant loss of revenues from that drug and impairments of any associated assets.
- Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.
- Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.
- Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the Company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.

A1. Legal Proceedings—Patent Litigation

Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, our patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, we note that the patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry related to patent enforcement litigation. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We are also subject to patent litigation pursuant to which one or more third parties is seeking damages and/or injunctive relief to compensate for the alleged infringement of its patents due to our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If the marketed product is ultimately found to infringe the valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of such product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed the valid patent rights of a third party.
Actions In Which We Are The Plaintiff

Sutent (sunitinib malate)
In May 2010, Mylan notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Sutent and challenging on various grounds the Sutent basic patent, which expires in 2021, and two other patents that expire in 2020 and 2021, respectively. In June 2010, we filed suit against Mylan in the U.S. District Court for the District of Delaware asserting the infringement of those three patents. The patent expiring in 2020 was dismissed from the case prior to trial. In October 2014, the court held that the two patents expiring in 2021 were valid and infringed. In October 2014, Mylan appealed the decision to the U.S. Court of Appeals for the Federal Circuit. In January 2016, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision upholding the validity and infringement of the two patents expiring in 2021.

EpiPen
In July 2010, King Pharmaceuticals, Inc. (King), which we acquired in 2011 and is a wholly owned subsidiary, brought a patent-infringement action against Sandoz, Inc., a division of Novartis AG (Sandoz), in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.

Toviaz (fesoterodine)
We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH, which owns the patents relating to Toviaz.

Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book”. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019, and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with four of the eight generic defendants. The trial relating to the remaining defendants occurred in July 2015, and we are waiting for a ruling from the court.

Tygacil (tigecycline)
In October 2013, we received notice of a Section 505(b)(2) new drug application filed by Fresenius Kabi USA LLC (Fresenius) for a tigecycline injectable product. Fresenius asserted the invalidity and non-infringement of the basic patent for Tygacil that expires in April 2016, the formulation patent for Tygacil that expires in 2029 and the polymorph patent for Tygacil that expires in 2030. In November 2013, we filed suit against Fresenius in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents in suit. In November 2015, we settled our claims against Fresenius on terms that permit Fresenius to launch a tigecycline injectable product in the U.S. prior to the expiration of certain of the patents that were the subject of the challenge.

In November 2014, Mylan Laboratories Limited (formerly Agila Specialties Private Limited) (Mylan Laboratories) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Tygacil. Mylan Laboratories asserts the invalidity and non-infringement of the polymorph patent for Tygacil and the formulation patent for Tygacil. Mylan Laboratories has not challenged the basic patent. In January 2015, we filed suit against Mylan Laboratories in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the polymorph patent and the formulation patent for Tygacil.

In addition, in September 2015 and December 2015, we received notices of Section 505(b)(2) new drug applications filed by each of Mylan and Accord Healthcare Inc. (Accord) for tigecycline injectable products. Mylan and Accord assert the invalidity and non-infringement of the polymorph patent for Tygacil, and two formulation patents for Tygacil that expire in 2028 and 2029, respectively. In October 2015, we filed suit against Mylan in the U.S. District Court for the District of Delaware and in the U.S. District Court for the District of West Virginia asserting the validity and infringement of the patents in suit. In February 2016, we filed suit against Accord in the U.S. District Court for the District of Delaware and in the U.S. District Court for the Middle District of North Carolina asserting the validity and infringement of the patents in suit.

Precedex Premix
In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent in suit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent in suit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma.

In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents in suit.

In December 2015, Fresenius notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents in suit.
Matters Involving Our Collaboration/Licensing Partners

Nexium 24HR (esomeprazole)

We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the over-the-counter (OTC) version of Nexium (Nexium 24HR). Beginning in October 2014, Actavis Laboratories FL, Inc., and subsequently Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited and, in October 2015, Dr. Reddy’s Laboratories, Inc. & Ltd. (Dr. Reddy’s) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca’s patents listed in the Orange Book for Nexium 24HR. From November 2014 through November 2015, AstraZeneca filed actions against each of Actavis Laboratories FL, Inc., Andrx, Perrigo, Lupin Limited and Dr. Reddy’s in the U.S. District Court for the District of New Jersey asserting the infringement of the challenged patents. We are not a party to AstraZeneca’s patent infringement actions.

Eliquis (apixaban) - Inter-Partes Review (IPR)

In August 2015, Bristol-Myers Squibb (BMS) received a Petition for Inter Partes Review (the Petition) of the composition of matter patent that contains claims that cover apixaban, the active ingredient in Eliquis, which is co-marketed by BMS and Pfizer. The patent expires in February 2023, but BMS has filed a request for patent term restoration with the U.S. Patent & Trademark Office (USPTO) which, if successful, will result in a patent expiration date of December 2026. The Petition was filed at the USPTO by the Coalition for Affordable Drugs and requests that the Patent Trial and Appeal Board (PTAB) initiate a proceeding to review the validity of the patent, including claims that cover apixaban. BMS responded to and opposed this Petition in November 2015 and, in February 2016, the PTAB rejected the Petition, declining to initiate a review of the patent.

Action In Which We Are The Defendant

Effexor XR (venlafaxine HCI)

In 2006, Wyeth and Wyeth Canada Limited (the Wyeth companies) filed an action in the Federal Court in Canada against Ratiopharm Inc. (Ratiopharm) seeking to prevent Ratiopharm from obtaining approval in Canada for its generic version of Effexor XR prior to the expiration of one of the Wyeth companies’ patents. As a result of that action, Ratiopharm was enjoined from obtaining regulatory approval for its generic product. However, in August 2007, the Federal Court of Appeal in Canada ruled that the patent at issue could not be asserted against Ratiopharm under the applicable Canadian regulations governing approvals, and it dismissed the Wyeth companies’ action.

Following the dismissal, in 2007, Ratiopharm filed an action in the Federal Court in Canada seeking damages from the Wyeth companies for preventing Ratiopharm from marketing its generic version of Effexor XR in Canada from January 2006 through August 2007. The Federal Court dismissed Ratiopharm’s action in 2011, but the Federal Court of Appeal reinstated it in 2012. In 2011 and 2012, Pfizer made payments to Teva Canada Limited, which had acquired Ratiopharm, totaling Canadian dollars 52.5 million in partial settlement of this action.

The trial in this action was held in January 2014, and the court issued various findings in March 2014. On June 30, 2014, the Federal Court in Canada issued a judgment based on those findings, awarding Teva Canada Limited damages of approximately Canadian dollars 125 million, consisting of compensatory damages, pre-judgment interest and legal costs. This judgment was satisfied by Pfizer Canada Inc., as successor to the Wyeth companies, in July 2014. In September 2014, Pfizer Canada Inc. appealed the judgment.

A2. Legal Proceedings—Product Litigation

Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.

Asbestos

Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of December 31, 2015, approximately 55,450 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is now a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.

Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products containing asbestos and other allegedly hazardous materials sold by Gibsonburg Lime Products Company (Gibsonburg). Gibsonburg was acquired by Pfizer in the 1960s and sold products containing small amounts of asbestos until the early 1970s.

There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.

Celebrex and Bextra

Beginning in late 2004, several purported class actions were filed in federal and state courts alleging that Pfizer and certain of our current and former officers violated federal securities laws by misrepresenting the safety of Celebrex and Bextra. In June 2005, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Pfizer Inc. Securities, Derivative and “ERISA” Litigation MDL-1688) in the U.S. District Court for the Southern District of New York. In March 2012, the court in the Multi-District Litigation certified a class consisting of all persons who purchased or acquired Pfizer stock between October 31, 2000 and October 19, 2005. In May 2014, the court in the Multi-District Litigation granted Pfizer’s motion to exclude the testimony of the plaintiffs’ loss causation and damages expert. We subsequently filed a motion for summary judgment seeking dismissal of the litigation, and the plaintiffs filed a motion for leave to submit an amended report by their expert. In July 2014, the court denied the plaintiffs’ motion for leave to submit an amended report, and granted our motion for summary judgment, dismissing the plaintiffs’ claims in their entirety. In August 2014, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Second Circuit.
Effexor

• **Personal Injury Actions**

A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (MDL-2342) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, have been administratively stayed.

Antitrust Actions

Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey.

In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs have appealed to the U.S. Court of Appeals for the Third Circuit. Motions to dismiss remain pending as to the end-payer plaintiffs’ remaining claims.

Zoloft

A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (MDL-2342) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions.

In 2004, a former employee filed a “whistleblower” action against us in the U.S. District Court for the Eastern District of New York. The complaint remained under seal until September 2007, at which time the U.S. Attorney for the Eastern District of New York declined to intervene in the case. We were served with the complaint in December 2007. Plaintiff alleges off-label promotion of Lipitor in violation of the Federal Civil False Claims Act and the false claims acts of certain states, and he seeks treble damages and civil penalties on behalf of the federal government and the specified states as the result of their purchase, or reimbursement of patients for the purchase, of Lipitor allegedly for such off-label uses. Plaintiff also seeks compensation as a whistleblower under those federal and state statutes. In addition, plaintiff alleges that he was wrongfully terminated, in violation of the anti-retaliation provisions of applicable federal and New York law, and he seeks damages and the reinstatement of his employment. In 2009, the District Court dismissed without prejudice the off-label promotion claims and, in 2010, plaintiff filed an amended complaint containing off-label promotion allegations that are substantially similar to the allegations in the original complaint. In November 2012, the District Court dismissed the amended complaint. In December 2012, plaintiff appealed the District Court’s decision to the U.S. Court of Appeals for the Second Circuit. In August 2014, the U.S. Court of Appeals for the Second Circuit dismissed the appeal for lack of jurisdiction and sent the case back to the District Court for clarification of its ruling regarding the plaintiff’s employment claims. In November 2014, the District Court granted plaintiff’s motion for a partial final judgment certifying the dismissal of the false claims counts, and plaintiff appealed the order dismissing those claims to the U.S. Court of Appeals for the Second Circuit.

Lipitor

• **Whistleblower Action**

In 2004, a former employee filed a “whistleblower” action against us in the U.S. District Court for the Eastern District of New York. The complaint remained under seal until September 2007, at which time the U.S. Attorney for the Eastern District of New York declined to intervene in the case. We were served with the complaint in December 2007. Plaintiff alleges off-label promotion of Lipitor in violation of the Federal Civil False Claims Act and the false claims acts of certain states, and he seeks treble damages and civil penalties on behalf of the federal government and the specified states as the result of their purchase, or reimbursement of patients for the purchase, of Lipitor allegedly for such off-label uses. Plaintiff also seeks compensation as a whistleblower under those federal and state statutes. In addition, plaintiff alleges that he was wrongfully terminated, in violation of the anti-retaliation provisions of applicable federal and New York law, and he seeks damages and the reinstatement of his employment. In 2009, the District Court dismissed without prejudice the off-label promotion claims and, in 2010, plaintiff filed an amended complaint containing off-label promotion allegations that are substantially similar to the allegations in the original complaint. In November 2012, the District Court dismissed the amended complaint. In December 2012, plaintiff appealed the District Court’s decision to the U.S. Court of Appeals for the Second Circuit. In August 2014, the U.S. Court of Appeals for the Second Circuit dismissed the appeal for lack of jurisdiction and sent the case back to the District Court for clarification of its ruling regarding the plaintiff’s employment claims. In November 2014, the District Court granted plaintiff’s motion for a partial final judgment certifying the dismissal of the false claims counts, and plaintiff appealed the order dismissing those claims to the U.S. Court of Appeals for the Second Circuit.

• **Antitrust Actions**

Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have
been consolidated for pre-trial proceedings in a Multi-District Litigation (MDL) (In re Lipitor Antitrust Litigation MDL-2332) in the U.S. District Court for the District of New Jersey.

In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other MDL plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the United States Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit.

Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.

**Personal Injury Actions**

A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes as a result of the purported ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502) in the U.S. District Court for the District of South Carolina.

**Chantix/Champix**

Beginning in December 2008, purported class actions were filed against us in the Ontario Superior Court of Justice (Toronto Region), the Superior Court of Quebec (District of Montreal), the Court of Queen’s Bench of Alberta, Judicial District of Calgary, and the Superior Court of British Columbia (Vancouver Registry) on behalf of all individuals and third-party payers in Canada who have purchased and ingested Chantix or reimbursed patients for the purchase of Chantix. Each of these actions asserts claims under Canadian product liability law, including with respect to the safety and efficacy of Chantix, and, on behalf of the putative class, seeks monetary relief, including punitive damages. In June 2012, the Ontario Superior Court of Justice certified the Ontario proceeding as a class action, defining the class as consisting of the following: (i) all persons in Canada who ingested Chantix during the period from April 2, 2007 to May 31, 2010 and who experienced at least one of a number of specified neuropsychiatric adverse events; (ii) all persons who are entitled to assert claims in respect of Chantix pursuant to Canadian legislation as the result of their relationship with a class member; and (iii) all health insurers who are entitled to assert claims in respect of Chantix pursuant to Canadian legislation. The Ontario Superior Court of Justice certified the class against Pfizer Canada Inc. only and ruled that the action against Pfizer should be stayed until after the trial of the issues that are common to the class members. The actions in Quebec, Alberta and British Columbia have been stayed in favor of the Ontario action, which is proceeding on a national basis.

**Celebrex**

Beginning in July 2014, purported class actions were filed in the U.S. District Court for the Eastern District of Virginia against Pfizer and certain subsidiaries of Pfizer relating to Celebrex. The plaintiffs seek to represent U.S. nationwide or multi-state classes consisting of persons or entities who directly purchased from the defendants, or indirectly purchased or reimbursed patients for some or all of the purchase price of, Celebrex or generic Celebrex from May 31, 2014 until the cessation of the defendants’ allegedly unlawful conduct. The plaintiffs allege delay in the launch of generic Celebrex in violation of federal antitrust laws or certain state antitrust, consumer protection and various other laws as a result of Pfizer fraudulently obtaining and improperly listing a patent on Celebrex, engaging in sham litigation, and prolonging the impact of sham litigation through settlement activity that further delayed generic entry. Each of the actions seeks treble damages on behalf of the putative class for alleged price overcharges for Celebrex since May 31, 2014. In December 2014, the District Court granted the parties’ joint motions to consolidate the direct purchaser and end-payer cases, and all such cases were consolidated as of March 2015. In October 2014 and March 2015, we filed motions to dismiss the direct purchasers’ and end-payers’ amended complaints, respectively. In November 2015, the District Court denied in part and granted in part our motion to dismiss the direct purchasers’ amended complaint. In February 2016, the District Court denied in part and granted in part our motion to dismiss the end-payers’ amended complaint.

**Reglan**

Reglan is a pro-motility medicine for the treatment of gastroesophageal reflux disease and diabetic gastroparesis that was marketed by Wyeth and a predecessor company from 1979 until the end of 2001, when Wyeth sold the product and transferred the new drug application to another pharmaceutical company. Generic versions of Reglan have been sold by other companies since 1985. Pfizer, as Wyeth’s parent company, and certain wholly-owned subsidiaries and limited liability companies, including Wyeth, along with several other pharmaceutical manufacturers, have been named as defendants in numerous actions in various federal and state courts alleging a variety of personal injuries, including movement disorders such as Tardive Dyskinesia, resulting from the use of Reglan and/or generic equivalents thereof. As of February 2016, we entered into agreements in principle to settle virtually all of the known Reglan lawsuits on terms not material to Pfizer. We expect that the resolution of the remaining Reglan cases would not be material to us.

**A3. Legal Proceedings—Commercial and Other Matters**

**Average Wholesale Price Litigation**

Pfizer, certain of its subsidiaries and other pharmaceutical manufacturers were sued in various state courts by a number of states alleging that the defendants provided average wholesale price (AWP) information for certain of their products that was higher than the actual average prices at which those products were sold. The AWP is used to determine reimbursement levels under Medicare Part B and Medicaid and in many private-sector insurance policies and medical plans. All but one of those actions have been resolved through settlement, dismissal or final judgment. The plaintiff state in the one remaining action claims that the alleged spread between the AWPs at which purchasers were reimbursed and the actual sale prices was promoted by the defendants as an incentive to purchase certain of their products. The action alleges, among other things, fraud and violation of the state’s unfair trade practices and consumer protection statutes, and seeks monetary and other relief, including civil penalties and treble damages.
Monsanto-Related Matters
In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia & Upjohn Company to form Pharmacia Corporation (Pharmacia). Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is now a wholly owned subsidiary of Pfizer.

In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto is defending and indemnifying Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business.

In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to, indemnify Pharmacia for these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and New Monsanto are defending and indemnifying Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses.

Environmental Matters
In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia’s discontinued industrial chemical facility in North Haven, Connecticut and a revised site-wide feasibility study with regard to Wyeth Holdings Corporation’s discontinued industrial chemical facility in Bound Brook, New Jersey. In September 2010, our corrective measures study report with regard to the North Haven facility was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility’s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, lodged a complaint and consent decree with the federal District Court for the District of New Jersey that will allow Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree was entered by the District Court. The estimated costs of the site remedy for the North Haven facility and the site remediation for the Bound Brook facility are covered by accruals previously taken by us.

India’s National Green Tribunal (NGT) and the Maharashtra Pollution Control Board (MPCB) are actively reviewing various industrial facilities in the vicinity of Aurangabad, India, to determine whether those facilities have contributed to alleged groundwater and soil contamination in the area. In July 2015, the NGT issued an order directing Hospira India, as the owner of a manufacturing facility in Aurangabad, to deposit approximately $1.8 million in escrow (subsequently reduced to $0.9 million) to be applied to any required costs of remediation in the event Hospira India is determined to have responsibility for the alleged contamination. Subsequent to the NGT order, MPCB ordered the immediate closure of Hospira India’s Aurangabad facility. Hospira India appealed the MPCB order and in November 2015, the closure order was overturned by the NGT.

We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.

A4. Legal Proceedings—Government Investigations
Like other pharmaceutical companies, we are subject to investigations and extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. As a result, we have interactions with government agencies on an ongoing basis. Criminal charges, and substantial fines and/or civil penalties, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from government investigations. Among the investigations by government agencies are the matters discussed below.

In 2009, the U.S. Department of Justice (DOJ) filed a civil complaint in intervention in two qui tam actions that had been filed under seal in the U.S. District Court for the District of Massachusetts. The complaint alleges that Wyeth’s practices relating to the pricing for Protonix for Medicaid rebate purposes between 2001 and 2006, prior to Wyeth’s acquisition by Pfizer, violated the Federal Civil False Claims Act and federal common law. The two qui tam actions have been unsealed and the complaints include substantially similar allegations. In addition, in 2009, several states and the District of Columbia filed a complaint under the same docket number in the U.S. District Court for the District of Massachusetts asserting violations of various state laws based on allegations substantially similar to those set forth in the civil complaint filed by the DOJ. On February 12, 2016, Wyeth and the DOJ reached an agreement in principle to resolve the actions pending in the U.S. District Court for the District of Massachusetts for $784.6 million. The agreement in principle does not include an admission of liability by Wyeth and is subject to the negotiation of final settlement agreements and court approval.
In 2012, Pfizer sold the UK Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition & Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws.

A5. Legal Proceedings—Matters Resolved During 2015

During 2015, certain matters, including the matters discussed below, were resolved or were the subject of definitive settlement agreements or settlement agreements-in-principle.

Lyrica (pregabalin)
In May and June 2011, Apotex Inc. notified us that it had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Lyrica oral solution and Lyrica capsules, respectively. Apotex Inc. asserts the invalidity and non-infringement of the basic patent, as well as the seizure patent that expired in October 2013. In July 2011, we filed an action against Apotex Inc. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the challenged patents in connection with both abbreviated new drug applications. In January 2015, the District Court entered a stipulated dismissal, and as a result, Apotex Inc. cannot obtain FDA approval for, or market in the U.S., its generic versions of Lyrica prior to the expiration of the basic patent in December 2018.

Viagra (sildenafil)
In October 2010, we filed a patent-infringement action with respect to Viagra in the U.S. District Court for the Southern District of New York against Apotex Inc. and Apotex Corp., Mylan Pharmaceuticals Inc. (Mylan) and Mylan Inc. and Actavis, Inc. These generic drug manufacturers have filed abbreviated new drug applications with the FDA seeking approval to market their generic versions of Viagra. They assert the invalidity and non-infringement of the Viagra method-of-use patent, which expires in 2020 (including the six-month pediatric exclusivity period resulting from the Company’s conduct of clinical studies to evaluate Revatio in the treatment of pediatric patients with pulmonary arterial hypertension; Viagra and Revatio have the same active ingredient, sildenafil).

In May and June 2011, Watson Laboratories Inc. (Watson) and Hetero Labs Limited (Hetero), respectively, notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market their generic versions of Viagra. Each asserts the invalidity and non-infringement of the Viagra method-of-use patent. In June and July 2011, we filed actions against Watson and Hetero, respectively, in the U.S. District Court for the Southern District of New York asserting the validity and infringement of the Viagra method-of-use patent.

In April 2015, we entered into settlement agreements with each of Mylan, Mylan Inc., Watson, Actavis, Inc., Apotex Inc. and other defendants pursuant to which we granted licenses to the method-of-use patent permitting Mylan, Mylan Inc., Watson, Actavis, Inc., Apotex Inc. and Apotex Corp. to launch generic versions of Viagra in the U.S. beginning on or after December 11, 2017. In June 2015, we entered into a settlement agreement with Hetero pursuant to which we granted a license to the method-of-use patent permitting Hetero to launch a generic version of Viagra in the U.S. beginning on or after December 11, 2017.

Celebrex (celecoxib)
In March 2013, the USPTO granted us a reissue patent covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex. The reissue patent, including the six-month pediatric exclusivity period, expired in December 2015. On the date that the reissue patent was granted, we filed suit against Teva Pharmaceuticals USA, Inc. (Teva USA), Mylan, Watson (as predecessor to Allergan plc), Lupin Pharmaceuticals USA, Inc. (Lupin), Apotex Corp. and Apotex Inc. in the U.S. District Court for the Eastern District of Virginia, asserting the infringement of the reissue patent. Each of the defendant generic drug companies had previously filed an abbreviated new drug application with the FDA seeking approval to market a generic version of celecoxib beginning in May 2014, upon the expiration of the basic patent (including the six-month pediatric exclusivity period) for celecoxib. In March 2014, the District Court granted the defendants’ motion for summary judgment, invalidating the reissue patent. In May 2014, we appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. In June 2015, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court’s decision.

In April 2014, we entered into settlement agreements with two of the defendants, Teva USA and Watson, pursuant to which we granted licenses to the reissue patent permitting Teva USA and Watson to launch generic versions of celecoxib in the U.S. beginning in December 2014. In June 2014 and October 2014, we entered into settlement agreements with Mylan and Lupin, respectively, pursuant to which we granted licenses to the reissue patent permitting Mylan and Lupin to launch generic versions of celecoxib in the U.S. beginning in December 2014. In December 2014, Teva USA, Watson, Mylan and Lupin commenced marketing of generic versions of celecoxib.

Various Drugs: Off-Label Promotion Action
In May 2010, a purported class action was filed in the U.S. District Court for the Southern District of New York against Pfizer and several of our current and former officers. The complaint alleges that the defendants violated federal securities laws by making or causing Pfizer to make false statements, and by failing to disclose or causing Pfizer to fail to disclose material information concerning the alleged off-label promotion of certain pharmaceutical products, alleged payments to physicians to promote the sale of those products and government investigations related thereto. Plaintiffs seek damages in an unspecified amount. In March 2012, the court certified a class consisting of all persons who purchased Pfizer common stock in the U.S. or on U.S. stock exchanges between January 19, 2006 and January 23, 2009 and were damaged as a result of the decline in the price of Pfizer common stock allegedly attributable to the claimed violations. In January 2015, the parties reached an agreement in principle to resolve the matter for $400 million. In July 2015, the court approved the settlement.
B. Guarantees and Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2015, recorded amounts for the estimated fair value of these indemnifications were not significant.

Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.

C. Purchase Commitments

As of December 31, 2015, we had agreements totaling $3.7 billion to purchase goods and services that are enforceable and legally binding and include amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur.

Note 18. Segment, Geographic and Other Revenue Information

A. Segment Information

We manage our commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments, each of which has been led by a single manager in 2015 and 2014—the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). Effective February 8, 2016, the Innovative Products business is led by a single manager. The Established Products business consists of the Global Established Pharmaceutical segment (GEP), which is also led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof of concept. Each business has a geographic footprint across developed and emerging markets. As our operations were not managed under the new structure until the beginning of fiscal 2014, certain costs and expenses could not be directly attributed to one of the new operating segments. As a result, our operating segment results for 2013 include allocations. The amounts subject to allocation methods in 2013 were approximately $2.1 billion of selling, informational and administrative expenses and approximately $800 million of research and development expenses:

- The selling, informational and administrative expenses were allocated using proportional allocation methods based on associated selling costs, revenues or product-specific costs, as applicable.
- The research and development expenses were allocated based on product-specific R&D costs or revenue metrics, as applicable.

Management believes that the allocations are reasonable.

We regularly review our segments and the approach used by management to evaluate performance and allocate resources.

Operating Segments

Some additional information about each business and operating segment follows:

<table>
<thead>
<tr>
<th>Innovative Products Business</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Innovative Pharmaceutical segment:</td>
</tr>
<tr>
<td>GIP focuses on developing and commercializing novel, value-creating medicines that significantly improve patients’ lives. Key therapeutic areas include inflammation/immunology, cardiovascular/metabolic, neuroscience/pain and rare diseases and include leading brands, such as Xeljanz, Eliquis, Lyrica (U.S. and Japan), Enbrel (outside the U.S. and Canada) and Viagra (U.S. and Canada).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Established Products Business</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global Vaccines, Oncology and Consumer Healthcare segment:</td>
</tr>
<tr>
<td>VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. Consumer Healthcare manufactures and markets several well known, over-the-counter (OTC) products. Each of the three businesses in VOC operates as a separate, global business, with distinct specialization in terms of the science and market approach necessary to deliver value to consumers and patients.</td>
</tr>
</tbody>
</table>

| Global Established Pharmaceutical segment: |
| GEP includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars and infusion systems. |

Additionally, GEP has the knowledge and resources within R&D to develop small molecules, including injectables, and biosimilars. On September 3, 2015, we acquired Hospira, and its commercial operations are now included within GEP. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income, primarily GEP’s operating results, for the year ended December 31, 2015 reflect four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.

Our chief operating decision maker uses the revenues and earnings of the three operating segments, among other factors, for performance evaluation and resource allocation.
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

- WRD, which is generally responsible for research projects until proof-of-concept is achieved and then for transitioning those projects to the appropriate operating segment for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. This organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities.

- Pfizer Medical, which, during the years 2013 through 2015, was responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, partnerships with global public health and medical associations, regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes.

- Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments.

- Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.

- Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, which include non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.

Segment Assets

We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $167 billion as of December 31, 2015 and approximately $168 billion as of December 31, 2014.

Selected Income Statement Information

The following table provides selected income statement information by reportable segment:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Revenues (b)</th>
<th>Earnings (a)</th>
<th>Depreciation and Amortization (b)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Year Ended December 31,</td>
<td>Year Ended December 31,</td>
<td>Year Ended December 31,</td>
</tr>
<tr>
<td>Reportable Segments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GIP</td>
<td>$13,954</td>
<td>$13,861</td>
<td>$14,317</td>
</tr>
<tr>
<td>VOC</td>
<td>12,803</td>
<td>10,144</td>
<td>9,285</td>
</tr>
<tr>
<td>GEP (c)</td>
<td>21,587</td>
<td>25,149</td>
<td>27,619</td>
</tr>
<tr>
<td>Total reportable segments</td>
<td>48,345</td>
<td>49,154</td>
<td>51,221</td>
</tr>
<tr>
<td>Other business activities (d)</td>
<td>506</td>
<td>253</td>
<td>232</td>
</tr>
<tr>
<td>Reconciling Items:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate (e)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase accounting adjustments (e)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquisition-related costs (e)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Certain significant items (f)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other unallocated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>$48,851</td>
<td>$49,605</td>
<td>$51,584</td>
</tr>
</tbody>
</table>

(a) Income from continuing operations before provision for taxes on income.
(b) Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.
(c) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
(d) Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, which in 2015 includes the revenues and expenses related to our manufacturing and supply agreements with Zoetis. Other business activities also includes the costs managed by our WRD organization and our Pfizer Medical organization.
(e) For a description, see the “Other Costs and Business Activities” section above.
(f) Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.

For Revenues in 2014 and 2013, certain significant items primarily represent revenues related to our manufacturing and supply agreements with Zoetis. For additional information, see Note 2D.

For Earnings in 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $584 million, (ii) foreign currency loss and inventory impairment related to Venezuela of $878 million, (iii) certain asset impairments of $787 million, (iv) a charge related to pension settlements of $491 million, (v) charges for business and legal entity alignment of $292 million, (vi) charges for certain legal matters of $968 million and (vii) other charges of $332 million. For additional information, see Note 3 and Note 4.

For Earnings in 2014, certain significant items includes: (i) charges for certain legal matters of $999 million, (ii) certain asset impairments of $440 million, (iii) a charge for an additional year of Branded Prescription Drug Fee of $215 million, (iv) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $598 million, (v) an upfront fee associated with collaborative arrangement with Merck KGaA of $1.2 billion, (vi) charges for business and legal entity alignment of $168 million and (vii) other charges of $165 million. For additional information, see Note 2C, Note 3 and Note 4.

For Earnings in 2013, certain significant items includes: (i) patent litigation settlement income of $1.3 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.3 billion, (iii) net charges for certain legal matters of $21 million, (iv) certain asset impairments of $836 million, (v) the gain associated with the transfer of certain product rights to Hisun Pfizer of $459 million, (vi) costs associated with the separation of Zoetis of $18 million and (vii) other charges of $290 million. For additional information, see Note 2E, Note 3 and Note 4.

Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments.

The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.

B. Geographic Information

Revenues exceeded $500 million in each of 12 countries outside the U.S. in 2015, 2014 and 2013. The U.S. is the only country to contribute more than 10% of total revenue in 2015 and 2014. The U.S. and Japan were the only countries to contribute more than 10% of total revenue in 2013.

The following table provides revenues by geographic area:

<table>
<thead>
<tr>
<th>Year Ended December 31, (Millions of Dollars)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>$21,704</td>
<td>$19,073</td>
<td>$20,274</td>
</tr>
<tr>
<td>Developed Europe (a), (b)</td>
<td>9,714</td>
<td>11,719</td>
<td>11,739</td>
</tr>
<tr>
<td>Developed Rest of World (a), (c)</td>
<td>6,298</td>
<td>7,314</td>
<td>8,346</td>
</tr>
<tr>
<td>Emerging Markets (a), (d)</td>
<td>11,136</td>
<td>11,499</td>
<td>11,225</td>
</tr>
<tr>
<td><strong>Revenues</strong></td>
<td><strong>48,851</strong></td>
<td><strong>49,605</strong></td>
<td><strong>51,584</strong></td>
</tr>
</tbody>
</table>

(a) On September 3, 2015, we acquired Hospira. Commencing from the acquisition date, and in accordance with our domestic and international reporting periods, our consolidated statement of income for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations. See Note 2A for additional information.
(b) Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries. Revenues denominated in euros were $7.4 billion in 2015, $9.0 billion in 2014 and $8.9 billion in 2013.
(c) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.
(d) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.

Long-lived assets by geographic region follow (a):

<table>
<thead>
<tr>
<th>Year Ended December 31, (Millions of Dollars)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Property, plant and equipment, net</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United States</td>
<td>$7,072</td>
<td>$5,575</td>
<td>$5,885</td>
</tr>
<tr>
<td>Developed Europe (a)</td>
<td>4,376</td>
<td>4,606</td>
<td>4,845</td>
</tr>
<tr>
<td>Developed Rest of World (c)</td>
<td>660</td>
<td>617</td>
<td>696</td>
</tr>
<tr>
<td>Emerging Markets (a)</td>
<td>1,658</td>
<td>963</td>
<td>971</td>
</tr>
<tr>
<td><strong>Property, plant and equipment, net</strong></td>
<td><strong>$13,766</strong></td>
<td><strong>$11,762</strong></td>
<td><strong>$12,397</strong></td>
</tr>
</tbody>
</table>

(a) Reflects legacy Hospira amounts in 2015 commencing on the Hospira acquisition date, September 3, 2015.
(b) Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.
(c) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand, and South Korea.
(d) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.
C. Other Revenue Information

Significant Customers

We sell our biopharmaceutical products primarily to customers in the wholesale sector. In 2015, sales to our three largest U.S. wholesaler customers represented approximately 14%, 11% and 10% of total revenues, respectively, and, collectively, represented approximately 23% of total trade accounts receivable as of December 31, 2015. In 2014, sales to our three largest U.S. wholesaler customers represented approximately 13%, 10% and 9% of total revenues, respectively, and, collectively, represented approximately 25% of total trade accounts receivable as of December 31, 2014. In 2013, sales to our three largest U.S. wholesaler customers represented approximately 12%, 9% and 8% of total revenues, respectively. For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses.
## Significant Product Revenues

The following table provides detailed revenue information:

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS)</th>
<th>Year Ended December 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td><strong>INNOVATIVE PRODUCTS BUSINESS</strong>(a)</td>
<td></td>
</tr>
<tr>
<td>GIP**(a)**</td>
<td>$26,758</td>
</tr>
<tr>
<td>Lyrica GIP**(a)**</td>
<td>$3,655</td>
</tr>
<tr>
<td>Enbrel (Outside the U.S. and Canada)</td>
<td>$3,333</td>
</tr>
<tr>
<td>Viagra GIP**(a)**</td>
<td>$1,297</td>
</tr>
<tr>
<td>BeneFIX</td>
<td>752</td>
</tr>
<tr>
<td>Chantix/Champix</td>
<td>671</td>
</tr>
<tr>
<td>Genotropin</td>
<td>617</td>
</tr>
<tr>
<td>Refacto AF/Xyntha</td>
<td>533</td>
</tr>
<tr>
<td>Xeljanz</td>
<td>523</td>
</tr>
<tr>
<td>Toviaz</td>
<td>267</td>
</tr>
<tr>
<td>BMP2</td>
<td>232</td>
</tr>
<tr>
<td>Somavert</td>
<td>218</td>
</tr>
<tr>
<td>Alliance revenue GIP**(a) (o)**</td>
<td>1,254</td>
</tr>
<tr>
<td>All other GIP**(a)**</td>
<td>405</td>
</tr>
<tr>
<td><strong>VOC</strong>(a)</td>
<td></td>
</tr>
<tr>
<td>Prevnar family**(a)**</td>
<td>6,245</td>
</tr>
<tr>
<td>Sutent</td>
<td>1,120</td>
</tr>
<tr>
<td>Ibrance</td>
<td>723</td>
</tr>
<tr>
<td>Xalkori</td>
<td>488</td>
</tr>
<tr>
<td>Inlyta</td>
<td>430</td>
</tr>
<tr>
<td>FSME-IMMUN/TicoVac</td>
<td>104</td>
</tr>
<tr>
<td>All other V/O**(a)**</td>
<td>298</td>
</tr>
<tr>
<td>Consumer Healthcare</td>
<td>3,395</td>
</tr>
<tr>
<td><strong>ESTABLISHED PRODUCTS BUSINESS</strong>(b)</td>
<td></td>
</tr>
<tr>
<td>Legacy Established Products**(b)**</td>
<td>$21,745</td>
</tr>
<tr>
<td>Lipitor</td>
<td>1,860</td>
</tr>
<tr>
<td>Premarin family</td>
<td>1,018</td>
</tr>
<tr>
<td>Norvasc</td>
<td>991</td>
</tr>
<tr>
<td>Xalatan/Xalacom</td>
<td>399</td>
</tr>
<tr>
<td>Zoloft</td>
<td>374</td>
</tr>
<tr>
<td>Relpax</td>
<td>352</td>
</tr>
<tr>
<td>EpiPen</td>
<td>339</td>
</tr>
<tr>
<td>Effexor</td>
<td>298</td>
</tr>
<tr>
<td>Zithromax/Zmax</td>
<td>275</td>
</tr>
<tr>
<td>Xanax/Xanax XR</td>
<td>224</td>
</tr>
<tr>
<td>Cardura</td>
<td>210</td>
</tr>
<tr>
<td>Neurontin</td>
<td>196</td>
</tr>
<tr>
<td>Dilucan</td>
<td>181</td>
</tr>
<tr>
<td>Tikosyn</td>
<td>179</td>
</tr>
<tr>
<td>Depo-Provera</td>
<td>170</td>
</tr>
<tr>
<td>Unasyn</td>
<td>118</td>
</tr>
<tr>
<td>All other Legacy Established Products**(b) (o)**</td>
<td>4,571</td>
</tr>
<tr>
<td><strong>Peri-LOE Products</strong>(c)</td>
<td></td>
</tr>
<tr>
<td>Lyrica GEP**(b)**</td>
<td>1,183</td>
</tr>
<tr>
<td>Zyvox</td>
<td>883</td>
</tr>
<tr>
<td>Celebrex</td>
<td>830</td>
</tr>
<tr>
<td>Pristiq</td>
<td>715</td>
</tr>
<tr>
<td>Vfend</td>
<td>682</td>
</tr>
<tr>
<td>Viagra GEP**(c)**</td>
<td>411</td>
</tr>
<tr>
<td>Revatio</td>
<td>260</td>
</tr>
<tr>
<td>All other Peri-LOE Products**(c)**</td>
<td>362</td>
</tr>
<tr>
<td><strong>Sterile Injectable Pharmaceuticals</strong>(c)</td>
<td></td>
</tr>
<tr>
<td>Medrol</td>
<td>402</td>
</tr>
<tr>
<td>Sulperazon</td>
<td>339</td>
</tr>
<tr>
<td>Fragmin</td>
<td>335</td>
</tr>
<tr>
<td>Tygacil</td>
<td>304</td>
</tr>
<tr>
<td>All other Sterile Injectable Pharmaceuticals**(c)**</td>
<td>2,563</td>
</tr>
<tr>
<td><strong>Infusion Systems</strong>(c)</td>
<td></td>
</tr>
<tr>
<td>All Other Established Products**(c)**</td>
<td></td>
</tr>
<tr>
<td><strong>OTHER</strong>(c)</td>
<td></td>
</tr>
<tr>
<td>Revenues</td>
<td>$48,851</td>
</tr>
<tr>
<td>Total Lyrica**(c)**</td>
<td>$4,839</td>
</tr>
<tr>
<td>Total Viagra**(c)**</td>
<td>$1,708</td>
</tr>
<tr>
<td>Total Alliance revenues**(a) (o)**</td>
<td>$1,312</td>
</tr>
</tbody>
</table>
The Innovative Products business is composed of two operating segments: GIP and VOC.

Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica-GEP. All other Lyrica revenues are included in Lyrica-GIP. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica-GIP and Lyrica-GEP.

Viagra revenues from the U.S. and Canada are included in Viagra-GIP. All other Viagra revenues are included in Viagra-GEP. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra-GIP and Viagra-GEP.

Includes Eliquis, Rebif and Enbrel (in the U.S. and Canada through October 31, 2013).

All other GIP and All other V/O are a subset of GIP and VOC, respectively. All other Legacy Established Products, All other Peri-LOE Products and All other Sterile Injectable Pharmaceuticals are subsets of Established Products.

In 2015, all revenues were composed of Prevnar 13/Prevenar 13. In 2014 and 2013, revenues were composed of the Prevnar family of products, which included Prevnar 13/Prevenar 13 and, to a much lesser extent, Prevenar (7-valent).

The Established Products business consists of GEP, which includes all legacy Hospira commercial operations. Commencing from the acquisition date, September 3, 2015, and in accordance with our domestic and international reporting periods, our consolidated statement of income, primarily GEP’s operating results, for the year ended December 31, 2015 reflects four months of legacy Hospira U.S. operations and three months of legacy Hospira international operations.

Legacy Established Products include products that lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products).

Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products primarily include Celebrex, Zyvox and Revatio in most developed markets, Lyrica in the EU, Pristiq in the U.S. and Inspra in the EU.

Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).

Infusion Systems include Medication Management Systems products composed of infusion pumps and related software and services, as well as I.V. Infusion Products, including large volume I.V. solutions and their associated administration sets.

Biosimilars include Inflectra (biosimilar infliximab), Nivestim (biosimilar filgrastim) and Retacrit (biosimilar epoetin zeta) in certain international markets.

Includes legacy Hospira’s One-to-One contract manufacturing and bulk pharmaceutical chemical sales organizations.

Other includes revenues from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and revenues related to our manufacturing and supply agreements with Zoetis.

Total Alliance revenues represent the aggregate of worldwide revenues from Alliance revenues GIP and Alliance revenues GEP, which is included in All other Legacy Established Products.
Note 19. Pending Combination with Allergan plc

On November 23, 2015, we announced that we have entered into a definitive merger agreement with Allergan, a global pharmaceutical company incorporated in Ireland, under which we have agreed to combine with Allergan in a stock transaction valued at $363.63 per Allergan share, for a total enterprise value of approximately $160 billion, based on the closing price of Pfizer common stock of $32.18 on November 20, 2015 (the last trading day prior to the announcement) and certain other assumptions. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares by virtue of a share split, and Pfizer shareholders will have the option of receiving one share of the combined company for each of their Pfizer shares or receiving cash instead of shares of the combined company for some or all of their Pfizer shares, provided that the aggregate amount of cash to be paid in the merger will not be less than $6 billion or greater than $12 billion. In the event that elections to receive cash and shares in the merger would otherwise result in an aggregate of less than $6 billion or greater than $12 billion of cash being paid out in the merger, then the share elections and cash elections will be subject to proration. The completion of the transaction, which is expected in the second half of 2016, is subject to certain conditions, including receipt of regulatory approval in certain jurisdictions, including the U.S. and EU, the receipt of necessary approvals from both Pfizer and Allergan shareholders, and the completion of Allergan’s pending divestiture of its generics business to Teva Pharmaceuticals Industries Ltd. The merger agreement also provides that the businesses of Pfizer and Allergan will be combined under the existing Allergan entity, which, subject to approval by Allergan shareholders, will be renamed “Pfizer plc.”
## Quarterly Consolidated Financial Data (Unaudited)

Pfizer Inc. and Subsidiary Companies

<table>
<thead>
<tr>
<th>(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)</th>
<th>Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First</td>
</tr>
<tr>
<td>Revenues (a)</td>
<td>$10,864</td>
</tr>
<tr>
<td>Costs and expenses(c)</td>
<td>7,722</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs(d), (e)</td>
<td>60</td>
</tr>
<tr>
<td>Income/(loss) from continuing operations before provision for taxes on income</td>
<td>3,082</td>
</tr>
<tr>
<td>Provision/(benefit) for taxes on income</td>
<td>706</td>
</tr>
<tr>
<td>Income/(loss) from continuing operations</td>
<td>2,376</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>5</td>
</tr>
<tr>
<td>Net income/(loss) before allocation to noncontrolling interests</td>
<td>2,381</td>
</tr>
<tr>
<td>Less: Net income attributable to noncontrolling interests</td>
<td>6</td>
</tr>
<tr>
<td>Net income/(loss) attributable to Pfizer Inc.</td>
<td>$2,376</td>
</tr>
</tbody>
</table>

| Earnings/(loss) per common share—basic:            |         |         |        |        |
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $0.38  | $0.43   | $0.34  | (0.03) |
| Discontinued operations—net of tax                | —      | —      | —      | —      |
| Net income/(loss) attributable to Pfizer Inc. common shareholders | $0.38  | $0.43   | $0.35  | (0.03) |

| Earnings/(loss) per common share—diluted:          |         |         |        |        |
| Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $0.38  | $0.42   | $0.34  | (0.03) |
| Discontinued operations—net of tax                | —      | —      | —      | —      |
| Net income/(loss) attributable to Pfizer Inc. common shareholders | $0.38  | $0.42   | $0.34  | (0.03) |

| Cash dividends paid per common share               | $0.28  | $0.28   | $0.28  | $0.28  |

| Stock prices                                       |         |         |        |        |
| High                                               | $35.45  | $35.53  | $36.46 | $36.07 |
| Low                                                | $31.01  | $33.21  | $28.47 | $30.64 |

(a) In accordance with our domestic and international reporting periods, our consolidated statement of income for the third quarter of 2015 reflects one month of legacy Hospira U.S. operations but do not include any financial results from legacy Hospira international operations.

(b) In accordance with our domestic and international reporting periods, our consolidated statement of income for the fourth quarter of 2015 reflects three months of legacy Hospira global operations.

(c) The fourth quarter of 2015 historically reflects higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses. The fourth quarter of 2015 includes (i) charges of $878 million related to Venezuelan monetary resulting from foreign currency loss ($806 million) and an inventory impairment charge ($72 million); (ii) a charge of $784.6 million for an agreement in principle to settle claims relating to Protonix; (iii) charges of $491 million related to pension settlements; (iv) a benefit of $306 million resulting from a change in the profit deferred in inventory relating to inventory that had not been sold to third parties; and (v) a charge of $245 million related to the write-down of assets to net realizable value, which is primarily recorded in Other (income)/deductions—net.

(d) The third quarter of 2015 reflects (i) restructuring charges of $469 million for employee termination costs, asset impairments and other exit costs largely associated with our acquisition of Hospira; (ii) transaction costs, such as banking, legal, accounting and other similar services, directly related to our acquisition of Hospira of $64 million; and (iii) integration costs, representing external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes of $48 million, largely related to our acquisition of Hospira.

(e) The fourth quarter of 2015 reflects (i) restructuring charges of $256 million for employee termination costs, asset impairments and other exit costs, which are largely associated with our acquisition of Hospira; (ii) transaction costs, such as banking, legal, accounting and other similar services, directly related to our pending combination with Allergan plc (Allergan) and our acquisition of Hospira of $52 million; and (iii) integration costs, representing external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes, of $116 million, primarily related to our acquisition of Hospira.

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.
<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$11,353</td>
<td>$12,773</td>
<td>$12,361</td>
<td>$13,118</td>
</tr>
</tbody>
</table>

**Costs and expenses**(a)

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>8,448</td>
<td>8,689</td>
<td>8,793</td>
<td>11,185</td>
</tr>
</tbody>
</table>

**Restructuring charges and certain acquisition-related costs**(b)

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>58</td>
<td>81</td>
<td>(19)</td>
<td>130</td>
</tr>
</tbody>
</table>

**Income from continuing operations before provision/(benefit) for taxes on income**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2,847</td>
<td>4,003</td>
<td>3,587</td>
<td>1,803</td>
</tr>
</tbody>
</table>

**Provision/(benefit) for taxes on income**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>582</td>
<td>1,082</td>
<td>911</td>
<td>545</td>
</tr>
</tbody>
</table>

**Income from continuing operations**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2,265</td>
<td>2,921</td>
<td>2,676</td>
<td>1,257</td>
</tr>
</tbody>
</table>

**Discontinued operations—net of tax**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>73</td>
<td>—</td>
<td>(3)</td>
<td>(21)</td>
</tr>
</tbody>
</table>

**Net income before allocation to noncontrolling interests**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2,338</td>
<td>2,921</td>
<td>2,672</td>
<td>1,236</td>
</tr>
</tbody>
</table>

**Less: Net income attributable to noncontrolling interests**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>9</td>
<td>9</td>
<td>6</td>
<td>8</td>
</tr>
</tbody>
</table>

**Net income attributable to Pfizer Inc.**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$2,329</td>
<td>$2,912</td>
<td>$2,666</td>
<td>$1,228</td>
</tr>
</tbody>
</table>

**Earnings per common share—basic:**

<table>
<thead>
<tr>
<th>Description</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc. common shareholders</td>
<td>$0.35</td>
<td>$0.46</td>
<td>$0.42</td>
<td>$0.20</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>$0.01</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders</td>
<td>$0.36</td>
<td>$0.46</td>
<td>$0.42</td>
<td>$0.20</td>
</tr>
</tbody>
</table>

**Earnings per common share—diluted:**

<table>
<thead>
<tr>
<th>Description</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income from continuing operations attributable to Pfizer Inc. common shareholders</td>
<td>$0.35</td>
<td>$0.45</td>
<td>$0.42</td>
<td>$0.20</td>
</tr>
<tr>
<td>Discontinued operations—net of tax</td>
<td>$0.01</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc. common shareholders</td>
<td>$0.36</td>
<td>$0.45</td>
<td>$0.42</td>
<td>$0.19</td>
</tr>
</tbody>
</table>

**Cash dividends paid per common share**

<table>
<thead>
<tr>
<th>Year</th>
<th>First</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$0.26</td>
<td>$0.26</td>
<td>$0.26</td>
<td>$0.26</td>
</tr>
</tbody>
</table>

**Stock prices**

<table>
<thead>
<tr>
<th>Year</th>
<th>High</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$32.96</td>
<td>$32.69</td>
<td>$31.31</td>
<td>$33.12</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Low</th>
<th>Second</th>
<th>Third</th>
<th>Fourth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$29.66</td>
<td>$28.77</td>
<td>$27.87</td>
<td>$27.51</td>
</tr>
</tbody>
</table>

(a) The fourth quarter of 2014 reflects historically higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development expenses.

(b) The fourth quarter of 2014 reflects higher employee termination costs.

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.
### Financial Summary

**Pfizer Inc. and Subsidiary Companies**

**Year Ended/As of December 31, (a)**

<table>
<thead>
<tr>
<th>(MILLIONS, EXCEPT PER COMMON SHARE DATA)</th>
<th>2015</th>
<th>2014</th>
<th>2013</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues (b)</td>
<td>$48,851</td>
<td>$49,605</td>
<td>$51,584</td>
<td>$54,657</td>
<td>$61,035</td>
</tr>
<tr>
<td>Income from continuing operations (b)</td>
<td>6,975</td>
<td>9,119</td>
<td>11,410</td>
<td>9,021</td>
<td>7,860</td>
</tr>
<tr>
<td>Total assets (b), (c)</td>
<td>167,460</td>
<td>167,566</td>
<td>170,415</td>
<td>182,974</td>
<td>184,629</td>
</tr>
<tr>
<td>Long-term obligations (b), (c), (d)</td>
<td>73,064</td>
<td>74,357</td>
<td>73,801</td>
<td>77,758</td>
<td>79,287</td>
</tr>
</tbody>
</table>

**Earnings per common share—basic**

| Income from continuing operations attributable to Pfizer Inc. common shareholders | $1.13 | $1.43 | $1.67 | $1.21 | $1.00 |
| Discontinued operations—net of tax (e) | — | 0.01 | 1.56 | 0.75 | 0.28 |
| Net income attributable to Pfizer Inc. common shareholders | $1.13 | $1.44 | $3.23 | $1.96 | $1.28 |

**Earnings per common share—diluted**

| Income from continuing operations attributable to Pfizer Inc. common shareholders | $1.11 | $1.41 | $1.65 | $1.20 | $0.99 |
| Discontinued operations—net of tax (e) | — | 0.01 | 1.54 | 0.74 | 0.28 |
| Net income attributable to Pfizer Inc. common shareholders | $1.11 | $1.42 | $3.19 | $1.94 | $1.27 |

**Cash dividends paid per common share**

| $1.12 | $1.04 | $0.96 | $0.88 | $0.80 |

(a) Reflects the acquisition of Hospira on September 3, 2015 and the acquisition of King on January 31, 2011.

(b) All amounts reflect the June 24, 2013 disposition of Zoetis and its presentation as a discontinued operation in all periods prior to 2014 presented.

(c) All amounts reflect the retrospective adoption of a new accounting standard as of December 31, 2015 that requires all deferred tax assets and liabilities to be classified as noncurrent in the balance sheet. See Notes to Consolidated Financial Statements—Note 1B. Adoption of New Accounting Standards.

(d) Defined as Long-term debt, Pension benefit obligations, net, Postretirement benefit obligations, net, Noncurrent deferred tax liabilities, Other taxes payable and Other noncurrent liabilities.

(e) Includes (i) the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, (ii) the Nutrition business through November 30, 2012, the date of disposal and (iii) the Capsugel business through August 1, 2011, the date of disposal.
The following graph assumes a $100 investment on December 31, 2010, and reinvestment of all dividends, in each of the Company’s Common Shares, the S&P 500 Index, and a composite peer group of the major U.S.- and European-based pharmaceutical companies, which are: Abbott Laboratories (for the period 2010-2012 only), AbbVie Inc. (for 2013, 2014 and 2015 only), Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly & Co., GlaxoSmithKline plc, Johnson & Johnson, Merck and Co., Inc., Novartis AG, Roche Holding AG and Sanofi SA.